User Image Cart Icon 0 Search Image

Glycation

  1. GLYCATION and diabetic complications
  2. Role of GLYCATION in aging
  3. Mechanisms of GLYCATION in atherogenesis
  4. The pathological implications of protein GLYCATION.
  5. GLYCATION products and the pathogenesis of diabetic complications
  6. Free radical generation by early GLYCATION products: a mechanism for accelerated atherogenesis in diabetes
  7. Advanced GLYCATION end-products and atherosclerosis
  8. Inhibition of protein GLYCATION and advanced GLYCATION end products by ascorbic acid and other vitamins and nutrients
  9. Advanced GLYCATION endproducts in ageing and Alzheimer’s disease
  10. GLYCATION and oxidation: a role in the pathogenesis of atherosclerosis
  11. Recent progress in advanced GLYCATION end products and diabetic complications
  12. Protein GLYCATION and oxidative stress in diabetes mellitus and ageing
  13. Tobacco smoke is a source of toxic reactive GLYCATION products
  14. Hydrogen peroxide production during experimental protein GLYCATION
  15. Diabetes, advanced GLYCATION endproducts and vascular disease
  16. Atherogenesis and Advanced GLYCATION: Promotion, Progression, and Preventiona
  17. Advanced GLYCATION end products in Alzheimer’s disease and other neurodegenerative diseases
  18. Recent progress in advanced GLYCATION and diabetic vascular disease: role of advanced GLYCATION end product receptors
  19. Lipoprotein GLYCATION and its metabolic consequences
  20. Advanced GLYCATION end products, oxidant stress and vascular lesions
  21. GLYCATION of collagen: the basis of its central role in the late complications of ageing and diabetes
  22. Formation of crossline as a fluorescent advanced GLYCATION end productin vitroandin vivo
  23. Advanced GLYCATION end products contribute to amyloidosis in Alzheimer disease
  24. GLYCATION of proteins as a source of superoxide.
  25. Advanced GLYCATION end products increase retinal vascular endothelial growth factor expression.
  26. Renal catabolism of advanced GLYCATION end products: the fate of pentosidine
  27. Survey of the distribution of a newly characterized receptor for advanced GLYCATION end products in tissues
  28. Plasma levels of pentosidine in diabetic patients: an advanced GLYCATION end product.
  29. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced GLYCATION endproducts
  30. Advanced GLYCATION endproducts and cigarette smoking.
  31. Cytotoxicity of advanced GLYCATION endproducts is mediated by oxidative stress
  32. GLYCATION induces expansion of the molecular packing of collagen
  33. In vitro kinetic studies of formation of antigenic advanced GLYCATION end products (AGEs): novel inhibition of post-Amadori GLYCATION pathways
  34. Lipoprotein GLYCATION and its metabolic consequences.
  35. Enhanced cellular oxidant stress by the interaction of advanced GLYCATION end products with their receptors/binding proteins
  36. Determination of advanced GLYCATION end products in serum by fluorescence spectroscopy and competitive ELISA
  37. Effect of phosphate on the kinetics and specificity of GLYCATION of protein.
  38. Pathways of formation of glycoxidation products during GLYCATION of collagen
  39. Breakers of advanced GLYCATION end products restore large artery properties in experimental diabetes
  40. Implication of an increased oxidative stress in the formation of advanced GLYCATION end products in patients with end-stage renal failure
  41. Non-enzymic GLYCATION of individual plasma proteins in normoglycemic and hyperglycemic patients.
  42. Role of fructose in GLYCATION and cross-linking of proteins
  43. The Advanced GLYCATION End Product, N∊-(Carboxymethyl) lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (∗)
  44. Advanced GLYCATION end products up-regulate gene expression found in diabetic glomerular disease
  45. Vascular hypertrophy in experimental diabetes. Role of advanced GLYCATION end products.
  46. Orally absorbed reactive GLYCATION products (glycotoxins): an environmental risk factor in diabetic nephropathy
  47. The role of GLYCATION cross-links in diabetic vascular stiffening
  48. The relationship between accumulation of advanced GLYCATION end products and expression of vascular endothelial growth factor in human diabetic retinas
  49. GLYCATION-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells.
  50. Advanced GLYCATION end products in age-related macular degeneration
  51. Modification of low density lipoprotein by advanced GLYCATION end products contributes to the dyslipidemia of diabetes and renal insufficiency
  52. Increased serum levels of advanced GLYCATION end-products and diabetic complications
  53. RAGE: a novel cellular receptor for advanced GLYCATION end products
  54. Identification of the site of GLYCATION of human insulin
  55. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced GLYCATION end products.
  56. Advanced GLYCATION end products induce glomerular sclerosis and albuminuria in normal rats
  57. Cellular receptors for advanced GLYCATION end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
  58. Protein GLYCATION in the kidney: role in diabetes and aging
  59. Alzheimer’s disease–synergistic effects of glucose deficit, oxidative stress and advanced GLYCATION endproducts
  60. Expression of receptors for advanced GLYCATION end products in peripheral occlusive vascular disease
  61. GLYCATION and advanced GLYCATION end-product formation with icodextrin and dextrose
  62. Advanced GLYCATION end products in vitreous: Structural and functional implications for diabetic vitreopathy.
  63. Oxidative GLYCATION and free radical production: a causal mechanism of diabetic complications
  64. Oxidation conspires with GLYCATION to generate noxious advanced GLYCATION end products in renal failure.
  65. ELISA of pentosidine, an advanced GLYCATION end product, in biological specimens
  66. Failure of common GLYCATION assays to detect GLYCATION by fructose
  67. GLYCATION and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites.
  68. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced GLYCATION end products
  69. Immunohistochemical detection of imidazolone, a novel advanced GLYCATION end product, in kidneys and aortas of diabetic patients.
  70. Evidence for the GLYCATION hypothesis of aging from the food-restricted rodent model
  71. Clearance of pentosidine, an advanced GLYCATION end product, by different modalities of renal replacement therapy
  72. Nonenzymatic GLYCATION of collagen in aging and diabetes
  73. Immunochemical approach to characterize advanced GLYCATION end products of the Maillard reaction: evidence for the presence of a common structure
  74. Advanced GLYCATION endproducts (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with …
  75. GLYCATION alters collagen fibril organization
  76. Advanced GLYCATION endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits
  77. GLYCATION, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction
  78. GLYCATION (non-enzymic glycosylation) inactivates glutathione reductase
  79. GLYCATION-induced inactivation and loss of antigenicity of catalase and superoxide dismutase
  80. Advanced GLYCATION endproducts stimulate interleukin‐6 production by human bone‐derived cells
  81. Advanced GLYCATION end product-induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells
  82. Specific fluorescence assay for advanced GLYCATION end products in blood and urine of diabetic patients
  83. N. epsilon.-(Carboxymethyl) lysine is a dominant advanced GLYCATION end product (AGE) antigen in tissue proteins
  84. Advanced GLYCATION end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
  85. Effect of curcumin on the advanced GLYCATION and cross-linking of collagen in diabetic rats
  86. Rapid formation of advanced GLYCATION end products by intermediate metabolites of glycolytic pathway and polyol pathway
  87. GLYCATION of amino groups in protein. Studies on the specificity of modification of RNase by glucose.
  88. Analysis of microtubule-associated protein tau GLYCATION in paired helical filaments.
  89. Role of protein-bound carbonyl groups in the formation of advanced GLYCATION endproducts
  90. Immunochemical evidence for the presence of advanced GLYCATION end products in human lens proteins and its positive correlation with aging.
  91. Role of advanced GLYCATION end-products (AGE) in late diabetic complications
  92. GLYCATION and Glycoxidation of Histones by ADP-ribose (∗)
  93. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental GLYCATION model of diabetes …
  94. The receptor for advanced GLYCATION end-products has a central role in mediating the effects of advanced GLYCATION end-products on the development of vascular …
  95. Advanced GLYCATION end products in neurodegeneration: more than early markers of oxidative stress?
  96. GLYCATION, oxidation, and lipoxidation in the development of diabetic complications
  97. GLYCATION of skin collagen in type I diabetes mellitus: correlation with long-term complications
  98. Nonenzymatic GLYCATION of type I collagen. The effects of aging on preferential GLYCATION sites.
  99. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by GLYCATION reaction. Implication of reactive oxygen species.
  100. Immunohistochemical and ultrastructural detection of advanced GLYCATION end products in atherosclerotic lesions of human aorta with a novel specific monoclonal …
  101. Long-term fructose consumption accelerates GLYCATION and several age-related variables in male rats
  102. Molecular identity and cellular distribution of advanced GLYCATION endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
  103. Advanced GLYCATION end products induce crosslinking of collagen in vitro
  104. Decrease in skin collagen GLYCATION with improved glycemic control in patients with insulin-dependent diabetes mellitus.
  105. Increased levels of advanced GLYCATION endproducts in the lenses and blood vessels of cigarette smokers
  106. GLYCATION products in aged thioglycollate medium enhance the elicitation of peritoneal macrophages
  107. Localization in human diabetic peripheral nerve of Nɛ-carboxymethyllysine-protein adducts, an advanced GLYCATION endproduct
  108. A microassay for protein GLYCATION based on the periodate method
  109. Advanced GLYCATION end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.
  110. Nonenzymatic GLYCATION of type IV collagen and matrix metalloproteinase susceptibility
  111. GLYCATION, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis
  112. Prevention of cardiovascular and renal pathology of aging by the advanced GLYCATION inhibitor aminoguanidine
  113. Increased pentosidine, an advanced GLYCATION end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory …
  114. Role of GLYCATION in modification of lens crystallins in diabetic and nondiabetic senile cataracts
  115. Advanced GLYCATION end-products in diabetic nephropathy
  116. Advanced GLYCATION end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS
  117. Specific GLYCATION of albumin depends on its half-life
  118. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced GLYCATION end-products: comparison with aminoguanidine
  119. The effects of ageing on GLYCATION and the interpretation of glycaemic control in Type 2 diabetes
  120. Nonenzymatic GLYCATION of collagen in aging and diabetes
  121. Chromatographic evidence for pyrraline formation during protein GLYCATION in vitro and in vivo
  122. Influence of advanced GLYCATION end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide
  123. Standardizing the immunological measurement of advanced GLYCATION endproducts using normal human serum
  124. Significance of fructose-induced protein oxidation and formation of advanced GLYCATION end product
  125. Production and characterization of antibodies to advanced GLYCATION products on proteins
  126. Involvement of GLYCATION and oxidative stress in diabetic macroangiopathy
  127. Nonenzymatic GLYCATION: a central mechanism in diabetic microvasculopathy?
  128. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the GLYCATION reaction
  129. Hyperglycemia in hummingbirds and its consequences for hemoglobin GLYCATION
  130. Advanced GLYCATION End Product (AGE)–mediated induction of tissue factor in cultured endothelial cells Is dependent on RAGE
  131. GLYCATION of proteins by ADP-ribose
  132. Protein GLYCATION Inhibitors from Thyme (Thymus vulgaris)
  133. GLYCATION of monoclonal antibodies impairs their ability to bind antigen
  134. Receptor for advanced GLYCATION end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
  135. Advanced GLYCATION end products induce expression of vascular endothelial growth factor by retinal Müller cells
  136. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced GLYCATION end products.
  137. Advanced GLYCATION end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
  138. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced GLYCATION end-product formation
  139. Advanced GLYCATION endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
  140. The Receptor for Advanced GLYCATION End Products (RAGE) Is a Cellular Binding Site for Amphoterin: MEDIATION OF NEURITE OUTGROWTH AND CO …
  141. Factors in human serum interfere with the measurement of advanced GLYCATION endproducts.
  142. Changes in biomechanical properties, composition of collagen and elastin, and advanced GLYCATION endproducts of the rat aorta in relation to age
  143. Cross-linking and fluorescence changes of collagen by GLYCATION and oxidation
  144. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced GLYCATION end product: carbonyl stress in uremia.
  145. Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein GLYCATION in NIDDM
  146. Non-enzymatic GLYCATION of peripheral nerve proteins in human diabetics
  147. Effects of advanced GLYCATION end-products on the proliferation and differentiation of osteoblast-like cells
  148. Possible involvement of advanced GLYCATION end-products in bone resorption
  149. Immunohistochemical localization of different epitopes of advanced GLYCATION end products in human atherosclerotic lesions
  150. Activation of the receptor for advanced GLYCATION end products triggers a p21 ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress
  151. GLYCATION of rat sciatic nerve tubulin in experimental diabetes mellitus
  152. The serum concentration of the advanced GLYCATION end-product Nε-(carboxymethyl) lysine is increased in uremia
  153. Enhanced interaction of advanced GLYCATION end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in …
  154. Autoxidative glycosylation: free radicals and GLYCATION theory.
  155. Role of the Maillard reaction in aging of tissue proteins: advanced GLYCATION end product-dependent increase in imidazolium cross-links in human lens proteins
  156. Protein GLYCATION by ADP-ribose: studies of model conjugates
  157. Non-enzymic GLYCATION of human extracellular superoxide dismutase
  158. In vitro formation of advanced GLYCATION end products in peritoneal dialysis fluid
  159. Advanced GLYCATION endproducts—associated parameters in the peripheral blood of patients with Alzheimer’s disease
  160. Advanced GLYCATION end products in diabetic complications
  161. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced GLYCATION end products blocks hyperpermeability in diabetic …
  162. The relative UV sensitizer activity of purified advanced GLYCATION endproducts
  163. Nε-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced GLYCATION End Products of the Maillard Reaction
  164. Advanced GLYCATION endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human …
  165. Recombinant advanced GLYCATION end product receptor pharmacokinetics in normal and diabetic rats
  166. … characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced GLYCATION endproduct-modified serum …
  167. Decreased platelet membrane fluidity due to GLYCATION or acetylation of membrane proteins
  168. Identification of polymorphisms in the receptor for advanced GLYCATION end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups.
  169. Free radicals generated during the GLYCATION reaction of amino acids by methylglyoxal: a model study of protein-cross-linked free radicals
  170. The role of GLYCATION in aging and diabetes mellitus
  171. Advanced GLYCATION end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine …
  172. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced GLYCATION endproduct formation and prevents hyperglycemia-induced …
  173. Immunohistochemical localisation of advanced GLYCATION end products in pulmonary fibrosis.
  174. Nonenzymatic GLYCATION of bovine serum albumin by fructose (fructation): comparison with the Maillard reaction initiated by glucose
  175. α-Lipoate can protect against GLYCATION of serum albumin, but not low-density lipoprotein
  176. Oxidative alterations in the experimental GLYCATION model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed …
  177. Accumulation of advanced GLYCATION end products of the Maillard reaction with age in human hippocampal neurons
  178. The relative roles of advanced GLYCATION, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley …
  179. Advanced GLYCATION end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the …
  180. GLYCATION of insulin results in reduced biological activity in mice
  181. The generation of superoxide anions in GLYCATION reactions with sugars, osones, and 3-deoxyosones
  182. Cytotoxic effects of autoxidative GLYCATION
  183. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced GLYCATION end products of the Maillard reaction
  184. Amyloid-β peptide–Receptor for Advanced GLYCATION Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory …
  185. Sites of GLYCATION of human and horse liver alcohol dehydrogenase in vivo.
  186. Protein GLYCATION: measurement and clinical relevance
  187. Kinetic analysis of GLYCATION as a tool for assessing the half-life of proteins
  188. Advanced GLYCATION end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells
  189. Influence of GLYCATION on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells
  190. Characterization of in vitro GLYCATION sites of tau
  191. Non-enzymatic GLYCATION of apolipoprotein B in the sera of diabetic and non-diabetic subjects
  192. Histones from diabetic rats contain increased levels of advanced GLYCATION end products
  193. The contribution of GLYCATION to cataract formation in diabetes.
  194. Immunochemical detection of advanced GLYCATION end products in lens crystallins from streptozocin-induced diabetic rat
  195. Role of polyol pathway in nonenzymatic GLYCATION
  196. Increased Aggregation of Human Platelets Produced by Advanced GLYCATION End Productsin Vitro
  197. DNA-GLYCATION leads to depurination by the loss of N2-carboxyethylguanine in vitro.
  198. Immunohistochemical localization of advanced GLYCATION end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer’s disease and aged …
  199. Neurotoxicity of advanced GLYCATION endproducts during focal stroke and neuroprotective effects of aminoguanidine.
  200. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced GLYCATION–modified proteins to a conserved motif
  201. Nonenzymatic GLYCATION alters protein structure and stability. A study of two eye lens crystallins.
  202. Non-enzymic GLYCATION of fibrous collagen: reaction products of glucose and ribose
  203. Advanced GLYCATION end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with …
  204. DNA cleavage induced by GLYCATION of Cu, Zn-superoxide dismutase
  205. … in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic GLYCATION affects biomechanical properties …
  206. Advanced GLYCATION endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1
  207. Identification of pentosidine as a native structure for advanced GLYCATION end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related …
  208. GLYCATION, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells
  209. Mutual interaction between GLYCATION and oxidation during non-enzymatic protein modification
  210. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced GLYCATION end products via a receptor-mediated mechanism
  211. Modification of vitronectin by advanced GLYCATION alters functional properties in vitro and in the diabetic retina.
  212. ADP-ribose in GLYCATION and glycoxidation reactions
  213. GLYCATION and microglial reaction in lesions of Alzheimer’s disease
  214. Progressive changes in lens crystallin GLYCATION and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats
  215. The receptor for advanced GLYCATION end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via …
  216. Advanced GLYCATION endproducts and diabetic nephropathy
  217. Site specificity of protein GLYCATION
  218. The advanced GLYCATION endproduct pentosidine and monocyte activation in uremia.
  219. Advanced GLYCATION end products and their recognition by macrophage and macrophage-derived cells
  220. Toxic action of advanced GLYCATION end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy
  221. GLYCATION of crystalline in lenses from aging and diabetic individuals
  222. Increased serum levels of advanced GLYCATION end products (AGEs) in children and adolescents with IDDM
  223. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced GLYCATION and diabetic complications
  224. Roles of advanced GLYCATION end-products in the progression of diabetic nephropathy
  225. The advanced GLYCATION end product Nepsilon-(carboxymethyl) lysine is increased in serum from children and adolescents with type 1 diabetes.
  226. Type II alveolar epithelial cells in lung express receptor for advanced GLYCATION end products (RAGE) gene
  227. Deposition of advanced GLYCATION end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
  228. Relative contributions of advanced GLYCATION and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats
  229. GLYCATION of insulin in the islets of Langerhans of normal and diabetic animals
  230. Advanced nonenzymatic GLYCATION endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications.
  231. GLYCATION changes the charge distribution of type I collagen fibrils
  232. Age-related increase in an advanced GLYCATION end product in penile tissue
  233. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced GLYCATION end products
  234. GLYCATION of brain actin in experimental diabetes
  235. Enhanced binding of advanced GLYCATION endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer’s disease
  236. Advanced GLYCATION endproducts are associated with Hirano bodies in Alzheimer’s disease
  237. GLYCATION accelerates the oxidation of low density lipoprotein by copper ions
  238. Relationships between GLYCATION and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study.
  239. β2-Microglobulin modified with advanced GLYCATION end products modulates collagen synthesis by human fibroblasts
  240. Nonenzymatic GLYCATION of peripheral and central nervous system proteins in experimental diabetes mellitus
  241. A preliminary note on inhibiting effect of alpha-tocopherol (vit. E) on protein GLYCATION.
  242. Acid-stable fluorescent advanced GLYCATION end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or …
  243. … of methylglyoxal-modified serum albumin. Competition with advanced GLYCATION end product-modified serum albumin at the advanced GLYCATION end product receptor.
  244. GLYCATION increases the permeability of proteins across the blood-nerve and blood-brain barriers
  245. Immunochemical detection of advanced GLYCATION end products in renal cortex from STZ-induced diabetic rat
  246. Advanced GLYCATION end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain
  247. Site specificity of GLYCATION of horse liver alcohol dehydrogenase in vitro
  248. The influence of advanced GLYCATION endproducts (AGE) on the expression of human endothelial adhesion molecules
  249. Prevention of lens protein GLYCATION by taurine
  250. Inhibition of GLYCATION of albumin and hemoglobin by acetylation in vitro and in vivo
  251. Kinetics of nonenzymatic GLYCATION of ribonuclease A leading to advanced GLYCATION end products. Paradoxical inhibition by ribose leads to facile isolation of protein …
  252. Cellular contraction of collagen lattices is inhibited by nonenzymatic GLYCATION
  253. Nonenzymatic GLYCATION of human lens crystallin. Effect of aging and diabetes mellitus.
  254. Comparison of advanced GLYCATION endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control
  255. Lens protein composition, GLYCATION and high molecular weight aggregation in aging rats.
  256. Effects of metformin on collagen GLYCATION and diastolic dysfunction in diabetic myocardium
  257. The endothelial cell binding site for advanced GLYCATION end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide
  258. Thiamine corrects delayed replication and decreases production of lactate and advanced GLYCATION end-products in bovine retinal and human umbilical vein …
  259. Are advanced GLYCATION end-products associated with amyloidosis in Alzheimer’s disease?
  260. Evidence for an increased GLYCATION of IgG in diabetic patients
  261. GLYCATION of very low density lipoprotein from rat plasma impairs its catabolism
  262. In vivo GLYCATION of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of GLYCATION sites
  263. The receptor for advanced GLYCATION end products mediates the chemotaxis of rabbit smooth muscle cells
  264. Atherosclerosis and GLYCATION
  265. Inhibitory effect of metformin on formation of advanced GLYCATION end products
  266. Advanced GLYCATION of rat liver histone octamers: an in vitro study
  267. The role of metal-catalyzed oxidation in the formation of advanced GLYCATION end products: an in vitro study on collagen
  268. Characterization of insulin GLYCATION in insulin-secreting cells maintained in tissue culture
  269. Glutathione inhibits the GLYCATION and crosslinking of lens proteins by ascorbic acid
  270. GLYCATION of human serum albumin: inhibition by Diclofenac
  271. GLYCATION of lens proteins by the oxidation products of ascorbic acid
  272. Immunohistochemical detection of advanced GLYCATION end products in dialysis-related amyloidosis
  273. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced GLYCATION endproducts in lesions, and extent of atherosclerosis in LDL receptor …
  274. Effect of alpha-tocopherol on LDL oxidation and GLYCATION: in vitro and in vivo studies
  275. Advanced GLYCATION endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis
  276. Decrease in GLYCATION of lens proteins by lysine and glycine by scavenging of glucose and possible mitigation of cataractogenesis
  277. The site of nonenzymic GLYCATION of human extracellular-superoxide dismutase in vitro
  278. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced GLYCATION end products in human tissues.
  279. Structural and functional changes of laminin and type IV collagen after nonenzymatic GLYCATION
  280. Advanced GLYCATION end products (AGE)-modified proteins and their potential relevance to atherosclerosis
  281. Plasma protein GLYCATION as measured by fructosamine assay.
  282. Immunohistochemical study of advanced GLYCATION end products in aging and Alzheimer’s disease brain
  283. Pathophysiology of advanced GLYCATION end-products in renal failure
  284. Advanced GLYCATION endproducts–receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B
  285. Inhibition of lens crystallin GLYCATION and high molecular weight aggregate formation by aspirin in vitro and in vivo.
  286. Oxidative stress caused by GLYCATION of Cu, Zn-superoxide dismutase and its effects on intracellular components
  287. Advanced GLYCATION end product (AGE): Characterization of the products from the reaction between D‐glucose and serum albumin
  288. Hb himeji or β140 (H18) ALA→ ASP a slightly unstable hemoglobin with increased βN-terminal GLYCATION
  289. Age-dependent accumulation of advanced GLYCATION end-products in adult Drosophila melanogaster
  290. Characterization of the non enzymatic GLYCATION of high density lipoprotein in diabetic patients.
  291. The advanced GLYCATION endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells
  292. Interaction between β2-microglobulin and advanced GLYCATION end products in the development of dialysis related-amyloidosis
  293. Fragmentation of ceruloplasmin following non-enzymatic GLYCATION reaction
  294. CARNOSINE PROTECTS PROTEINS AGAINST IN VITRO GLYCATION AND CROSS–LINKING
  295. Non-enzymic glycosylation (GLYCATION) of lens proteins by galactose and protection by aspirin and reduced glutathione
  296. Role of advanced GLYCATION end products in aging collagen
  297. The role of oxidative stress in the long‐term GLYCATION of LDL
  298. Imidazolone, a novel advanced GLYCATION end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes
  299. Plasma protein GLYCATION in Alzheimer’s disease
  300. Influence of age and long-term dietary restriction on enzymatically mediated crosslinks and nonenzymatic GLYCATION of collagen in mice
  301. Localization of advanced GLYCATION endproducts in the kidney of experimental diabetic rats
  302. Nonenzymatic GLYCATION of immunoglobulins leads to an impairment of immunoreactivity
  303. Depletion of reactive advanced GLYCATION endproducts from diabetic uremic sera using a lysozyme-linked matrix.
  304. GLYCATION of cataractous lens in non-diabetic senile subjects and in diabetic patients.
  305. Non enzymatic GLYCATION of apolipoprotein AI. Effects on its self-association and lipid binding properties
  306. Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic GLYCATION and the inhibitory agent aminoguanidine
  307. The relationship of glycaemic level to advanced GLYCATION end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
  308. Isolation and characterization of advanced GLYCATION end products derived from the in vitro reaction of ribose and collagen
  309. GLYCATION of albumin: reaction with glucose, fructose, galactose, ribose or glyceraldehyde measured using four methods
  310. A fluorescamine-based assay for the degree of GLYCATION in bovine serum albumin
  311. Effect of GLYCATION on the properties of lipoprotein (a)
  312. Aminoguanidine and its pro-oxidant effects on an experimental model of protein GLYCATION
  313. … -alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein GLYCATION in patients with …
  314. Generation of active oxygen species from advanced GLYCATION end-products (AGE) under ultraviolet light A (UVA) irradiation
  315. The relative extent of GLYCATION of haemoglobin and albumin
  316. Monocyte/macrophage response to β2-microglobulin modified with advanced GLYCATION end products
  317. Aminoguanidine inhibits advanced GLYCATION end products formation on beta2-microglobulin.
  318. Evaluation of the fructosamine test for the measurement of plasma protein GLYCATION
  319. D-lysine effectively decreases the non-enzymic GLYCATION of proteins in vitro.
  320. Inhibition of matrix-induced bone differentiation by advanced GLYCATION end-products in rats
  321. Effect of Matrix GLYCATION on Expression of Type IV Collagen, MMP-2, MMP-9 and TIMP-1 by Human
  322. DNA damage by the GLYCATION products of glyceraldehyde 3-phosphate and lysine
  323. GLYCATION mediated lens crystallin aggregation and cross-linking by various sugars and sugar phosphates in vitro
  324. Accelerated formation of Nϵ-(carboxymethyl) lysine, an advanced GLYCATION end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons
  325. Localization of identified advanced GLYCATION end‐product structures, Nε=(carboxymethyl) lysine and pentosidine, in age‐related inclusions in human brains
  326. Effect of advanced GLYCATION end product–modified albumin on tissue factor expression by monocytes: role of oxidant stress and protein tyrosine kinase activation
  327. Membrane fluidity is related to the extent of GLYCATION of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes …
  328. Advanced GLYCATION endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells
  329. Role of GLYCATION in human lens protein structure change
  330. The effectiveness of putative anti-cataract agents in the prevention of protein GLYCATION.
  331. Good glycaemic control reduces oxidation and GLYCATION end-products in collagen of diabetic rats
  332. Human erythrocyte bisphosphoglycerate mutase: inactivation by GLYCATION in vivo and in vitro
  333. Association between the GLYCATION of erythrocyte membrane proteins and membrane fluidity
  334. Impairment by GLYCATION of immunoglobulin G Fc fragment function
  335. Induction of macrophage growth by advanced GLYCATION end products of the Maillard reaction.
  336. Decreased interaction of fibronectin, type iv collagen, and heparin due to nonenzymic GLYCATION. Implications for diabetes mellitus
  337. GLYCATION: a pathological modification in neuropathies?: a hypothesis.
  338. The effects of aminoguanidine on the GLYCATION (non-enzymic glycosylation) of lens proteins
  339. Nonenzymatic GLYCATION of transferrin: decrease of iron-binding capacity and increase of oxygen radical production
  340. Modification of β2m with advanced GLYCATION end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum
  341. Non‐enzymatic GLYCATION of histones
  342. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced GLYCATION end products
  343. beta 2-Microglobulin modified with advanced GLYCATION end products is a major component of hemodialysis-associated amyloidosis.
  344. Nonenzymatic GLYCATION and extractability of collagen in human atherosclerotic plaques
  345. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to GLYCATION
  346. The erythrocyte calcium pump is inhibited by non-enzymic GLYCATION: studies in situ and with the purified enzyme
  347. Tetracyclines inhibit protein GLYCATION in experimental diabetes
  348. Identification of the site of non-enzymatic GLYCATION of glutathione peroxidase: rationalization of the GLYCATION-related catalytic alterations on the basis of three …
  349. Identification of galectin-3 as a high-affinity binding protein for advanced GLYCATION end products (AGE): a new member of the AGE-receptor complex
  350. GLYCATION of human lens proteins from diabetic and (nondiabetic) senile cataract patients
  351. GLYCATION and inactivation of sorbitol dehydrogenase in normal and diabetic rats
  352. Circulating advanced GLYCATION peptides in streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light chains
  353. Changes in solubility, non-enzymatic GLYCATION, and fluorescence of collagen in tail tendons from diabetic rats
  354. Advanced GLYCATION end products modulate transcriptional regulation in mesangial cells
  355. Increased serum levels of advanced GLYCATION end products in NIDDM patients with diabetic complications
  356. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced GLYCATION end products (AGEs): amino acid oxidation products as a possible …
  357. Reaction of advanced GLYCATION endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold …
  358. Nonenzymatic GLYCATION of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus
  359. … of methylglyoxal, glyoxalase I inhibitor diesters and SD-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced GLYCATION …
  360. Possible significance of advanced GLYCATION end products in serum in end-stage renal disease and in late complications of diabetes
  361. Molecular chaperones protect against GLYCATION‐induced inactivation of glucose‐6‐phosphate dehydrogenase
  362. Association of elastin GLYCATION and calcium deposit in diabetic rat aorta
  363. Nonenzymatic GLYCATION of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge
  364. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced GLYCATION end product, in uremia
  365. Accumulation of advanced GLYCATION endproducts in the rat nephron: link with circulating AGEs during aging
  366. Immunohistochemical study of human advanced GLYCATION end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with …
  367. Advanced GLYCATION end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients
  368. Distribution of advanced GLYCATION end products in the cerebellar neurons of dogs
  369. Specific detections of the early process of the GLYCATION reaction by fructose and glucose in diabetic rat lens
  370. Growth modulation of retinal microvascular cells by early and advanced GLYCATION products
  371. Amyloidosis, advanced GLYCATION end products and Alzheimer disease
  372. Flavonoid treatment reduces GLYCATION and lipid peroxidation in experimental diabetic rats
  373. A study on in vitro GLYCATION processes by matrix-assisted laser desorption ionization mass spectrometry
  374. Effect of extracellular matrix GLYCATION on endothelial cell adhesion and spreading: involvement of vitronectin
  375. Spectroscopic study on the effects of nonenzymatic GLYCATION in human alpha-crystallin.
  376. GLYCATION ligand binding motif in lactoferrin
  377. … isomerization (Amadori rearrangement) potential at the individual nonenzymic GLYCATION sites of hemoglobin A: preferential inhibition of GLYCATION by nucleophiles at …
  378. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced GLYCATION end products (AGEs)
  379. Ascorbic acid GLYCATION: the reactions of L-threose in lens tissue
  380. Evaluation of IgG GLYCATION levels by matrix‐assisted laser desorption/ionization mass spectrometry
  381. Identification of Deoxy-D-Fructosyl Phosphatidylethanolamine as a Non-enzymic GLYCATION Product of Phosphatidylethanolamine and its Occurrence in Human Blood …
  382. Tau GLYCATION is involved in aggregation of the protein but not in the formation of filaments.
  383. GLYCATION of albumin, not glomerular basement membrane, alters permeability in an in vitro model
  384. Immunochemical quantification of crossline as a fluorescent advanced GLYCATION endproduct in erythrocyte membrane proteins from diabetic patients with or without …
  385. Temporal association between lens protein GLYCATION and cataract development in diabetic rats
  386. Fluorescence and immunochemical studies of advanced GLYCATION-related lens pigments.
  387. β2-Microglobulin modified with advanced GLYCATION end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis …
  388. Differential GLYCATION of rat α-, β-and γ-crystallins
  389. Receptors for advanced GLYCATION end-products (AGE)—expression by endothelial cells in non-diabetic uraemic patients
  390. Monitoring the progress of non‐enzymatic GLYCATION in vitro
  391. GLYCATION of human lens proteins: preferential GLYCATION of αA subunits
  392. Free alanine, aspartic acid, or glutamic acid reduce the GLYCATION of human lens proteins
  393. In vitro non-enzymatic GLYCATION and formation of browning products in the bovine lens α-crystallin
  394. Nonenzymatic GLYCATION of human platelet membrane proteins in vitro and in vivo.
  395. Amyloid β2-microglobulin is modified with imidazolone, a novel advanced GLYCATION end product, in dialysis-related amyloidosis
  396. Role of Albumin GLYCATION on the Erythrocyte Aggregation: An In Vitro Study
  397. Site-specific GLYCATION of lens crystallins by ascorbic acid
  398. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced GLYCATION end products
  399. Protein GLYCATION and fluorescent material in human atheroma
  400. Reduction of plasma apolipoprotein-B by effective removal of circulating GLYCATION derivatives in uremia
  401. Identification of advanced GLYCATION end products of the Maillard reaction in Pick’s disease
  402. D-Lysine reduces the non-enzymatic GLYCATION of proteins in experimental diabetes mellitus in rats
  403. GLYCATION of calmodulin: chemistry and structural and functional consequences
  404. Protein GLYCATION in the aging male Sprague-Dawley rat: effects of antiaging diet restrictions
  405. Involvement of beta 2-microglobulin modified with advanced GLYCATION end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human …
  406. Nonenzymatic glycosylation (GLYCATION) of lens crystallins in diabetes and aging.
  407. Nonenzymatic GLYCATION of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells
  408. GLYCATION of Human. beta. 2-Microglobulin in Patients with Hemodialysis-Associated Amyloidosis: Identification of the Glycated Sites
  409. Immunochemical evidence for increased formation of advanced GLYCATION end products and inhibition by aminoguanidine in diabetic rat lenses
  410. Amadori rearrangement potential of hemoglobin at its GLYCATION sites is dependent on the three-dimensional structure of protein
  411. The effect of δ-gluconolactone, an oxidised analogue of glucose, on the nonenzymatic GLYCATION of human and rat haemoglobin
  412. 3-Deoxyglucosone, a promoter of advanced GLYCATION end products in fluids for peritoneal dialysis
  413. A highly specific method for the characterization of GLYCATION and glyco‐oxidation products of globins
  414. The In Vitro GLYCATION of Lysozyme and the Influence of Buffer Concentration Investigated by Mass Spectrometry
  415. Biochemical alterations in collagen IV induced by in vitro GLYCATION
  416. GLYCATION and autoxidation of proteins in aging and diabetes
  417. Role of reactive oxygen species in the generation of fluorescence by GLYCATION
  418. GLYCATION of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus
  419. Potential benefit of inhibitors of advanced GLYCATION end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice
  420. Inhibition of advanced protein GLYCATION by 8-quinolinecarboxylic hydrazide
  421. GLYCATION increases the vascular clearance rate of IgG in mice
  422. GLYCATION-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, α-crystallin
  423. On glucose transport and non-enzymic GLYCATION of proteins in vivo
  424. Effect of nonenzymatic GLYCATION on the structure of immunoglobulin G
  425. Effects of matrix GLYCATION on mesangial cell adhesion, spreading and proliferation
  426. GLYCATION of lens membrane intrinsic proteins
  427. Differential expression of receptors for advanced GLYCATION end products on monocytes in patients with IDDM
  428. Nonenzymatic GLYCATION of cartilage proteoglycans: an in vivo and in vitro study
  429. The role of oxidation and GLYCATION in the pathogenesis of diabetic atherosclerosis
  430. Fructose-related GLYCATION
  431. Advanced GLYCATION end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats
  432. Sites of GLYCATION of βB2-crystallin by glucose and fructose
  433. Advanced GLYCATION end products of the Maillard reaction and their relation to aging
  434. Acceleration of fructose mediated collagen GLYCATION
  435. Advanced GLYCATION modification of Rosenthal fibers in patients with Alexander disease
  436. In vitro GLYCATION of glomerular basement membrane alters its permeability: a possible mechanism in diabetic complications
  437. Effect of GLYCATION of albumin on its renal clearance in normal and diabetic rats
  438. Alterations of biochemical and biomechanical properties of rat tail tendons caused by non-enzymatic GLYCATION and their inhibition by dibasic amino acids arginine and …
  439. Expression of receptors for advanced GLYCATION end-products in occlusive vascular and renal disease
  440. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and “in vitro” GLYCATION of lipoproteins enhance the transfer rate of cholesteryl ester from HDL …
  441. Glyburide protein binding and the effect of albumin GLYCATION in children, young adults, and older adults with diabetes
  442. Formation of advanced GLYCATION end (AGE) products in diabetes: Prevention by pyruvate and a-keto glutarate
  443. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced GLYCATION endproducts in bovine endothelial cells.
  444. Nonenzymatic GLYCATION* of Basement Membranes From Human Glomeruli and Bovine Sources: Effect of Diabetes and Age
  445. GLYCATION of proteinous inhibitors: Loss in trypsin inhibitory activity by the blocking of arginine and lysine residues at their reactive sites
  446. Advanced GLYCATION endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA).
  447. Evidence for a relationship between protein GLYCATION and red blood cell membrane fluidity
  448. Advanced GLYCATION end products in peritoneal dialysis
  449. Ribozyme targeting of receptor for advanced GLYCATION end products in mouse mesangial cells
  450. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced GLYCATION
  451. A study of the age-related acceleration of GLYCATION of tissue proteins in rats
  452. Some physico‐chemical properties and structural changes of bovine β‐casein upon GLYCATION
  453. GLYCATION index of hair for non-invasive estimation of diabetic control
  454. Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: changes in carbohydrate metabolism, skin GLYCATION, and pancreatic islets
  455. Non-enzymatic GLYCATION reduces heparin cofactor II anti-thrombin activity
  456. Non-enzymatic GLYCATION of lipoprotein (a) in vitro and in vivo
  457. Post-translational non-enzymatic modification of proteins II. Separation of selected protein species after GLYCATION and other carbonyl-mediated modifications
  458. Inhibitory effect of nonenzymatic GLYCATION on ubiquitination and ubiquitin-mediated degradation of lysozyme
  459. Ascorbic acid GLYCATION of lens proteins produces UVA sensitizers similar to those in human lens
  460. Nonenzymatic GLYCATION of Na, K-ATPase. Effects on ATP hydrolysis and K+ occlusion.
  461. GLYCATION of myofibrillar protein in aged rats and mice
  462. Ageing promotes the increase of early GLYCATION Amadori product as assessed by ϵ-N-(2-furoylmethyl)-l-lysine (furosine) levels in rodent skin collagen: The …
  463. GLYCATION and inactivation of aspartate aminotransferase in diabetic rat tissues
  464. Amino terminal GLYCATION of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells
  465. GLYCATION of glucagon-like peptide-1 (7–36) amide: characterization and impaired action on rat insulin secreting cells
  466. The principal site of GLYCATION of human complement factor B
  467. Computer models of albumin and haemoglobin GLYCATION
  468. Interactions between the sorbitol pathway, non-enzymatic GLYCATION, and diabetic vascular dysfunction
  469. Angiogenic effects of advanced GLYCATION end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells
  470. Nonenzymatic GLYCATION of human blood platelet proteins
  471. GLYCATION of albumin with aging and diabetes in rats: changes in its renal handling
  472. Increased GLYCATION of plasma lipoproteins in diabetic cynomolgus monkeys.
  473. Nonenzymic GLYCATION of human immunoglobulins does not impair their immunoreactivity.
  474. GLYCATION of the human erythrocyte glucose transporter in vitro and its functional consequences
  475. Age-and diabetes-accelerated GLYCATION in the human aorta
  476. Purification of α-ketoaldehyde dehydrogenase from the human liver and its possible significance in the control of GLYCATION
  477. Aging of the vitreous body. Role of GLYCATION and free radicals
  478. Non-enzymatic GLYCATION of epidermal proteins of the stratum corneum in diabetic patients
  479. Non-enzymatic GLYCATION and altered renal structure and function in the diabetic rat
  480. Primary Sequence and GLYCATION at Lysine‐548 of Bovine Serum Albumin
  481. Age-related acceleration of GLYCATION of tissue proteins in rats
  482. Change in the functional properties of actin by its GLYCATION in vitro.
  483. Site selectivity in the GLYCATION of αA-crystallin and αB-Crystallins by glucose
  484. Fructose-induced fluorescence generation of reductively methylated glycated bovine serum albumin: evidence for nonenzymatic GLYCATION of Amadori adducts
  485. Identification of GLYCATION at the N-terminus of albumin by gas chromatography-mass spectrometry
  486. Hyperglycemia and non-enzymatic GLYCATION of serum and tissue proteins in chickens
  487. The influence of GLYCATION on the peroxidase activity of haemoglobin
  488. GLYCATION of erythrocyte superoxide dismutase reduces its activity
  489. Determination of GLYCATION crosslinking by the sugar-dependent incorporation of [14C] lysine into protein
  490. Non-enzymatic GLYCATION of phosphoglucoisomerase.
  491. Impaired agglutination of IgM resulting from non-enzymatic GLYCATION in diabetes mellitus
  492. The GLYCATION hypothesis of atherosclerosis
  493. Improvement of physicochemical and enzymatic properties of bovine trypsin by non-enzymatic GLYCATION
  494. Non-enzymatic GLYCATION of elastin
  495. In vivo GLYCATION of bovine lens crystallins
  496. The pyridoindole antioxidant stobadine inhibited GLYCATION-induced absorbance and fluorescence changes in albumin
  497. … may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic GLYCATION.
  498. Peripheral nerve protein GLYCATION and muscle fructolysis: evidence of abnormal carbohydrate metabolism in ALS.
  499. Nonenzymatic GLYCATION alters properties of collagen as a substratum for cells
  500. Free lysine, glycine, alanine, glutamic acid and aspartic acid reduce the GLYCATION of human lens proteins by galactose.
  501. In vitro studies of histone GLYCATION
  502. Post-translational non-enzymatic modification of proteins I. Chromatography of marker adducts with special emphasis to GLYCATION reactions
  503. Crystallin composition of human cataractous lens may be modulated by protein GLYCATION
  504. NA+/K+ ATPase Impairment and Experimental GLYCATION: The Role of Glucose Autoxidation
  505. Contribution of GLYCATION to human lens coloration
  506. ADVANCED GLYCATION TOXICITY AND DIABETIC COM PLI CATIONS
  507. Protein GLYCATION and in vivo distribution of human lens fluorescence
  508. GLYCATION of platelet protein in diabetes mellitus: lack of correlation with platelet function
  509. GLYCATION of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy
  510. Polyclonal immunoglobulin M: location of GLYCATION sites
  511. Pathobiology of the heart in experimental diabetes: immunolocalization of lipoproteins, immunoglobulin G, and advanced GLYCATION endproducts proteins in diabetic …
  512. … of a serine protease in erythrocyte cytosol that is adherent to oxidized membranes and preferentially degrades proteins modified by oxidation and GLYCATION
  513. IgG GLYCATION and function during continuous ambulatory peritoneal dialysis.
  514. The Role of α-and ε-Amino Groups in the GLYCATION-mediated Cross-linking of γB-crystallin: STUDY OF THREE SITE-DIRECTED MUTANTS
  515. Characterization of the GLYCATION of albumin in freeze-dried and frozen human serum
  516. Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced GLYCATION endproducts in the skin and peritoneum.
  517. L-Arginine inhibits in vitro nonenzymatic GLYCATION and advanced glycosylated end product formation of human serum albumin
  518. Matrix‐assisted laser desorption/ionization mass spectrometric studies on protein GLYCATION. 2. The reaction of ribonuclease with hexoses
  519. The effect of fructose on collagen GLYCATION.
  520. GLYCATION of lens MIP26 affects the permeability in reconstituted liposomes
  521. The in vivo GLYCATION of diabetic tendon collagen studied by neutron diffraction
  522. Increased GLYCATION and pigmentation of collagen in aged and young parabiotic rats and mice
  523. GLYCATION-induced crosslinking of calf lens crystallins
  524. Some factors that influence the nonenzymatic GLYCATION of peptides and polypeptides by glyceraldehyde
  525. In vitro GLYCATION of red blood cell proteins: high levels of glucose lower lipid fluidity of erythrocyte membranes
  526. Relationship between lens protein GLYCATION and membrane structure in human cataract
  527. Comparison of the effect of different inhibitors on the non-enzymatic GLYCATION of rat tail tendons and bovine serum albumin
  528. GLYCATION and diabetic complications
  529. Nonenzymatic GLYCATION of platelet proteins in diabetic patients
  530. Identification of the site of GLYCATION of γ-II-crystallin by (14C)-fructose
  531. Nonenzymic GLYCATION of apolipoprotein B in patients with insulin-and noninsulin-dependent diabetes mellitus
  532. Non-enzymatic GLYCATION and protein recognition.
  533. The GLYCATION-associated crosslinking of lens proteins by ascorbic acid is not mediated by oxygen free radicals
  534. Inhibition of protein non-enzymic GLYCATION induced by Bendazac.
  535. Defects of copper deficiency in rats are modified by dietary treatments that affect GLYCATION
  536. Diminished adhesion of endothelial aortic cells on fibronectin and collagen layers after nonenzymatic GLYCATION
  537. Nonenzymic GLYCATION of albumin by acyl glucuronides in vitro comparison of reactions with reducing sugars
  538. Importance of advanced GLYCATION end products–AGE products
  539. Identification of furoyl-containing advanced GLYCATION products in collagen samples from diabetic and healthy rats
  540. GLYCATION of human lens crystallins: effect of age and aspirin treatment
  541. The nonenzymatic GLYCATION of proteins and nucleic acids, their importance for the development of diabetic complications, possible molecular basis of aging and …
  542. Non-enzymatic GLYCATION of antithrombin III in vitro
  543. Nonenzymatic GLYCATION of immunoglobulins does not impair antigen-antibody binding.
  544. Lysine vasopressin undergoes rapid GLYCATION in the presence of reducing sugars
  545. Kinetics of the GLYCATION of bovine serum albumin by mannose and fucose in vitro
  546. Non-enzymatic GLYCATION of human albumin does not alter its palmitate binding
  547. The GLYCATION and cross-linking of isolated lens crystallins by ascorbic acid
  548. Reduced membrane fluidity and increased GLYCATION of membrane proteins of platelets from diabetic subjects are not associated with increased platelet adherence to …
  549. Impaired immunoglobulin G Fc fragment function in diabetics is caused by a mechanism different from GLYCATION
  550. GLYCATION and oxidation of human low density lipoproteins reduces heparin binding and modifies charge
  551. In vitro GLYCATION and acetylation (by aspirin) of rat crystallins
  552. Matrix‐assisted laser desorption/ionization capabilities in the study of non‐enzymatic protein GLYCATION
  553. Effects of aminoguanidine on serum advanced GLYCATION endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane …
  554. Bendazac decreases in vitro GLYCATION of human lens crystallins
  555. GLYCATION of human tissue and serum creatine kinase
  556. Nonenzymic GLYCATION of isolated human glomerular basement membrane changes its physicochemical characteristics and binding properties
  557. Inhibitory effects of some Chinese herbs on the non-enzymatic GLYCATION of proteins [J]
  558. GLYCATION decreases the stability of the triple-helical strands of fibrous collagen against proteolytic degradation by pepsin in a specific temperature range
  559. GLYCATION reaction of aspartate aminotransferase by various carbohydrates in an in vitro system
  560. Prevention and reversible solubilization of advanced GLYCATION and products (AGE) by organic germanium compounds as derivatives of amino acids
  561. GLYCATION of hemoglobin C in the heterozygous state in diabetic patients
  562. Improved metabolic control in patients with non‐insulin‐dependent diabetes mellitus is associated with a slower accumulation of GLYCATION products in collagen
  563. High galactose levels in vitro and in vivo impair ascorbate regeneration and increase ascorbate-mediated GLYCATION in cultured rat lens
  564. Determination of the non-enzymatic GLYCATION of hemoglobin by isoelectrofocusing of its globin chains
  565. Low GLYCATION level and browning in human cataracts
  566. Localization of advanced GLYCATION end products of Maillard reaction in bovine tissues and their endocytosis by macrophage scavenger receptors
  567. Advanced GLYCATION end products induce specific glycoprotein alterations in retinal microvascular cells
  568. Amyloid, advanced GLYCATION end products, and dialysis related arthropathy
  569. Role of Glycine 1 and Lysine 2 in the GLYCATION of Bovine γB-Crystallin: SITE-DIRECTED MUTAGENESIS OF LYSINE TO THREONINE (∗)
  570. Lens protein GLYCATION and the subsequent degree of opacity in streptozotocin-diabetic rats
  571. Protein GLYCATION: Effects upon protein recognition by the proximal tubule
  572. Variable GLYCATION of serum proteins in patients with diabetes mellitus
  573. Colorimetric assay of glycoprotein GLYCATION free of interference from glycosylation residues
  574. GLYCATION mediated crosslinking between α-crystallin and MP26 in intact lens membranes
  575. Advanced GLYCATION end-products reduce the viability of human peritoneal mesothelial cells
  576. The permselectivity of glomerular basement membrane can be compromised by GLYCATION or by exposure to low levels of hypochlorite
  577. Rapid assessment of early GLYCATION products by mass spectrometry
  578. Captopril inhibits the fluorescence development associated with GLYCATION of proteins.
  579. Advanced GLYCATION end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells
  580. Immunochemical detection of N2-[1-(1-carboxy) ethyl] guanosine, an advanced GLYCATION end product formed by the reaction of DNA and reducing sugars or L …
  581. Aging of aorta and atherosclerosis–role of nonenzymatic GLYCATION of collagen
  582. Plasma protein’s GLYCATION is decreased in Sprague Dawley rats under caloric restriction
  583. Retinol binding protein: a short half life determinant of protein non enzymatic GLYCATION in diabetes.
  584. Hepatic advanced GLYCATION endproduct binding is increased in experimental diabetes.
  585. Effects of GLYCATION process on the macromolecular structure of the glomerular basement membranes and on the glomerular functions in aging and diabetes mellitus
  586. Effect of creatine on GLYCATION of albumin in vitro
  587. Effect of alpha-glucosidase inhibition on the nonenzymatic GLYCATION of glomerular basement membrane.
  588. … by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced GLYCATION …
  589. … chromatofocusing and column affinity chromatography of in vitro14C-glycated human serum albumin: Demonstration of a GLYCATION-induced anionic heterogeneity
  590. Studies on advanced GLYCATION end products by recent mass spectrometric techniques
  591. Effect of GLYCATION on the heterogeneity of human serum albumin analysed by reversed-phase high-performance liquid chromatography in a solvent containing formic …
  592. Hair protein GLYCATION as a long-term index of blood glucose in diabetics
  593. Effects of advanced GLYCATION endproducts on the generation of macrophage-mediated oxidized low-density lipoprotein
  594. Susceptibility of Gamma‐Irradiated Proteins to In Vitro GLYCATION: Exposure to Oxygen Free Radicals Increases GLYCATION‐Induced Modifications
  595. Clinical application of hair protein GLYCATION in the assessment of blood glucose control and diabetic neuropathy.
  596. Comparison of normal and in vitro aging by non-enzymatic GLYCATION as verified by differential scanning calorimetry
  597. Effects of aminoguanidine and pyridoxal phosphate on GLYCATION reaction of aspartate aminotransferase and serum albumin
  598. Structural elucidation of a novel lysine-lysine crosslink generated in a GLYCATION reaction with L-threose
  599. … of synthesis and secretion of interleukin 1β in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced GLYCATION …
  600. Immunohistochemical study with anti‐advanced GLYCATION end‐products antibody in murine amyloidosis
  601. The lysine GLYCATION 1. A preliminary investigation on the products arising from the reaction of protected lysine and D-glucose
  602. GLYCATION of hepatocyte cytosolic proteins in streptozotocin-induced diabetic rats
  603. Advanced GLYCATION end products and β2-microglobulin. The story unfolds
  604. Quantitation of the GLYCATION intermediate 3-deoxyglucosone by oxidation with rabbit liver oxoaldehyde dehydrogenase to 2-keto-3-deoxygluconic acid followed by …
  605. Reduction of advanced GLYCATION end‐product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of …
  606. Polypeptide-polysaccharide conjugates produced by spontaneous non-enzymatic GLYCATION
  607. GLYCATION of fibrinogen in diabetic patients: a practical colorimetric assay
  608. The role of GLYCATION in cataract lens in diabetic patients
  609. GLYCATION of granulocyte and monocyte membrane proteins in diabetic patients
  610. Reactivity of 6-phosphogluconolactone with hydroxylamine: the possible involvement of glucose-6-phosphate dehydrogenase in endogenous GLYCATION reactions
  611. Effect of protein GLYCATION on subsequent volatile formation
  612. Calmodulin GLYCATION in diabetic rat lenses
  613. Spectrophotometric determination of browning products of GLYCATION of protein amino groups based on their reactivity with nitro blue tetrazolium salts
  614. Lens glutathione, lens protein GLYCATION and electrophoretic patterns of lens proteins in STZ induced diabetic rats
  615. GLYCATION of collagen in hypertriglyceridemic rats
  616. Evidence for GLYCATION of horse liver alcohol dehydrogenase in vivo
  617. Automated fructosamine assay with improved accuracy used to quantify nonenzymatic GLYCATION of serum proteins in diabetes mellitus and chronic renal failure
  618. Serum levels of 3-deoxyglucosone and tissue contents of advanced GLYCATION end products are increased in streptozotocin-induced diabetic rats with nephropathy
  619. Application of the Time-Resolved Immunofluorometric Assay to the Study of C3 Complement Component GLYCATION in vitro and in vivo
  620. … and HDL-cholesterol independent of fasting triglycerides in a Caucasian population: evidence for enhanced cholesterol ester transfer induced by in vivo GLYCATION
  621. The adverse effect of GLYCATION of human serum albumin on its preservative activity in the freeze-drying and accelerated degradation of alkaline phosphatase
  622. … staining of renal biopsy samples in patients with diabetic nephropathy in non‐insulin dependent diabetes mellitus using monoclonal antibody to advanced GLYCATION …
  623. The effect of non-enzymic GLYCATION on ligand binding to human serum albumin
  624. Parent ion spectroscopy in the identification of advanced GLYCATION products
  625. Protein GLYCATION: Its role in the changes induced by diabetes in the properties of the serum insulin-like growth factor-I binding proteins
  626. The effect of non-enzymatic GLYCATION of serum proteins on their permeation into peripheral nerve in normal and streptozotocin-diabetic rats
  627. Molecular characterization of a mouse genomic element mobilized by advanced GLYCATION endproduct modified-DNA (AGE-DNA)
  628. Crossline-like structure accumulates as fluorescent advanced GLYCATION end products in renal tissues of rats with diabetic nephropathy
  629. Nonenzymatic GLYCATION of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells
  630. Influence of GLYCATION on cis/trans isomerization and tautomerization in novel morphiceptin-related Amadori compounds
  631. Protection by acetylsalicylic acid against hyperglycemia-induced GLYCATION and neural tube defects in cultured early somite mouse embryos.
  632. Effect of GLYCATION upon activity of liver alcohol dehydrogenase
  633. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced GLYCATION end products in renal failure
  634. … monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced GLYCATION …
  635. GLYCATION of H1-histone
  636. Relationship between vascular endothelial growth factors and advanced GLYCATION end products in the human vitreous
  637. Kinetics of histone protein GLYCATION.
  638. GLYCATION of MP26 and MP22 in bovine lens membranes
  639. An Electrospray Investigation on in vitro GLYCATION of Ribonuclease
  640. Effect of GLYCATION of low-density lipoprotein on the immunological determination of apolipoprotein B.
  641. Non-enzymic GLYCATION of proteins: analysis of N-(1-deoxyhexitol-1-yl) amino acids by high-performance liquid chromatography
  642. GLYCATION in neuropathies
  643. GLYCATION of myofibrillar proteins and ATPase activity after incubation with eleven sugars
  644. Effect of GLYCATION of albumin on its binding to renal brush-border membrane vesicles: influence of aging in rats
  645. Decreased actin activated myosin ATPase activity by non-enzymatic GLYCATION
  646. Phosphate promotes GLYCATION of antithrombin III which interferes with heparin binding
  647. Scheimpflug densitometric analysis of cataracts in diabetic rats: correlation with GLYCATION
  648. 132 Total antioxidant status, protein GLYCATION, lipid hydroperoxides in non insulin dependent diabetes mellitus
  649. Immunochemical determination of advanced GLYCATION end products in erythrocyte peripheral-membrane proteins from diabetic patients
  650. … -6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid (‘pyrraline’) as an early-stage product or advanced GLYCATION end product in non-enzymic protein GLYCATION
  651. Specific non-enzymatic GLYCATION of the rat histone H1 nucleotide binding site in vitro in the presence of AlF4−. A putative mechanism for impaired chromatin function
  652. Mass spectrometry in the study of advanced GLYCATION processes, responsible for long‐term diabetes complications
  653. The role of bound lipid and transition metal in the formation of fluorescent advanced GLYCATION endproducts by human serum albumin
  654. GLYCATION of tau protein
  655. Evidence that dimethyl sulfoxide inhibits defects of copper deficiency by inhibition of GLYCATION
  656. Formation of early and advanced GLYCATION products of lens crystallins with erythrose, ribose and glucose
  657. Enhanced nonenzymatic GLYCATION of eye lens proteins in experimental diabetes mellitus: an approach for the study of protein alterations as mediators of normal aging …
  658. Accelerated GLYCATION of the aorta in diabetic rats
  659. Nonenzymatic advanced GLYCATION in the lens membranes
  660. Influence of blood proteins on biomedical analysis. XII. Effects of GLYCATION on gliclazide (oral hypoglycemic drug)-binding with serum albumin in diabetics
  661. GLYCATION and Oxidation of Proteins: A Role in the Pathogenesis of Atherosclerosis?
  662. The GLYCATION of bovine lens βL-, βS-and γ-crystallins demonstrated by isoelectric focusing and lectin staining
  663. Kinetic behaviour of liver glucokinase in diabetes. II. Possible role of non-enzymatic protein GLYCATION.
  664. Experimental effect of puerarin on the formation of advanced GLYCATION end products and expression of RAGE in the arota of diabetic rats
  665. Diagnosis of the diabetic metabolic status using fructosamine (and HbA1c) determination. The GLYCATION quotient Glyc-Q, the GLYCATION nomogram
  666. Inactivation of glucose-6-phosphate dehydrogenase by GLYCATION
  667. GLYCATION of proteins and methods of its assessment
  668. Non‐Enzymatic GLYCATION of Fetal Tissue in Diabetic Pregnancy: Estimation of the Glucitollysine Content of Umbilical Cord Extracts
  669. Formation and ways of detecting advanced GLYCATION end-products in isolated human glomerular basement membrane and human serum albumin nonenzymatically …
  670. Effect of germanium-132 on galactose cataracts and GLYCATION in rats
  671. Studies on L-threose as substrate for aldose reductase: A possible role in preventing protein GLYCATION
  672. The Use of Solid Phase Extraction Cartridges as a Pre-Fractionation Step in the Quantisation of Intermolecular Collagen Crosslinks and Advanced GLYCATION End …
  673. The stable products of the non-enzymatic GLYCATION of pig crystallins: new findings related to the pathogenesis of diabetic cataracts.
  674. Isotope effects in the non enzymic GLYCATION of hemoglobin catalyzed by DPG
  675. GLYCATION of hair protein in the assessment of long-term control of blood glucose
  676. The effect of non-enzymatic GLYCATION on mechanical properties of articular cartilage
  677. Differences in nonenzymatic GLYCATION of histones.
  678. [48] GLYCATION of copper/zinc superoxide dismutase and its inactivation: Identification of glycated sites
  679. Synthesis of novel imidazolidinones from hexose–peptide adducts: model studies of the Maillard reaction with possible significance in protein GLYCATION
  680. Investigations on protein nonenzymatic GLYCATION by a new and effective mass spectrometric method
  681. GLYCATION precedes lens crystallin aggregation
  682. Diabetic erythrocytes bearing advanced GLYCATION end products induce vascular dysfunctions
  683. Mass Spectrum in the Study of Advanced GLYCATION End Products
  684. Pancreatic bile-salt-dependent lipase activity in serum of diabetic patients: is there a relationship with GLYCATION?
  685. The advanced GLYCATION endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: comparison with idiopathic …
  686. AL0671, a new potassium channel opener, inhibits nonenzymatic GLYCATION of protein and LDL oxidation.
  687. Enhanced binding of advanced GLYCATION endproducts (age) by apo e4 isotype linkt mechanisms of plaque deposition in alzheimer’s disease
  688. Identification of N2-(1-carboxymethyl) guanine (CMG) as a guanine advanced GLYCATION end product
  689. The assessment of protein GLYCATION in human atherosclerotic plaques by affinity chromatography
  690. The effects of 5% and 25% galactose diets on lens polyols, glutathione and protein GLYCATION in male and female pigs
  691. GLYCATION of blood proteins during pregnancy and lactation in the rat.
  692. Non-enzymic GLYCATION of collagen inhibits binding of oxidized low-density lipoprotein
  693. Influence of factors affecting GLYCATION on defects of dietary copper deficiency
  694. Analysis of furosine as an indicator of lysine residue GLYCATION in milk protein by HPLC
  695. The role of GLYCATION and autoxidation on crystallin aggregation
  696. GLYCATION of human serum albumin in long-term incubation with low and high concentrations of glucose
  697. Massive GLYCATION of protein HC, a low molecular weight lipocalin, in non-diabetic individuals
  698. Alterations in biological activities induced by GLYCATION of leucine-enkephalin with different monosaccharide moieties
  699. Accumulation of GLYCATION products in α‐H pig lens crystallin and its bearing to diabetic cataract genesis
  700. Quantification of GLYCATION-Induced Browning in Lens Crystalline
  701. The effects of silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in aorta of streptozocin-induced diabetic rats
  702. The 32nd Annual Meeting off the European Association for the Study off Diabetes: Neuropathy, health care, and GLYCATION
  703. GLYCATION of Copper, Zine-superoxide Dismutase and Its Effect on the Thiol-Metal Catalyzed Oxidation Mediated DNA Damage
  704. … of the Maillard Reaction by Organic Germanium Compounds. Molecular Mechanism on the Prevention and Reversible Solubilization of Advanced GLYCATION …
  705. Effects of parathyroid hormone and 1, 25 (OH2) D3 on protein GLYCATION in moderate uraemia
  706. Release of fructose and hexose phosphates from perivascular cells induced by low density lipoprotein and acceleration of protein GLYCATION in vitro
  707. Increased GLYCATION of human erythrocyte Cu, Znsuperoxide dismutase in diabetic patients with cataracts and retinopathy
  708. Effects of nonenzymatic GLYCATION on molecular interactions of basement membrane molecules
  709. The GLYCATION of bovine lens β L-, β S-and γ-crystallins demonstrated by frozen-sectioning and isoelectric focusing
  710. Higher GLYCATION of βL-and βS-Crystallins in the Anterior Lens Cortex and Maximum GLYCATION of γ-Crystallins in the Bovine Lens Nucleus, Demonstrated by Frozen …
  711. Characterization of the GLYCATION of human insulin by reversed-phase HPLC
  712. Protein GLYCATION and diabetic vascular disease
  713. GLYCATION of lysozyme in a restricted water environment.
  714. Effect of a low protein diet on the relationship of nonenzymatic GLYCATION to altered renal structure and function in diabetes mellitus
  715. 2-D electrophoresis distribution of stable 14C-GLYCATION products from pig lens crystallins in relation to diabetic cataract formation
  716. The effects of silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in aorta of streptozocin-induced diabetic rats
  717. Effect of aminoguanidine on the GLYCATION.
  718. Failure of glucose-binding lectins Con A and Lentil Lectin to identify GLYCATION of haemoglobin
  719. The pro-oxidant activity of aminoguanidine and protein GLYCATION
  720. 23 GLYCATION and Diabetic Complications
  721. Inhibitory effect of pycnogenol on generation of advanced GLYCATION end products in vitro
  722. Effect of sialic acid on GLYCATION-induced fluorescence of albumin
  723. Expression of advanced GLYCATION end products receptors on human joint synovial cells
  724. Diabetic Atherosclerosis and GLYCATION of LDL (Low Density Lipoprotein)
  725. AMINOPHOSPHOLIPID GLYCATION CAUSES LIPID BILAYER STRUCTURE ALTERATIONS AND INHIBITION OF MEMBRANE-BOUND
  726. … changes in pancreatic islets obtained from obese Zucker rats (fa/fa) on a diabetogenic diet. No evidence for non-enzymatic protein GLYCATION in endocrine cells
  727. Alzheimers disease synergistic effects of glucose deficit, oxidative stress and advanced GLYCATION endproducts
  728. Relation between dialysis-related amyloidosis and advanced GLYCATION end products (AGEs)
  729. Interaction of glycyl-phenylalanine with carbohydrates as a model of N-terminal GLYCATION of proteins
  730. The detection of an early advanced GLYCATION product which co-elutes with the Amadori product on aminophenylboronate affinity chromatography.
  731. GLYCATION and inactivation of rat aldehyde reductase, a major 3-deoxyglucosone reducing enzyme
  732. Influence of aspartic acid and glutamic acid on non-enzymatic GLYCATION of lens proteins in vitro
  733. Advanced GLYCATION end products-induced TNF-? and IL-6 production by peripheral lymphocytes of diabetic patients
  734. Nonenzymatic GLYCATION of human fibrinogen and myelin basic protein
  735. The effect of phenobarbital on the nonenzymatic GLYCATION of hemoglobin.
  736. Alterations of retinal microvascular cell glycoproteins by advanced GLYCATION end products
  737. The effect of non-enzymatic GLYCATION on recombinant human aldose reductase
  738. Establishment of a quantitative RT-pCR for detection of vascular cell adhesion molecule-1 transcripts in endothelial cells after stimulation with advanced GLYCATION …
  739. GLYCATION of human serum albumin by dl-glyceraldehyde: a fluorescence quenching study
  740. Covalent modifications of eye lens proteins by oxidation and GLYCATION
  741. Diabetic control: Studies of protein GLYCATION, microangiopathy and diabetic pregnancy.
  742. International diabetes federation meeting, 1997: nephropathy, retinopathy, and GLYCATION
  743. Non-enzymatic GLYCATION of human serum albumin: influence on thebinding kinetics of the benzodiazepine binding sites
  744. Neuroelectrophysiological abnormalities are related to metabolic and advanced non-enzymatic GLYCATION changes in prospectively evaluated diabetic Sprague …
  745. Blocking effect of quercetin on the nonenzymatic GLYCATION of aortic collagen [J]
  746. Dietary restriction diminishes early GLYCATION adducts on murine hepatic cytosolic proteins
  747. Depolymerization of hyaluronan induced by GLYCATION reaction: possible role in vitreous liquefaction
  748. The effects of Silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in kidneys of streptozocin-induced diabetic rats [J]
  749. Monocyte/macrophage receptors for proteins modified by advanced GLYCATION end products: role in normal tissue remodeling and in pathology
  750. Flavonoids and flavonoid metabolites inhibit monosaccharide-induced protein damage of the advanced GLYCATION end product (AGE) type
  751. PREVENTION OF THE MAILLARD REACTION AND REVERSIBLE DESTRUCTION OF ADVANCED GLYCATION END PRODUCTS (AGE) BY NOVEL ORGANIC …
  752. GLYCATION and the Development of Arteriosclerosis
  753. Alteration in coagulation and fibrinolytic activities of glycated fibrinogen from diabetic patients and inhibitory effect of drugs on GLYCATION of fibrinogen
  754. Factors affecting the GLYCATION of proteins
  755. The Effect of Vitamin E on Protein GLYCATION in NIDDM Patients
  756. Method for analyzing the GLYCATION of hemoglobin
  757. GLYCATION and the Development of Diabetic Retinopathy
  758. Cellular Receptors for Advanced GLYCATION Endproducts
  759. Pharmacologic importance of GLYCATION of plasma proteins
  760. Faba bean albumins GLYCATION
  761. In vitro GLYCATION of dried serum
  762. GLYCATION of liver alcohol dehydrogenase.
  763. GLYCATION Inhibitors and the Prevention of Diabetic Complications
  764. Role of Fructose in GLYCATION
  765. GLYCATION of proteins and development of vascular disease in diabetes mellitus
  766. GLYCATION: A vascular enemy of many faces
  767. Nonenzymic GLYCATION of Hemoglobin: Structural Determinants of Site Selectivity
  768. GLYCATION of H1-histone.
  769. The possible role of GLYCATION in the pathogenesis of atherosclerosis
  770. IN VITRO GLYCATION OF HEMOGLOBIN (HB): CHOOSING THE APPROPRIATE MODEL
  771. Enzyme-linked immunosorbent assay development for advanced GLYCATION end products and brochocin-C.
  772. Advanced GLYCATION end-products induce global endothelial activation
  773. GLYCATION of apolipoprotein E in vitro and its binding to heparin
  774. Evidence for Nonenzymic GLYCATION of Antithrombin III in Diabetic Patients
  775. GLYCATION of basement membranes: Location of advanced GLYCATION end products within type IV collagen and their effect on degradation by matrix proteases.
  776. Influence of Albumin GLYCATION on the Protein Binding of Drugs
  777. Bendazac decreases in vitro GLYCATION of human lens crystallins
  778. Effects of vitamin E on secretion of inflammatory mediators of human monocytes by advanced GLYCATION end products
  779. Impaired glucose tolerance, angiopathy and advanced GLYCATION end products
  780. ADVANCED GLYCATION END PRODUCTS MODIFIED PROTEIN UP-REGULATES EXPRESSION OF ADHESION MOLECULES ON HUMAN ENDOTHELIAL CELLS
  781. GLYCATION and the Maillard Reaction in vitro: Implications for Diabetes Mellitus
  782. THE RELEVANCE OF PROTEIN GLYCOSYLATION TO DIABETES AND AGEING (ADVANCED GLYCATION ENDPRODUCTS, GLYCAEMIC CONTROL).
  783. Impaired Immunoglobulin G Fc Fragment Function in Diabetics is Caused by a Mechanism Different from GLYCATION
  784. The influence of aging and GLYCATION on protein-thiol mixed disulfides in the eye lens.
  785. GLYCATION-dependent, Reactive Oxygen Species-mediated Suppression of the Insulin Gene Promoter Activity in HIT Cells
  786. The role of GLYCATION and free radicals in hyperglycemia-induced malformations
  787. Participation of advanced GLYCATION end products in actinic elastosis.
  788. Advanced GLYCATION end products cross-links and diabetic-induced endothelium dysfunction
  789. Advanced GLYCATION Dependent Formation of Modified o-Crystallin and High Molecular Weight Aggregates
  790. Advanced GLYCATION End Products and Loss of Pericytes in Early Diabetic Retinopathy
  791. Advanced GLYCATION endproducts stimulate interleukin-6 production by human bone-derived cells
  792. In vivo GLYCATION of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of GLYCATION sites
  793. Effect of advanced GLYCATION end-products on the generation of macrophage-mediated oxidized low-density lipoprotein
  794. Structural and functional consequences of non-enzymatic GLYCATION of apolipoprotein AI and its impact on the reverse cholesterol transport
  795. The Effects of Nonenzymatic GLYCATION on Human Antithrombin III in vitro
  796. The receptor for advanced GLYCATION products (rage): Implications for the pathogenesis of diabetic complications.
  797. GLYCATION and inactivation of sorbitol dehydrogenase in normal and diabetic rats
  798. The Receptor for Advanced GLYCATION End Products Mediates the Chemotaxis of
  799. Aminophospholipid GLYCATION Causes Lipid Bilayer Structure Alterations and Inhibition of Membrane-Bound Na+,K+-ATPase
  800. Diabetic erythrocytes bearing advanced GLYCATION end products (age) bind to the receptor for age and increase vascular permeability
  801. Advanced GLYCATION endproducts and the development of accelerated atherosclerosis in diabetic apolipoprotein E deficient mice
  802. Identification of Deoxy-D-Fructosyl Phosphatidylethanollamine as a Non-enzymic GLYCATION Product of Product of Phopshatidylethanolamine and its Occurrence in …
  803. Effects of pro-inflammatory mediators on advanced GLYCATION end product receptors in type-b synovial cells
  804. Advanced GLYCATION End Products (AGEs) Induce Glomerular Sclerosis and Albuminuria in Normal Rats
  805. The Advanced GLYCATION End Product, N-(Carboxymethyl) lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions
  806. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by advanced GLYCATION end products
  807. Relationship of non-enzymatic GLYCATION to altered renal structural and functional changes in the diabetic rat
  808. Advanced GLYCATION end-products decreases THP-1 macrophages expression of peroxisome proliferator activated receptor-?
  809. GLYCATION of lens proteins in relation to aldose reductase activity and galactose-induced cataracts
  810. Advanced GLYCATION End Products Induce Expression of Vascular Endothelial Growth Factor by Retinal Müller Cells.
  811. Evidence that L-Arginine inhibits GLYCATION of human serum albumin (HSA) in vitro
  812. Effects of advanced GLYCATION end products on the survival and the morphology of bovine retinal endothelial cells and pericytes
  813. Effects of advanced GLYCATION end products on protein and mRNA expression of macrophage inflammatory protein-1? in cultured human umbilical vein endothelial …
  814. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by GLYCATION reaction: Implication of reactive oxygen species
  815. Localization of advanced GLYCATION end products (AGE) in actinic elastosis.
  816. Puerarin reduces serum levels of advanced GLYCATION end products and monocyte chemoattractant protein-1 in diabetic rats
  817. Mechanism of migration of vascular adventitial fibroblasts enhanced by advanced GLYCATION end-products and the inhibition effect of candesartan
  818. Immunohistochemical demonstration of advanced GLYCATION end products in synovial amyloid deposits of patients on long-term hemodialysis
  819. Receptor-mediated endocytosis of serum albumins modified by methylglyoxal and glucose-derived advanced GLYCATION endproducts.
  820. Serum lipoprotein and atherogenicity–relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and GLYCATION
  821. The Effects of Nonenzymatic GLYCATION on Human α2-Plasmin Inhibitor in Vitro
  822. Advanced GLYCATION end products-induced MCP-1 expression via its receptor RAGE in mouse podocytes
  823. Effects of advanced GLYCATION endproducts on proliferation of pericytes of bovine retinal capillary vessels and expression of transforming growth factor?
  824. Cholesteryl ester-HDL transfer rate to apoB-containing lipoproteins is distinctly influenced by GLYCATION of the HDL components and of CETP
  825. Nonenzymatic GLYCATION of phosphatidylethanolamine in erythrocyte vesicles
  826. The effects of Silymarin on the inhibition of nonenzymatic GLYCATION and oxidation in kidneys of streptozocin-induced diabetic rats
  827. Study on human gamma-crystallins: V. Non-enzymatic GLYCATION of fetal lens gamma 1-and gamma 3-crystallins in vitro
  828. Some Factors That Influence the Nonenzymatic GLYCATION of Peptides and Polypeptides by Glyceraldehyde
  829. The relationship between nonenzymatic GLYCATION of lens crystallins and diabetic cataract formation
  830. Nonenzymatic GLYCATION: A study of the post-translational modification of proteins by the nonenzymatic, covalent attachment of glucose and fructose.
  831. Identification of N ε carboxymethyl lysine as a native structure for advanced GLYCATION end products in circulation and amyloid fibrils in chronic hemodialysis patients
  832. Screening and identification of proteins that interact with receptor for advanced GLYCATION end products (RAGE) via T7 select phage display system
  833. Blood glucose and non-enzymatic GLYCATION of proteins in rats injected with low-dose streptozotocin and fed diets either high in sucrose or starch
  834. Isolation of glycated and non-glycated D-glyceraldehyde-3-phosphate dehydrogenase and detection of GLYCATION
  835. Diabetes and advanced GLYCATION endproducts
  836. Negative consequences of GLYCATION
  837. Advanced GLYCATION end-products: a review
  838. Novel inhibitors of advanced GLYCATION endproducts
  839. Protein GLYCATION, diabetes, and aging
  840. Advanced GLYCATION end products in diabetic corneas
  841. Advanced GLYCATION end products: a Nephrologist’s perspective
  842. Increase in the advanced GLYCATION end product pentosidine in Bruch’s membrane with age.
  843. Role of advanced GLYCATION end products in diabetic nephropathy
  844. Effect of collagen turnover on the accumulation of advanced GLYCATION end products
  845. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced GLYCATION endproducts
  846. GLYCATION—a sweet tempter for neuronal death
  847. GLYCATION in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options
  848. Angiogenesis induced by advanced GLYCATION end products and its prevention by cerivastatin
  849. Advanced GLYCATION end products and the progressive course of renal disease
  850. Quantitative screening of advanced GLYCATION endproducts in cellular and extracellular proteins by tandem mass spectrometry
  851. GLYCATION impairs high-density lipoprotein function
  852. Advanced GLYCATION end products and diabetic complications
  853. The role of advanced GLYCATION in the pathogenesis of diabetic retinopathy
  854. Chelating activity of advanced GLYCATION end-product inhibitors
  855. Metformin inhibition of GLYCATION processes
  856. Advanced GLYCATION end products and nutrition
  857. Advanced GLYCATION end products and mortality in hemodialysis patients
  858. Glucose, advanced GLYCATION end products, and diabetes complications: what is new and what works
  859. Advanced GLYCATION end products and endothelial dysfunction in type 2 diabetes
  860. Advanced GLYCATION in D-galactose induced mouse aging model
  861. The biology of the receptor for advanced GLYCATION end products and its ligands
  862. GLYCATION as the glucose link to diabetic complications
  863. Regulation of vascular endothelial growth factor expression by advanced GLYCATION end products
  864. Immunological detection of a novel advanced GLYCATION end-product
  865. Differential accumulation of advanced GLYCATION end products in the course of diabetic retinopathy
  866. The effect of advanced GLYCATION end-product formation upon cell-matrix interactions
  867. Exploiting GLYCATION to stiffen and strengthen tissue equivalents for tissue engineering
  868. Protein GLYCATION: creation of catalytic sites for free radical generation
  869. Improved arterial compliance by a novel advanced GLYCATION end-product crosslink breaker
  870. Renoprotective effects of a novel inhibitor of advanced GLYCATION
  871. GLYCATION in food and metabolic transit of dietary AGEs (advanced GLYCATION end-products): studies on the urinary excretion of pyrraline
  872. High and low hemoglobin GLYCATION phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control
  873. Advanced GLYCATION end-products and advanced oxidation protein products in patients with diabetes mellitus
  874. Glyoxalase I–structure, function and a critical role in the enzymatic defence against GLYCATION
  875. Changes in myosin structure and function in response to GLYCATION
  876. The role of GLYCATION in the pathogenesis of diabetic polyneuropathy
  877. A role for advanced GLYCATION end products in diminished bone healing in type 1 diabetes
  878. Advanced GLYCATION: an important pathological event in diabetic and age related ocular disease
  879. GLYCATION induces formation of amyloid cross-β structure in albumin
  880. Differential effects between amphoterin and advanced GLYCATION end products on colon cancer cells
  881. Structural requirements of flavonoids for inhibition of protein GLYCATION and radical scavenging activities
  882. Amadorins: novel post-Amadori inhibitors of advanced GLYCATION reactions
  883. Increased protein GLYCATION in cerebrospinal fluid of Alzheimer’s disease
  884. The enzymatic defence against GLYCATION in health, disease and therapeutics: a symposium to examine the concept
  885. Detection of noncarboxymethyllysine and carboxymethyllysine advanced GLYCATION end products (AGE) in serum of diabetic patients
  886. Advanced GLYCATION end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced GLYCATION end products (RAGE)
  887. Advanced GLYCATION endproducts and osteoarthritis
  888. Advanced GLYCATION end products in nondiabetic patients with coronary artery disease
  889. Restriction of dietary glycotoxins reduces excessive advanced GLYCATION end products in renal failure patients
  890. Advanced GLYCATION end products, their receptors and diabetic angiopathy
  891. Mechanisms of stiffening and strengthening in media-equivalents fabricated using GLYCATION
  892. Neurotoxicity of advanced GLYCATION end-products for cultured cortical neurons
  893. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced GLYCATION end product formation
  894. Novel inhibitors of advanced GLYCATION endproducts
  895. Reduction of the accumulation of advanced GLYCATION end products by ACE inhibition in experimental diabetic nephropathy
  896. A breaker of advanced GLYCATION end products attenuates diabetes-induced myocardial structural changes
  897. Serum levels of advanced GLYCATION end products are increased in patients with type 2 diabetes and coronary heart disease.
  898. Advanced GLYCATION end-products pentosidine and Nϵ-carboxymethyllysine are elevated in serum of patients with osteoporosis
  899. Advanced GLYCATION end products in human optic nerve head
  900. Novel inhibitors of advanced GLYCATION endproducts (part II)
  901. Receptor for advanced GLYCATION endproducts (RAGE) and the complications of diabetes
  902. Influence of nonenzymatic GLYCATION on biomechanical properties of cortical bone
  903. GLYCATION, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond
  904. Dietary glycotoxins correlate with circulating advanced GLYCATION end product levels in renal failure patients
  905. Lipid peroxidation and advanced GLYCATION end products in the brain in normal aging and in Alzheimer’s disease
  906. Increased levels of advanced GLYCATION end products in human cataractous lenses
  907. Genotoxicity of advanced GLYCATION end products in mammalian cells
  908. Serum levels of advanced GLYCATION end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
  909. The receptor for advanced GLYCATION end products is induced by the GLYCATION products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β …
  910. Therapeutic potential of breakers of advanced GLYCATION end product–protein crosslinks
  911. Effects of glucose intolerance on myocardial function and collagen-linked GLYCATION.
  912. Protein GLYCATION inhibitory and antioxidative activities of some plant extracts in vitro
  913. Age-related changes in cells and tissues due to advanced GLYCATION end products (AGEs)
  914. Scavenger receptors that recognize advanced GLYCATION end products
  915. Antioxidative and Anti-GLYCATION Activity of Garcinol from Garcinia indica Fruit Rind
  916. Neurovascular disease, antioxidants and GLYCATION in diabetes
  917. Alternative routes for the formation of immunochemically distinct advanced GLYCATION end-products in vivo
  918. The role of advanced GLYCATION end products in retinal microvascular leukostasis
  919. Impairment of vascular endothelial nitric oxide synthase activity by advanced GLYCATION end products
  920. Advanced GLYCATION end products in uremia
  921. Active GLYCATION in neurofibrillary pathology of Alzheimer disease: Nε-(carboxymethyl) lysine and hexitol-lysine
  922. Induction of advanced GLYCATION end products and alterations of the tensile properties of articular cartilage
  923. Advanced GLYCATION end product precursors impair epidermal growth factor receptor signaling
  924. Hyperglycaemia: the bridge between non-enzymatic GLYCATION and oxidative stress in the pathogenesis of diabetic complications.
  925. The breakdown of pre‐existing advanced GLYCATION end products is associated with reduced renal fibrosis in experimental diabetes
  926. Expression of advanced GLYCATION end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
  927. Advanced GLYCATION end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses
  928. Methylglyoxal-derived hydroimidazolone advanced GLYCATION end-products of human lens proteins
  929. Quantitative screening of protein biomarkers of early GLYCATION, advanced GLYCATION, oxidation and nitrosation in cellular and extracellular proteins by tandem mass …
  930. GLYCATION and diabetes: The RAGE connection
  931. Blockade of receptor for advanced GLYCATION end-products restores effective wound healing in diabetic mice
  932. An advanced GLYCATION endproduct cross-link breaker can reverse age-related increases in myocardial stiffness
  933. Glucose, GLYCATION, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy
  934. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of GLYCATION
  935. Characterization of the advanced GLYCATION end-product receptor complex in human vascular endothelial cells
  936. Pyridoxamine, an inhibitor of advanced GLYCATION reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine
  937. Advanced GLYCATION endproducts co-localize with inducible nitric oxide synthase in Alzheimer’s disease
  938. Receptor for advanced GLYCATION endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings
  939. Advanced GLYCATION endproduct-induced calcium handling impairment in mouse cardiac myocytes
  940. Advanced GLYCATION end products induce blood–retinal barrier dysfunction in normoglycemic rats
  941. GLYCATION-induced matrix stability in the rabbit achilles tendon
  942. Activation of receptor for advanced GLYCATION end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
  943. Serum levels of non-carboxymethyllysine advanced GLYCATION endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes
  944. Expression of receptors for advanced GLYCATION end‐products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer
  945. Pyridoxamine, an inhibitor of advanced GLYCATION and lipoxidation reactions: a novel therapy for treatment of diabetic complications
  946. Immunological evidence that non-carboxymethyllysine advanced GLYCATION end-products are produced from short chain sugars and dicarbonyl compounds in …
  947. Receptor for advanced GLYCATION end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis
  948. Differences in Rates of GLYCATION (GLYCATION Index) May Significantly Affect Individual Hba1c Results in Type 1 Diabetes
  949. Identification of Nω-carboxymethylarginine as a novel acid-labile advanced GLYCATION end product in collagen
  950. Role of oxidative stress in advanced GLYCATION end product-induced mesangial cell activation
  951. Serum levels of low molecular weight advanced GLYCATION end products in diabetic subjects
  952. Increased advanced GLYCATION end products in atherosclerotic lesions of patients with end-stage renal disease
  953. High molecular weight hyaluronic acid inhibits advanced GLYCATION endproduct-induced NF-κB activation and cytokine expression
  954. RAGE‐mediated neutrophil dysfunction is evoked by advanced GLYCATION end products (AGEs)
  955. GLYCATION during human dermal intrinsic and actinic ageing: an in vivo and in vitro model study
  956. Reactivities of d-glucose and d-fructose during GLYCATION of Bovine Serum Albumin
  957. The effect of GLYCATION on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants
  958. Formation of advanced GLYCATION end products during CAPD
  959. … of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced GLYCATION end product inhibitor, OPB …
  960. Increased serum concentrations of advanced GLYCATION end products: a marker of coronary artery disease activity in type 2 diabetic patients
  961. Effects of mesangium GLYCATION on matrix metalloproteinase activities: possible role in diabetic nephropathy
  962. Inactivation of cellular enzymes by carbonyls and protein-bound GLYCATION/glycoxidation products
  963. Crosslinking by advanced GLYCATION end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which …
  964. Accumulation of advanced GLYCATION end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.
  965. Blockade of receptor for advanced GLYCATION endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders
  966. CD36, serves as a receptor for advanced GLYCATION endproducts (AGE)
  967. Receptor for advanced GLYCATION end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities
  968. Role of advanced GLYCATION end products in adynamic bone disease in patients with diabetic nephropathy
  969. Advanced GLYCATION end products in end-stage renal disease and their removal
  970. Role of advanced GLYCATION end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
  971. Immunohistochemical distribution of the receptor for advanced GLYCATION end products in neurons and astrocytes in Alzheimer’s disease
  972. Glucose‐mediated in vitro GLYCATION modulates biomechanical integrity of the soft tissues but not hard tissues
  973. Advanced GLYCATION endproducts accelerate calcification in microvascular pericytes
  974. Blockade of advanced GLYCATION end-product formation restores ischemia-induced angiogenesis in diabetic mice
  975. Evolving concepts in advanced GLYCATION, diabetic nephropathy, and diabetic vascular disease
  976. Effects of Oriental medicines on the production of advanced GLYCATION endproducts
  977. The effect of flavonoid treatment on the GLYCATION and antioxidant status in Type 1 diabetic patients.
  978. Advanced GLYCATION end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human …
  979. Markedly elevated levels of plasma advanced GLYCATION end products in patients with liver cirrhosis–amelioration by liver transplantation
  980. Effect of GLYCATION of high density lipoproteins on their physicochemical properties and on paraoxonase activity
  981. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced GLYCATION end products (RAGE) activation
  982. Inhibitors and breakers of advanced GLYCATION endproducts (AGEs): a review
  983. Corneal advanced GLYCATION end products increase in patients with proliferative diabetic retinopathy
  984. Advanced GLYCATION end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes
  985. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced GLYCATION end-product accumulation
  986. Detection of autoantibodies against advanced GLYCATION endproducts and AGE-immune complexes in serum of patients with diabetes mellitus
  987. Serum concentrations of advanced GLYCATION endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with …
  988. Co-expression of receptor for advanced GLYCATION end products and the ligand amphoterin associates closely with metastasis of colorectal cancer
  989. N ε-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced GLYCATION end products that activate cell signaling pathways and modulate gene …
  990. Involvement of microglial receptor for advanced GLYCATION endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism
  991. Advanced GLYCATION end products and advanced oxidation protein products in hemodialyzed patients
  992. Receptor for advanced GLYCATION end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different …
  993. Accumulation of fructosyl-lysine and advanced GLYCATION end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats
  994. Longitudinal determination of skin collagen GLYCATION and glycoxidation rates predicts early death in C57BL/6NNIA mice
  995. Inflammation and advanced GLYCATION end products in uremia: Simple coexistence, potentiation or causal relationship?
  996. Age‐related decrease in susceptibility of human articular cartilage to matrix metalloproteinase–mediated degradation: The role of advanced GLYCATION end products
  997. Crosslinking of α-synuclein by advanced GLYCATION endproducts—an early pathophysiological step in Lewy body formation?
  998. Maillard GLYCATION of β‐lactoglobulin induces conformation changes
  999. Receptor for advanced GLYCATION endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes
  1000. … system of human phagocytes generates Nε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced GLYCATION end products at sites of …
  1001. GLYCATION of bovine β‐Lactoglobulin: effect on the protein structure
  1002. Advanced GLYCATION end products induce angiogenesis in vivo
  1003. Enhancing effect of advanced GLYCATION end products on serotonin-induced platelet aggregation in patients with diabetes mellitus
  1004. Amino acid specificity of GLYCATION and protein–AGE crosslinking reactivities determined with a dipeptide SPOT library
  1005. Anti-hypertensive agents inhibit in vivo the formation of advanced GLYCATION end products and improve renal damage in a type 2 diabetic nephropathy rat model
  1006. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced GLYCATION end products
  1007. Relationship of GLYCATION, antioxidant status and oxidativestress to vascular endothelial damage in diabetes
  1008. Advanced GLYCATION end products in human senile and diabetic cataractous lenses
  1009. Novel splice variants of the receptor for advanced GLYCATION end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in …
  1010. Efficacy of benfotiamine versus thiamine on function and GLYCATION products of peripheral nerves in diabetic rats
  1011. Chronic diabetes increases advanced GLYCATION end products on cardiac ryanodine receptors/calcium-release channels
  1012. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced GLYCATION end products.
  1013. Plasma levels of advanced GLYCATION end products in healthy, long-term vegetarians and subjects on a western mixed diet
  1014. The receptor for advanced GLYCATION end-products (RAGE) directly binds to ERK by a D-domain-like docking site
  1015. Age‐related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic GLYCATION
  1016. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced GLYCATION end products: biochemical …
  1017. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced GLYCATION end products
  1018. Role of receptor for advanced GLYCATION end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells
  1019. Protecting the genome: defence against nucleotide GLYCATION and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy
  1020. Effect of advanced GLYCATION endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development
  1021. Effects of thermal denaturation on protein GLYCATION
  1022. Age-related accumulation of the advanced GLYCATION endproduct pentosidine in human articular cartilage aggrecan: the use of pentosidine levels as a quantitative …
  1023. Accumulation of advanced GLYCATION endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage
  1024. Effect of metformin on advanced GLYCATION endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats
  1025. N‐Glycans on the receptor for advanced GLYCATION end products influence amphoterin binding and neurite outgrowth
  1026. Advanced GLYCATION end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells
  1027. Assay of advanced GLYCATION endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl …
  1028. Early GLYCATION products produce pentosidine cross-links on native proteins: novel mechanism of pentosidine formation and propagation of GLYCATION
  1029. Advanced GLYCATION end‐products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes
  1030. Reduction of advanced GLYCATION end product levels by on-line hemodiafiltration in long-term hemodialysis patients
  1031. Protective action on human LDL against oxidation and GLYCATION by four organosulfur compounds derived from garlic
  1032. Collagen structure and nonlinear susceptibility: effects of heat, GLYCATION, and enzymatic cleavage on second harmonic signal intensity
  1033. Advanced GLYCATION end products (AGEs), free radicals and diabetes
  1034. Daily haemodialysis improves indices of protein GLYCATION
  1035. Membrane proteins of human erythrocytes are modified by advanced GLYCATION end products during aging in the circulation
  1036. Advanced GLYCATION end-products in diabetic nephropathy.
  1037. Familial amyloid polyneuropathy: receptor for advanced GLYCATION end products-dependent triggering of neuronal inflammatory and apoptotic pathways
  1038. Advanced GLYCATION and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism
  1039. Glyoxalase I deficiency is associated with an unusual level of advanced GLYCATION end products in a hemodialysis patient
  1040. Advanced GLYCATION end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications
  1041. Receptor for advanced GLYCATION end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E–null mice
  1042. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced GLYCATION end product-induced injury through its antioxidative properties
  1043. GLYCATION end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart
  1044. Increased formation of methylglyoxal and protein GLYCATION, oxidation and nitrosation in triosephosphate isomerase deficiency
  1045. Advanced GLYCATION end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells
  1046. Identification of the advanced GLYCATION end products Nε-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis
  1047. Evidence of the GLYCATION and denaturation of LTP1 during the malting and brewing process
  1048. Modification of bovine β-lactoglobulin by GLYCATION in a powdered state or in an aqueous solution: effect on association behavior and protein conformation
  1049. Glycolaldehyde, a reactive intermediate for advanced GLYCATION end products, plays an important role in the generation of an active ligand for the macrophage …
  1050. Receptors for proteins modified by advanced GLYCATION endproducts (AGE)—their functional role in atherosclerosis
  1051. Effect of advanced GLYCATION end products on lens epithelial cells in vitro
  1052. Accumulation of advanced GLYCATION end products decreases collagen turnover by bovine chondrocytes
  1053. Calcium antagonists as inhibitors ofin vitro low density lipoprotein oxidation and GLYCATION
  1054. Expression and function of receptors for advanced GLYCATION end products in bovine corneal endothelial cells
  1055. Plasma levels of advanced GLYCATION end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality
  1056. Glucosylated glycerophosphoethanolamines are the major LDL GLYCATION products and increase LDL susceptibility to oxidation: evidence of their presence in …
  1057. Anti‐inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced GLYCATION endproducts in murine microglia
  1058. … of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced GLYCATION end-products through binding …
  1059. Interaction of the receptor for advanced GLYCATION end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation
  1060. Effects of Advanced GLYCATION End-products on the Proliferation and Fibronectin Production of Smooth Muscle Cells
  1061. Activation of protein-bound copper ions during early GLYCATION: study on two proteins
  1062. GLYCATION and post-translational processing of human interferon-γ expressed in Escherichia coli
  1063. GLYCATION of apolipoprotein E impairs its binding to heparin: identification of the major GLYCATION site
  1064. Up‐regulated expression of the receptor for advanced GLYCATION end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts
  1065. Effects of inhibition of GLYCATION and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats
  1066. Are advanced GLYCATION end‐product‐modified proteins of pathogenetic importance in fibromyalgia?
  1067. Advanced GLYCATION and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds
  1068. Advanced GLYCATION end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
  1069. Nitric oxide inhibits the formation of advanced GLYCATION end products
  1070. Generation of active oxygen species from advanced GLYCATION end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell …
  1071. Two Flavone C-Glycosides from the Style of Zea mays with GLYCATION Inhibitory Activity
  1072. Plasma levels of advanced GLYCATION end products in children with renal disease
  1073. Chromatographic assay of GLYCATION adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and …
  1074. Advanced GLYCATION endproducts in human diabetic and non-diabetic cataractous lenses
  1075. Inhibiting effects of Achyranthes bidentata polysaccharide and Lycium barbarum polysaccharide on nonenzyme GLYCATION in D-galactose induced mouse aging model.
  1076. Lowering of dietary advanced GLYCATION endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice
  1077. Effects of a diet rich in advanced GLYCATION end products in the rat remnant kidney model
  1078. Increased concentration of pentosidine, an advanced GLYCATION end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy
  1079. GLYCATION cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice
  1080. β2-Microglobulin modified with advanced GLYCATION end products delays monocyte apoptosis
  1081. Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic GLYCATION
  1082. Are advanced GLYCATION end products cardiovascular risk factors in patients with CRF?
  1083. Non-enzymatic GLYCATION of IgG: an in vivo study
  1084. The diabetic milieu modulates the advanced GLYCATION end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression.
  1085. The role of mass spectrometry in the study of non‐enzymatic protein GLYCATION in diabetes
  1086. Skin collagen GLYCATION, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of …
  1087. Effects of inhibition of GLYCATION and oxidative stress on the development of diabetic nephropathy in rats
  1088. Acetyl-L-carnitine decreases GLYCATION of lens proteins: in vitro studies
  1089. Identification of Nω-carboxymethylarginine, a new advanced GLYCATION endproduct in serum proteins of diabetic patients: possibility of a new marker of aging and …
  1090. Thermal GLYCATION of proteins by D-glucose and D-fructose.
  1091. Proteomic analysis of the site specificity of GLYCATION and carboxymethylation of ribonuclease
  1092. Advanced GLYCATION end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the …
  1093. Inhibition of nonenzymatic protein GLYCATION and lipid peroxidation by drugs with antioxidant activity
  1094. Receptor for advanced GLYCATION end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation
  1095. Age-related increase of protein GLYCATION in peripheral blood lymphocytes is restricted to preferential target proteins
  1096. Advanced GLYCATION end products: a highly complex set of biologically relevant compounds detected by mass spectrometry
  1097. … and quantification of phosphatidylethanolamine-derived glucosylamines and aminoketoses from human erythrocytes—influence of GLYCATION products on lipid …
  1098. Inhibition of advanced GLYCATION end‐products protects against retinal capillary basement membrane expansion during long‐term diabetes
  1099. Advanced GLYCATION end products and receptor for advanced GLYCATION end products in AA amyloidosis
  1100. Advanced GLYCATION end products in children with chronic renal failure and type 1 diabetes
  1101. Advanced GLYCATION end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis
  1102. Effect of GLYCATION on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells …
  1103. Advanced GLYCATION end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro
  1104. Dietary G-rutin suppresses GLYCATION in tissue proteins of streptozotocin-induced diabetic rats
  1105. Inhibition of advanced GLYCATION endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol
  1106. An expeditious synthesis of pentosidine, an advanced GLYCATION end product
  1107. Pigment epithelium-derived factor prevents advanced GLYCATION end products-induced monocyte chemoattractant protein-1 production in microvascular …
  1108. An immunochemical study on tau GLYCATION in paired helical filaments
  1109. Rat tissue collagen modified by advanced GLYCATION: correlation with duration of diabetes and glycemic control
  1110. Application of monoclonal antibody libraries for the measurement of GLYCATION adducts
  1111. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced GLYCATION end products
  1112. GLYCATION and glycoxidation of low‐density lipoproteins by glucose and low‐molecular mass aldehydes: Formation of modified and oxidized particles
  1113. Estimation of age of human cadavers by immunohistochemical assessment of advanced GLYCATION end products in the hippocampus
  1114. Maillard GLYCATION of -lactoglobulin with several sugars: comparative study of the properties of the obtained polymers and of the substituted sites
  1115. Monitoring GLYCATION of lysozyme by electrospray ionization mass spectrometry
  1116. Helical peptide models for protein GLYCATION: proximity effects in catalysis of the Amadori rearrangement
  1117. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced GLYCATION end-products (AGEs) and a proinflammatory response
  1118. Advanced GLYCATION endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y
  1119. Low-molecular but not high-molecular advanced GLYCATION end products (AGEs) are removed by high-flux dialysis.
  1120. Advanced GLYCATION end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages
  1121. Induction of GLYCATION suppresses glucokinase gene expression in HIT-T15 cells
  1122. cDNA cloning of a novel secreted isoform of the human receptor for advanced GLYCATION end products and characterization of cells co-expressing cell-surface …
  1123. Relationship between autofluorescence and advanced GLYCATION end products in diabetic lenses
  1124. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced GLYCATION end products
  1125. Radio fluorination and positron emission tomography (PET) as a new approach to study the in vivo distribution and elimination of the advanced GLYCATION endproducts Nϵ …
  1126. CD36-mediated endocytic uptake of advanced GLYCATION end products (AGE) in mouse 3T3-L1 and human subcutaneous adipocytes
  1127. Inhibition of GLYCATION reaction in tissue protein incubations by water soluble rutin derivative
  1128. Determination of membrane protein GLYCATION in diabetic tissue
  1129. Advanced GLYCATION end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress …
  1130. Inhibition of lipid peroxidation, protein GLYCATION and elevation of membrane ion pump activity by taurine in RBC exposed to high glucose
  1131. Development of a polyclonal antibody with broad epitope specificity for advanced GLYCATION endproducts and localization of these epitopes in Bruch’s …
  1132. Vitamin C supplementation decreases insulin GLYCATION and improves glucose homeostasis in obese hyperglycemic (ob/ob) mice
  1133. Advanced GLYCATION endproducts (AGEs) as uremic toxins
  1134. β‐Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon‐γ and ‘advanced GLYCATION endproducts’ in a murine microglia cell …
  1135. Activation of astrocytes by advanced GLYCATION end products: cytokines induction and nitric oxide release
  1136. Impact of metabolic control and serum lipids on the concentration of advanced GLYCATION end products in the serum of children and adolescents with type 1 diabetes …
  1137. Nonoxidative protein GLYCATION is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation
  1138. Advanced GLYCATION endproduct precursor alters intracellular amyloid-β/AβPP carboxy-terminal fragment aggregation and cytotoxicity
  1139. Advanced GLYCATION endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts
  1140. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced GLYCATION end-product-induced cellular mitogenesis in …
  1141. Nonenzymatic GLYCATION of histones in vitro and in vivo
  1142. … ) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced GLYCATION end products during inflammation
  1143. Advanced GLYCATION end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal …
  1144. An evaluation of level of oxidative stress and protein GLYCATION in nondiabetic undialyzed chronic renal failure patients
  1145. Polymorphism screening of four genes encoding advanced GLYCATION end-product putative receptors: association study with nephropathy in type 1 diabetic patients
  1146. Transition Metal–Catalyzed Oxidation of Ascorbate in Human Cataract Extracts: Possible Role of Advanced GLYCATION End Products
  1147. In vitro effect of advanced GLYCATION end‐products on human polymorphonuclear superoxide production
  1148. Glutathione reverses early effects of GLYCATION on myosin function
  1149. Evaluation of autofluorescent property of hemoglobin-advanced GLYCATION end product as a long-term glycemic index of diabetes
  1150. The receptor for advanced GLYCATION end products (RAGE) is elevated in women with preeclampsia
  1151. Incadronate disodium inhibits advanced GLYCATION end products-induced angiogenesis in vitro
  1152. Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic GLYCATION
  1153. Intraneuronal advanced GLYCATION endproducts in presenilin-1 Alzheimer’s disease
  1154. Susceptibility of rhDNase I to GLYCATION in the dry-powder state
  1155. Pharmaceutical intervention of advanced GLYCATION endproducts
  1156. Autoantibody against N (epsilon)-(carboxymethyl) lysine: an advanced GLYCATION end product of the Maillard reaction.
  1157. Regulation of receptor for advanced GLYCATION end products during bleomycin-induced lung injury
  1158. Effect of diabetes and aminoguanidine therapy on renal advanced GLYCATION end-product binding
  1159. Modulating cellular aging in vitro: hormetic effects of repeated mild heat stress on protein oxidation and GLYCATION
  1160. Advanced GLYCATION end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells …
  1161. Effect of age and menopause on serum concentrations of pentosidine, an advanced GLYCATION end product
  1162. Is GLYCATION of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre‐oxidative condition?
  1163. The effect of caloric restriction on GLYCATION and glycoxidation in skin collagen of nonhuman primates
  1164. GLYCATION of the amyloid β-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer’s disease
  1165. Characterization of glycated hemoglobin in diabetic patients: usefulness of electrospray mass spectrometry in monitoring the extent and distribution of GLYCATION
  1166. Accumulation of advanced GLYCATION endproducts in aging male Fischer 344 rats during long-term feeding of various dietary carbohydrates
  1167. Scanning force microscopy reveals structural alterations in diabetic rat collagen fibrils: role of protein GLYCATION
  1168. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of nonenzymatic GLYCATION of IgG
  1169. Acute modulation of albumin microvascular leakage by advanced GLYCATION end products in microcirculation of diabetic rats in vivo.
  1170. Inhibition of collagen GLYCATION and crosslinking in vitro by methanolic extracts of Finger millet (Eleusine coracana) and Kodo millet (Paspalum scrobiculatum)
  1171. Inhibitors of advanced GLYCATION end product-associated protein cross-linking
  1172. A systematic approach to evaluate the modification of lens proteins by GLYCATION-induced crosslinking
  1173. The liver is the main site for metabolism of circulating advanced GLYCATION end products
  1174. Role of megalin in endocytosis of advanced GLYCATION end products: implications for a novel protein binding to both megalin and advanced GLYCATION end products
  1175. Advanced GLYCATION endproducts as UVA photosensitizers of tryptophan and ascorbic acid: consequences for the lens
  1176. Methylglyoxal-induced GLYCATION affects protein topography
  1177. Removal of advanced GLYCATION end products in clinical renal failure by peritoneal dialysis and haemodialysis
  1178. Dysfunction of dermal fibroblasts induced by advanced GLYCATION end-products (AGEs) and the contribution of a nonspecific interaction with cell membrane and AGEs
  1179. A novel inhibitor of advanced GLYCATION end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
  1180. Immunohistochemical distribution and quantitative biochemical detection of advanced GLYCATION end products in fetal to adult rats and in rats with …
  1181. Advanced GLYCATION end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol …
  1182. Advanced GLYCATION end product receptor interactions on microvascular cells occur within caveolin‐rich membrane domains
  1183. Expression of receptor for advanced GLYCATION end products (RAGE) in human biliary cancer cells.
  1184. Selective formation of certain advanced GLYCATION end products in spinal cord astrocytes of humans and mice with superoxide dismutase-1 mutation
  1185. New therapies for advanced GLYCATION end product nephrotoxicity: current challenges
  1186. … isolated from human cataracts with those from ascorbic acid-modified calf lens proteins: evidence for ascorbic acid GLYCATION during cataract formation
  1187. Advanced GLYCATION end products in Descemet’s membrane and their effect on corneal endothelial cell
  1188. Inhibitor for advanced GLYCATION end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats
  1189. Receptor for advanced GLYCATION end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis
  1190. Solid‐state GLYCATION of β‐lactoglobulin monitored by electrospray ionisation mass spectrometry and gel electrophoresis techniques
  1191. Inhibition of advanced protein GLYCATION by a Schiff base between aminoguanidine and pyridoxal
  1192. Food restriction prevents advanced GLYCATION end product accumulation and retards kidney aging in lean rats
  1193. Clinical potential of advanced GLYCATION end-product inhibitors in diabetes mellitus
  1194. Advanced GLYCATION end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells
  1195. Effects of OPB‐9195, anti‐GLYCATION agent, on experimental diabetic neuropathy
  1196. Isolation and characterization of a new advanced GLYCATION endproduct of dehydroascorbic acid and lysine
  1197. Advanced GLYCATION endproducts and pro‐inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology
  1198. Circulating advanced GLYCATION end product levels in rats rapidly increase with acute renal failure
  1199. Serum levels of glucose-derived advanced GLYCATION end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal …
  1200. Inhibiting albumin GLYCATION ameliorates diabetic nephropathy in the db/db mouse
  1201. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced GLYCATION endproducts and glycated basic fibroblast growth factor in cultured …
  1202. N2-(1-carboxyethyl) deoxyguanosine, a nonenzymatic GLYCATION adduct of DNA, induces single-strand breaks and increases mutation frequencies
  1203. Role of advanced GLYCATION end products and growth factors in peritoneal dysfunction in CAPD patients
  1204. Qualitative determination of specific protein GLYCATION products by matrix-assisted laser desorption/ionization mass spectrometry peptide mapping
  1205. Detection of N epsilon-(carboxymethyl) lysine (CML) and non-CML advanced GLYCATION end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord.
  1206. GLYCATION of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity
  1207. Advanced GLYCATION endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 …
  1208. High levels of urinary pentosidine, an advanced GLYCATION end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress
  1209. Link between GLYCATION and lipoxidation in red blood cells in diabetes
  1210. Mechanisms involved in the stimulatory effect of advanced GLYCATION end products on growth of rat aortic smooth muscle cells
  1211. Advanced GLYCATION end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis
  1212. Effect of advanced GLYCATION endproducts on cell cycle and their relevance for Alzheimer’s disease
  1213. Lysozyme enhances renal excretion of advanced GLYCATION endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE …
  1214. Effects of advanced GLYCATION end products on cytosolic Ca2+ signaling of cultured human mesangial cells
  1215. GLYCATION, carbonyl stress, EAGLEs, and the vascular complications of diabetes
  1216. Advanced GLYCATION End Products Stimulate an Enhanced Neutrophil Respiratory Burst Mediated Through the Activation of Cytosolic Phospholipase A2 and …
  1217. GLYCATION proceeds faster in mutated Cu, Zn‐superoxide dismutases related to familial amyotrophic lateral sclerosis
  1218. Intracellular protein GLYCATION in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration.
  1219. Distribution of the receptor for advanced GLYCATION end products gene polymorphisms in patients with chronic periodontitis: a preliminary study
  1220. Cellular oxidant stress and advanced GLYCATION endproducts of albumin: caveats of the dichlorofluorescein assay
  1221. Non-enzymatic GLYCATION in corneas from normal and diabetic donors and its effects on epithelial cell attachment in vitro.
  1222. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the GLYCATION of proteins by glucose
  1223. Selective vulnerability of spinal motor neurons to reactive dicarbonyl compounds, intermediate products of GLYCATION, in vitro: implication of inefficient glutathione …
  1224. FEEL-1 and FEEL-2 are endocytic receptors for advanced GLYCATION end products
  1225. Effect of chronic aminoguanidine treatment on age-related GLYCATION, glycoxidation, and collagen cross-linking in the Fischer 344 rat
  1226. Rate of formation of AGEs during ascorbate GLYCATION and during aging in human lens tissue
  1227. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced GLYCATION end-products) for atherogenesis in …
  1228. Advanced GLYCATION endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation
  1229. Advanced GLYCATION endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism
  1230. In vivo treatment with stobadine prevents lipid peroxidation, protein GLYCATION and calcium overload but does not ameliorate Ca2+-ATPase activity in heart and …
  1231. Inhibition of nitric oxide synthase activity by early and advanced GLYCATION end products in cultured rabbit proximal tubular epithelial cells
  1232. Amadori albumin and advanced GLYCATION end-product formation in peritoneal dialysis using icodextrin
  1233. Renal proximal tubular metabolism of protein-linked pentosidine, an advanced GLYCATION end product
  1234. Application of shielding boronate affinity chromatography in the study of the GLYCATION pattern of haemoglobin
  1235. Fortification of milk with iron-ascorbate promotes lysine GLYCATION and tryptophan oxidation
  1236. A new flavone C-glycoside from the style of Zea mays L. with GLYCATION inhibitory activity
  1237. Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced GLYCATION end products in RAW264. 7 mouse macrophages
  1238. Structure of a synthetic glucose derived advanced GLYCATION end product that is immunologically cross-reactive with its naturally occurring counterparts
  1239. Receptor for advanced GLYCATION end products plays a more important role in cellular survival than in neurite outgrowth during retinoic acid-induced differentiation of …
  1240. Advanced GLYCATION end products impair the scavenger function of rat hepatic sinusoidal endothelial cells
  1241. Non-enzymatic GLYCATION and oxidative stress in chronic illnesses and diabetes mellitus
  1242. Accurate mass measurements by Fourier transform mass spectrometry in the study of advanced GLYCATION end products/peptides
  1243. The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced GLYCATION end products, an interaction that may play a role in the …
  1244. Effects of advanced GLYCATION end-product inhibition and cross-link breakage in diabetic rats
  1245. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced GLYCATION end products in lipofuscin of human retinal pigment epithelium
  1246. Neurotoxicity of acetaldehyde-derived advanced GLYCATION end products for cultured cortical neurons
  1247. Roles of advanced GLYCATION endproducts (AGE) and receptor for AGE on vascular smooth muscle cell growth
  1248. Aminoguanidine inhibits albuminuria, but not the formation of advanced GLYCATION end-products in skin collagen of diabetic rats
  1249. Serum levels of total homocysteine, homocysteine metabolites and of advanced GLYCATION end-products (AGEs) in patients after renal transplantation.
  1250. Advanced GLYCATION end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan
  1251. Pathogenic role of advanced GLYCATION end-products (AGEs): an overview
  1252. Collagen as a model system to investigate the use of aspirin as an inhibitor of protein GLYCATION and crosslinking
  1253. Damaging effects of advanced GLYCATION end-products in the murine macrophage cell line J774A. 1
  1254. Inhibitory effect of GLYCATION on catalytic activity of alanine aminotransferase
  1255. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced GLYCATION end products and ways of protection
  1256. Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to GLYCATION, oxidative stress and cytokine production in stz diabetic rats
  1257. Regional variations in intestinal brush border membrane fluidity and function during diabetes and the role of oxidative stress and non-enzymatic GLYCATION
  1258. Effects of eparlestat on plasma levels of advanced GLYCATION end products in patients with type 2 diabetes.
  1259. Early and advanced GLYCATION end-products are increased in dietary copper deficiency
  1260. GLYCATION of aspartate aminotransferase and conformational flexibility
  1261. Advanced GLYCATION end product in familial amyloidotic polyneuropathy (FAP)
  1262. GLYCATION amplifies lipoprotein (a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells
  1263. Endocytic uptake of advanced GLYCATION end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage …
  1264. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced GLYCATION end products
  1265. Neuronal and glial advanced GLYCATION end product [Nε-(carboxymethyl)lysine] in Alzheimer’s disease brains
  1266. Augmentation of the neutrophil respiratory burst through the action of advanced GLYCATION end products: a potential contributor to vascular oxidant stress
  1267. Differences in the modulating potential of advanced GLYCATION end product (AGE) peptides versus AGE proteins
  1268. Antibodies to advanced GLYCATION end products in children with diabetes mellitus
  1269. The role of galectin-3 in endocytosis of advanced GLYCATION end products and modified low density lipoproteins
  1270. Enhanced plasma levels of advanced GLYCATION end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after …
  1271. Role of advanced GLYCATION endproducts in adynamic bone disease
  1272. Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic GLYCATION–a twin study
  1273. Benfotiamine inhibits intracellular formation of advanced GLYCATION end products in vivo
  1274. Inhibiting albumin GLYCATION in vivo ameliorates glomerular overexpression of TGF-β1
  1275. Site-Specific Quantitative Evaluation of the Protein GLYCATION Product N6-(2,3-Dihydroxy-5,6-dioxohexyl)-l-lysinate by LC−(ESI)MS Peptide Mapping:  Evidence for …
  1276. Modification of bovine β-lactoglobulin by GLYCATION in a powdered state or in an aqueous solution: immunochemical characterization
  1277. GLYCATION of plasma low density lipoproteins increases interaction with arterial proteoglycans
  1278. Efficient total synthesis of pentosidine, an advanced GLYCATION endproduct
  1279. Advanced GLYCATION end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1
  1280. Antibodies against advanced GLYCATION end product Nɛ-(carboxymethyl) lysine in healthy controls and diabetic patients
  1281. Protein carbonylation and GLYCATION in human lenses
  1282. Increased protein GLYCATION in non-diabetic pediatric nephrotic syndrome: possible role of lipid peroxidation
  1283. Advanced GLYCATION end-products as a potential target for treatment of cardiovascular disease
  1284. The effect of advanced GLYCATION end-products and aminoguanidine on TNFα production by rat peritoneal macrophages
  1285. The human and rat recombinant receptors for advanced GLYCATION end products have a high degree of homology but different pharmacokinetic properties in rats
  1286. Products of advanced GLYCATION in patients with type 2 diabetes and vascular disease
  1287. Advanced GLYCATION end products in adolescents and young adults with diabetic angiopathy
  1288. GLYCATION and glycoxidation in diabetic vascular disease
  1289. GLYCATION and glycoxidation studies in vitro on isolated human vitreous collagen
  1290. Matrix protein GLYCATION impairs agonist‐induced intracellular Ca2+ signaling in endothelial cells
  1291. Lens proteins block the copper-mediated formation of reactive oxygen species during GLYCATION reactions in vitro
  1292. Effect of advanced GLYCATION end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media
  1293. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced GLYCATION end products (AGE)
  1294. Rapid determination of advanced GLYCATION end products of proteins using MALDI-TOF-MS and PERL script peptide searching algorithm
  1295. Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of advanced GLYCATION end-products, during heat-sterilization of glucose-based peritoneal …
  1296. Neurotoxicity of methylglyoxal and 3‐deoxyglucosone on cultured cortical neurons: synergism between GLYCATION and oxidative stress, possibly involved in …
  1297. Advanced GLYCATION end products and the pathogenesis of diabetic nephropathy
  1298. Advanced GLYCATION endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation
  1299. Pathological significance and mechanism of advanced GLYCATION end-products [J]
  1300. Advanced GLYCATION and lipoxidation end products: reactive carbonyl compounds‐related uraemic toxicity
  1301. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced GLYCATION end products (RAGE) in plaque psoriasis
  1302. GLYCATION by ascorbic acid causes loss of activity of ribulose-1, 5-bisphosphate carboxylase/oxygenase and its increased susceptibility to proteases
  1303. HPLC method for pentosidine determination in urine, serum, and tissues as a marker of GLYCATION and oxidation loading of the organism
  1304. GLYCATION decreases calmodulin binding to lens transmembrane protein, MIP
  1305. A food chemist’s view of advanced GLYCATION end-products
  1306. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced GLYCATION end products in vitro
  1307. Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL GLYCATION in diabetes mellitus
  1308. Hemoglobin Görwihl [α2β25(A2)Pro→Ala], an Electrophoretically Silent Variant with Impaired GLYCATION
  1309. α-Lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced GLYCATION end …
  1310. Modification of lipoproteins in uremia: oxidation, GLYCATION and carbamoylation
  1311. Effect of nonenzymatic GLYCATION of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro
  1312. γIII-Crystallin is the primary target of GLYCATION in the bovine lens incubated under physiological conditions
  1313. Importance of GLYCATION in the acceleration of low density lipoprotein (LDL) uptake into macrophages in patients with diabetes mellitus
  1314. The effect of UVA light on the anaerobic oxidation of ascorbic acid and the GLYCATION of lens proteins
  1315. Advanced GLYCATION endproducts induce changes in glucose consumption, lactate production, and ATP levels in SH-SY5Y neuroblastoma cells by a redox-sensitive …
  1316. Is diabetic hypercoagulability an acquired annexinopathy? GLYCATION of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients
  1317. Nonenzymatic GLYCATION/enzymatic deGLYCATION: a novel hypothesis on the etiology of diabetic complications
  1318. Mechanism of the inhibitory effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced GLYCATION end product and advanced …
  1319. Evaluation of high temperature GLYCATION of proteins and peptides by electrospray ionization mass spectrometry.
  1320. Carnosine prevents the GLYCATION‐induced changes in electrophoretic mobility of aspartate aminotransferase
  1321. ALT-946 and aminoguanidine, inhibitors of advanced GLYCATION, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat
  1322. Comparison between modifications of lens proteins resulted from GLYCATION with methylglyoxal, glyoxal, ascorbic acid, and fructose
  1323. Hyper-vascular change and formation of advanced GLYCATION endproducts in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite
  1324. Advanced GLYCATION end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce …
  1325. Oxidative modification of serum albumin in an experimental GLYCATION model of diabetes mellitus in vitro: effect of the pyridoindole antioxidant stobadine
  1326. Immunolocalization and quantification of advanced GLYCATION end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization
  1327. Analytical strategy for the assessment of the protein GLYCATION status in uremic patients by high-performance liquid chromatography
  1328. Erythrocyte membrane and cytoskeletal protein GLYCATION and oxidation in short-term diabetic rabbits
  1329. Advanced GLYCATION end-products/peptides: a preliminary investigation by LC and LC/MS
  1330. Astrocytic hyaline inclusions contain advanced GLYCATION endproducts in familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation …
  1331. Early-GLYCATION of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates
  1332. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced GLYCATION (AGE) and lipoxidation …
  1333. Study of degradation pathways of Amadori compounds obtained by GLYCATION of opioid pentapeptide and related smaller fragments: Stability, reactions, and …
  1334. Pentosidine in advanced GLYCATION end-products (AGEs) during UVA irradiation generates active oxygen species and impairs human dermal fibroblasts
  1335. Glycosphingolipid changes induced by advanced GLYCATION end-products
  1336. Hemodialysis techniques and advanced GLYCATION end products
  1337. Novel anti-GLYCATION therapeutic agents: glyoxalase I mimetics
  1338. Peptide mapping and characterisation of GLYCATION patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients
  1339. … converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced GLYCATION end product formation
  1340. The molecular chaperone α‐crystallin incorporated into red cell ghosts protects membrane Na/K‐ATPase against GLYCATION and oxidative stress
  1341. The role of nonenzymatic GLYCATION and glyco-oxidation in the development of diabetic vascular complications
  1342. Collagen GLYCATION and skin aging
  1343. Formation of advanced GLYCATION end‐product‐modified superoxide dismutase‐1 (SOD1) is one of the mechanisms responsible for inclusions common to familial …
  1344. Suppression of early and advanced GLYCATION by dietary water-soluble rutin derivative in diabetic rats
  1345. Serum levels of advanced GLYCATION end products in poorly metabolically controlled children with diabetes mellitus: relation to HbA1c.
  1346. Local application of advanced GLYCATION end products and intimal hyperplasia in the rabbit collared carotid artery
  1347. [11] Advanced GLYCATION end products: Detection and reversal
  1348. Modification of bovine β-lactoglobulin by GLYCATION in a powdered state or in aqueous solution: adsorption at the air–water interface
  1349. Hereditary ceruloplasmin deficiency increases advanced GLYCATION end products in the brain
  1350. The involvement of advanced GLYCATION endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and …
  1351. Ultrastructural changes and immunohistochemical localization of nitric oxide synthase, advanced GLYCATION end products and NF-κB in aorta of streptozotocin treated …
  1352. LR-90 a new advanced GLYCATION endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
  1353. Catalysis by organic phosphates of the GLYCATION of human hemoglobin
  1354. Signal transduction pathways in mouse microglia N‐11 cells activated by advanced GLYCATION endproducts (AGEs)
  1355. Renal clearance of GLYCATION adducts: anti-GLYCATION defence in uraemia and dialysis
  1356. Advanced GLYCATION end products (AGEs)‐induced expression of TGF‐β1 is suppressed by a protease in the tubule cell line LLC‐PK1
  1357. Diabetic nephropathy and advanced GLYCATION end products
  1358. Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non‐enzymatic GLYCATION and polyol pathway activation
  1359. … in tail tendon collagen of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced GLYCATION endproduct (AGE)-related …
  1360. Advanced GLYCATION end products impair protein turnover in LLC-PK1: Amelioration by trypsin
  1361. Beneficial role of amino acids in mitigating cytoskeletal actin GLYCATION and improving F-actin content: in vitro
  1362. Advanced GLYCATION end product-modified β2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis
  1363. Effect of intraperitoneal administration of heparin on advanced GLYCATION end-products in CAPD
  1364. Phosphatidylinositol 3′-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced GLYCATION end products
  1365. Whole-body metabolic rate appears to determine the rate of DNA oxidative damage and GLYCATION involved in aging
  1366. STAT5 activation induced by diabetic LDL depends on LDL GLYCATION and occurs via src kinase activity
  1367. Erythrocyte membrane GLYCATION and NA+–K+ levels in NIDDM
  1368. Ultrastructural localization of advanced GLYCATION end products and beta2-microglobulin in dialysis amyloidosis.
  1369. The role of antioxidants in the long-term GLYCATION of low density lipoprotein and its Cu2+-catalyzed oxidation
  1370. GLYCATION of human serum albumin by acylglucuronides of nonsteroidal anti-inflammatory drugs of the series of phenylpropionates
  1371. Effects of GLYCATION on erythrocyte carbonic anhydrase-I and II in patients with diabetes mellitus
  1372. Effect of carnosine and related compounds on glucose oxidation and protein GLYCATION in vitro
  1373. Substituted Guanidine Compounds as Inhibitors of Nonenzymatic GLYCATION in vitro
  1374. An inhibitor of advanced GLYCATION end product formation reducesNϵ-(carboxymethyl) lysine accumulation in glomeruli of diabetic rats
  1375. Lipoprotein GLYCATION and glycoxidation: their importance in diabetes mellitus
  1376. GLYCATION induced crosslinking of link proteins, in vivo and in vitro
  1377. Synthesis of hexose-related imidazolidinones: Novel GLYCATION products in the Maillard reaction
  1378. High glucose and advanced GLYCATION end products induce phospholipid hydrolysis and phospholipid enzyme inhibition in bovine retinal pericytes
  1379. Suppressive effects of tea polyphenol and conformational changes with receptor for advanced GLYCATION end products (RAGE) expression in human hepatoma cells.
  1380. Multicomponent analysis by off-line combination of synchronous fluorescence spectroscopy and capillary electrophoresis of collagen GLYCATION adducts
  1381. Oleate, not ligands of the receptor for advanced GLYCATION end-products, promotes proliferation of human arterial smooth muscle cells
  1382. Advanced GLYCATION end-products in anterior chamber aqueous of cataractous patients
  1383. Advanced GLYCATION end products quench nitric oxide in vitro
  1384. Formation of a protein-bound pyrazinium free radical cation during GLYCATION of histone H1
  1385. Possible participation of advanced GLYCATION endproducts and their receptor system in the development of diabetic vascular complications
  1386. Pathological significance and mechanism of advanced GLYCATION end-products
  1387. Capillary electrophoresis separation of autocondensation GLYCATION products of glucosamine.
  1388. N‐phenacylthiazolium bromide decreases renal and increases urinary advanced GLYCATION end products excretion without ameliorating diabetic nephropathy in …
  1389. N-terminal GLYCATION of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells
  1390. Studies on the processing of herbal medicines (III)-HPLC analysis of magnolol and inhibitory effects on the formation of advanced GLYCATION endproducts (AGEs) in …
  1391. Vascular permeability increase as induced by histamine or bradykinin is enhanced by advanced GLYCATION endproducts (AGEs)
  1392. Advanced GLYCATION end product (AGE) inhibition as a possible pharmacotherapeutic strategy in the treatment of Alzheimer’s disease
  1393. Levels of mature cross-links and advanced GLYCATION end product cross-links in human vitreous
  1394. Effects of vitamin E and vitamin C on nonenzymatic GLYCATION and peroxidation in experimental diabetic rats
  1395. Decreased Na, K-ATPase activity by GLYCATION at the catalytic center
  1396. Beraprost sodium, a prostaglandin I 2 analogue, protects against advanced GLYCATION end products-induced injury in cultured retinal pericytes
  1397. The early GLYCATION products of the Maillard reaction: mass spectrometric characterization of novel imidazolidinones derived from an opioid pentapeptide and glucose
  1398. Isolation and identification of the 3-hydroxy-5-hydroxymethyl-pyridinium compound as a novel advanced GLYCATION end product on glyceraldehyde-related Maillard …
  1399. Advanced GLYCATION end products are involved in microvascular permeability changes observed in microcirculation of diabetic rats in vivo
  1400. Role of nonenzymatic GLYCATION and oxidative stress on the development of complicated diabetic cataracts
  1401. Determination of advanced GLYCATION end products
  1402. Modulation of physico-chemical properties of bovine b-casein by nonenzymatic GLYCATION associated with enzymatic dephosphorylation
  1403. Advanced GLYCATION end-products in corneas of patients with keratoconus
  1404. The-429 T/C and-374 T/A gene polymorphisms of the receptor of advanced GLYCATION end products gene are not risk factors for diabetic retinopathy in Caucasians with …
  1405. Effect of aminophospholipid GLYCATION on order parameter and hydration of phospholipid bilayer
  1406. Pyridoxamine, a versatile inhibitor of advanced GLYCATION and lipoxidation reactions
  1407. Ultrastructural changes and immunohistochemical localization of advanced GLYCATION end products in the heart of streptozotocin-treated Mongolian gerbils
  1408. A practical method to study functional impairment of proteins by GLYCATION and effects of inhibitors using current coagulation/fibrinolysis reagent kits
  1409. Gramicidin S: a peptide model for protein GLYCATION and reversal of GLYCATION using nucleophilic amines
  1410. Non-enzymatic glycosylation (or GLYCATION) and inhibition of the pig heart cytosolic aspartate aminotransferase by glyceraldehyde 3-phosphate
  1411. Advanced GLYCATION alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells
  1412. Evaluation of the site (s) of GLYCATION in human proinsulin by ion-trap LCQ electrospray ionization mass spectrometry
  1413. Inhibition of aspartate aminotransferase by GLYCATION in vitro under various conditions
  1414. Study of autoantibodies against advanced GLYCATION endproducts of the Maillard reaction
  1415. Molecular heterogeneity of amyloid β2-microglobulin and modification with advanced GLYCATION end products
  1416. 3-Deoxyosone-related advanced GLYCATION end products in foods and biological systems
  1417. Formation of advanced GLYCATION endproducts from low molecular weight model compounds
  1418. Possible involvement of altered RGD sequence in reduced adhesive and spreading activities of advanced GLYCATION end product-modified fibronectin to vascular …
  1419. Methods for studying the binding of advanced glycated proteins to receptors for advanced GLYCATION endproducts (AGE receptors)
  1420. Nitric oxide, advanced GLYCATION end products, and uremia
  1421. Proliferation-inhibiting effect of advanced GLYCATION end products modified human serum albumin to vascular endothelial cell ecv304
  1422. The potential role of advanced GLYCATION end product and iNOS in chronic renal failure-related testicular dysfunction
  1423. Impact of chronic renal failure and peritoneal dialysis fluids on advanced GLYCATION end product and iNOS levels in penile tissue: an experimental study
  1424. Intraperitoneal infusion of glucose-based dialysate in the rat—an animal model for the study of peritoneal advanced GLYCATION end-products formation and effect on …
  1425. Prediction of possible sites for posttranslational modifications in human gamma crystallins: Effect of GLYCATION on the structure of human gamma‐b‐crystallin as …
  1426. Effects of aging and advanced GLYCATION on gene expression in cerebrum and spleen of mice.
  1427. RAGE engagement and vascular cell derangement by short chain sugar-derived advanced GLYCATION end products
  1428. Advanced GLYCATION end products, their receptors and diabetic angiopathy
  1429. In vitro-prepared advanced GLYCATION end-products and the modulating potential of their low-molecular weight degradation products in IRPTC-A rat proximal-tubular …
  1430. Induction of GM-CSF production of macrophages by advanced GLYCATION end products of the Maillard reaction
  1431. Changes in GLYCATION of fibrous type I collagen during long-term in vitro incubation with glucose
  1432. Protective effect of inducible type nitric oxide synthase against intracellular oxidative stress caused by advanced GLYCATION end-products in vascular smooth muscle …
  1433. The relation between impaired wound healing and advanced GLYCATION end products [J]
  1434. Role of lipid peroxidation products in the formation of advanced GLYCATION end products: An in vitro study on collagen
  1435. Effect of physical load on serum protein GLYCATION in rats with induced diabetes
  1436. … anterior horn of the amyotrophic lateral sclerosis and spinobulbar muscular atrophy spinal cord: evidence for early involvement of GLYCATION in motoneuron diseases
  1437. Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced GLYCATION end …
  1438. Advanced GLYCATION end products inhibit production of nitric oxide by human endothelial cells through activation of the p38 signal pathway
  1439. Protein GLYCATION–clinical and chemical aspects
  1440. Advanced GLYCATION end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio
  1441. Non‐enzymatic GLYCATION of lens proteins and haemoglobin–inhibition by pyruvate: an in‐vivo study
  1442. Effect of non-enzymatic GLYCATION on biological properties of morphiceptin.
  1443. Limited effects of parsley (Petroselinum crispum) on protein GLYCATION and glutathione in lenses of streptozotocin-induced diabetic rats
  1444. In vitro GLYCATION of aminotransferases: A process closely depending on the employed experimental conditions
  1445. Advanced GLYCATION in uraemic toxicity
  1446. The effects of GLYCATION/glycoxidation on the liberation of 8-epi-PGF2αfrom low density lipoprotein during its in vitro oxidation
  1447. The effect of Somac, Cinnamomun and black pepper on albumin GLYCATION in-vitro
  1448. Study of the− 429 T/C and− 374 T/A receptor for advanced GLYCATION end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular …
  1449. Inhibitory effect of peptide-free forms of advanced GLYCATION end products on the proliferation and extracellular matrix protein production of cultured cells
  1450. … colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: comparative study of advanced GLYCATION end products, carboxymethyllysine and …
  1451. Biochemical properties and clinical significance of protein GLYCATION products
  1452. Age-dependent accumulation of advanced GLYCATION endproducts is accelerated in combined hyperlipidemia and hyperglycemia, a process attenuated by L-arginine
  1453. Increased levels of circulating advanced GLYCATION end products in a model of acute renal insufficiency in rats
  1454. Expression of receptor for advanced GLYCATION end product mRNA by human peritoneal mesothelial cells
  1455. A GLYCATION inhibitor, aminoguanidine and pyridoxal adduct, suppresses the development of diabetic nephropathy
  1456. Effects of Advanced GLYCATION Endproducts (AGE) on Rat Glomerular Epithelial Cells (GEC): Roles of Reactive Oxygen Species (ROS)
  1457. L-lysine reduces nonenzymatic GLYCATION of glomerular basement membrane collagen and albuminuria in diabetic rats
  1458. Advanced GLYCATION end products stimulate human endothelial cells to produce monocyte chemoattractant protein-1
  1459. Detection of GLYCATION end products in the urine of diabetic patients
  1460. Capillary electrophoretic separation by double-strand polyaniline-coate capillaries of the advanced GLYCATION endproducts formed from N-alpha-acetyl-L-lysine with …
  1461. Sodium sulfite and N-acetylcysteine: new additives to dialysate for inhibiting formation of glucose degradation products and advanced GLYCATION end-products
  1462. Evidence for accumulation of advanced GLYCATION end products in acute renal failure
  1463. Advanced GLYCATION end products induce apoptosis and expression of apoptotic genes in cultured bovine retinal capillary pericytes
  1464. GLYCATION and Age in Diabetes and Complications
  1465. Activation of smad signaling and collagenⅠ synthesis in NRK52E cells induced by advanced GLYCATION end products
  1466. Effect of vitamin C and E on nonenzymatic GLYCATION and physico-chemical properties of isolated erythrocyte membranes in diabetic patients
  1467. Identification of Nω-carboxymethylarginine, as a new advanced GLYCATION endproduct in serum proteins of diabetic patients
  1468. Inhibitory effect of dilazep hydrochloride on the formation of advanced GLYCATION end products
  1469. Effects of advanced GLYCATION end-products on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes
  1470. ADVANCED GLYCATION END PRODUCT LEVELS IN EYE LENSES, AORTA, AND TAIL TENDON IN TRANSPLANTED DIABETIC INBRED LEWIS RATS1
  1471. Autoantibodies against advanced GLYCATION products in patients with type 1 diabetes mellitus
  1472. Detection of structural alterations in LDL isolated from type 2 diabetic patients: application of the fructosamine assay to evaluate the extent of LDL GLYCATION
  1473. Advanced GLYCATION end products and coronary heart disease in type 2 diabetes.
  1474. The effect of ethanol on histone GLYCATION in diabetic rats
  1475. Outer Blood-retinal Barrier Alteration Induced by Intraocular Ad vanced GLYCATION Endproduct
  1476. GLYCATION of radioiodinated octreotates increases renal excretion and tumor uptake
  1477. Effect of advanced GLYCATION end products on rat aortic vascular smooth muscle cells
  1478. Expression of receptors for advanced GLYCATION end products at surface of peripheral blood monocytes and relationship thereof to plasma proinflammatory cytokines in …
  1479. Effect of some essential oils on albumin GLYCATION in vitro
  1480. Platelet protein damage by free radicals and GLYCATION in vitro: the pathological consequences
  1481. Recombinant human interleukin-10 inhibits proliferation of vascular smooth muscle cells stimulated by advanced GLYCATION end products and neointima hyperplasia …
  1482. Repression of fibroblast migration into the collagen gel incubated with glucose is due to GLYCATION-mediated cross-linking of collagen
  1483. In vitro glycoxidation of insoluble fibrous type I collagen: solubilization and advanced GLYCATION end products
  1484. Inhibitory effect of HXMTZG on the deposition of advanced GLYCATION endproducts (AGEs) and the role of downregulating RAGE mRNA transcription in the renal cortex …
  1485. Assessment of nonenzymatic GLYCATION in protein by FTIR spectroscopy
  1486. Assessment of nonenzymatic GLYCATION in protein by FTIR spectroscopy
  1487. A modulatory role for advanced GLYCATION end-products (AGEs) in retinal microvascular leukostasis
  1488. Advanced GLYCATION end products-induced TNF-α and IL-6 production by peripheral lymphocytes of diabetic patients [J]
  1489. An in vitro evaluation of the GLYCATION potential of a natural disaccharide, trehalose
  1490. In vitro effects of flavone from leaves of Diospyros kaki on rat cardiac myocyte apoptosis induced by hypoxia-reoxygenation and advanced GLYCATION end products.
  1491. Effects of flavone from leaves of Diospyros kaki on adventitial fibroblast proliferation induced by advanced GLYCATION end-products in vitro
  1492. The pathobiological effect of β_2-microglobulin modified with advanced GLYCATION end products on human type B synovial cells [J]
  1493. Induction of Age-related Macular Degeneration (AMD) by Advanced GLYCATION End (AGE) Products and S100B
  1494. Immunohistochemistry of advanced GLYCATION end products in neurofilamentous axonal spheroids induced by β-β′-iminodipropionitrile in lower motor neurons of rat
  1495. Protein GLYCATION reactions
  1496. Comparison of in vitro protein modification with advanced GLYCATION endproduct (AGE) precursors methylglyoxal, glyoxal, 3-deoxyglucosone and glucose using mass …
  1497. Autoantibodies against advanced GLYCATION endproducts (AGEs) in IDDM
  1498. Influence of some natural antioxidants on GLYCATION of aminotransferases
  1499. Assay of early and advanced GLYCATION adducts by enzymatic hydrolysis of proteins and HPLC of 6-aminoquinolylcarbonyl adducts
  1500. Intracellular changes in astrocytes and NG 108-15 neuroblastoma X glioma cells induced by advanced GLYCATION end products
  1501. Effect of iron on peroxidation and non-enzymatic GLYCATION in diabetic rats
  1502. Synthesis of [5-(4-pyrrol-1-yl-benzoyl)-1 H-pyrrol-2-yl)]-acetic acid and in vitro study of its inhibitory activity on aldose reductase enzyme and on protein GLYCATION.
  1503. GLUCOSAMINE INHIBITS FORMATION OF ADVANCED GLYCATION ENDPRODUCTS IN HUMAN ARTICULAR CARTILAGE: A MECHANISM FOR …
  1504. Effect of drinking green tea on GLYCATION and oxidation of aortic collagen in diabetic rat
  1505. Role of genetic variability in systems of receptor-mediated and enzymatic defence against GLYCATION in the long-term consequences of diabetes mellitus
  1506. Inhibitory effects of radix puerariae on the GLYCATION
  1507. Effect of Wenjintong Composita on mRNA expression of receptor of the advanced GLYCATION end products in sciatic nerve of streptozotocin-induced diabetic rats
  1508. Effects of sodium ferulate on the nonenzymatic GLYCATION and oxidation in kidneys of diabetic rats
  1509. Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile: effects of hyperglycemia, lipoprotein GLYCATION, and comparison with standard lipid profile
  1510. Effects of advanced GLYCATION end products and hypoxia on endothelin-1 secretion by bovine retinal microvascular pericytes
  1511. Polymorphism 2184A/G in the gene encoding Receptor of Advanced GLYCATION End products (RAGE) is a newly identified risk factor for diabetic nephropathy
  1512. Effects of advanced GLYCATION end products on changes of glomerulus of STZ-induced diabetic rat
  1513. Selective increase in decorin core mRNA level in cultured vascular smooth muscle cells after exposure to advanced GLYCATION endproducts
  1514. The effects of GLYCATION on the material properties of porcine meniscus
  1515. Advanced GLYCATION end-products and diabetic renal disease
  1516. Soluble receptor for advanced GLYCATION endproducts (sRAGE) effectively reduces tumor growth as a single agent and in combination with doxorubicin in a …
  1517. IR spectroscopic investigation of the inhibition of the GLYCATION process by acetylsalicylic acid
  1518. Dietary Copper Deficiency Causes Elevation of Early and Advanced GLYCATION End-Products
  1519. Effect of advanced GLYCATION end products (AGEs) on proliferation of vascular endothelial cells cultured in vitro
  1520. Determination of Early GLYCATION Products by Mass Spectrometry and Quantification of GLYCATION Mediated Protein Crosslinks by the Incorporation of [14C]lysine into …
  1521. by GLYCATION
  1522. … on the Processing of Herbal Medicines (V)-Quantitative Analysis of Puerarin and Inhibitory Effects on the Formation of Advanced GLYCATION Endproducts (AGEs) in …
  1523. Effects of Zhixiaotongmaining Extract on Renal Advance GLYCATION End Products in Diabetic Rats
  1524. Advanced GLYCATION end products induce apoptosis in corneal endothelium
  1525. Effect of Different Advanced GLYCATION End Products on Proliferation of Vascular Smooth Muscle Cell
  1526. Diabetic nephropathy and low molecular weight advanced GLYCATION end-product in urine
  1527. A new model of age-related macular degeneration induced by advanced GLYCATION end products
  1528. Processing of collagen gels using non-enzymatic GLYCATION
  1529. Recombinant human interleukin-10 inhibits proliferation of rat vascular smooth muscle cells stimulated by advanced GLYCATION end products [J]
  1530. Effects of advanced GLYCATION end products on the expression of plasminogen activator inhibitor-1 in rat mesangial cells
  1531. The role of lens protein GLYCATION, oxidation and enzyme inactivation in cataract formation
  1532. Two advanced GLYCATION molecules, carboxymethyllysine and pentosidine, and dialysis membrane in dialysis-related amyloidosis
  1533. Advanced GLYCATION end-products-LDL stimulates adhesion molecule expression by human aortic endothelial cells
  1534. Nonenzymatic GLYCATION increases the severity of osteoarthritis in the canine ACLT model: a biochemical basis for age as a risk factor of OA
  1535. Chronic or delayed treatment with an oral dithiocarbamate analog decreases GLYCATION and protects diabetic arteries
  1536. Recombinant Lapemis hardwickii phospholipase A2 inhibits rat vascular smooth muscle cell proliferation stimulated by advanced GLYCATION end products
  1537. Inhibitory effect of total flavones of buckwheat flower on the non-enzymatic GLYCATION of protein in vivoand vitro
  1538. Enhancement of inhibitory effects of glycoprotein IIb/IIIa antagonists in patients with diabetes: Effects of GLYCATION on the kinetics of fibrinogen binding
  1539. Advanced GLYCATION endproducts accumulate in RPE lysosomal compartments and induce widespread alteration in gene expression: possible role in age-related …
  1540. Endocytic uptake of advanced GLYCATION endproducts by mouse liver sinusoidal endothelial cells is mediated by a receptor distinct from the class A scavenger receptor
  1541. In vitro GLYCATION and advanced GLYCATION endproduct formation with icodextrin and oligosaccharides
  1542. Expression of receptor for advanced GLYCATION end products (RAGE) and its ligands S100/calgranulins and amphoterin is increased in the vitreous cavity of patients …
  1543. Gly82Ser polymorphism in the receptor for advanced GLYCATION end products (RAGE) gene is not associated with the progression of diabetic nephropathy and …
  1544. Advanced GLYCATION End Products in Nephrology
  1545. Influence of advanced GLYCATION end-products in the development of atherosclerosis
  1546. Methods for measuring the protein GLYCATION products formed in the human organism
  1547. ADVANCED GLYCATION ENDPRODUCTS IN THE DEVELOPMENT OF JOINT DISEASE
  1548. Structure-Function Relationship of Advanced GLYCATION Endproducts (AGEs)
  1549. In vitro GLYCATION of aminotransferases: a process closely depending on the employed experimental conditions……………. 89
  1550. The effect of an insulin releasing agent, BTS 67 582, on advanced GLYCATION end product formation in vitro
  1551. Advanced GLYCATION of proteins. Molecular characteristics and cellular responses.
  1552. Study of the protein GLYCATION in Alzheimer’s disease
  1553. Advanced GLYCATION End Products Act As A Skin Tumor Initiator in Mice
  1554. Chromatographic assay of advanced GLYCATION endproducts and application to the study of human disease.
  1555. Postprandial glucose/GLYCATION supplements?
  1556. Effects of Advanced GLYCATION End Products on Rat Bladder Fibroblast
  1557. Interaction of reactive oxygen species in atherogenetic properties of advanced GLYCATION end products in diabetes
  1558. Implications of Advanced GLYCATION Endproducts in Oxidative Stress and Neurodegenerative Disorders
  1559. GLYCATION Of Matrix Proteins Alters Endothelial Cell [Ca. sup. 2+] Signaling
  1560. The occurrence of a novel hydrophilic hydroperoxide, 3-hydroxy-5-hydroperoxy-2-methyl-5, 6-dihydropyran-4-one, as a reactive GLYCATION product in human plasma
  1561. Effect of advanced GLYCATION end products on inflammation in cultured cardiomyocytes
  1562. ADVANCED GLYCATION ENDPRODUCTS REDUCE TURNOVER OF HUMAN ARTICULAR CARTILAGE IN VITRO
  1563. Role of advanced GLYCATION end products (AGE) in the development of diabetic microangiopathies and the beneficial effects of AGE inhibitors
  1564. Isolation and characterization of low-density lipoprotein lipid GLYCATION products
  1565. GLYCATION as a post-translational modification of myosin structure and function; Role of glutathione; GLYCATION and aging
  1566. Biochemical Analysis of Inter-Connection between Types of Nuclear Opacity, Oxidative Stress and GLYCATION in Cataractous Lens
  1567. EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGES) ON ADHESION AND MULTIPLICATION IN E. coli
  1568. Circulating Advanced GLYCATION Endproducts (AGEs) An Indicator Of Long-Term Glycemic Control
  1569. Effects of advanced GLYCATION end-products on skin keratinocytes by NF-? B activation
  1570. Advanced GLYCATION endproducts and microvasculopathy: A pathogenic basis for initiation and progression of diabetic retinopathy.
  1571. Plasma protein GLYCATION and its correlation to the levels of magnesium and manganese in diabetic patients
  1572. The demonstration of the thesis of nonenzymatic GLYCATION inducing aging
  1573. INHIBITORY ACTION OF PROCESSED HERBAL MEDICINES ON THE PRODUCTION OF ADVANCED GLYCATION ENDPRODUCTS (AGEs)
  1574. The effect of advanced GLYCATION and products on the proliferation of vascular smooth muscle cell.
  1575. The presence and activity of the receptor for advanced GLYCATION end products in osteoblasts
  1576. Effect of Advanced GLYCATION Endproducts on Rat Aortic Vascular Smooth Muscle Cells
  1577. Effects of advanced GLYCATION end products on activi ty and expression of matrix metalloproteinase-2 in renal cortex of rats
  1578. Thermal GLYCATION of Proteins by D-Glucose and D-Fructose
  1579. Expression of advanced GLYCATION end product (AGE) receptors in corneal endothelial cells
  1580. Cellular oxidant stress mediated by advanced GLYCATION endproducts: the role of native albumin
  1581. Advanced GLYCATION end products (AGE) enhance vascular endothelial growth factor (VEGF) production in promonocytic leukaemia THP-1 cells
  1582. Effect of GLYCATION by acyl glucuronides on protein function
  1583. GLYCATION and tubulointerstitial injury; in vitro and in vivo studies
  1584. HP-Lysine-A New Advanced GLYCATION Endproduct in Cataractous and Aged Human Lenses
  1585. GLYCATION of Leucine-Enkephalin: Imidazolidinones and Amadori Compounds
  1586. Glyoxalase I deficiency is associated with an unusual level of advanced GLYCATION end products in a hemodialysis patient
  1587. Advanced GLYCATION and Ubiquitination of Cytosolic Proteins in Experimental Diabetes San Francisco, CA
  1588. FGF2 (bFGF) GLYCATION induced by TGF-beta1 in human lens epithelial cells
  1589. EXPRESSION AND REGULATION OF THE BINDING PROTEINS FOR ADVANCED GLYCATION END PRODUCTS ON HUMAN JOINT SYNOVIAL CELLS
  1590. Effect of iron on peroxidation and non-enzymatic GLYCATION in diabetic rats
  1591. Advanced GLYCATION End Products (AGEs) Reduce Vesicular Transport in RPE Cells
  1592. Low density lipoprotein GLYCATION mediated modifications in diabetic atherosclerosis
  1593. Effects of Benazepril on Nonenzymatic GLYCATION in Diabetic Rats
  1594. Inhibition of Advanced GLYCATION Endproduct (AGE) Formation by the Alcohol Metabolite Acetaldehyde: Role in the” French Paradox”
  1595. The role of advanced GLYCATION end-products in pericyte dysfunction and death during diabetic retinopathy.
  1596. Effects of advanced GLYCATION end products on the expression of plasminogen activator inhibitor-1 in rat mesangial cells
  1597. Rates of Skin Collagen GLYCATION and Glycoxidation Predict Early Death in Nondiabetic C57BL/6NNia Mice: A Longitudinal Study
  1598. Advanced GLYCATION of mesangial matrix induces endothelins secretion and gene expression in mesangial cells
  1599. Activation of Receptor for Advanced GLYCATION End Products A Mechanism for Chronic Vascular Dysfunction in Diabe…
  1600. Improvement of β-casein functionality by non-enzymatic GLYCATION in relation to its structural changes.
  1601. Estimation of the genotoxic properties of novel class of advaneed GLYCATION and products (AGE) by measuring in human lymphocytes in vitro
  1602. The Receptor for Advanced GLYCATION End Products Is Induced by the GLYCATION Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by …
  1603. Advanced GLYCATION End Products Activate Endothelium Through Signal-Transduction Receptor RAGE
  1604. Biodistribution of the 18F-labelled Advanced GLYCATION End Products Ne-carboxymethyllysine (CML) and Ne-carboxyethyllysine (CEL)
  1605. Basement Membrane-immobilised Advanced GLYCATION Endproducts Induce Capillary Endothelial Dysfunction And Apoptosis
  1606. Formation of advanced GLYCATION end products by glyceraldehyde and glyceraldehyde-3-phosphate with proteins
  1607. Advanced GLYCATION end products (AGEs) lower the clearance function of hepatic scavenger endothelial cells (SEC)
  1608. Dialysis-related amyloidosis: role of advanced GLYCATION end product-β-microglobulin in joint inflammation
  1609. Effects of Advanced GLYCATION End-Product Inhibition and Protein Cross-Link Breaking in Diabetic Rats
  1610. Relationship between the advanced GLYCATION end products content and expressions of RAGE, ICAM-1 in vascular tissue of diabetic rats
  1611. Human Erythrocyte Bisphosphoglycerate Mutase: Inactivation by GLYCATION In Vivo and In Vitro
  1612. Advanced GLYCATION end products-induced inflammatory reaction in human monocytes: cellular receptor pathway & intracellular signaling
  1613. < SYMPOSIUM: Biology of Aging and Age-associated Skin Disorders> POSSIBLE ROLES OF ADVANCED GLYCATION END-PRODUCTS IN PROMOTING SKIN …
  1614. Effects of Probenecid on the Elimination of the Advanced GLYCATION End-products Ne-Carboxymethyllysine (CML) and Ne-Carboxyethyllysine (CEL) Using …
  1615. Specific detections of the early process of the GLYCATION reaction by fructose and glucose in diabetic rat lens
  1616. The expression of receptor for advanced GLYCATION end product in gingival tissues of type 2 diabetic patients with periodontitis
  1617. Effects of Wen-Jin-Tong on the formation of advanced GLYCATION end products and expressions of RAGE and ICAM-1 in cardiovascular tissues of diabetic rats
  1618. NON-ENZYMATIC GLYCATION ALTERS THE CREEP AND VISCOPLASTIC PROPERTIES OF HUMAN CORTICAL BONE
  1619. Effect of aminoguanidine on mRNA expression of specific receptor of the advanced GLYCATION end products in diabetic kidney tissue in rats
  1620. Inhibitory effects of taurine on oxidative stress and nonenzymatic GLYCATION in kidney of diabetic rats
  1621. Prevention of CML Accumulation by A Novel Inhibitor of Advanced GLYCATION Ameliorates Nephropathy in Spontaneous Diabetic Rats
  1622. Effects of tetramethylpyrazine on the expression of nuclear factorkappa B induced by advanced GLYCATION end products in retinal pigment epithelium
  1623. THE EFFECTS OF MATRIX STABILIZATION USING GLUTARALDEHYDE AND GLYCATION WITH RIBOSE ON THE MATERIAL PROPERTIES OF PORCINE …
  1624. N-acetylcysteine inhibits advanced GLYCATION end products-induced VCAM-1 expression in mouse cardiac microvascular endothelial cells
  1625. In vitro Inhibitory Effect of Coptidis Rhizoma before and after Processing and Berberine on the Advanced GLYCATION Endproducts (AGEs) formation
  1626. Advanced GLYCATION end products inhibit pressure-induced vasorelaxation in rabbit femoral artery in vivo
  1627. Immunohistochemical detection of products of lipid peroxidation and protein GLYCATION in the cerebellum of Menkes’ kinky hair disease patients
  1628. Nonenzymatic formation of advanced GLYCATION endproducts by glucosamine autocondensation and glucosamine with proteins
  1629. The advanced GLYCATION end-product inhibitor pyridoxamine traps intermediates formed during lipid peroxidation reactions in vitro and in vivo: Mechanism of …
  1630. GLYCATION Proceeds Faster in Mutated Cu, Zn-Superoxide Dismutases Related to Familial Amyotrophic Lateral Sclerosis
  1631. Matrix stabilization using glutaraldehyde and GLYCATION: Effects on the material properties of the knee meniscus
  1632. Advanced GLYCATION endproduct (AGE) receptor interactions on microvascular cells occur within the caveolae membrane system
  1633. Modification of enzymatic antioxidants in bovine retinal capillary pericytes by advanced GLYCATION end products
  1634. Inhibitory effect of total flavones of buckwheat flower on the non-enzymatic GLYCATION of protein in vivoand vitro
  1635. N-(carboxymethyl) valine adduct in hemoglobin: a biomarker of advanced GLYCATION end product formation and oxidative stress
  1636. Ginkgo biloba extract attenuates advanced GLYCATION end products-induced TGF-? _1, CTGF mRNA expression and oxidative stress in NRK-49F cells
  1637. Functional and immunochemical characterization of advanced GLYCATION end-product (AGE)-modified low-density lipoproteins (AGE-LDL).
  1638. Angiotensin-Converting Enzyme Inhibition Influences Serum Levels of Advanced GLYCATION End Products in Patients with Coronary Artery Disease: Results from a …
  1639. Effects of advanced GLYCATION end-products on expression of acyl coenzyme A: cholesterol acyltransferase-1 in THP-1 macrophages
  1640. Functional Hyperhomocysteinemia in Healthy Vegetar-ians: No Association with Advanced GLYCATION End Products, Markers of Protein Oxidation, or Lipid …
  1641. Pioglitazone reduces expression of advanced GLYCATION end product receptor mRNA in renal cortex of streptozotocin-induced diabetic rats
  1642. FAILURE OF PANCREAS TRANSPLANTATION TO PREVENT DEPOSITION OF AN ADVANCED GLYCATION END-PRODUCT IN TRANSPLANTED KIDNEYS …
  1643. Induction of Decorin Core Protein Synthesis by Advanced GLYCATION Endproducts in Cultured Vascular Smooth Muscle Cells (PROCEEDINGS OF 24TH SYMPOSIUM …
  1644. … Retinal Microvascular Pathology is Prevented by Sulindac, a Non-steroidal Anti-inflammatory Drug, without Inhibition of Advanced GLYCATION, Polyol Pathway Activity …
  1645. NONENZYMATIC GLYCATION IMPAIRS MMP-AND AGGRECANASE-MEDIATED MATRIX DEGRADATION BY BOVINE ARTICULAR CHONDROCYTES …
  1646. Macrokinetic Regularities of Chemiluminescence Development in the Course of Non-Enzymatic GLYCATION in Aqueous Solutions of Glycine and D-Glucose (Maillard …
  1647. The protection of aminoguanidine, silymarin and anisodamine on growth and cytosolic free calcium changes of retinal capillary pericytes cultured in GLYCATION products
  1648. Selective vulnerability of spinal motor neurons to reactive dicarbonyl compounds, intermediate products of GLYCATION, in vitro: Implication of inefficient glutathione …
  1649. 39. Synthesis of Labelled Advanced GLYCATION End Products Using N-Succinimidyl 4-[18F] Fluorobenzoate
  1650. Biodistribution of the 18F-labelled advanced GLYCATION end products Nε-carboxymethyllysine (CML) and Nε-carboxyethyllysine (CEL)
  1651. Biodistribution of the {sup 18} F-labelled advanced GLYCATION end products N {sup {epsilon}}-carboxymethyllysine (CML) and N {sup {epsilon}}-carboxyethyllysine (CEL …
  1652. Galectin-3,[Beta]-Galactoside-Binding Lectin, as a Receptor for Advanced GLYCATION End Products
  1653. Advanced GLYCATION endproducts—role in pathology of diabetic complications
  1654. Advanced GLYCATION end products and the kidney
  1655. Simple non-invasive assessment of advanced GLYCATION endproduct accumulation
  1656. Advanced GLYCATION in health and disease: role of the modern environment
  1657. Advanced GLYCATION end products: sparking the development of diabetic vascular injury
  1658. Analysis and prediction of mammalian protein GLYCATION
  1659. Advanced GLYCATION end-products and the progress of diabetic vascular complications
  1660. Inhibitory effect of naturally occurring flavonoids on the formation of advanced GLYCATION endproducts
  1661. The role of advanced GLYCATION end products in the development of atherosclerosis
  1662. GLYCATION endproducts in osteoporosis—is there a pathophysiologic importance?
  1663. Advanced GLYCATION endproducts (AGEs): pharmacological inhibition in diabetes
  1664. Glucose, GLYCATION and aging
  1665. Advanced GLYCATION end products and diabetic complications: a general overview
  1666. Protein GLYCATION: a firm link to endothelial cell dysfunction
  1667. Advanced GLYCATION endproduct crosslinking in the cardiovascular system
  1668. Advanced GLYCATION end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
  1669. Importance of measuring products of non-enzymatic GLYCATION of proteins
  1670. GLYCATION products as markers and predictors of the progression of diabetic complications
  1671. Advanced GLYCATION end product interventions reduce diabetes-accelerated atherosclerosis
  1672. Advanced GLYCATION end products and bone loss during aging
  1673. Randomized trial of an inhibitor of formation of advanced GLYCATION end products in diabetic nephropathy
  1674. Understanding RAGE, the receptor for advanced GLYCATION end products
  1675. Advanced GLYCATION end products and diabetic nephropathy
  1676. The clinical relevance of advanced GLYCATION endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation
  1677. Role of advanced GLYCATION end products and their receptors in development of diabetic neuropathy
  1678. Advanced GLYCATION end products in renal failure
  1679. Advanced GLYCATION end product ligands for the receptor for advanced GLYCATION end products: biochemical characterization and formation kinetics
  1680. Advanced GLYCATION end products (AGEs) and diabetic vascular complications
  1681. Involvement of advanced GLYCATION end-products (AGEs) in Alzheimer’s disease
  1682. Importance of advanced GLYCATION end products in diabetes-associated cardiovascular and renal disease
  1683. Association between serum levels of soluble receptor for advanced GLYCATION end products and circulating advanced GLYCATION end products in type 2 diabetes
  1684. Possible participation of advanced GLYCATION end products in the pathogenesis of osteoporosis in diabetic patients
  1685. Accumulation of advanced GLYCATION end products as a molecular mechanism for aging as a risk factor in osteoarthritis
  1686. Toxic advanced GLYCATION end products (TAGE) theory in Alzheimer’s disease
  1687. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic GLYCATION and oxidative damage
  1688. Advanced GLYCATION and endothelial functions: a link towards vascular complications in diabetes
  1689. Characterization of advanced GLYCATION end products for biochemical studies: side chain modifications and fluorescence characteristics
  1690. Advanced GLYCATION end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
  1691. Role of advanced GLYCATION end products (AGEs) in thrombogenic abnormalities in diabetes
  1692. Advanced GLYCATION end product receptor‐mediated cellular dysfunction
  1693. Positive association between serum levels of advanced GLYCATION end products and the soluble form of receptor for advanced GLYCATION end products in nondiabetic …
  1694. Soluble receptor for advanced GLYCATION end products: from disease marker to potential therapeutic target
  1695. Advanced GLYCATION End Product Cross‐Linking: Pathophysiologic Role and Therapeutic Target in Cardiovascular Disease
  1696. Assessment of protein GLYCATION markers in infant formulas
  1697. Association between acute-phase reactants and advanced GLYCATION end products in type 2 diabetes
  1698. Advanced GLYCATION and retinal pathology during diabetes
  1699. The receptor for advanced GLYCATION end products is highly expressed in the skin and upregulated by advanced GLYCATION end products and tumor necrosis …
  1700. Inhibitors of advanced GLYCATION end product formation and neurovascular dysfunction in experimental diabetes
  1701. Advanced GLYCATION end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study
  1702. Relationship of serum advanced GLYCATION end products with deterioration of periodontitis in type 2 diabetes patients
  1703. Purification and characterization of mouse soluble receptor for advanced GLYCATION end products (sRAGE)
  1704. Soluble receptor for advanced GLYCATION end products in patients with decreased renal function
  1705. Plasma levels of soluble receptor for advanced GLYCATION end products and coronary artery disease in nondiabetic men
  1706. Inhibition of advanced GLYCATION end product formation on collagen by rutin and its metabolites
  1707. Receptor for advanced GLYCATION end-products is a marker of type I cell injury in acute lung injury
  1708. Advanced GLYCATION end products in clinical nephrology
  1709. Pseudophosphorylation and GLYCATION of tau protein enhance but do not trigger fibrillization in vitro
  1710. Advanced GLYCATION endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells
  1711. Age-related changes in the GLYCATION of human aortic elastin
  1712. RAGE (receptor for advanced GLYCATION end products): a central player in the inflammatory response
  1713. Profound mishandling of protein GLYCATION degradation products in uremia and dialysis
  1714. Degradation products of proteins damaged by GLYCATION, oxidation and nitration in clinical type 1 diabetes
  1715. GLYCATION of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation
  1716. Assay of advanced GLYCATION endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection
  1717. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced GLYCATION end products
  1718. Advanced GLYCATION end products and nephrotoxicity of high-protein diets
  1719. Effect of nonenzymatic GLYCATION on functional and structural properties of hemoglobin
  1720. Skin autofluorescence, a measure of cumulative metabolic stress and advanced GLYCATION end products, predicts mortality in hemodialysis patients
  1721. Advanced GLYCATION End Products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and Argpyrimidine
  1722. Advanced GLYCATION end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process
  1723. Preventing activation of receptor for advanced GLYCATION endproducts in Alzheimer’s disease
  1724. Enzymatic digestion and mass spectrometry in the study of advanced GLYCATION end products/peptides
  1725. Protein-bound advanced GLYCATION endproducts (AGEs) as bioactive amino acid derivatives in foods
  1726. Increased accumulation of skin advanced GLYCATION end-products precedes and correlates with clinical manifestation of diabetic neuropathy
  1727. Fructose‐mediated non‐enzymatic GLYCATION: sweet coupling or bad modification
  1728. Decreased plasma levels of soluble receptor for advanced GLYCATION end-products in patients with essential hypertension
  1729. Peptide and amino acid GLYCATION: new insights into the Maillard reaction
  1730. Advanced GLYCATION endproducts in nondiabetic patients with obstructive sleep apnea
  1731. Oxidative stress, advanced GLYCATION end product, and coronary artery calcification in hemodialysis patients
  1732. Receptor for advanced GLYCATION end products (RAGE) regulates sepsis but not the adaptive immune response
  1733. Hyperglycemia, lipoprotein GLYCATION, and vascular disease
  1734. Oxidative stress and protein GLYCATION in diabetes mellitus
  1735. Age-and stage-dependent accumulation of advanced GLYCATION end products in intracellular deposits in normal and Alzheimer’s disease brains
  1736. Receptor for advanced-GLYCATION end products: key modulator of myocardial ischemic injury
  1737. Interactions between renin angiotensin system and advanced GLYCATION in the kidney
  1738. Receptor for advanced GLYCATION end‐products is a marker of type I lung alveolar cells
  1739. Roles of the receptor for advanced GLYCATION endproducts in diabetes-induced vascular injury
  1740. Flavonol glycosides from the leaves of Eucommia ulmoides O. with GLYCATION inhibitory activity
  1741. Tomato paste fraction inhibiting the formation of advanced GLYCATION end-products
  1742. Advanced GLYCATION end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings
  1743. Diabetes increases formation of advanced GLYCATION end products on Sarco (endo) plasmic reticulum Ca2+-ATPase
  1744. The effect of non-enzymatic GLYCATION on the unfolding of human serum albumin
  1745. Advanced GLYCATION end products and vascular structure and function
  1746. Increased levels of serum advanced GLYCATION end‐products in women with polycystic ovary syndrome
  1747. Thiazolidinediones reduce endothelial expression of receptors for advanced GLYCATION end products
  1748. Measurement of protein GLYCATION, glycated peptides, and GLYCATION free adducts
  1749. Characterisation of advanced GLYCATION endproducts in saliva from patients with diabetes mellitus
  1750. Contribution of the advanced GLYCATION end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar …
  1751. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced GLYCATION endproducts: an overview of current clinical studies, evidence …
  1752. Non-enzymatic GLYCATION of proteins: a cause for complications in diabetes
  1753. Receptor for advanced GLYCATION end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development
  1754. Advanced GLYCATION end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways
  1755. Advanced GLYCATION end products activate Smad signaling via TGF‐β‐dependent and‐independent mechanisms: implications for diabetic renal and vascular disease
  1756. Role of receptor for advanced GLYCATION end-products and signalling events in advanced GLYCATION end-product-induced monocyte chemoattractant protein-1 …
  1757. Enhanced expression of receptor for advanced GLYCATION end products in chronic kidney disease
  1758. Articular chondrocytes express the receptor for advanced GLYCATION end products: potential role in osteoarthritis
  1759. Mass spectrometry for the study of protein GLYCATION in disease
  1760. Accumulation of advanced GLYCATION end products, measured as skin autofluorescence, in renal disease
  1761. Receptor for advanced GLYCATION end products is involved in impaired angiogenic response in diabetes
  1762. The receptor for advanced GLYCATION end products and its ligands: a new inflammatory pathway in lung disease?
  1763. The expression of advanced GLYCATION endproduct receptors in rpe cells associated with basal deposits in human maculas
  1764. GLYCATION and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control …
  1765. Circulating levels of soluble receptor for advanced GLYCATION end products in Alzheimer disease and vascular dementia
  1766. Stimulation of glucose utilization and inhibition of protein GLYCATION and AGE products by taurine
  1767. Decreased endogenous secretory advanced GLYCATION end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications
  1768. GLYCATION of lysine‐containing dipeptides
  1769. Receptor for advanced GLYCATION end products and its ligands: a journey from the complications of diabetes to its pathogenesis
  1770. Advanced GLYCATION end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor
  1771. Increased methylglyoxal and advanced GLYCATION end products in kidney from spontaneously hypertensive rats
  1772. Advanced GLYCATION end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages
  1773. Advanced GLYCATION endproducts in peripheral nerve in type 2 diabetes with neuropathy
  1774. Expression profiling of endogenous secretory receptor for advanced GLYCATION end products in human organs
  1775. The role of mass spectrometry in the study of non‐enzymatic protein GLYCATION in diabetes: An update
  1776. Modulation of soluble receptor for advanced GLYCATION end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy
  1777. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced GLYCATION end products
  1778. S100P stimulates cell proliferation and survival via receptor for activated GLYCATION end products (RAGE)
  1779. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced GLYCATION end products
  1780. Receptor for advanced GLYCATION end products and age-related macular degeneration
  1781. Reduced cell replication and induction of apoptosis by advanced GLYCATION end products in rat Schwann cells
  1782. Advanced GLYCATION end‐products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone
  1783. Cross-linking in collagen by nonenzymatic GLYCATION increases the matrix stiffness in rabbit achilles tendon
  1784. Connective tissue growth factor plays an important role in advanced GLYCATION end product–induced tubular epithelial-to-mesenchymal transition: implications for …
  1785. Evaluation of advanced GLYCATION end products and carbonyl compounds in patients with different conditions of oxidative stress
  1786. Benfotiamine prevents macro-and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced GLYCATION end products in individuals …
  1787. Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced GLYCATION endproducts and protein modification
  1788. Advanced GLYCATION end-products in patients with chronic alcohol misuse
  1789. Role of collagen enzymatic and GLYCATION induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats
  1790. Circulating soluble receptor for advanced GLYCATION end products is inversely associated with glycemic control and S100A12 protein
  1791. Decreased levels of soluble receptor for advanced GLYCATION end products in patients with rheumatoid arthritis indicating deficient inflammatory control
  1792. Argpyrimidine, a methylglyoxal-derived advanced GLYCATION end-product in familial amyloidotic polyneuropathy
  1793. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and GLYCATION
  1794. GLYCATION stimulates amyloid formation
  1795. Down-regulation of the receptor for advanced GLYCATION end-products (RAGE) supports non-small cell lung carcinoma
  1796. Advanced GLYCATION end product precursors impair ABCA1-dependent cholesterol removal from cells
  1797. Glyceraldehyde-derived advanced GLYCATION end products in Alzheimer’s disease
  1798. Effect of advanced GLYCATION end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells
  1799. GLYCATION, ageing and carnosine: are carnivorous diets beneficial?
  1800. Soluble levels of receptor for advanced GLYCATION endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?
  1801. Effect of lipid peroxides and antioxidants on GLYCATION of hemoglobin: an in vitro study on human erythrocytes
  1802. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced GLYCATION end products
  1803. Expression of receptor for advanced GLYCATION end products and HMGB1/amphoterin in colorectal adenomas
  1804. Effect of advanced GLYCATION end products on accelerated apoptosis of retinal capillary cells under in vitro conditions
  1805. GLYCATION increases human annulus fibrosus stiffness in both experimental measurements and theoretical predictions
  1806. Evidence for independent heritability of the GLYCATION gap (glycosylation gap) fraction of HbA1c in nondiabetic twins
  1807. Trabecular microfracture and the influence of pyridinium and non-enzymatic GLYCATION-mediated collagen cross-links
  1808. Advanced GLYCATION end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway
  1809. GLYCATION inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes
  1810. A novel advanced GLYCATION index and its association with diabetes and microangiopathy
  1811. Improvement of functional properties of whey protein isolate through GLYCATION and phosphorylation by dry heating
  1812. Positive association of serum levels of advanced GLYCATION end products with thrombogenic markers in humans
  1813. Extracellular GLYCATION crosslinks: prospects for removal
  1814. Impaired retinal angiogenesis in diabetes: role of advanced GLYCATION end products and galectin-3
  1815. Effects of oxidative modifications induced by the GLYCATION of bovine serum albumin on its structure and on cultured adipose cells
  1816. Protein GLYCATION, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment
  1817. Advanced GLYCATION endproducts interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix
  1818. Possible participation of advanced GLYCATION end products in the pathogenesis of colorectal cancer in diabetic patients
  1819. Expression of the receptor of advanced GLYCATION end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing …
  1820. Impact of Maillard type GLYCATION on properties of beta-lactoglobulin
  1821. Advanced GLYCATION end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent …
  1822. Naphthopyrone glucosides from the seeds of Cassia tora with inhibitory activity on advanced GLYCATION end products (AGEs) formation
  1823. Analysis of protein GLYCATION products by MALDI‐TOF/MS
  1824. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in GLYCATION-induced pentosidine in the femoral neck cortex in cases of …
  1825. GLYCATION free adduct accumulation in renal disease: the new AGE
  1826. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced GLYCATION end-products
  1827. Elevated serum levels of N ε-carboxymethyl-lysine, an advanced GLYCATION end product, are associated with proliferative diabetic retinopathy and macular …
  1828. Blockade of receptor for advanced GLYCATION end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice
  1829. Characterization of advanced GLYCATION end products: mass changes in correlation to side chain modifications
  1830. Advanced-GLYCATION end products in insulin-resistant states
  1831. Clinical studies of advanced GLYCATION end product inhibitors and diabetic kidney disease
  1832. Increased serum concentrations of soluble receptor for advanced GLYCATION endproducts in patients with type 1 diabetes
  1833. High serum levels of advanced GLYCATION end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a …
  1834. Expression of receptor for advanced GLYCATION end products (RAGE) and MMP-9 in human pancreatic cancer cells.
  1835. Advanced GLYCATION endproduct-induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response
  1836. Accumulation of advanced GLYCATION end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress
  1837. Increased serum levels of the specific advanced GLYCATION end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 …
  1838. Ascorbic acid, GLYCATION, glycohemoglobin and aging
  1839. Activation of receptor for advanced GLYCATION end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes
  1840. Type IV collagen is transcriptionally regulated by Smad1 under advanced GLYCATION end product (AGE) stimulation
  1841. Key role of Src kinase in S100B-induced activation of the receptor for advanced GLYCATION end products in vascular smooth muscle cells
  1842. Inhibitory effect of some selected nutraceutic herbs on LDL GLYCATION induced by glucose and glyoxal
  1843. Pigment epithelium-derived factor inhibits advanced GLYCATION end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated …
  1844. Soluble receptor for advanced GLYCATION end products triggers a proinflammatory cytokine cascade via β2 integrin Mac‐1
  1845. Advanced GLYCATION end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes
  1846. Protection against GLYCATION and similar post-translational modifications of proteins
  1847. High levels of soluble receptor for advanced GLYCATION end products may be a marker of extreme longevity in humans
  1848. High levels of dietary advanced GLYCATION end products transform low-dersity lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in …
  1849. Protein and low molecular mass thiols as targets and inhibitors of GLYCATION reactions
  1850. Effect of buformin and metformin on formation of advanced GLYCATION end products by methylglyoxal
  1851. Receptor for advanced GLYCATION end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine
  1852. Inhibition of human endothelial cell nitric oxide synthesis by advanced GLYCATION end-products but not glucose: relevance to diabetes
  1853. Effect of advanced GLYCATION end-products on cell proliferation and cell death
  1854. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced GLYCATION end product cross-link breaker ALT-711 via a protein kinase C-α …
  1855. Rapid method for the preparation of an AGE‐BSA standard calibrator using thermal GLYCATION
  1856. … GLYCATION end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced GLYCATION …
  1857. Diabète sucré, stress oxydant et produits de GLYCATION avancée
  1858. A comparison of the glycosylation gap and hemoglobin GLYCATION index in patients with diabetes
  1859. Below the Radar: Advanced GLYCATION End Products that Detour “around the side”: Is HbA1c not an accurate enough predictor of long term progression and …
  1860. The advanced GLYCATION end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis
  1861. Yeast protein GLYCATION in vivo by methylglyoxal: Molecular modification of glycolytic enzymes and heat shock proteins
  1862. Serum levels of advanced GLYCATION end products are associated with in-stent restenosis in diabetic patients
  1863. Association of expression of receptor for advanced GLYCATION end products and invasive activity of oral squamous cell carcinoma
  1864. Relationship between the expression of advanced GLYCATION end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy
  1865. Increased protein GLYCATION in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin
  1866. Advanced GLYCATION End Products Activate a Chymase-Dependent Angiotensin II–Generating Pathway in Diabetic Complications
  1867. GLYCATION and advanced GLYCATION end-products in laboratory experiments in vivo and in vitro
  1868. Advanced GLYCATION end products and oxidative stress are increased in chronic allograft nephropathy
  1869. Advanced GLYCATION end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes
  1870. Atorvastatin decreases serum levels of advanced GLYCATION end products (AGEs) in patients with type 2 diabetes
  1871. Autofluorescence characterization of advanced GLYCATION end products of hemoglobin
  1872. Candesartan reduced advanced GLYCATION end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice
  1873. From benefit to damage. Glutamate and advanced GLYCATION end products in Alzheimer brain
  1874. Expression of a novel secreted splice variant of the receptor for advanced GLYCATION end products (RAGE) in human brain astrocytes and peripheral blood …
  1875. Advanced GLYCATION End Products in Diabetes‐Associated Atherosclerosis and Renal Disease: Interventional Studies
  1876. Increased pentosidine, an advanced GLYCATION end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric …
  1877. Increased expression of receptor for advanced GLYCATION end products by synovial tissue macrophages in rheumatoid arthritis
  1878. Constituents of the roots of Pueraria lobata inhibit formation of advanced GLYCATION end products (AGEs)
  1879. The role of reactive oxygen species in TNFα-dependent expression of the receptor for advanced GLYCATION end products in human umbilical vein endothelial …
  1880. Are food advanced GLYCATION end products toxic in biological systems?
  1881. Effects of sterilization, packaging, and storage on vitamin C degradation, protein denaturation, and GLYCATION in fortified milks
  1882. Processing of protein GLYCATION, oxidation and nitrosation adducts in the liver and the effect of cirrhosis
  1883. Synergistic action of advanced GLYCATION end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic …
  1884. Pathological roles of advanced GLYCATION end product receptors SR‐A and CD36
  1885. Elevation of Nε-(carboxymethyl) lysine-modified advanced GLYCATION end products in chronic liver disease is an indicator of liver cirrhosis
  1886. Increased protein GLYCATION in fructosamine 3-kinase-deficient mice
  1887. Decreased levels of advanced GLYCATION end-products in patients with Gilbert syndrome.
  1888. The role of advanced GLYCATION in reduced organic cation transport associated with experimental diabetes
  1889. Puerariafuran, a new inhibitor of advanced GLYCATION end products (AGEs) isolated from the roots of Pueraria lobata
  1890. Genotoxicity of advanced GLYCATION end products: involvement of oxidative stress and of angiotensin II type 1 receptors
  1891. Protein GLYCATION in Saccharomyces cerevisiae Argpyrimidine formation and methylglyoxal catabolism
  1892. Advanced GLYCATION end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts
  1893. Advanced GLYCATION end products can induce glial reaction and neuronal degeneration in retinal explants
  1894. Advanced GLYCATION end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy
  1895. GLYCATION, glycoxidation and diabetes mellitus
  1896. S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced GLYCATION endproducts in human endothelial cells
  1897. Advanced GLYCATION end products increase collagen-specific chaperone protein in mouse diabetic nephropathy
  1898. Advanced GLYCATION end-products and peritoneal sclerosis
  1899. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced GLYCATION end-product, tissue factor and TNF-α
  1900. Significance of proximal tubular metabolism of advanced GLYCATION end products in kidney diseases
  1901. Advanced GLYCATION end‐products in sickle cell anaemia
  1902. Carnosine protects against the inactivation of esterase induced by GLYCATION and a steroid
  1903. Role of vitamin E-coated membrane in reducing advanced GLYCATION end products in hemodialysis patients: a pilot study
  1904. Site specificity of GLYCATION and carboxymethylation of bovine serum albumin by fructose
  1905. Identification of the receptor for advanced GLYCATION end products in synovial tissue of patients with rheumatoid arthritis
  1906. Bimodal effect of advanced GLYCATION end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids
  1907. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced GLYCATION end products
  1908. Increased expression of advanced GLYCATION end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats
  1909. An in Vitro Approach to the Chronological Aging of Skin by GLYCATION of the Collagen: The Biological Effect of GLYCATION on the Reconstructed Skin Model
  1910. The advanced GLYCATION end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney …
  1911. GLYCATION of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells
  1912. Increased protein GLYCATION in cirrhosis and therapeutic strategies to prevent it
  1913. Lipoic acid improves glucose utilisation and prevents protein GLYCATION and AGE formation
  1914. Blockade of the receptor for advanced GLYCATION end products attenuates acetaminophen‐induced hepatotoxicity in mice
  1915. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced GLYCATION end-products in renal transplant …
  1916. Advanced GLYCATION end‐products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor‐induced ICAM‐1 expression …
  1917. Advanced GLYCATION end products modulate the maturation and function of peripheral blood dendritic cells
  1918. High‐fat diet enhances visceral advanced GLYCATION end products, nuclear O‐Glc‐Nac modification, p38 mitogen‐activated protein kinase activation and apoptosis
  1919. Identification of mouse orthologue of endogenous secretory receptor for advanced GLYCATION end-products: structure, function and expression
  1920. Nonenzymatic GLYCATION of DNA nucleosides with reducing sugars
  1921. Angiotensin II augments advanced GLYCATION end product-induced pericyte apoptosis through RAGE overexpression
  1922. Solid‐state GLYCATION of β‐lactoglobulin by lactose and galactose: localization of the modified amino acids using mass spectrometric techniques
  1923. Suppression of nNOS expression in rat enteric neurones by the receptor for advanced GLYCATION end‐products
  1924. Aminophospholipid GLYCATION and its inhibitor screening system: a new role of pyridoxal 5′-phosphate as the inhibitor
  1925. Evidence for inactivation of cysteine proteases by reactive carbonyls via GLYCATION of active site thiols
  1926. A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced GLYCATION end-products
  1927. Depression of progenitor cell function by advanced GLYCATION endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes
  1928. Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced GLYCATION end products (AGE)-elicited retinal leukostasis
  1929. Differential effects of “advanced GLYCATION endproducts” and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y
  1930. Concentrations of pentosidine, an advanced GLYCATION end-product, in umbilical cord blood
  1931. Polymorphisms of the receptor of advanced GLYCATION endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients
  1932. Telmisartan inhibits expression of a receptor for advanced GLYCATION end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of …
  1933. Effect of limited solid-state GLYCATION on the conformation of lysozyme by ESI-MSMS peptide mapping and molecular modeling
  1934. Advanced GLYCATION endproducts: implications for accelerated atherosclerosis in diabetes
  1935. Two immunochemical assays to measure advanced GLYCATION end-products in serum from dialysis patients
  1936. Morroniside and loganin extracted from Cornus officinalis have protective effects on rat mesangial cell proliferation exposed to advanced GLYCATION end products by …
  1937. Hepatocyte growth factor protects human endothelial cells against advanced GLYCATION end products-induced apoposis
  1938. Chemoselective synthesis of peptides containing major advanced GLYCATION end‐products of lysine and arginine
  1939. In vitro GLYCATION of human immunoglobulin G
  1940. Low‐Molecular Weight Advanced GLYCATION End Products: Markers of Tissue AGE Accumulation and More?
  1941. Evaluation of the site specific protein GLYCATION and antioxidant capacity of rare sugar− protein/peptide conjugates
  1942. Antioxidants and an inhibitor of advanced GLYCATION ameliorate death of retinal microvascular cells in diabetic retinopathy
  1943. Characterisation of the advanced GLYCATION endproduct receptor complex in the retinal pigment epithelium
  1944. Effect of advanced GLYCATION end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells.
  1945. Receptor for advanced GLYCATION end products is a promising target of diabetic nephropathy
  1946. Inhibition by L-arginine and spermidine of hemoglobin GLYCATION and lipid peroxidation in rats with induced diabetes
  1947. C-Reactive protein upregulates receptor for advanced GLYCATION end products expression in human endothelial cells
  1948. Gender-related differences in advanced GLYCATION endproducts, oxidative stress markers and nitric oxide synthases in rats
  1949. Green tea impedes dyslipidemia, lipid peroxidation, protein GLYCATION and ameliorates Ca2+-ATPase and Na+/K+-ATPase activity in the heart of streptozotocin …
  1950. The effects of valsartan on the accumulation of circulating and renal advanced GLYCATION end products in experimental diabetes
  1951. Expression of the receptor for advanced GLYCATION end products in Huntington’s disease caudate nucleus
  1952. Advanced GLYCATION end product in diabetic rat skeletal muscle in vivo
  1953. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced GLYCATION end-products
  1954. Advanced GLYCATION end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction
  1955. Low molecular weight advanced GLYCATION end products predict mortality in asymptomatic patients receiving chronic haemodialysis
  1956. Intrinsic toxicity of glucose, due to non-enzymatic GLYCATION, is controlled in-vivo by deGLYCATION systems including: FN3K-mediated deGLYCATION of fructosamines and …
  1957. Substrates modified by advanced GLYCATION end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet …
  1958. The amphoterin (HMGB1)/receptor for advanced GLYCATION end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and …
  1959. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced GLYCATION end products (AGEs) may be a promising biomarker for early detection of …
  1960. Tissue‐Specific Variation in GLYCATION of Proteins in Diabetes: Evidence for a Functional Role of Amadoriase Enzymes
  1961. Advanced GLYCATION end-products (AGEs) in hyperglycemic patients
  1962. High‐dose thiamine therapy counters dyslipidemia and advanced GLYCATION of plasma protein in streptozotocin‐induced diabetic rats
  1963. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced GLYCATION end products links oxidative stress to altered retinal …
  1964. Analysis of protein GLYCATION products by matrix-assisted laser desorption ionization time-of-flight mass spectrometry
  1965. The breakdown of preformed advanced GLYCATION end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative …
  1966. Immunohistochemical localization of advanced GLYCATION end products in pinguecula
  1967. Relation between development of nephropathy and the p22phox C242T and receptor for advanced GLYCATION end product G1704T gene polymorphisms in type 2 …
  1968. Nifedipine inhibits gene expression of receptor for advanced GLYCATION end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
  1969. Regulation of inducible nitric oxide synthase expression in advanced GLYCATION end product–stimulated RAW 264.7 cells: the role of heme oxygenase-1 and …
  1970. Changes in GLYCATION and oxidation markers in patients starting peritoneal dialysis: a pilot study
  1971. Advanced GLYCATION End Products/Peptides: An in Vivo Investigation
  1972. GLYCATION-induced inactivation of NADP+-dependent isocitrate dehydrogenase: implications for diabetes and aging
  1973. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced GLYCATION end products formation
  1974. Susceptibility of brain microvascular endothelial cells to advanced GLYCATION end products-induced tissue factor upregulation is associated with intracellular reactive …
  1975. Advanced GLYCATION end product free adducts are cleared by dialysis
  1976. Genomic damage in end-stage renal failure: potential involvement of advanced GLYCATION end products and carbonyl stress
  1977. Receptor for advanced GLYCATION endproduct (RAGE)–mediated nuclear factor‐κB activation in vasculitic neuropathy
  1978. Peroxisome proliferator-activated receptor γ down-regulates receptor for advanced GLYCATION end products and inhibits smooth muscle cell proliferation in a diabetic …
  1979. Therapeutic effect of green tea extract on advanced GLYCATION and cross‐linking of collagen in the aorta of streptozotocin diabetic rats
  1980. Bridging advanced GLYCATION end product, receptor for advanced GLYCATION end product and nitric oxide with hormonal replacement/estrogen therapy in …
  1981. The advanced GLYCATION end-product Nɛ-(carboxymethyl) lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
  1982. C16, a novel advanced GLYCATION endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats1
  1983. Differential expression of receptors for advanced GLYCATION end‐products in peritoneal mesothelial cells exposed to glucose degradation products
  1984. Expression and purification of recombinant human receptor for advanced GLYCATION endproducts in Escherichia coli
  1985. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced GLYCATION end products
  1986. Advanced GLYCATION end products and hyperglycaemia
  1987. Advanced GLYCATION and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy
  1988. The− 374A allele of the receptor for advanced GLYCATION end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with …
  1989. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced GLYCATION end products in endothelial cells
  1990. Hydrazine compounds inhibit GLYCATION of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low …
  1991. Conversion of arginine into ornithine by advanced GLYCATION in senescent human collagen and lens crystallins
  1992. GLYCATION of CD59 impairs complement regulation on erythrocytes from diabetic subjects
  1993. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced GLYCATION end products
  1994. Identification of monoclonal antibody of advanced GLYCATION end products
  1995. Receptor for advanced GLYCATION end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing
  1996. Hepatic clearance of advanced GLYCATION end products (AGEs)—myth or truth?
  1997. Blockade of angiotensin II receptors reduces the expression of receptors for advanced GLYCATION end products in human endothelial cells
  1998. In Vitro Nonenzymatic GLYCATION Enhances the Role of Myoglobin as a Source of Oxidative Stress
  1999. Clinical implications of Nε‐(carboxymethyl)lysine, advanced GLYCATION end product, in children and adolescents with type 1 diabetes
  2000. Collagen GLYCATION and its role in fracture properties of bone
  2001. GLYCATION of Proteins in Escherichia Coli: Effect of Nutrient Broth Ingredients on GLYCATION
  2002. Induction of reactive oxygen species and cell survival in the presence of advanced GLYCATION end products and similar structures
  2003. Renal accumulation and clearance of advanced GLYCATION end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and …
  2004. Therapeutic potentials of unicellular green alga Chlorella in advanced GLYCATION end product (AGE)-related disorders
  2005. A comparative study of lens protein GLYCATION in various forms of cataract
  2006. Advanced GLYCATION end product (age) inhibitors and their therapeutic implications in diseases.
  2007. … and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by β-amyloid peptide acting through receptor for advanced GLYCATION end products (RAGE …
  2008. Amino acids injure mesangial cells by advanced GLYCATION end products, oxidative stress, and protein kinase C
  2009. Effects of in Vitro GLYCATION on Fe3+ Binding and Fe3+ Isoforms of Transferrin
  2010. Immunochemical crossreactivity of antibodies specific for “advanced GLYCATION endproducts” with “advanced lipoxidation endproducts”
  2011. Effect of phosphate buffer on the kinetics of GLYCATION of proteins
  2012. Study on the effect of garlic on the in vitro albumin GLYCATION reaction
  2013. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced GLYCATION end products
  2014. Advanced GLYCATION and oxidation products in patients with atherosclerosis
  2015. GLYCATION of caseinate by fructose and fructo‐oligosaccharides during controlled heat treatment in the ‘dry’state
  2016. Skin autofluorescence, a marker of advanced GLYCATION end products and oxidative stress, is increased in recently preeclamptic women
  2017. Effects of advanced GLYCATION end products on hyaluronan photolysis: a new mechanism of diabetic vitreopathy
  2018. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and GLYCATION in Japanese type 2 diabetic subjects: blood pressure-independent effect of …
  2019. Exploring the antioxidant property of bioflavonoid quercetin in preventing DNA GLYCATION: A calorimetric and spectroscopic study
  2020. An oral load of the early GLYCATION compound lactuloselysine fails to accumulate in the serum of uraemic patients
  2021. Expression and purification of the soluble isoform of human receptor for advanced GLYCATION end products (sRAGE) from Pichia pastoris
  2022. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced GLYCATION end-product–induced proliferation in renal fibroblasts
  2023. Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced GLYCATION end product expression in human microvascular …
  2024. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced GLYCATION end products: inhibitory effect of gliclazide
  2025. Dietary bread crust advanced GLYCATION end products bind to the receptor for AGEs in HEK‐293 kidney cells but are rapidly excreted after oral administration to healthy …
  2026. Developmental expression of receptor for advanced GLYCATION end products (RAGE), amphoterin and sulfoglucuronyl (HNK‐1) carbohydrate in mouse cerebellum and …
  2027. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced GLYCATION …
  2028. Advanced GLYCATION end-product induces fractalkine gene upregulation in normal rat glomeruli
  2029. N-Terminal pyrazinones: a new class of peptide-bound advanced GLYCATION end-products
  2030. Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced GLYCATION end products
  2031. Nonenzymatic GLYCATION at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies
  2032. Advanced GLYCATION end-products downregulating intervertebral disc cell production of proteoglycans in vitro
  2033. Effect of GLYCATION of hemoglobin on its interaction with trifluoperazine
  2034. Advanced GLYCATION end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous …
  2035. Oxidative stress and protein GLYCATION in patients with chronic obstructive pulmonary disease
  2036. Evidence for the role of lipid peroxides on GLYCATION of hemoglobin and plasma proteins in non-diabetic asthma patients
  2037. Advanced GLYCATION end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36
  2038. a-Series gangliosides mediate the effects of advanced GLYCATION end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal …
  2039. Effect of high-dose thiamine and pyridoxine on advanced GLYCATION end products and other oxidative stress markers in hemodialysis patients: a randomized placebo …
  2040. Advanced GLYCATION end‐product‐induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK‐49F cells
  2041. Diabetes mellitus exacerbates advanced GLYCATION end product accumulation in the veins of end-stage renal failure patients
  2042. Pentoxyphylline and propentophylline are inhibitors of TNF-α release in monocytes activated by advanced GLYCATION endproducts
  2043. Pigment epithelium-derived factor (PEDF) inhibits advanced GLYCATION end product (AGE)-induced C-reactive protein expression in hepatoma cells by …
  2044. Age-dependent expression of advanced GLYCATION end product receptor genes in the human heart
  2045. Age-related loss in bone toughness is explained by non-enzymatic GLYCATION of collagen
  2046. In vitro nonenzymatic GLYCATION of DNA nucleobases: an evaluation of advanced GLYCATION end products under alkaline pH
  2047. Redox-related cytotoxic responses to different casein GLYCATION products in Caco-2 and Int-407 cells
  2048. Reassessing the increased GLYCATION of hemoglobin in nondiabetic chronic renal failure patients: a hypothesis on the role of lipid peroxides
  2049. Leptin and connective tissue growth factor in advanced GLYCATION end‐product‐induced effects in NRK‐49F cells
  2050. GLYCATION-induced inactivation of antioxidant enzymes and modulation of cellular redox status in lens cells
  2051. Urinary excretion of advanced GLYCATION endproducts in patients with type 2 diabetes and various stages of proteinuria
  2052. Advanced GLYCATION end products induce death of retinal neurons via activation of nitric oxide synthase
  2053. Oxidative stress and non-enzymatic GLYCATION in IgA nephropathy.
  2054. A novel method to quantify in vivo transferrin GLYCATION: applications in diabetes mellitus
  2055. … inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced GLYCATION end products (RAGE)
  2056. The effect of non-enzymatic GLYCATION of extracellular matrix proteins on axonal regeneration in vitro
  2057. Effect of GLYCATION on stability and kinetic parameters of thermostable glucoamylase from Aspergillus niger
  2058. Nuclear factor-κB and advanced GLYCATION end-products expression in lacrimal glands of aging rats
  2059. Advanced GLYCATION end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells THIS ARTICLE HAS BEEN RETRACTED
  2060. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced GLYCATION end product-induced vascular cell adhesion molecule-1 expression in endothelial …
  2061. Nitrite-modified extracellular matrix proteins deleteriously affect retinal pigment epithelial cell function and viability: a comparison study with nonenzymatic GLYCATION …
  2062. Glucose metabolism, advanced GLYCATION endproducts, and cognition
  2063. Cytotoxicity of acetaldehyde‐derived advanced GLYCATION end‐products (AA‐AGE) in alcoholic‐induced neuronal degeneration
  2064. Mechanism of advanced GLYCATION end products-induced hyperpermeability in endothelial cells
  2065. Advanced GLYCATION end product is implicated in amyloid‐related kidney complications
  2066. Effect of buffer carbonate and arsenate on the kinetics of GLYCATION of human hemoglobin
  2067. ε-GLYCATION, APP and Aβ in ageing and Alzheimer disease: a hypothesis
  2068. Polyclonal antibodies inhibit the GLYCATION‐induced inactivation of bovine Cu, Zn‐superoxide dismutase
  2069. Apoptotic killing of fibroblasts by matrix-bound advanced GLYCATION endproducts
  2070. Detection of DNA‐bound advanced GLYCATION end‐products by immunoaffinity chromatography coupled to HPLC‐diode array detection
  2071. Screening of Korea Traditional Herbal Medicines with Inhibitory Activity on Advanced GLYCATION End Products (AGEs) Formation
  2072. N2-carboxyethyl-2′-deoxyguanosine, a DNA GLYCATION marker, in kidneys and aortas of diabetic and uremic patients
  2073. GLYCATION of interferon-beta-1b and human serum albumin in a lyophilized glucose formulation: Part III: Application of proteomic analysis to the manufacture of …
  2074. Influence of hemodialysis membrane permeability on serum levels of advanced GLYCATION end products (AGEs) and homocysteine metabolites.
  2075. Monitoring the effect of glucosamine and glyceraldehyde GLYCATION on the secondary structure of human serum albumin and immunoglobulin G: An analysis based on …
  2076. Renoprotective and Lipid‐Lowering Effects of LR Compounds, Novel Advanced GLYCATION End Product Inhibitors, in Streptozotocin‐Induced Diabetic Rats
  2077. Can advanced GLYCATION end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
  2078. Advanced GLYCATION end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation …
  2079. Interaction between the polyol pathway and non-enzymatic GLYCATION on mesangial cell gene expression
  2080. Cardiovascular risk in patients with end-stage renal disease: a potential role for advanced GLYCATION end products
  2081. Chemistry and Biological Effects of Melanoidins and Glyceraldehyde‐Derived Pyridinium as Advanced GLYCATION End Products
  2082. Compounds that combine aldose reductase inhibitory activity and ability to prevent the GLYCATION (glucation and/or fructation) of proteins as putative …
  2083. The roles of protein GLYCATION, glycoxidation, and advanced GLYCATION end-product formation in diabetes-induced atherosclerosis
  2084. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced GLYCATION end products in aortic wall of cholesterol and fructose-fed rabbits
  2085. Overexpression of receptor of advanced GLYCATION end products hypersensitizes cells for amyloid beta peptide-induced cell death
  2086. Insulin resistance and enhanced protein GLYCATION in men with prehypertension
  2087. Pentosidine, an advanced GLYCATION endproduct, and arthritis
  2088. Advanced GLYCATION end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression
  2089. Flavonols from Houttuynia cordata with protein GLYCATION and aldose reductase inhibitory activity
  2090. Interaction between the polyol pathway and non-enzymatic GLYCATION on aortic smooth muscle cell migration and monocyte adhesion
  2091. In vitro GLYCATION of human IgG and its effect on interaction with anti-IgG
  2092. Meniscal material properties are minimally affected by matrix stabilization using glutaraldehyde and GLYCATION with ribose
  2093. Immunolocalization of lipid peroxidation/advanced GLYCATION end products in amyloid A amyloidosis
  2094. A matrix‐assisted laser desorption/ionization mass spectrometry study of the non‐enzymatic GLYCATION products of human globins in diabetes
  2095. Association of advanced GLYCATION end products with A549 cells, a human pulmonary epithelial cell line, is mediated by a receptor distinct from the scavenger receptor …
  2096. Non‐enzymatic model GLYCATION reactions—a comprehensive study of the reactivity of a modified arginine with aldehydic and diketonic dicarbonyl compounds by …
  2097. The effect of packed red blood cell storage on arachidonic acid and advanced GLYCATION end-product formation
  2098. Impact of in vivo GLYCATION of LDL on platelet aggregation and monocyte chemotaxis in diabetic Psammomys obesus
  2099. The effect of GLYCATION on the chemical and enzymatic stability of the endogenous opioid peptide, leucine–enkephalin, and related fragments
  2100. Advanced GLYCATION end products: a possible link to angiotensin in an animal model
  2101. Advanced GLYCATION endproduct modified basement membrane attenuates endothelin-1 induced [Ca 2+] i signalling and contraction in retinal microvascular …
  2102. Advanced GLYCATION end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature
  2103. Immunological consequences of methamphetamine protein GLYCATION
  2104. Advanced GLYCATION end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner
  2105. Advanced GLYCATION: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy
  2106. The complexity of non-enzymatic GLYCATION product sets of human globins
  2107. Inhibition by advanced GLYCATION end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.
  2108. Glyceraldehyde-derived advanced GLYCATION end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes
  2109. Increased expression of tissue factor and receptor for advanced GLYCATION end products in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus …
  2110. Detection of dideoxyosone intermediates of GLYCATION using a monoclonal antibody: characterization of major epitope structures
  2111. Mass spectrometry of advanced GLYCATION end products
  2112. Paradox of circulating advanced GLYCATION end product concentrations in patients with congestive heart failure and after heart transplantation
  2113. Effects of aspirin on GLYCATION, glycoxidation, and crosslinking of collagen
  2114. Phototransformations of advanced GLYCATION end products in the human eye lens due to ultraviolet A light irradiation
  2115. Receptor of advanced GLYCATION end product (RAGE) expression in the minor salivary glands of patients with Sjo˝ gren’s syndrome: a preliminary study
  2116. Early GLYCATION products of endothelial plasma membrane proteins in experimental diabetes
  2117. Protective ability and binding affinity of captopril towards serum albumin in an in vitro GLYCATION model of diabetes mellitus
  2118. Histone H1 as a reporter protein to investigate GLYCATION in bacteria
  2119. Effects of Glucose and α‐Tocopherol on Low‐Density Lipoprotein Oxidation and GLYCATION
  2120. Nonenzymatic GLYCATION affects bone fracture by modifying creep and inelastic properties of collagen
  2121. Advanced GLYCATION end products accelerate atherosclerosis via enhancement of oxidative stress
  2122. … in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin GLYCATION at specific sites
  2123. The effect of GLYCATION of CD59 on complement-mediated cytolysis
  2124. The Gly82Ser polymorphism of the receptor of advanced GLYCATION end product (RAGE) gene is not associated with type 1 or type 2 diabetes in a Brazilian population
  2125. Advanced GLYCATION endproducts in the development of osteoarthritis
  2126. Capillary electrophoretic analysis of advanced GLYCATION endproducts formed from the reaction of reducing sugars with the amino group of glucosamine
  2127. GLYCATION and RAGE: Common links in the pathogenesis of microvascular and macrovascular complications of diabetes
  2128. Troglitazone inhibits long-term GLYCATION and oxidation of low-density lipoprotein
  2129. Cloning and characterization of the canine receptor for advanced GLYCATION end products
  2130. Green tea polyphenols inhibit advanced GLYCATION end product-induced rat vascular smooth muscle cell proliferation.
  2131. Enzyme GLYCATION influences product yields during oligosaccharide synthesis by reverse hydrolysis
  2132. 2-ammonio-6-(3-oxidopyridinium-1-yl) hexanoate (OP-lysine) is a newly identified advanced GLYCATION end product in cataractous and aged human lenses
  2133. Intact GLYCATION end products containing carboxymethyl-lysine and glyoxal lysine dimer obtained from synthetic collagen model peptide
  2134. Effect of non-enzymatic GLYCATION on aluminium-induced lipid peroxidation of human high density lipoproteins (HDL)
  2135. 2, 3-Dimethoxy-5-methyl-1, 4-benzoquinones and 2-methyl-1, 4-naphthoquinones: GLYCATION inhibitors with lipid peroxidation activity
  2136. In vitro screening of nonenzyme GLYCATION inhibitor
  2137. Antioxidant effect of Turmeric and saffron on the oxidation of hepatocytes, LDL and non-enzymatic GLYCATION of hemoglobin
  2138. The induction of surface β-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced GLYCATION end products
  2139. Experimental effect of Puerarin on the formation of advanced GLYCATION end products and expression of RAGE in the arota of diabetic rats [J]
  2140. Processing Advanced GLYCATION End Product‐Modified Albumin by the Renal Proximal Tubule and the Early Pathogenesis of Diabetic Nephropathy
  2141. Towards the control and inhibition of GLYCATION—the role of the guanidine reaction center with aldehydic and diketonic dicarbonyls. A mass spectrometry study
  2142. Protective effects of carnosine and relative compounds on DNA cleavage by advanced GLYCATION end products
  2143. GLYCATION of caseinmacropeptide
  2144. … expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced GLYCATION endproduct-specific receptor …
  2145. Analysis of serum of patients with Alzheimer’s disease for the level of advanced GLYCATION end products
  2146. Detection and determination of glyceraldehyde-derived advanced GLYCATION end product
  2147. Nonenzymatic GLYCATION causes loss of toughening mechanisms in human cancellous bone
  2148. GLYCATION-induced inactivation of aspartate aminotransferase, effect of uric acid
  2149. Magnesium-dependent phosphatase-1 is a protein-fructosamine-6-phosphatase potentially involved in GLYCATION repair
  2150. Constituents of the stems of Rumex japonicus with advanced GLYCATION end products (AGEs) and rat lens aldose reductase (RLAR) inhibitory activity
  2151. Nonenzymatic GLYCATION of plasma proteins in smokers
  2152. Isolation and identification of 5-methyl-imidazolin-4-one derivative as glyceraldehyde-derived advanced GLYCATION end product
  2153. Effects of Advanced GLYCATION End Products on Ezrin‐Dependent Functions in LLC‐PK1 Proximal Tubule Cells
  2154. AU-rich elements in the mRNA 3′-untranslated region of the rat receptor for advanced GLYCATION end products and their relevance to mRNA stability
  2155. The–429 T/C and–374 T/A gene polymorphisms of the receptor of advanced GLYCATION end products gene (RAGE) are not risk factors for coronary artery disease in …
  2156. The experimental study of Radix Puerariae inhibiting GLYCATION in rats induced by D-galactose
  2157. Expression of receptor for advanced GLYCATION end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 …
  2158. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced GLYCATION end product (age)-injected …
  2159. Influence of non‐enzymatic glycosylation (GLYCATION) of pea (Pisum sativum) albumins on their enzymatic hydrolysis
  2160. Involvement of caspase-10 in advanced GLYCATION end-product-induced apoptosis of bovine retinal pericytes in culture
  2161. Quantitation of N2-[1-(1-Carboxy)ethyl]folic Acid, a Nonenzymatic GLYCATION Product of Folic Acid, in Fortified Foods and Model Cookies by a Stable Isotope Dilution …
  2162. The fructosamine 3-kinase knockout mouse: a tool for testing the GLYCATION hypothesis of intracellular protein damage in diabetes and aging
  2163. Hepatocyte growth factor protects against apoptosis induced by advanced GLYCATION end products in endothelial cells.
  2164. Evidence that high-doseL-arginine may be inappropriate for use by diabetic patients as a prophylactic blocker of methylglyoxal GLYCATION
  2165. Endogenous secretory receptor for advanced GLYCATION end product levels are inversely associated with HbA1c in type 2 diabetic patients
  2166. GLYCATION Does Not Alter LDL‐Induced Secretion of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor‐1 from Human Aortic Endothelial Cells
  2167. Decrease in the glyceraldehyde derived advanced GLYCATION end products in the sera of patients with Vogt-Koyanagi-Harada disease
  2168. GLYCATION of human IgG induces structural alterations leading to changes in its interaction with anti-IgG
  2169. Maillard GLYCATION of Peptides Containing the (N α His) Ac Chelator for 99m Tc (CO) 3 Labeling
  2170. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced GLYCATION end product (AGE)-related disorders
  2171. Lipid peroxidation, advanced GLYCATION end products and antioxidant status in patients on dialysis
  2172. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced GLYCATION end product (AGE)-injected rats.
  2173. Synthesis, tandem MS-and NMR-based characterization, and quantification of the carbon 13-labeled advanced GLYCATION endproduct, 6-N-carboxymethyllysine
  2174. Blockade by nifedipine of advanced GLYCATION end product-induced CD40-CD40 ligand interaction in endothelial cells.
  2175. Possible involvement of cross-linking advanced GLYCATION endproducts in long-term CAPD peritoneal degeneration
  2176. Non-enzymatic GLYCATION of type I collagen: Effects of aging
  2177. Effect of extracellular matrix GLYCATION on dermal fibroblast
  2178. Correlation between molecular weight of plasma albumin determined with mass spectrometry and GLYCATION indices in factory workers
  2179. GLYCATION of proteins in Escherichia coli. Interference of strain diversity and growth conditions with GLYCATION
  2180. Advanced GLYCATION end products (AGEs) and renal failure
  2181. Activation of receptor for advanced GLYCATION end products: a mechanism for monocyte-mediated inflammation in chronic renal failure
  2182. Modeling of Protein and Aminophospholipid GLYCATION Using Low Molecular Weight Analogs. A Comparative Study
  2183. Proteins modified with GLYCATION or oxidation products accelerate atherosclerosis in experimental hypercholesterolemic rabbits
  2184. The Mechanism of Advanced GLYCATION End Products-Induced Morphological Changes of Tight Junction in Endothelial Cell
  2185. Preparation of monoclonal antibodies against different epitopes on extracellular domain of human receptor for advanced GLYCATION end product.
  2186. Advanced GLYCATION endproducts (AGE) and their role in the pathogenesis of chronic complications of diabetes mellitus
  2187. In vacuo GLYCATION of enzymes: A novel approach for increasing enzyme stability
  2188. Cell culture efforts to reduce GLYCATION in recombinant humanized antibody
  2189. Advanced GLYCATION and advanced oxidation protein products: The effect of peritoneal dialysis
  2190. Trehalose and 6-aminohexanoic acid stabilize and renature glucose-6-phosphate dehydrogenase inactivated by GLYCATION and by guanidinium hydrochloride
  2191. Detection of AGE-Lipids In Vivo: GLYCATION and Carboxymethylation of Aminophospholipids in Red-Cell Membranes
  2192. The haemoglobin GLYCATION index is reproducible in dysglycaemic individual but is not explained by post‐challenge plasma glucose levels
  2193. Evidence of biomembrane lipid GLYCATION
  2194. Expression and function of receptors for advanced GLYCATION end products in bovine corneal endothelial cells
  2195. Activation of receptors for advanced GLYCATION endproducts (RAGEs) in human monocytes
  2196. Comparing inhibition effects of four drugs on ADM and advanced GLYCATION endproducts in rats [J]
  2197. Advanced GLYCATION end products in intervertebral discs and hip joint capsules: Correlation with senile amyloid?
  2198. In vacuo GLYCATION of proteins
  2199. Molecular mechanism of diabetic retinopathy: role of advanced GLYCATION end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy
  2200. Proteins of Thermus thermophilus Are Resistant to GLYCATION‐Induced Protein Precipitation: An Evolutionary Adaptation to Life at Extreme Temperatures?
  2201. Effects of tonifying shen recipe on advanced GLYCATION end products, amyloid-beta peptide in telencephalon and hippocampus of ovariectomized rats
  2202. Effects of Advanced GLYCATION End-products on Expression of Peroxisome Proliferator Activated Receptor-γ mRNA in Cultured Human Vascular Endothelial Cells [J]
  2203. Pharmacological blockade of the receptor for advanced GLYCATION endproducts (RAGE) improves age‐related endothelial dysfunction in rats
  2204. The role of GLYCATION and glycoxidation of low-density lipoproteins in foam cell formation.
  2205. The effect of turmeric, cardamom and ginger on in vitro albumin GLYCATION
  2206. Screening of natural resources with inhibitory activity on free radicals and advanced GLYCATION end products (AGEs) formation
  2207. The Effect of Advanced GLYCATION End Products on Macrophage Matrix Metalloproteinase-9 Activity and the Intervention Effect of Simvastatin
  2208. AGE (Advanced GLYCATION end products) receptors in age–related macular degeneration
  2209. Cellular receptors for advanced GLYCATION endproducts
  2210. Advanced GLYCATION endproducts enhance proliferation, but not tube formation in choroidal microvascular endothelial cells
  2211. Advanced GLYCATION end-product cross-link breakers: a novel therapeutic pathway for cardiovascular disease
  2212. Advanced GLYCATION end product (AGE)‐immunoreactive materials in chronic prurigo patients receiving a long‐standing haemodialysis
  2213. Catalytic aspects of the GLYCATION hot spots of proteins
  2214. The Effects of Melatonin On The Oxidative Stress, Protein GLYCATION, Microalbuminuria and Lipid Profile In Type II Diabetes Mellitus
  2215. Sodium ferulate inhibits nonenzymatic GLYCATION of myocardial tissue in diabetic rats [J]
  2216. Effects of advanced GLYCATION end products on oxidative stress in endothelial cells
  2217. Advanced GLYCATION end products accumulate in the diabetic gallbladder
  2218. Effects of advanced GLYCATION end products on the activity of NF-kappaB and the expression of fibronectin mRNA in the endothelial cells in aged rats
  2219. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase (Cu, Zn-SOD) by GLYCATION reaction: implication of reactive oxygen species
  2220. Structure and function of the metal-binding protein S100B and its interaction with the receptor for advanced GLYCATION end products
  2221. Effects of carvedilol and metoprolol on plasma advanced GLYCATION end products (AGE) and advanced oxidation protein products (AOPP) in patients with chronic heart …
  2222. Advanced GLYCATION end products and pseudoexfoliation–correlation between clinical outcome and histological findings
  2223. The aldose reductase activity in lens extracts protects, but does not prevent, the GLYCATION of lens proteins by L-Threose
  2224. The changes of advanced GLYCATION end products in a rat liver fibrosis model and the interventional effect of aminoguanidin
  2225. Evaluation of Advanced GLYCATION End–Products in Diabetic and Inherited Canine Cataracts
  2226. Non-invasive assessment of advanced GLYCATION end products, markers of oxidative stress, in recently preeclamptic women
  2227. Effects of advanced GLYCATION end products on activity and expression of eNOS in human umbilical vein endothelial cells
  2228. Inhibition of protein GLYCATION by skins and seeds of the muscadine grape
  2229. Elevated Level of Imidazolone and Pyrraline, Major Components of Advanced GLYCATION End Products, in the Vitreous Fluid of Patients With Diabetic Retinopathy
  2230. Relationship between Serum Advanced GLYCATION End Products Levels of Diabetic Mothers and Adverse Cardiovascular Function of Newborn Infants
  2231. GLYCATION, Oxidation, and Glycoxidation of Short-and Long-Lived Proteins and the Pathogenesis of Diabetic Complications
  2232. Non-enzymatic GLYCATION for the processing of type I collagen gels for cartilage tissue engineering
  2233. The Correlation Between Serum Advanced GLYCATION End Products and Nitric Oxide Levels in Type 2 Diabetes and Chronic Complications of Diabetes
  2234. Correlative study of advanced GLYCATION end products (AGE) and diabetic skin with microangiopathy
  2235. Scattering model of whole blood at hemoglobin GLYCATION monitored by refractive index measurement with OCT
  2236. The relative oxidation, GLYCATION and crosslinking activity of glucose and ascorbic acid in vitro
  2237. Chemical modification induced by GLYCATION increased lysine binding site activity of human serum lipoprotein (a)
  2238. The experimental study of angiogenes effect of puerarin on the chick embryo chorioallantoic membrane induced by advanced GLYCATION endproducts
  2239. Inhibitory effects of extracts from Ginkgo biloba and grape seed on the generation of advanced GLYCATION end products in vitro
  2240. Proteolysis of the receptor for advanced GLYCATION end products by matrix metalloproteinases
  2241. Pattern of CTGF mRNA expression induced by advanced GLYCATION end products in mesangial cells [J]
  2242. Transient cytosolic free calcium changes in cultured neonatal rat cardiac myocytes in response to advanced GLYCATION end-product treatment
  2243. Accelerated Aging in Glaucoma: Immunohistochemical Assessment of Advanced GLYCATION End–Products in the Human Retina and Optic Nerve Head
  2244. Vitamin C mediates lens crystallin aging by GLYCATION in a humanized transgenic mouse model
  2245. Effects of perindopril on expression of transformation growth factor-β type receptorⅡ in cultured human vascular endothelial cells by advanced GLYCATION end products
  2246. The effect of non-enzymatic GLYCATION of keratins on the physical properties of plantar epidermis in Type II diabetic and non-diabetic individuals
  2247. Nonenzymatic GLYCATION reaction of folate with reducing sugars: A case study on [6S]-5-methyltetrahydrofolate and fructose
  2248. Diabetic cataract: GLYCATION of the molecular chaperone α-crystallin and its binding to the membrane protein MIP26
  2249. Effects of advanced GLYCATION end products on protein and mRNA expression of macrophage inflammatory protein-1α in cultured human umbilical vein endothelial …
  2250. Role of peroxisome proliferators activated receptor gamma in mediating proliferation of rat vascular smooth muscle cells induced by advanced GLYCATION end products
  2251. Inhibitory effects of total flavones of buckwheat flower on the non-enzymatic GLYCATION of proteins in vivo and in vitro
  2252. 135: Interruption of the Receptor for Advanced GLYCATION End product pathway attenuates pulmonary reperfusion injury
  2253. P-194: Effect of calcium channel blocker, azelnidipine on GLYCATION in patients with essential hypertension
  2254. New pathways for the metabolism of fructosamines and other GLYCATION products in bacteria
  2255. Advanced GLYCATION–New AGE Focus for Diabetes
  2256. Protein GLYCATION and Eye Diseases
  2257. Should we reconsider the advanced GLYCATION end product issue in hemodialysis patients?
  2258. In vitro GLYCATION of human IgG and its effect on interaction with anti-IgG
  2259. Immunohistochemical localization of advanced GLYCATION end products in pinguecula.
  2260. Advanced GLYCATION end products and senile dementia
  2261. Advanced GLYCATION endproducts act as an initiator of skin tumors in mice
  2262. GLYCATION products in diabetic urine—What do they mean?
  2263. ADVANCED GLYCATION END-PRODUCTS AND DIABETIC RENAL DISEASE
  2264. GLYCATION and physiological mechanisms of its prevention in Alzheimer’s disease
  2265. Advanced GLYCATION Endproducts In Periodontal Disease
  2266. The relationship between the advanced GLYCATION ends products and the diabetes nephropathy [J]
  2267. Animal model of GLYCATION induced by D–galactose
  2268. Studies on the formation, metabolism and GLYCATION reactions of endogenous and exogenous alpha-oxoaldehydes in uraemia.
  2269. Skin autofluorescence and advanced GLYCATION endproducts
  2270. Effects of advanced GLYCATION end products on osteoblastic cells
  2271. Effect of quercetin on generation of advanced GLYCATION end products in vitro
  2272. Examination of Site Specificity of GLYCATION of Alcohol Dehydrogenase by Computer Modeling
  2273. GLYCATION of human IgG induces structural alterations leading to changes in its interaction with Anti-IgG
  2274. Animal model of GLYCATION induced by D-galactose
  2275. Effects of crocetin on formation of advanced GLYCATION end products and expression of releptor for advanced GLYCATION and prodmts protein in diabetic rats
  2276. Osteoblast apoptosis is induced by an advanced GLYCATION enproduct
  2277. Serum Advanced GLYCATION Endproducts (AGE) Correlate With Cognition in the Very Elderly
  2278. An investigation of the effect of advanced GLYCATION on age-related RPE dysfunction.
  2279. Hypertension and Atherosclerosis: Advanced GLYCATION End Products—A Common Link
  2280. Serum levels of advanced GLYCATION endproducts are associated with the development of acute coronary syndrome in diabetic patients
  2281. Deposition of Advanced GLYCATION End Products in Climatic Droplet Keratopathy
  2282. High Serum Level of Pentosidine, an Advanced GLYCATION End Product (AGE), is a Risk Factor of Patients with Heart Failure
  2283. Changes of Anticomplememt Function of Human Mutant CD59 before and after GLYCATION
  2284. Advanced GLYCATION End Products (AGEs) related complications in diabetic nephropathy
  2285. Advanced GLYCATION end products in urine: Are some sugar-derived products better than others?
  2286. Gender‐related differences in advanced GLYCATION endproducts and oxidative stress markers in rats
  2287. Effects of advanced GLYCATION end products on the expression of ICAM-1 and VCAM-1 in ECV-304 cells
  2288. Effects of advanced GLYCATION end products on expression and activity of PAI-1 in rat renal cortex
  2289. Immunological Approach to Advanced GLYCATION End Products of the Maillard Reaction
  2290. Effects of Arctium Fruit and Its Extracts on Renocortical GLYCATION End Products in Rats
  2291. Role of lipid peroxidation and protein GLYCATION in non diabetic pediatric nephrotic syndrome
  2292. Role of Advanced GLYCATION in Blood–Retinal Barrier Dysfunction During Diabetes
  2293. Serum levels of advanced GLYCATION end products are associated with in-stent restenosis in diabetic patients
  2294. The Impact of GLYCATION on the Anti-inflammatory Properties of High Density Lipoproteins in vivo
  2295. Advanced GLYCATION end Products are Associated With Diabetic Peripheral Macrovascular Complications
  2296. GLYCATION of Ubiquitin May Underlie the Molecular Mechanism of Diabetic Cataract
  2297. Biochemical and biophysical characterization of hemoglobin-advanced GLYCATION end product and its relevance to diabetes mellitus
  2298. Inhibition of Inflammation due to Advanced GLYCATION End‐products by Pentoxifylline
  2299. Determination of in vivo transferrin GLYCATION in diabetes mellitus: A novel method of quantification
  2300. Endocytosis of Advanced GLYCATION End Products in Bovine Choriocapillary Endothelial Cells
  2301. The effect of exogenous advanced GLYCATION end products on the alteration of visual evoked potential in the rats
  2302. Leptin and connective tissue growyh factor in advanced GLYCATION end-product efects in NRK-49F cells.
  2303. … of receptor of advanced GLYCATION endproducts, nuclear factor-? B double gene antisense RNA on productions of inflammatory factor treated by advanced GLYCATION …
  2304. Fibrinogen GLYCATION and glycaemic control in type 2 diabetic subjects
  2305. Efects of Non-Surgical periodontal therapy without the use of chemotherapeutics on protein GLYCATION
  2306. Effect of ROS-generating system on nonenzymatic protein GLYCATION
  2307. Capillary Zone Electrophoresis study of the in vitro albumin GLYCATION process
  2308. Once More, With Feeling: Hobbling GLYCATION-detecting protein restores feeling in diabetic mice
  2309. GLYCATION OF PROTEINS IN ESCHERICHIA COLI: DETECTION OF GLYCATING COMPOUNDS USING HISTONE H1 AS A SUBSTRATE
  2310. Nurture vs. nature in diabetic vasculopathy: roles of advanced GLYCATION endproducts and the receptor for them
  2311. … of receptor of advanced GLYCATION endproducts, nuclear factor-κB double gene antisense RNA on productions of inflammatory factor treated by advanced GLYCATION …
  2312. Effects of in vitro GLYCATION on iron (III)-binding and iron (III)-isoforms of transferrin
  2313. GLYCATION–Induced Aggregation of Lens Proteins by the Oxidation Products of Ascorbic Acid
  2314. In Vitro Quantitation of Advanced GLYCATION Endproducts in Porcine Dermis using Raman Spectroscopy
  2315. The Accumulation of Advanced GLYCATION End Products in the Retinal Pigment Epithelium and in Bruch’s membrane of human donors.
  2316. EFFECTS OF VITAMIN C AND VITAMIN E ON RECEPTORS OF ADVANCED GLYCATION END PRODUCTS IN EXPERIMENTAL DIABETIC RATS [J]
  2317. Aminoguanidine Increases Hydrogen Peroxide Formation during GLYCATION In Vitro
  2318. Do advanced GLYCATION end products and glucose induce similar signaling events in mesangial cells?
  2319. GLYCATION OF COLLAGEN: THE INFLUENCE OF AMINOGUANIDINE AND CU 2 IN THE FORMATION OF FLUORESCENT AGEs
  2320. A Survey of Advanced GLYCATION Endproduct Receptors Expressed by Human Retinal Pigment Epithelial Cells in situ
  2321. Endogenous secretory receptor for advanced GLYCATION endproducts in non-small cell
  2322. Chemopreventive activity of natural source compounds against advanced GLYCATION endproduct induced carcinogenesis.
  2323. Advanced GLYCATION endproducts and oxidative stress from the neutrophil respiratory burst
  2324. Evaluation of advanced GLYCATION end-products in diabetic and inherited canine cataracts
  2325. Reduced Pericyte Adhesion and Death on Advanced GLYCATION Endproduct (Age)–Modified Substrate
  2326. Effects of advanced GLYCATION end products on peroxisome proliferator activated receptor-? mRNA expression in rat renal cortex
  2327. Advanced GLYCATION end products induce proliferation of vascular smooth muscle cells and antagonism of drugs
  2328. Modulation of proliferation and function of progenitor cells by diabetes and age associated advanced GLYCATION endproducts (AGEs)
  2329. Advanced GLYCATION Dependent Formation of Modified α-Crystallin and High Molecular Weight Aggregates
  2330. GLYCATION of Proteins in Escherichia coli. Detection of Glycating Compounds Using Histone Hi as a Substrate
  2331. The effect of exogenous advanced GLYCATION end products on the expreesion of monocyte chemotactic protein-1 in the healthy rats’ retina
  2332. Effect of high concentration glucose and advanced GLYCATION end products on MIP-1# alpha# mRNA expression in cultured human umbilical vein endothelial cells
  2333. Reducing Sugars Induce Apoptosis in Pancreatic β-Cells by Provoking Oxidative Stress via a GLYCATION Reaction
  2334. Use of fluorescence and near-infrared spectroscopies for noninvasive measurement of skin-collagen Advanced GLYCATION Endproducts: a feasibility study
  2335. Galectin–3 mediates advanced GLYCATION endproduct (AGE)–induced breakdown of the blood–retinal barrier
  2336. Advanced GLYCATION End Product and Amadori Product Are Increased and Related to Apoptosis in the Human Diabetic Retina.
  2337. 2P052 Solution Structure of Variable-type Domain of Receptor for Advanced GLYCATION Endproducts (29. Protein structure and dynamics (II), Poster Session, Abstract …
  2338. Screening breaker of advanced-GLYCATION end-product cross-links by enzyme-linked immunosorbent assay method in vitro
  2339. MOLECULAR ANALYSIS OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS ISOFORMS EXPRESSED IN TISSUES AND CELL LINES.: 123
  2340. Effects of advanced GLYCATION end products on the expression of peroxisome proliferator-activated receptors in endothelial cells
  2341. Advanced GLYCATION End Products (AGEs)-Mediated Cell Growth of Human Acute Myelogenous Leukemia Via Mitogen-Activated Protein (MAP) Kinase Pathways.
  2342. Study of serum advanced GLYCATION endproducts and endothelium-dependent vasodilation function in patients both with coronary artery disease and type 2 diabetes
  2343. ADVANCED GLYCATION END PRODUCTS MEDIATE ANG II-DEPENDENT PRO-INFLAMMATORY RESPONSES IN A TRANSGENIC RAT MODEL: 2C. 5
  2344. Association of Soluble Receptor for advanced GLYCATION end product (sRAGE) with increasing central aortic stiffness in hypertensive patients
  2345. Advanced GLYCATION end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells.
  2346. Prokaryotic expression and activity identification of recombinant human soluble receptor for advanced GLYCATION end products
  2347. Advanced GLYCATION endproduct modified basement membrane attenuates endothelin-1 induced [Ca2+]
  2348. Advanced GLYCATION End Products Increases U937 Macrophages Expression of Scavenger Receptor Class B Type I
  2349. Effect of advanced GLYCATION end product receptor signal transduction on MCP-1 expression of podocyte induced by carboxymethyllysine
  2350. Inhibitory effects of extracts from {\sl Ginkgo biloba} and grape seed on the generation of advanced GLYCATION end products {\sl in vitro}
  2351. The effect of GLYCATION of culture medium on phagocytic and respiratory burst of peritoneal macrophages from Balb/c mice
  2352. Advanced GLYCATION endproducts analysis of glucosamine with reducing sugars, DNA nucleosides and serum proteins
  2353. Inhibition of green tea polyphenols on proliferation of rat vascular smooth muscle cells stimulated by advanced GLYCATION end products
  2354. Advanced GLYCATION Impairs Endothelial Progenitor Cell Attachment and Repair in a New Model of Retinal Vascular Endothelial Injury
  2355. Modulation of nicotine and advanced GLYCATION end product (AGE) mediated effects by the antioxidant glutathione (G) in fibroblasts
  2356. Receptor for advanced GLYCATION end products (RAGE) in pulmonary fibrosis
  2357. The deposition of advanced GLYCATION endproducts (AGEs) in renal tissue and association of AGEs with phenotypic changes in renal cells in diabetic nephropathy
  2358. Advanced GLYCATION end products induce actin rearrangement and subsequent hyperpermeability in endothelial cells
  2359. Macrophage Scavenger Receptor Mediates The Endocytic Uptake of Advanced GLYCATION End Products (AGEs)
  2360. Conformational Transitions and GLYCATION of Serum Albumin in Patients with Minimal-Change Glomerulopathy
  2361. Regulation of adhesion molecule expression on retinal capillary endothelium by exposure to high glucose: a role for advanced GLYCATION end–products (AGEs)?
  2362. RACEMIZTION OF ASPARTIC ACID AND NON-ENZYMATIC GLYCATION OF HUMAN INTERVERTEBRAL DISC CONSTITUENTS AS MEASURES OF …
  2363. 2-Ammonio-6-(3-oxidopyridinium-1-yl) hexanoate (OP-lysine) is a newly identified advanced GLYCATION end product in cataractous and aged human lenses. Vol. 279 …
  2364. Inhibitory effects of total extract and flavonols from hardy rubber tree (Eucommia ulmoides Oliver) leaves on the GLYCATION of hemoglobin
  2365. Advanced GLYCATION end products (AGES) stimulate NADPH dependent oxidant stress in cultured neonatal rat myocytes
  2366. Role of Advanced GLYCATION End Products in TGF-β1 and Fibronectin Expression in Mesangial Cells Cultured under High Glucose
  2367. Insulin Accelerates the Endocytic Uptake and Degradation of Advanced GLYCATION End-Products Mediated by The Macrophage Scavenger Receptor
  2368. Advanced GLYCATION end products and thiobarbituric acid reactive substance in gingival tissues of diabetic and non-diabetic patients with chronic periodontitis
  2369. Advanced GLYCATION end products (AGEs) exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice
  2370. Advanced GLYCATION end products and thiobarbituric acid reactive substance in gingival tissues of diabetic and non-diabetic patients with chronic periodontitis
  2371. The inflammatory and immunogenic properties of the receptor for advanced GLYCATION end products and its ligand, high mobility group box chromosomal …
  2372. Inhibition of Diabetic Leukostasis and Blood–Retinal Barrier Breakdown With a Soluble Form of a Receptor for Advanced GLYCATION End Products
  2373. Superoxide Mediates Through ERK Signaling TGF-β1 Expression in Rat Kidney Proximal Tubule Epithelial Cells Treated with Advanced GLYCATION End Products
  2374. Effects of advanced GLYCATION end products on expression of scavenger receptor class B type I (SR-BI) in U937 macrophages
  2375. Combined soluble receptor for advanced GLYCATION endproducts (sRAGE) with cytotoxic chemotherapy effectively reduces metastatic tumor growth in a spontaneous …
  2376. Essential role of receptor for advanced GLYCATION end products (RAGE) in the inflammatory response and mucosal injury after hemorrhagic shock (HS)
  2377. SUPPRESSION OF ADVANCED GLYCATION AND LIPOXIDATION END PRODUCTS BY AN ANGIOTENSIN II TYPE-1 RECEPTOR BLOCKER IN ESSENTIAL …
  2378. Exposure of Retinal Pigment Epithelium (RPE) to Advanced GLYCATION Endproduct (AGE)–Modified Substrate in vitro Alters RPE Lysosomal Capacity and Leads to …
  2379. Food Advanced GLYCATION Endproducts (AGE) Acutely Induce Postprandial Impairment of Microvascular Function in Patients with Type 2 Diabetes Mellitus (T2DM), an …
  2380. Small Interfering RNA (siRNA) Targeting Receptor for Advanced GLYCATION End Products (RAGE) Downregulates Stromal Cell Derived Factor 1 (SDF-1) in …
  2381. … V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ: Advanced GLYCATION end product intervention …
  2382. 18 Advanced GLYCATION End Products in Clinical Nephrology
  2383. 3.3 INHIBITON OF PROTEIN GLYCATION AND ADVANCED GLYCATION END PRODUCTS BY FOODSTATE® VITAMIN C AND OTHER VITAMINS AND …
  2384. 2–Guanidinoethyl Mercaptan Derivatives as Potent Inhibitors of GLYCATION–Mediated Protein Crosslinking
  2385. 298 INVERSE RELATIONSHIP BETWEEN ADVANCED GLYCATION END PRODUCTS AND GLUTATHIONE IN SICKLE CELL ANEMIA
  2386. … , hemodynamic and clinical improvements among patients with advanced heart failure treated with Alagebrium (a novel oral advanced GLYCATION end-product crosslink …
  2387. … DIABETES MELLITUS BY EPLERENONE: RELATIONSHIP BETWEEN MINERALOCORTICOID RECEPTOR, ADVANCED GLYCATION END PRODUCT RECEPTOR …
  2388. … of Renin-Angiotensin System (RAS) Inhibits Increased Matrix Metalloproteinase-9 Expression and Apoptosis Induced by Advanced GLYCATION End Products (AGE) and …
  2389. Advanced GLYCATION endproducts: what is their relevance to diabetic complications?
  2390. The role of advanced GLYCATION end products in progression and complications of diabetes
  2391. The road to advanced GLYCATION end products: a mechanistic perspective
  2392. Advanced GLYCATION end products and insulin resistance
  2393. Advanced GLYCATION end products, diabetes and ageing
  2394. Role of advanced GLYCATION end products in diabetic neuropathy
  2395. The clinical relevance of assessing advanced GLYCATION endproducts accumulation in diabetes
  2396. Advanced GLYCATION end products and diabetic foot disease
  2397. Dietary advanced GLYCATION endproducts (AGEs) and their health effects–PRO
  2398. Advanced GLYCATION end‐products (AGEs) and heart failure: pathophysiology and clinical implications
  2399. Possible involvement of advanced GLYCATION end-products (AGEs) in the pathogenesis of Alzheimer’s disease
  2400. Advanced GLYCATION end-products and arterial stiffness in hypertension
  2401. Mechanisms of disease: advanced GLYCATION end-products and their receptor in inflammation and diabetes complications
  2402. Advanced GLYCATION end-products (AGEs): involvement in aging and in neurodegenerative diseases
  2403. Novel inhibitors of GLYCATION and AGE formation
  2404. Advanced GLYCATION end products (AGEs) and their involvement in liver disease
  2405. Advanced GLYCATION end products and cardiovascular disease
  2406. Circulating glycotoxins and dietary advanced GLYCATION endproducts: two links to inflammatory response, oxidative stress, and aging
  2407. GLYCATION during storage and administration of monoclonal antibody formulations
  2408. Receptor for advanced GLYCATION endproducts and atherosclerosis: from basic mechanisms to clinical implications
  2409. Calcitriol blunts the deleterious impact of advanced GLYCATION end products on endothelial cells
  2410. Food-derived advanced GLYCATION end products (AGEs): a novel therapeutic target for various disorders
  2411. Inhibition of protein GLYCATION by extracts of culinary herbs and spices
  2412. GLYCATION as an atherogenic modification of LDL
  2413. Collagen, cross-linking, and advanced GLYCATION end products in aging human skeletal muscle
  2414. High serum level of pentosidine, an advanced GLYCATION end product (AGE), is a risk factor of patients with heart failure
  2415. Evidence against dietary advanced GLYCATION endproducts being a risk to human health
  2416. A review of glycated albumin as an intermediate GLYCATION index for controlling diabetes
  2417. Clinical and prognostic value of advanced GLYCATION end-products in chronic heart failure
  2418. Advanced GLYCATION endproducts in chronic heart failure
  2419. A study in GLYCATION of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior
  2420. Plasma receptor for advanced GLYCATION end products and clinical outcomes in acute lung injury
  2421. Advanced GLYCATION end products in renal failure: an overview
  2422. Effects of non-enzymatic GLYCATION on cancellous bone fragility
  2423. Advanced GLYCATION endproducts: a biomarker for age as an outcome predictor after cardiac surgery?
  2424. Role of advanced GLYCATION end products (AGEs) and oxidative stress in diabetic retinopathy
  2425. Collagen GLYCATION triggers the formation of aged skin in vitro
  2426. A role for the receptor for advanced GLYCATION end products in idiopathic pulmonary fibrosis
  2427. Prevention of non-enzymic GLYCATION of proteins by dietary agents: prospects for alleviating diabetic complications
  2428. Dietary advanced GLYCATION end products–a risk to human health? A call for an interdisciplinary debate
  2429. Compensatory secondary structure alterations in protein GLYCATION
  2430. Receptor for advanced GLYCATION end products (RAGEs) and experimental diabetic neuropathy
  2431. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced GLYCATION endproducts
  2432. Methylglyoxal and advanced GLYCATION endproducts: new therapeutic horizons?
  2433. Role of advanced GLYCATION end products in hypertension and atherosclerosis: therapeutic implications
  2434. The role of the receptor for advanced GLYCATION end-products in lung fibrosis
  2435. In vitro GLYCATION and antigenicity of soy proteins
  2436. Elevated levels of serum advanced GLYCATION end products in patients with non‐alcoholic steatohepatitis
  2437. Advanced GLYCATION: a novel outlook on atherosclerosis
  2438. Effect of GLYCATION on α-crystallin structure and chaperone-like function
  2439. Advanced GLYCATION: implications in tissue damage and disease
  2440. Advanced GLYCATION end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways
  2441. The extracellular region of the receptor for advanced GLYCATION end products is composed of two independent structural units
  2442. Receptor for advanced GLYCATION end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
  2443. Unveiling a GLYCATION hot spot in a recombinant humanized monoclonal antibody
  2444. The LC/MS analysis of GLYCATION of IgG molecules in sucrose containing formulations
  2445. Non-enzymatic GLYCATION of bone collagen modifies osteoclastic activity and differentiation
  2446. Advanced GLYCATION of apolipoprotein AI impairs its anti-atherogenic properties
  2447. Receptor for advanced GLYCATION end products activation injures primary sensory neurons via oxidative stress
  2448. Action of pelargonidin on hyperglycemia and oxidative damage in diabetic rats: implication for GLYCATION-induced hemoglobin modification
  2449. Advanced GLYCATION end products increases matrix metalloproteinase-1,-3, and-13, and TNF-α in human osteoarthritic chondrocytes
  2450. Collagen maturity, GLYCATION induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs
  2451. The impact of GLYCATION on apolipoprotein AI structure and its ability to activate lecithin: cholesterol acyltransferase
  2452. Dicarbonyls linked to damage in the powerhouse: GLYCATION of mitochondrial proteins and oxidative stress
  2453. Advanced GLYCATION end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease
  2454. Advanced GLYCATION endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
  2455. Effects of low-and high-advanced GLYCATION endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes …
  2456. Structural basis for pattern recognition by the receptor for advanced GLYCATION end products (RAGE)
  2457. The dicarbonyl proteome: proteins susceptible to dicarbonyl GLYCATION at functional sites in health, aging, and disease
  2458. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced GLYCATION end products, and myocyte resting tension
  2459. Advanced GLYCATION end products enhance the proliferation and activation of hepatic stellate cells
  2460. GLYCATION of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen GLYCATION
  2461. Oxidative stress and advanced GLYCATION in diabetic nephropathy
  2462. Receptor for advanced GLYCATION end products is subjected to protein ectodomain shedding by metalloproteinases
  2463. Accumulation of advanced GLYCATION endproducts in patients with systemic lupus erythematosus
  2464. Aged garlic extract and S-allyl cysteine prevent formation of advanced GLYCATION endproducts
  2465. Elevation of soluble form of receptor for advanced GLYCATION end products (sRAGE) in diabetic subjects with coronary artery disease
  2466. Reconstructed skin modified by GLYCATION of the dermal equivalent as a model for skin aging and its potential use to evaluate anti-GLYCATION molecules
  2467. Inhibition of NADPH oxidase prevents advanced GLYCATION end product–mediated damage in diabetic nephropathy through a protein kinase C-α–dependent pathway
  2468. Single oral challenge by advanced GLYCATION end products acutely impairs endothelial function in diabetic and nondiabetic subjects
  2469. Endothelial dysfunction in patients with chronic kidney disease results from advanced GLYCATION end products (AGE)-mediated inhibition of endothelial nitric oxide …
  2470. Advanced GLYCATION end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis
  2471. Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced GLYCATION endproducts in tissue damage
  2472. Vimentin is the specific target in skin GLYCATION: structural prerequisites, functional consequences, and role in skin aging
  2473. Role of soluble receptor for advanced GLYCATION end products on endotoxin-induced lung injury
  2474. Effects of advanced GLYCATION end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes
  2475. Advanced GLYCATION end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes
  2476. Fructose consumption and consequences for GLYCATION, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies
  2477. Formation of the molten globule-like state during prolonged GLYCATION of human serum albumin
  2478. Increased serum levels of advanced GLYCATION endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population …
  2479. Role of advanced GLYCATION end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice
  2480. GLYCATION inhibitory activity and the identification of an active compound in Plantago asiatica extract
  2481. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced GLYCATION endproducts
  2482. Immunohistochemical localization of advanced GLYCATION end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries
  2483. Advanced GLYCATION and lipoxidation end products–amplifiers of inflammation: the role of food
  2484. Accelerated aging in glaucoma: immunohistochemical assessment of advanced GLYCATION end products in the human retina and optic nerve head
  2485. Structural and GLYCATION site changes of albumin in diabetic patient with very high glycated albumin
  2486. Serum levels of sRAGE, the soluble form of receptor for advanced GLYCATION end products, are associated with inflammatory markers in patients with type 2 …
  2487. Advanced GLYCATION end product homeostasis: exogenous oxidants and innate defenses
  2488. Increased serum advanced GLYCATION end‐products is a distinct finding in lean women with polycystic ovary syndrome (PCOS)
  2489. Involvement of advanced GLYCATION end products in the pathogenesis of diabetic complications: the protective role of regular physical activity
  2490. Metformin reverts deleterious effects of advanced GLYCATION end-products (AGEs) on osteoblastic cells
  2491. A soluble form of the receptor for advanced GLYCATION endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a …
  2492. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced GLYCATION end products
  2493. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin GLYCATION
  2494. A novel nutraceutical property of select sorghum (Sorghum bicolor) brans: inhibition of protein GLYCATION
  2495. Regulation of advanced GLYCATION end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells
  2496. Characterization of nonenzymatic GLYCATION on a monoclonal antibody
  2497. Advanced GLYCATION end-product accumulation and associated protein modification in type II skeletal muscle with aging
  2498. Receptor for advanced GLYCATION end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial …
  2499. Advanced GLYCATION endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor
  2500. Effects of advanced GLYCATION end products on renal fibrosis and oxidative stress in cultured NRK-49F cells
  2501. Receptor for Advanced GLYCATION Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging
  2502. Free radical scavenging, anti-GLYCATION and tyrosinase inhibition properties of a polysaccharide fraction isolated from the rind from Punica granatum
  2503. Agents that block advanced GLYCATION end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular …
  2504. Receptor for advanced GLYCATION end products (RAGE): a novel therapeutic target for diabetic vascular complication
  2505. Advanced GLYCATION and ROS: a link between diabetes and heart failure
  2506. Protein GLYCATION inhibitors from the fruiting body of Phellinus linteus
  2507. The hemoglobin GLYCATION index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial
  2508. Advanced GLYCATION end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor
  2509. Oxidative stress and protein GLYCATION in primary hypothyroidism. Male/female difference
  2510. Comparative LC–MS/MS profiling of free and protein-bound early and advanced GLYCATION-induced lysine modifications in dairy products
  2511. Receptor for advanced GLYCATION end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress
  2512. Protective effect of (−)-epigallocatechin gallate against advanced GLYCATION endproducts-induced injury in neuronal cells
  2513. Monitoring of blood proteins GLYCATION by refractive index and spectral measurements
  2514. GLYCATION by ascorbic acid oxidation products leads to the aggregation of lens proteins
  2515. In skeletal muscle advanced GLYCATION end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for …
  2516. Opposing effects of bisphosphonates and advanced GLYCATION end-products on osteoblastic cells
  2517. Advanced GLYCATION of type I collagen and fibronectin modifies periodontal cell behavior
  2518. Modulation of insulin action by advanced GLYCATION endproducts: a new player in the field
  2519. Skin autofluorescence, a marker for advanced GLYCATION end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease
  2520. Distribution of the receptor for advanced GLYCATION end products in the human male reproductive tract: prevalence in men with diabetes mellitus
  2521. Advanced GLYCATION end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways
  2522. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced GLYCATION end products (RAGE) signaling pathways via high mobility group B1 …
  2523. Receptor for advanced GLYCATION end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer
  2524. Advanced GLYCATION end-products induce cell cycle arrest and hypertrophy in podocytes
  2525. Inhibitors of aldose reductase and advanced GLYCATION end-products formation from the leaves of Stelechocarpus cauliflorus RE Fr.
  2526. Carnosine and its constituents inhibit GLYCATION of low-density lipoproteins that promotes foam cell formation in vitro
  2527. Thiazolidinedione increases serum soluble receptor for advanced GLYCATION end-products in type 2 diabetes
  2528. Inhibitory effects of Nelumbo nucifera leaves on rat lens aldose reductase, advanced GLYCATION endproducts formation, and oxidative stress
  2529. Anti-inflammatory effects of the advanced GLYCATION end product inhibitor LR-90 in human monocytes
  2530. Inhibitors of advanced GLYCATION end products (AGEs): potential utility for the treatment of cardiovascular disease
  2531. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced GLYCATION end product precursors on tau aggregation and filament formation
  2532. Dietary advanced GLYCATION endproducts and oxidative stress: in vivo effects on endothelial function and adipokines
  2533. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced GLYCATION endproducts (RAGE)–an introduction
  2534. Inhibitory effect of the compounds isolated from Rhus verniciflua on aldose reductase and advanced GLYCATION endproducts
  2535. Detergency effects of nanofibrillar amyloid formation on GLYCATION of human serum albumin
  2536. Receptor for advanced GLYCATION end products expression on T cells contributes to antigen-specific cellular expansion in vivo
  2537. Protein GLYCATION in vivo: functional and structural effects on yeast enolase
  2538. GLYCATION associated skin autofluorescence and skin elasticity are related to chronological age and body mass index of healthy subjects
  2539. Confocal Raman microscopy can quantify advanced GLYCATION end product (AGE) modifications in Bruch’s membrane leading to accurate, nondestructive prediction of …
  2540. Plasma protein advanced GLYCATION end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with …
  2541. Solution Structure of the Variable-Type Domain of the Receptor for Advanced GLYCATION End Products: New Insight into AGE−RAGE Interaction,
  2542. Implication of receptor for advanced GLYCATION end product (RAGE) in pulmonary health and pathophysiology
  2543. Decreased formation of advanced GLYCATION end-products in peritoneal fluid by carnosine and related peptides
  2544. An in vitro model to test the contribution of advanced GLYCATION end products to bone biomechanical properties
  2545. Propagation of protein GLYCATION damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine
  2546. The expression of receptor for advanced GLYCATION end products is associated with angiogenesis in human oral squamous cell carcinoma
  2547. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced GLYCATION end products) immunoglobulin domains
  2548. GLYCATION and phosphorylation of β-lactoglobulin by dry-heating: Effect on protein structure and some properties
  2549. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced GLYCATION end products
  2550. The combination of high glucose and advanced GLYCATION end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced …
  2551. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced GLYCATION end-products
  2552. Anthraquinones from the seeds of Cassia tora with inhibitory activity on protein GLYCATION and aldose reductase
  2553. Receptor for advanced GLYCATION endproducts mediates neutrophil migration across intestinal epithelium
  2554. Induction of apoptosis of β cells of the pancreas by advanced GLYCATION end‐products, important mediators of chronic complications of diabetes mellitus
  2555. GLYCATION of paraoxonase‐1 inhibits its activity and impairs the ability of high‐density lipoprotein to metabolize membrane lipid hydroperoxides
  2556. Combination therapy with the advanced GLYCATION end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or …
  2557. The role of advanced GLYCATION end-products (AGEs) in the development of vascular diabetic complications
  2558. Methylglyoxal induces advanced GLYCATION end product (AGEs) formation and dysfunction of PDGF receptor‐β: implications for diabetic atherosclerosis
  2559. Collagen in its fibrillar state is protected from GLYCATION
  2560. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced GLYCATION end products (sRAGE) in diabetes
  2561. A new advanced GLYCATION inhibitor, LR-90, prevents experimental diabetic retinopathy in rats
  2562. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced GLYCATION endproducts
  2563. Characterization of GLYCATION adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
  2564. A novel function of the receptor for advanced GLYCATION end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC
  2565. Induction of novel cytokines and chemokines by advanced GLYCATION endproducts determined with a cytometric bead array
  2566. Soluble Receptor for advanced GLYCATION end products (RAGE) is a prognostic factor for heart failure
  2567. Increased GLYCATION of hemoglobin in chronic renal failure patients and its potential role of oxidative stress
  2568. Decreased plasma levels of soluble receptor for advanced GLYCATION end products in mild cognitive impairment
  2569. Weight increase is associated with skeletal muscle immunostaining for advanced GLYCATION end products, receptor for advanced GLYCATION end products, and oxidation …
  2570. Receptor for advanced GLYCATION end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic …
  2571. Advanced GLYCATION end-product pentosidine accumulates in various tissues of rats with high fructose intake.
  2572. Immunoglobulin GLYCATION with fructose: a comparative study
  2573. Consequential alterations in haemoglobin structure upon GLYCATION with fructose: prevention by acetylsalicylic acid
  2574. Receptor for advanced GLYCATION end products—soluble form and gene polymorphisms in chronic haemodialysis patients
  2575. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced GLYCATION end-products
  2576. Aspirin inhibits the formation of pentosidine, a cross-linking advanced GLYCATION end product, in collagen
  2577. Accumulation of free adduct GLYCATION, oxidation, and nitration products follows acute loss of renal function
  2578. Advanced GLYCATION endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts
  2579. L-Carnitine inhibits protein GLYCATION in vitro and in vivo: evidence for a role in diabetic management
  2580. Effect of metformin administration on plasma advanced GLYCATION end product levels in women with polycystic ovary syndrome
  2581. The receptor for advanced GLYCATION end products (RAGE) system in women with intraamniotic infection and inflammation
  2582. Do advanced GLYCATION end products contribute to the development of long-term diabetic complications?
  2583. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced GLYCATION end-product-mediated renal injury in streptozotocin-treated diabetic rats
  2584. Clinical relevance of advanced GLYCATION endproducts for vascular surgery
  2585. Application of mass spectrometry for the detection of GLYCATION and oxidation products in milk proteins
  2586. Gly82Ser polymorphism of the receptor for advanced GLYCATION end products is associated with an increased risk of gastric cancer in a Chinese population
  2587. Advanced GLYCATION end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
  2588. Effect of advanced GLYCATION endproducts on gene expression profiles of human dermal fibroblasts
  2589. Arguing for the motion: yes, RAGE is a receptor for advanced GLYCATION endproducts
  2590. Serum levels of soluble form of receptor for advanced GLYCATION end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in …
  2591. Antioxidant properties of soy protein–fructooligosaccharide GLYCATION systems and its hydrolyzates
  2592. Chemical constituents of the style of Zea mays L. with GLYCATION inhibitory activity
  2593. Advanced GLYCATION end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines
  2594. Advanced GLYCATION end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina
  2595. Advanced GLYCATION end products induce in vitro cross‐linking of α‐synuclein and accelerate the process of intracellular inclusion body formation
  2596. Plasma receptor for advanced GLYCATION end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation
  2597. Aldose reductase and advanced GLYCATION endproducts inhibitory effect of Phyllostachys nigra
  2598. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced GLYCATION end products and potentiates inflammation with highly homologous but …
  2599. Receptor for advanced GLYCATION end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix
  2600. Advanced GLYCATION end products (AGEs) and cardiovascular disease (CVD) in diabetes
  2601. Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced GLYCATION end products in cultured mouse …
  2602. Proteomic analysis defines altered cellular redox pathways and advanced GLYCATION end-product metabolism in glomeruli of db/db diabetic mice
  2603. Advanced GLYCATION endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes
  2604. Circulating advanced GLYCATION end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte …
  2605. Advanced GLYCATION of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy
  2606. Erigeroflavanone, a Flavanone Derivative from the Flowers of Erigeron annuus with Protein GLYCATION and Aldose Reductase Inhibitory Activity
  2607. Metformin reduces endothelial cell expression of both the receptor for advanced GLYCATION end products and lectin-like oxidized receptor 1
  2608. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced GLYCATION end products by suppressing generation of reactive oxygen species
  2609. Inhibition of advanced GLYCATION and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes
  2610. In vivo time-resolved autofluorescence measurements to test for GLYCATION of human skin
  2611. Association of the Gly82Ser polymorphism in the receptor for advanced GLYCATION end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory …
  2612. Interactions of the advanced GLYCATION end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat
  2613. Non‐enzymatic GLYCATION of type I collagen diminishes collagen–proteoglycan binding and weakens cell adhesion
  2614. Spectroscopic studies of the effects of GLYCATION of human serum albumin on L-Trp binding
  2615. Demonstration of the cytotoxic effect of Advanced GLYCATION Endproducts (AGE-s)
  2616. Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced GLYCATION endproducts
  2617. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced GLYCATION end-products (TAGE) in early detection of Alzheimer’s disease
  2618. Cytotoxicity of advanced GLYCATION endproducts in human micro-and astroglial cell lines depends on the degree of protein GLYCATION
  2619. Blockade of receptor for advanced GLYCATION end product attenuates pulmonary reperfusion injury in mice
  2620. Receptors for advanced GLYCATION end products and their physiological and clinical significance
  2621. Possible link of food-derived advanced GLYCATION end products (AGEs) to the development of diabetes
  2622. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced GLYCATION endproducts
  2623. Skin-autofluorescence, a measure of tissue advanced GLYCATION end-products (AGEs), is related to diastolic function in dialysis patients
  2624. Pigment-epithelium-derived factor suppresses expression of receptor for advanced GLYCATION end products in the eye of diabetic rats
  2625. Serum levels of soluble form of receptor for advanced GLYCATION end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects
  2626. Advanced GLYCATION endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-κB and extracellular signal-regulated …
  2627. Soluble receptor for advanced GLYCATION end products in multiple sclerosis: a potential marker of disease severity
  2628. Restricted intake of dietary advanced GLYCATION end products retards renal progression in the remnant kidney model
  2629. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced GLYCATION end product formation in type 2 diabetic patients
  2630. … is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced GLYCATION end …
  2631. Inhibition of non‐enzymatic GLYCATION by silk extracts from a Mexican land race and modern inbred lines of maize (Zea mays)
  2632. Albumin competitively inhibits GLYCATION of less abundant proteins
  2633. Receptor for advanced GLYCATION end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma
  2634. Increased serum advanced GLYCATION end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy
  2635. Effect of green tea extract on advanced GLYCATION and cross-linking of tail tendon collagen in streptozotocin induced diabetic rats
  2636. The expression of the receptor for GLYCATION endproducts (RAGE) in oral squamous cell carcinomas
  2637. Pathobiological role of advanced GLYCATION endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy
  2638. Increased serum endogenous secretory receptor for advanced GLYCATION end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function
  2639. Effect of long‐term orlistat treatment on serum levels of advanced GLYCATION end‐products in women with polycystic ovary syndrome
  2640. Role of maltol in advanced GLYCATION end products and free radicals: in-vitro and in-vivo studies
  2641. Olmesartan blocks advanced GLYCATION end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
  2642. Expression of the receptor for advanced GLYCATION end products in oligodendrocytes in response to oxidative stress
  2643. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance GLYCATION end products and its proinflammatory ligand S100A12
  2644. A neutralizing antibody against receptor for advanced GLYCATION end products (RAGE) reduces atherosclerosis in uremic mice
  2645. Advanced GLYCATION end products in pregnancies complicated with diabetes mellitus or preeclampsia
  2646. Developmental expression of the receptor for advanced GLYCATION end-products (RAGE) and its response to hyperoxia in the neonatal rat lung
  2647. Inhibition of protein GLYCATION by skins and seeds of the muscadine grape
  2648. Analysis and biological relevance of advanced GLYCATION end‐products of DNA in eukaryotic cells
  2649. Plantar fascia thickness, a measure of tissue GLYCATION, predicts the development of complications in adolescents with type 1 diabetes
  2650. Effect of non-enzymatic GLYCATION on esterase activities of hemoglobin and myoglobin
  2651. GLYCATION improves the thermostability of trypsin and chymotrypsin
  2652. Inhibitory effect of vanillic acid on methylglyoxal-mediated GLYCATION in apoptotic Neuro-2A cells
  2653. The effect of peptide GLYCATION on local secondary structure
  2654. Advanced GLYCATION End Products of DNA: Quantification of N2-(1-Carboxyethyl)-2′-deoxyguanosine in Biological Samples by Liquid Chromatography …
  2655. Analysis of DNA-bound advanced GLYCATION end-products by LC and mass spectrometry
  2656. A novel class of advanced GLYCATION inhibitors ameliorates renal and cardiovascular damage in experimental rat models
  2657. Inhibition of advanced GLYCATION end products (AGEs): An implicit goal in clinical medicine for the treatment of diabetic nephropathy?
  2658. Immunohistochemical demonstration of advanced GLYCATION end products and the effects of advanced GLYCATION end products in ossified ligament tissues in vitro
  2659. Advanced GLYCATION end products and the absence of premature atherosclerosis in glycogen storage disease Ia
  2660. Expression of the receptor of advanced GLYCATION end products in the gingival tissue of smokers with generalized periodontal disease and after nornicotine induction in …
  2661. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced GLYCATION end products: evidence for the multiple-hit agent?
  2662. Soluble receptor for advanced GLYCATION end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and …
  2663. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced GLYCATION end products and retinal damage in a rat model of type 2 diabetes
  2664. Serum level of advanced GLYCATION end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population
  2665. Advanced GLYCATION end product deposits in climatic droplet keratopathy
  2666. Aldose‐Reductase‐ and Protein‐GLYCATION‐Inhibitory Principles from the Whole Plant of Duchesnea chrysantha
  2667. Non‐enzymatic GLYCATION of chondrocyte‐seeded collagen gels for cartilage tissue engineering
  2668. Effect of taurine on advanced GLYCATION end products-induced hypertrophy in renal tubular epithelial cells
  2669. Lung level of HMBG1 is elevated in response to advanced GLYCATION end product‐enriched food in vivo
  2670. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced GLYCATION end products (sRAGE): results of a pilot study
  2671. Protein GLYCATION and methylglyoxal metabolism in yeast: finding peptide needles in protein haystacks
  2672. DNA damage during GLYCATION of lysine by methylglyoxal: assessment of vitamins in preventing damage
  2673. Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced GLYCATION end-products.
  2674. Beneficial effects of C36, a novel breaker of advanced GLYCATION endproducts cross‐links, on the cardiovascular system of diabetic rats
  2675. Effects of phosphatidylethanolamine GLYCATION on lipid–protein interactions and membrane protein thermal stability
  2676. Assaying soluble forms of receptor for advanced GLYCATION end products
  2677. GLYCATION damage targets glutamate dehydrogenase in the rat liver mitochondrial matrix during aging
  2678. Measurement of advanced GLYCATION endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non …
  2679. Peroxyl radicals are essential reagents in the oxidation steps of the Maillard reaction leading to generation of advanced GLYCATION end products
  2680. Adverse effects of advanced GLYCATION end products on embryonal development
  2681. Effects of cross-link breakers, GLYCATION inhibitors and insulin sensitisers on HDL function and the non-enzymatic GLYCATION of apolipoprotein AI
  2682. Receptor for advanced GLYCATION end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis
  2683. Advanced GLYCATION index and its association with severity of diabetic retinopathy in type 2 diabetic subjects
  2684. Reduced systemic advanced GLYCATION end products in children receiving peritoneal dialysis with low glucose degradation product content
  2685. Receptor for advanced GLYCATION end products (RAGE) mediates neuronal differentiation and neurite outgrowth
  2686. Associated links among mtDNA GLYCATION, oxidative stress and colony sectorization in Metarhizium anisopliae
  2687. Protective effect of Withania somnifera (Solanaceae) on collagen GLYCATION and cross-linking
  2688. Inhibitory effect of GSPE on RAGE expression induced by advanced GLYCATION end products in endothelial cells
  2689. Induction of receptor for advanced GLYCATION end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis …
  2690. Expression of receptor for advanced GLYCATION end products in sarcoid granulomas
  2691. … candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced GLYCATION, oxidative stress and …
  2692. Kinetic analysis on the sensitivity of glucose-or glyoxal-induced LDL GLYCATION to the inhibitory effect of Psidium guajava extract in a physiomimic system
  2693. GLYCATION of a lysine-containing tetrapeptide by d-glucose and d-fructose—influence of different reaction conditions on the formation of Amadori/Heyns products
  2694. Site-selective protein GLYCATION and PEGylation
  2695. Specific siRNA targeting the receptor for advanced GLYCATION end products inhibits experimental hepatic fibrosis in rats
  2696. Pigment epithelium-derived factor (PEDF) ameliorates advanced GLYCATION end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 …
  2697. Raman spectroscopy of advanced GLYCATION end products (AGEs), possible markers for progressive retinal dysfunction
  2698. Protein seeding of gold nanoparticles and mechanism of GLYCATION sensing
  2699. Possible involvement of tobacco-derived advanced GLYCATION end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former …
  2700. Endogenous secretory receptor for advanced GLYCATION end products in non–small cell lung carcinoma
  2701. Studies on N-Terminal GLYCATION of Peptides in Hypoallergenic Infant Formulas:  Quantification of α-N-(2-Furoylmethyl) Amino Acids
  2702. Investigation of pathways of advanced GLYCATION end‐products accumulation in macrophages
  2703. Skin advanced GLYCATION end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9)
  2704. Sinomenine inhibits activation of rat retinal microglia induced by advanced GLYCATION end products
  2705. Advanced GLYCATION end products and sorbitol in blood from differently compensated diabetic dogs
  2706. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced GLYCATION end products through activation of …
  2707. Serum levels of soluble form of receptor for advanced GLYCATION end products (sRAGE) may reflect tissue RAGE expression in diabetes
  2708. Advanced GLYCATION end products and receptors in Fuchs’ dystrophy corneas undergoing Descemet’s stripping with endothelial keratoplasty
  2709. The formation of argpyrimidine in glyceraldehyde-related GLYCATION
  2710. … glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced GLYCATION end product inhibitors
  2711. Modification of vimentin: a general mechanism of nonenzymatic GLYCATION in human skin
  2712. Evaluation of advanced GLYCATION end-products in diabetic and inherited canine cataracts
  2713. Receptor for advanced GLYCATION end product expression in experimental diabetic retinopathy
  2714. Genomic damage and malignancy in end-stage renal failure: do advanced GLYCATION end products contribute?
  2715. The structural modification of DNA nucleosides by nonenzymatic GLYCATION: an in vitro study based on the reactions of glyoxal and methylglyoxal with 2 …
  2716. Advanced GLYCATION End Products Upregulate C‐reactive Protein Synthesis by Human Hepatocytes Through Stimulation of Monocyte IL‐6 and IL‐1β Production
  2717. Inhibitors of advanced GLYCATION end‐products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats
  2718. Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin GLYCATION
  2719. Detection and determination of glyceraldehyde-derived pyridinium-type advanced GLYCATION end product in streptozotocin-induced diabetic rats
  2720. Concentrations of receptor for advanced GLYCATION end products, VEGF and CML in plasma, follicular fluid, and peritoneal fluid in women with and without …
  2721. Relationship between proinsulin-to-insulin ratio and advanced GLYCATION endproducts in Japanese type 2 diabetic subjects
  2722. The HMG-CoA reductase inhibitor cerivastatin lowers advanced GLYCATION end products in patients with type 2 diabetes
  2723. Endogenous secretory receptor for advanced GLYCATION end-products and cardiovascular disease in end-stage renal disease
  2724. Effect of pyridoxamine (K-163), an inhibitor of advanced GLYCATION end products, on type 2 diabetic nephropathy in KK-Ay/Ta mice
  2725. Pigment epithelium-derived factor (PEDF) prevents advanced GLYCATION end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its …
  2726. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced GLYCATION end products, are related to the cognitive …
  2727. Increased pentosidine, an advanced GLYCATION end‐product, in urine and tissue reflects disease activity in inflammatory bowel diseases
  2728. Effect of protocatechualdehyde on receptor for advanced GLYCATION end products and TGF-β1 expression in human lens epithelial cells cultured under diabetic …
  2729. Validation of Hemoglobin GLYCATION Models Using Glycemia Monitoring In Vivo and Culturing of Erythrocytes In Vitro
  2730. Decreased levels of soluble receptor for advanced GLYCATION end products in patients with primary Sjögren’s syndrome
  2731. Evaluating the extent of protein damage in dairy products: simultaneous determination of early and advanced GLYCATION‐induced lysine modifications
  2732. Advanced GLYCATION as a basis for understanding retinal aging and noninvasive risk prediction
  2733. Studies on the Effect of Amadoriase from Aspergillus fumigatus on Peptide and Protein GLYCATION In Vitro
  2734. Glyceraldehyde-derived advanced GLYCATION end products (AGEs). A novel biomarker of postprandial hyperglycaemia in diabetic rats
  2735. Telmisartan inhibits advanced GLYCATION end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome …
  2736. Pregnancy-associated plasma protein a and soluble receptor for advanced GLYCATION end products after kidney transplantation
  2737. Blockade of the advanced GLYCATION end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial …
  2738. Enhancement of epithelial sodium channel expression in renal cortical collecting ducts cells by advanced GLYCATION end products
  2739. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced GLYCATION end products
  2740. The binding of advanced GLYCATION end products to cell surfaces can be measured using bead-reconstituted cellular membrane proteins
  2741. Unchanged serum levels of advanced GLYCATION endproducts in patients with liver disease
  2742. Relationship of prospective GHb to glycated serum proteins in incident diabetic retinopathy: implications of the GLYCATION gap for mechanism of risk prediction
  2743. Effects of Compounds Isolated from the Fruits of Rumex japonicus on the Protein GLYCATION
  2744. Effects of advanced GLYCATION end product modification on proximal tubule epithelial cell processing of albumin
  2745. GLYCATION of low‐density lipoprotein results in the time‐dependent accumulation of cholesteryl esters and apolipoprotein B‐100 protein in primary human monocyte …
  2746. Kinetic study of the reaction of glycolaldehyde with two GLYCATION target models
  2747. Inhibiting albumin GLYCATION attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
  2748. A novel inhibitor of advanced GLYCATION and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia
  2749. Methylglyoxal inhibits GLYCATION-mediated loss in chaperone function and synthesis of pentosidine in α-crystallin
  2750. Extracellular superoxide released from mitochondria mediates mast cell death by advanced GLYCATION end products
  2751. In vitro GLYCATION of brain aminophospholipids by acetoacetate and its inhibition by urea
  2752. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced GLYCATION end products following hypoxia/ischemia
  2753. Advanced GLYCATION end products, oxidative stress and metalloproteinases are altered in the cerebral microvasculature during aging
  2754. Endogenous secretory receptor for advanced GLYCATION endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes
  2755. Inhibition of advanced GLYCATION end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
  2756. Constituents of the flowers of Erigeron annuus with inhibitory activity on the formation of advanced GLYCATION end products (AGEs) and aldose reductase
  2757. Advanced GLYCATION end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis.
  2758. Development of receptor for advanced GLYCATION end products–directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis
  2759. Reduced expression of endogenous secretory receptor for advanced GLYCATION endproducts in hippocampal neurons of Alzheimer’s disease brains
  2760. Rosiglitazone reduces angiotensin II and advanced GLYCATION end product-dependent sustained nuclear factor-κB activation in cultured human proximal tubular …
  2761. Identification of AGE-precursors and AGE formation in GLYCATION-induced BSA peptides
  2762. Non-enzymatic interactions of glyoxylate with lysine, arginine, and glucosamine: a study of advanced non-enzymatic GLYCATION like compounds
  2763. Formation mechanisms of melanoidins and fluorescent pyridinium compounds as advanced GLYCATION end products
  2764. Nonenzymatic GLYCATION of guanosine 5′-triphosphate by glyceraldehyde: an in vitro study of AGE formation
  2765. Effects of advanced GLYCATION end products‐inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UK …
  2766. Protein GLYCATION and endothelium dysfunction
  2767. Rosiglitazone prevents advanced GLYCATION end products–induced renal toxicity likely through suppression of plasminogen activator inhibitor-1
  2768. Advanced GLYCATION endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling
  2769. Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced GLYCATION end …
  2770. Assay validation and biological variation of serum receptor for advanced GLYCATION end-products
  2771. TRC4149 a novel advanced GLYCATION end product breaker improves hemodynamic status in diabetic spontaneously hypertensive rats
  2772. Advanced GLYCATION end-product-induced mitogenesis is dependent on Janus kinase 2-induced heat shock protein 70 in normal rat kidney interstitial fibroblast cells
  2773. … Nuclear Ribonuclear Protein K and microRNA-16 in Cyclooxygenase-2 RNA Stability Induced by S100b, a Ligand of the Receptor for Advanced GLYCATION End …
  2774. Advanced GLYCATION end products inhibit production and activity of matrix metalloproteinase-2 in human umbilical vein endothelial cells
  2775. Simultaneous determination of the advanced GLYCATION end product N ɛ-carboxymethyllysine and its precursor, lysine, in exhaled breath condensate using isotope …
  2776. Cell cycle related signaling in Neuro2a cells proceeds via the receptor for advanced GLYCATION end products
  2777. Advanced GLYCATION end products serve as ligands for lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1): biochemical and binding characterizations …
  2778. Advanced GLYCATION end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors
  2779. Fetal hemoglobin: assessment of GLYCATION and acetylation status by electrospray ionization mass spectrometry
  2780. Dihydroxyacetone‐induced death is accompanied by advanced GLYCATION endproduct formation in selected proteins of Saccharomyces cerevisiae and Caenorhabditis …
  2781. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced GLYCATION end-product (AGE)-induced monocyte chemoattractant protein-1 expression in …
  2782. Endogenous secretory receptor for advanced GLYCATION endproducts as a novel prognostic marker in chondrosarcoma
  2783. Pigment epithelium-derived factor (PEDF) blocks advanced GLYCATION end product (AGE)-induced angiogenesis in vitro
  2784. … of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble rage (receptor for advanced GLYCATION endproducts) and the …
  2785. Involvement of inducible nitric oxide synthase and receptor for advanced GLYCATION end products in periapical granulomas
  2786. Endogenous soluble receptor for advanced GLYCATION endproducts is increased in preeclampsia
  2787. Screening of Korean herbal medicines with inhibitory activity on advanced GLYCATION end products (AGEs) formation (II)
  2788. Model studies on protein GLYCATION: influence of cysteine on the reactivity of arginine and lysine residues toward glyoxal
  2789. Therapeutic interruption of advanced GLYCATION in diabetic nephropathy: do all roads lead to Rome?
  2790. Inhibition of renin-angiotensin system and advanced GLYCATION end products formation: a promising therapeutic approach targeting on cardiovascular diseases
  2791. In vitro nonenzymatic GLYCATION of guanosine 5′-triphosphate by dihydroxyacetone phosphate
  2792. Enhanced GLYCATION of hemoglobin and plasma proteins is associated with increased lipid peroxide levels in non-diabetic hypertensive subjects
  2793. GLYCATION Methods for Bombesin Analogs Containing the (NαHis)Ac chelator for 99mTc(CO)3 Radiolabeling
  2794. Serum Levels of the Advanced GLYCATION End Products Nε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II …
  2795. Photosensitizing activity of advanced GLYCATION endproducts on tryptophan, glucose 6‐phosphate dehydrogenase, human serum albumin and ascorbic acid evaluated …
  2796. Analyses of the in vitro non-enzymatic GLYCATION of peptides/proteins by matrix-assisted laser desorption/ionization mass spectrometry
  2797. Mass spectrometry to detect the site specificity of advanced GLYCATION/lipoxidation end-product formation on protein: some challenges and solutions
  2798. Relationship between the− 374T/A receptor of advanced GLYCATION end products gene polymorphism and peritoneal solute transport status at the initiation of peritoneal …
  2799. GLYCATION does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: The response to glycated and nonglycated BSA is lost in metabolic …
  2800. Hepatic expression of galectin-3 and receptor for advanced GLYCATION end products in patients with liver disease
  2801. The association of advanced GLYCATION end-products with glutathione status
  2802. Receptor for advanced GLYCATION end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis
  2803. Receptor for advanced GLYCATION end product polymorphisms and type 2 diabetes: the CODAM study
  2804. Role of the specifically targeted lysine residues in the GLYCATION dependent loss of chaperone activity of αA-and αB-crystallins
  2805. Urinary excretion of fluorescent advanced GLYCATION end products (AGEs) in the elderly
  2806. GLYCATION of plasma lipoprotein lipid membrane and screening for lipid GLYCATION inhibitor
  2807. Positive correlation between vitreous levels of advanced GLYCATION end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently …
  2808. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced GLYCATION end product (AGE)-related disorders
  2809. Expression and characterization of recombinant C-terminal biotinylated extracellular domain of human receptor for advanced GLYCATION end products (hsRAGE) in …
  2810. Determination of glyceraldehyde formed in glucose degradation and GLYCATION
  2811. A novel pleiotropic effect of atorvastatin on advanced GLYCATION end product (AGE)-related disorders
  2812. Study on anti-oxidation and inhibitory effect on nonenzymatic GLYCATION reaction of fermentation extract from biotransformation of Ginkgo biloba L.(EGB) by Hericium …
  2813. Nifedipine, a calcium-channel blocker, inhibits advanced GLYCATION end-product-induced expression of monocyte chemoattractant protein-1 in human cultured …
  2814. Does renal function influence plasma levels of advanced GLYCATION and oxidation protein products in patients with chronic rheumatic diseases complicated by …
  2815. Macronutrients, advanced GLYCATION end products, and vascular reactivity
  2816. Advanced GLYCATION end-products in senile diabetic and non-diabetic patients with cardiovascular complications
  2817. Preparation of nucleotide advanced GLYCATION endproducts—imidazopurinone adducts formed by GLYCATION of deoxyguanosine with glyoxal and methylglyoxal
  2818. Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and GLYCATION …
  2819. A possible involvement of crosstalk between advanced GLYCATION end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase …
  2820. MMP9 is involved in GLYCATION end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline
  2821. Markers of endothelial activity are related to components of the metabolic syndrome, but not to circulating concentrations of the advanced GLYCATION end-product Nɛ …
  2822. Advanced GLYCATION end products and their receptors elevate the activity of endothelin-1 in rat cavernosum
  2823. Up-regulation of the receptor for advanced GLYCATION end product (RAGE) in esophageal cancer and down-regulation in lung cancer and their relationship to …
  2824. CHANGES IN REDOX RATIO AND PROTEIN GLYCATION IN PRECATARACTOUS LENS FROM FRUCTOSE‐FED RATS: EFFECTS OF EXOGENOUS l‐CARNITINE
  2825. Involvement of Na+/H+ exchanger 1 in advanced GLYCATION end products-induced proliferation of vascular smooth muscle cell
  2826. N‐terminal GLYCATION of Proteins and Peptides in Foods and in Vivo: Evaluation of N‐(2‐Furoylmethyl) Valine in Acid Hydrolyzates of Human Hemoglobin
  2827. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced GLYCATION end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator …
  2828. Effect of GLYCATION on the structure and dynamics of DNA: a critical spectroscopic approach
  2829. Amplifiers of systemic inflammation-the role advanced GLYCATION and and lipoxidation end products in foods
  2830. In vitro GLYCATION of Hemoglobin by Acetone and-hydroxibutirate
  2831. Advanced GLYCATION end-product-inhibited cell proliferation and protein expression of β-catenin and cyclin D1 are dependent on glycogen synthase kinase 3β in LLC …
  2832. Advanced GLYCATION and lipoxidation end products–amplifiers of inflammation: the role of food
  2833. Inhibition of advanced GLYCATION by flavonoids. A nutritional implication for preventing diabetes complications?
  2834. Impact of glucose levels on advanced GLYCATION end products in hemodialysis
  2835. Constituents of the seeds of Cornus officinalis with inhibitory activity on the formation of advanced GLYCATION end products (AGEs)
  2836. Preparation of advanced GLYCATION end products in vitro
  2837. Increased GLYCATION of hemoglobin and plasma proteins in normotensive, non-diabetic obese Indian subjects: putative role of lipid peroxides
  2838. Fructose‐induced N‐terminal GLYCATION of enkephalins and related peptides
  2839. Nε-(Carboxymethyl)Lysine, a Major Advanced GLYCATION End Product in Exhaled Breath Condensate as a Biomarker of Small Airway Involvement in Asthma
  2840. Preparation of mannan–protein conjugates using high‐temperature GLYCATION
  2841. The −374A allele of the receptor for advanced GLYCATION end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes …
  2842. Retinol up-regulates the receptor for advanced GLYCATION endproducts (RAGE) by increasing intracellular reactive species
  2843. Endproducts and receptor of advanced GLYCATION and lipoxidation (AGE, ALE, RAGE) and chronic diseases–a food perspective
  2844. Self-vaccination by methamphetamine GLYCATION products chemically links chronic drug abuse and cardiovascular disease
  2845. An ellagic acid rhamnoside from the roots of Potentilla discolor with protein GLYCATION and rat lens aldose reductase inhibitory activity
  2846. Co-injury effects of advanced GLYCATION end products and homocysteine on endothelial cells
  2847. Association of serum carboxymethyl-lysine, a dominant advanced GLYCATION end product, with anemia in adults: the Baltimore Longitudinal Study of Aging
  2848. Editorial [Advanced GLYCATION End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi]
  2849. Localization of the ezrin binding epitope for advanced GLYCATION endproducts
  2850. Effects of 12-month valsartan therapy on GLYCATION and oxidative stress markers in type 2 diabetic subjects with hypertension
  2851. In vitro effect of α-tocopherol, ascorbic acid and lycopene on low density lipoprotein GLYCATION
  2852. 17β‐OESTRADIOL PARTIALLY ATTENUATES THE INHIBITION OF NITRIC OXIDE SYNTHASE‐3 BY ADVANCED GLYCATION END‐PRODUCTS IN HUMAN …
  2853. Protein GLYCATION and cataract: a conformational disease
  2854. Flavan-3-ols from Ulmus davidiana var. japonica with inhibitory activity on protein GLYCATION
  2855. The morphological changes of vascular endothelial cadherin in human umbilical vein endothelial cells induced by advanced GLYCATION end products
  2856. Atorvastatin inhibits advanced GLYCATION end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation
  2857. Advanced GLYCATION endproduct-induced diabetic complications
  2858. Immunogenicity of advanced GLYCATION end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation
  2859. Regulation of Src homology 2–containing protein tyrosine phosphatase by advanced GLYCATION end products: the role on atherosclerosis in diabetes
  2860. The HLA 8.1 ancestral haplotype is strongly linked to the C allele of− 429T> C promoter polymorphism of receptor of the advanced GLYCATION endproduct (RAGE) gene …
  2861. Inihbition of Protein GLYCATION with Varying Concentrations of Lysine
  2862. … impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced GLYCATION …
  2863. Advanced‐GLYCATION end products (AGEs) derived from glycated albumin suppress early β1‐adrenergic preconditioning
  2864. … and fluorine-18 radiolabeling of recombinant S100 proteins—potential probes for molecular imaging of receptor for advanced GLYCATION endproducts (RAGE) in vivo
  2865. … (3-[4, 5-dimethylthioazol-2-yl]-2, 5-diphenyl tetrazolium bromide), and the lactate dehydrogenase assay applied in brain cells after exposure to advanced GLYCATION …
  2866. The RAGE connection to diabetes and atherosclerosis: an intertwined web of advanced GLYCATION and inflammation
  2867. A patient with hyperglycaemia and normal HbA Ic due to impaired GLYCATION.
  2868. Method for chronological recording of antigen appearance in human head-hair shafts and its use for monitoring GLYCATION products in diabetes
  2869. Alteration of the thermodynamic characteristics of corneal collagen denaturation as a result of nonenzymatic GLYCATION
  2870. The effect of nonenzymatic GLYCATION on the stability and conformation of two deoxyoligonucleotide duplexes: A spectroscopic analysis by circular dichroism
  2871. Impairment effect and mechanism of advanced GLYCATION end products on hippocampi rats
  2872. Association of Gly82Ser polymorphism of receptor for advanced GLYCATION end products gene in a type 2 diabetic Chinese population
  2873. Puerarol from the roots of Pueraria lobata inhibits the formation of advanced GLYCATION end products (AGEs) in vitro
  2874. Physiology of the skin: the impact of GLYCATION on the skin, part 2
  2875. Monitoring the effect of glyoxal and methylglyoxal GLYCATION on the secondary structure of human serum albumin: an analysis based on CD, ESI‐MALDI‐TOF/MS …
  2876. Can tryptophan oxidation lead to lower tryptophan level in diabetes? A commentary on” Propagation of protein GLYCATION damage involves modification of tryptophan …
  2877. Rutin metabolites as powerful inhibitors of advanced GLYCATION end products
  2878. Establishment of An Analyzing Approach for Advanced GLYCATION End Products Formed in Vitro by Flow Injection Assay [J]
  2879. Correlation of low molecular weight advanced GLYCATION end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients
  2880. Increased reactive oxygen species in endothelial cells stimulated by advanced GLYCATION end products mediated by NADPH oxidase
  2881. The Role of Advanced GLYCATION in Diabetic Retinopathy
  2882. Non-enzymatic GLYCATION in diabetic complications
  2883. Effect of advanced GLYCATION end products on injuring of rat renal microvascular endothelial cells and protective effect of probucol
  2884. Telmisartan blocks advanced GLYCATION end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of …
  2885. Effects of Shenkangwan on renal advanced GLYCATION end products and their receptor expression in early diabetic nephropathy rats [J]
  2886. Cardiac troponin T and advanced GLYCATION end-products in hemodialysis patients
  2887. Effect of treatment with anti-receptor for advanced GLYCATION end products antibody on multiple organ dysfunction and mortality in rats after severe thermal injury
  2888. … of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced GLYCATION end products/inducible nitric …
  2889. What is the influence of renal function on the prognostic value of advanced GLYCATION end-products and sRAGE in heart failure?
  2890. Letter by Connelly et al regarding article,“Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced GLYCATION end products, and myocyte resting …
  2891. Effecs of Advanced GLYCATION end products (AGEs) on Diabetic Microangiopathy [J]
  2892. Comment on: Lachin et al.(2007) The Hemoglobin GLYCATION Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control …
  2893. Mutant mice provide new insight into the role of (mis-) GLYCATION in IgA nephropathy and other glomerular diseases
  2894. Comment on: Thallas-Bonke et al.(2008) Inhibition of NADPH Oxidase Prevents Advanced GLYCATION End Product–Mediated Damage in Diabetic Nephropathy …
  2895. Oxidative damage to DNA and lipids: correlation with protein GLYCATION in patients with type 1 diabetes
  2896. Effect of advanced GLYCATION end products on the content of nitric oxide and the activity of nitric oxide synthase in rat cavernosum
  2897. … dependent DNA Immune complex mediated cell activation by High Mobility Group Box Protein 1 (HMGB1) and Receptor for Advanced GLYCATION End products (RAGE …
  2898. Advanced GLYCATION end-products and mechanical properties are altered in cortical bone of beagle dogs following 1-year treatment with high-doses, but not …
  2899. Nucleophilic compounds decrease advanced GLYCATION end products (AGEs) from ascorbic acid in the hSVCT2 transgenic mouse model of lenticular aging
  2900. Study on the Effects of Catechin, Caffeine and Gallic Acid on In Vitro GLYCATION Reaction of Albumin
  2901. GLYCATION Mechanism of D-Galactose-Induced Kidney Injury in Rats and Its Drug Intervention [J]
  2902. A possible mechanism for link between advanced GLYCATION end products and the development of osteoarthritis
  2903. Amount of Nω-(Carboxymethyl)Arginine Generated in Collagen and Bovine Serum Albumin during GLYCATION Reactions is Significantly Different
  2904. Clinical significance of serum concentrations of advanced oxidation protein products and advanced GLYCATION end products in patients with acute coronary syndrome
  2905. Correlation between the expression of high mobility group box 1 and receptor for advanced GLYCATION end products and the onset of pre-eclampsia
  2906. P4‐389: An oral antagonist of the receptor for advanced GLYCATION end products (RAGE) is safe and well‐tolerated in the treatment of Alzheimer’s disease: Results from …
  2907. Effect of succinic acid monoethyl ester on hemoglobin GLYCATION and tail tendon collagen properties in type 2 diabetic rats
  2908. Effects of Jiejufushenning on advanced GLYCATION end products in serum and expression of receptor for advanced GLYCATION end products in kidney in diabetic rats
  2909. Impact of plasma protein GLYCATION on lipid profile in diabetics with and without complications.
  2910. Clinical and prognostic value of advanced GLYCATION end-products (AGEs) in chronic heart failure
  2911. Clinical significance of serum advanced GLYCATION end products in coronary artery disease patients with metabolic syndrome [J]
  2912. Study on the nonenzymatic GLYCATION of nucleosides/nucleotides and proteins with sugars: An in vitro investigation of advanced GLYCATION endproducts (AGEs) …
  2913. The effects of caspase-3 in apoptosis of cultured retinal microvascular pericytes induced by advanced GLYCATION end products
  2914. Inhibitory effect of some acetyl esters and acetamides on GLYCATION of the histone H1
  2915. The Effect of Advanced GLYCATION End Products on Primary Culture of Neonatal Rat Kidney Cells
  2916. Inhibition of Protein GLYCATION by Dietary Agents: Implications in the Prevention of Diabetic Ocular Complications
  2917. Biochemical effects of protein GLYCATION by methylglyoxal in Saccharomyces cerevisiae
  2918. The immunocytochemical location of exogenous advanced GLYCATION end products on the expression of vascular endothelial growth factor in the rats [J]
  2919. Chemopreventive activity of natural source compounds against advanced GLYCATION endproduct induced carcinogenesis
  2920. Response to Comment on: Lachin et al.(2007) The Hemoglobin GLYCATION Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the …
  2921. Increased Advanced GLYCATION End-Products (AGEs) in Trabecular Meshwork of Patients With Primary and Secondary Glaucoma
  2922. Effects of advanced GLYCATION end products on proliferation and apotosis of human renal tubular epithelial cells [J]
  2923. Advanced GLYCATION end-products (AGEs) in the anterior chamber angle of patients with glaucoma
  2924. THE ROLE OF FOOD IN GLYCATION AND LIPOXIDATION OF END PRODUCTSAND–AMPLIFIERS OF INFLAMMATION
  2925. Effects of advanced GLYCATION end products on insulin-like growth factor-1 expression in rat mesangial cells [J]
  2926. Expression of receptor for advanced GLYCATION end products in pancreatic stellate cells of rats [J]
  2927. Early GLYCATION of Critical Fibronectin domains inhibits human dermal fibroblast migration
  2928. Increased serum advanced GLYCATION end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy
  2929. Effect of advanced GLYCATION end-products on the gene expression of osteoprotegerin in cultured rat vascular smooth muscle cells [J]
  2930. Inhibition of protein GLYCATION by polyphenolic extracts of culinary herbs and spices
  2931. EFFECT OF GRAPE SEED PROANTHOCYANIDIN ON ADVANCED GLYCATION END PRODUCTSINDUCED TUMOR NECROSIS FACTOR-α SECRETION IN …
  2932. Role of receptor for advanced GLYCATION end products (RAGE) in brain ischemia injury and its mechanisms
  2933. Pentosidine and soluble receptor for advanced GLYCATION end-product (RAGE) are important prognostic factors independent of renal function in heart failure
  2934. Crocetin reduces expression of receptor for advanced GLYCATION end products (RAGE) on endothelial cells induced by AGE
  2935. Research on advanced GLYCATION endproducts detecting methods
  2936. Response to Letter Regarding Article,“Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced GLYCATION End Products, and Myocyte Resting …
  2937. Advanced GLYCATION and lipoxidation end-products amplify inflammation. The role of a healthy diet
  2938. Evidence for independent heritability of the GLYCATION gap (glycosylation gap) fraction of HbA1c in nondiabetic twins: response to Cohen et al.
  2939. Studies on protein GLYCATION
  2940. Establishment of a real-time quantitative polymerase chain reaction for detection of human receptor for advanced GLYCATION end products (RAGE) mRNA and its …
  2941. DEPRESSANT EFFECT OF SILYBIN-PHOSPHATIDYLCHOLINE COMPOUND (SPC) ON ADVANCED GLYCATION END PRODUCTS (AGEs) IN ALLOXAN …
  2942. Editorial [Receptor for Advanced GLYCATION Endproducts (RAGE): Coming Full Circle in Unraveling the Pathogenesis of Chronic Disease Guest Editor: Ann Marie …
  2943. Erythropoietin (Epo) Protects Retinal Neurons From Advanced GLYCATION End Products (AGEs)-Induced Apoptosis via Erk and AKT Pathways
  2944. HMGB1 is an early mediator of inflammation and may be negatively regulated by soluble receptor for advanced GLYCATION end products in experimental endotoxinemia …
  2945. THE EFFECTS OF EXTRACT GINGKO BILOBA THE INHIBITION OF NONENZYMATIC GLYCATION AND OXIDATION IN MYO-CARDIAL TISSUE OF TYPE 2 …
  2946. No evidence for advanced GLYCATION endproducts in cancer
  2947. Anti-GLYCATION Activities from Various Agricultural Products
  2948. The receptor for advanced GLYCATION endproducts and S100A11 modulate pathologic chondrocyte differentiation and dysregulated cartilage matrix catabolism …
  2949. The orgin of advanced GLYCATION endproducts and development of diabetic complications
  2950. Lysine as an Inhibito of Protein GLYCATION in an In Vitro System
  2951. The role of advanced GLYCATION end products in periodontal diseases [J]
  2952. Non-invasive measurement of advanced GLYCATION end products in patients with cerebral infarction
  2953. Application of spectral method for monitoring of hemoglobin GLYCATION
  2954. Influence of flavonols as in vitro on low density lipoprotein GLYCATION
  2955. Diabetic retinopathy: from GLYCATION to clinical aspects
  2956. The role of advanced GLYCATION end products in brain aging
  2957. ROLE OF ADVANCED GLYCATION END PRODUCTS (AGES) IN CELL GROWTH AND DEATH
  2958. Accumulation of advanced GLYCATION end products in canine atherosclerosis
  2959. … anti-glucose oxidase antibodies or the F (ab)′ 2/F (ab)′ fragments derived therefrom protects both the enzyme and antibody/antibody fragments against GLYCATION
  2960. Enzymes involved in the repair of GLYCATION by sugar phosphates
  2961. Monitoring of hemoglobin GLYCATION using spectral and refraction measurements
  2962. Herb and spice extracts inhibit protein GLYCATION
  2963. Accumulation of advanced GLYCATION end products in intensive care patients
  2964. New insights into the pathogenic role of advanced GLYCATION in diabetic retinopathy
  2965. Mechanism of Advanced GLYCATION End Products Induced Oxidative Effects in Cultured ECV304 Cells
  2966. Quantitative Analysis of GLYCATION Sites on HSA by 18 o-Labelling MALDI-TOF MS
  2967. Assessing the potential of carboxylic acids as inhibitors of GLYCATION
  2968. GLYCATION of platelet derived growth factor: relevance to diabetic wound healing
  2969. The analysis of avian plasma for the GLYCATION of serum albumin
  2970. Examination of advanced GLYCATION end-products in children with type 1 diabetes
  2971. GLYCATION May Cause Slower Insulin Releases than C-Peptides: A Theoretical Approach.
  2972. Long-standing diabetes in Africa and recent ideas about advanced GLYCATION end products: 39 patients in Dakar
  2973. OCT activity and GLYCATION damage in rat liver mitochondria
  2974. Actions of Advanced GLYCATION Endproducts (AGE) on coronary artery vascular smooth muscle cells
  2975. 26: The soluble form of the receptor for advanced GLYCATION end-products (sRAGE), a decoy for rage, is increased in the serum level of women with severe …
  2976. Rosiglitazone inhibits expression of acyl-coenzyme A: cholesterol acyltransferase-1 in THP-1 macrophages induced by advanced GLYCATION end-products⋆
  2977. Advanced GLYCATION End Products in Polycystic Ovarian Syndrome
  2978. INHIBITORY ACTIVITY OF VITAMIN C ON THE SUSCEPTIBILITY OF ALBUMIN TO GLYCATION REACTION
  2979. Advanced GLYCATION endproduct analysis of GTP and ATP with reducing sugars
  2980. GLYCATION Mechanism of Brain Damage Induced by D-Galactose in Rats
  2981. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced GLYCATION end-products
  2982. Urinary excretion of fluorescent advanced GLYCATION end products (AGEs) in the elderly
  2983. Do green tea polyphenols inhibit protein GLYCATION?
  2984. The Effect of Advanced GLYCATION End Product Inhibition on the Development of Diabetic Encephalopathy in Rats
  2985. Impact of interaction of advanced GLYCATION end product and its receptor on podocytes apoptosis
  2986. BLOCKADE OF ADVANCED GLYCATION IN CHRONIC ALLOGRAFT DYSFUNCTION: 1371
  2987. Impact of GLYCATION on duodenal digestibility of Bowman-Birk inhibitors
  2988. Advanced GLYCATION End Products Increase Matrix Metalloproteinases in Human Osteoarthritic Chondrocytes
  2989. Effect Donglian Capsule on Nonenzymatic Protein GLYCATION in Diabetes Melitus Rat
  2990. Effects of advanced GLYCATION end-products on differentiation of vascular endothelial cells from bone marrow stem cells of mice
  2991. EFFECT OF ADVANCED GLYCATION END PRODUCTS ON THE EXPRESSION OF ADIPONECTIN IN 3T3-L1 ADIPOCYTES [J]
  2992. Role of Advanced GLYCATION Products with Oxidative Stress in Resistance Artery Dysfunction in Type 2 Diabetic mice
  2993. OXIDATIVE DAMAGE TO DNA AND LIPIDS: CORRELATION WITH PROTEIN GLYCATION IN PATIENTS WITH TYPE 1 DIABETES
  2994. In-Vitro Studies on banana flower and stem as the inhibitors of formation of Advanced GLYCATION End Products (AGEs)
  2995. Relationship between receptor for advanced GLYCATION end products and preeclampsia
  2996. Effect of advanced GLYCATION end products on expression of vascular endothelial growth factor in cultured rabbit retinal M? ller cells
  2997. LC-MS Analysis of Markers for Advanced GLYCATION Endprocducts-Protein/Peptides Adducts
  2998. Biochemical effects of protein GLYCATION by methylglyoxal in Saccharomyces cerevisiae
  2999. Advanced GLYCATION Endprocucts Is Involved in the Development of Age-Associated Glomeruloselerosis through Growth Arrest Specific Gene 6.
  3000. Advanced GLYCATION Endproducts on Bruch’s Membrane Can Be Detected by Raman Microscopy and Correlate With Chronological Age
  3001. Effects of non-enzymatic GLYCATION on the biomechanical behavior of bone
  3002. The effect of advanced GLYCATION end products (AGE) breaker, alagebrium on the cardiac structural and functional change in type I diabetic rat model
  3003. Badania kliniczne i doświadczalne w chorobach serca, płuc i naczyń Advanced GLYCATION end products (AGE) in the pathogenesis of ischaemic cardiomyopathy in …
  3004. Inhibition effects of Alpina officicarum on the formation of advanced GLYCATION end products and the activity of aldose reductase
  3005. Co-effects of human cytomegalovirus infection and advanced GLYCATION end products on vascular endothelial cells
  3006. Non-enzymatic GLYCATION of fibrillin-1.
  3007. Effect of alcoholic extraction of the Cornel on advanced GLYCATION end products and DNA damage induced by D-gal in aging rats [J]
  3008. The Effects of Advanced GLYCATION End Products (AGEs) on Primary Human Microvascular Retinal Endothelial Cells (HMRECs)
  3009. Does a high protein diet induce renal dysfunction via activation of the advanced GLYCATION pathway?
  3010. Decreased plasma levels of soluble receptor for advanced GLYCATION end-products in patients with essential hyper…
  3011. C Reactive Protein Increases the Expression of Receptor for Advanced GLYCATION End-products in Human Endothelial Cells
  3012. HOTSPOTS SITES FOR GLYCATION OF HUMAN SERUM ALBUMIN AND EFFECT ON FUNCTIONAL ACTIVITY AND DEGRADATION
  3013. A novel inhibitor of advanced GLYCATION and endoplasmic reticulum stress reduces infarct volume in rat transient focal ischemia
  3014. Effect of advanced GLYCATION end products on the oxidative damage of PC12 cells induced by amyloid beta protein 25-35 [J]
  3015. EXPRESSION OF SOCS GENE IN RENAL TUBULAR CELLS INDUCED BY ADVANCED GLYCATION END PRODUCTS (AGEs)
  3016. Elevated serum advanced GLYCATION end products and poor grip strength in older community‐dwelling women
  3017. Endocytosis of Advanced GLYCATION End Products in Bovine Retinal Pigment Epithelial Cells
  3018. Production of advanced GLYCATION end products from the glycosylation of avian serum albumin
  3019. EVALUTION OF EFFECT OF α-TOCOPHEROL, ASCORBIC ACID AND LYCOPENE ON LOW DENSITY LIPOPROTEIN GLYCATION BY MODEL SYSTEM IN VITRO
  3020. Pathobiological role of advanced GLYCATION endproducts via MAPK dependent pathway in the diabetic vasculopathy
  3021. ADVANCED GLYCATION END-PRODUCTS (AGES) IN DEVELOPMENT OF ISCHEMIC AND DILATED CARDIOMYOPATHY IN PATIENTS WITH DIABETES …
  3022. Immunohistochemical Study of the Receptor for Advanced GLYCATION End Products in Alzheimer’s Disease Optic Nerves
  3023. Metformin Improves HDL-Mediated Cholesterol Efflux Through the Inhibition of HDL GLYCATION.
  3024. Thermal GLYCATION of chicken egg white cystatin
  3025. Advanced GLYCATION End Products (AGEs) Cause β-Cell Dysfunction in Mice by Impairing Mitochondrial Function.
  3026. Effect of advanced GLYCATION end products on the human gingival fibroblast proliferation and type I collagen synthesis
  3027. Structural characterization of the receptor for advanced GLYCATION end products reveals a two domain modular architecture
  3028. Effect of Advanced GLYCATION End Product on Cellular Proliferation and Expression of Plasminogen Activator Inhibitor-1 in Rat Vascular Smooth Muscle Cell
  3029. Serum advanced GLYCATION end-products in saudi women with polycystic ovary syndrome: a prospective study
  3030. The ratio of protein GLYCATION versus its ligand activity to AGE-receptors: are AGE-receptors really working as AGE-receptors in vivo?
  3031. Insulin resistance and oxidative stress induce advanced GLYCATION end products formation in patients with clinical and subclinical hypothyroidism
  3032. P100-S Analyses of In Vitro Non-Enzymatic GLYCATION of Normal and Variant Hemoglobins by MALDI-TOF Mass Spectrometry
  3033. Effect of taurine on advanced GLYCATION end products-induced hypertrophy in renal tubular epithelial cells
  3034. Advanced GLYCATION Endproducts (AGEs) Directly Damage the Myocardium by Reducing Calcium Transients via NADPH Oxidase
  3035. P36. An Analysis of Collagen Cross Linking via Nonenzymatic GLYCATION in the Intervertebral Disc
  3036. Association of endogenous secretory receptor for advanced GLYCATION end products with carotid atherosclerosis in type 2 diabetes mellitus
  3037. Inhibition of Aldose Reductase, Protein GLYCATION and Delay of Diabetic Cataract in Rats by Rutin
  3038. Effect of advanced GLYCATION end products on the gene expression of EMMPRIN in human renal mesangial cells
  3039. Effects of advanced GLYCATION end products on peroxisome proliferator activated receptor-γ mRNA expression in rat renal cortex [J]
  3040. Functional analysis of the susceptibility haplotype in the Receptor for Advanced GLYCATION End-products gene and its role in the hyperglycemia-driven pathology
  3041. Raman Spectroscopic Evaluation of Advanced GLYCATION & Lipoxidation Adducts in RPE
  3042. Inhibitory effects of compounds isolated from Thuja orientalis on human recombinant aldose reductase and advanced GLYCATION end-products
  3043. Targeted Imaging of Peripheral Angiogenesis in Type-1 Diabetes Demonstrates Impairment of Alpha-v Integrin Activation Associated with GLYCATION.
  3044. Amplifiers of systemic inflammation-the role advanced GLYCATION and lipoxidation end products in foods
  3045. Effect of valsartan on expression of receptor for advanced GLYCATION end-products in renal tissues of diabetic rats
  3046. The Glyoxalase System Modulates Advanced GLYCATION Mediated Pathology in Retinal Müller Glia
  3047. Expression of Receptor for Advanced GLYCATION end-products (RAGE) and the Relation of Metastatic Activity in Gastric Carcinomas′ tissue
  3048. Receptor for Advanced GLYCATION Endproducts Amplifies Vascular Inflammation Elicited by a Periodontal Pathogen
  3049. Hydrolyzable tannins from the cores of Cornus officinalis with inhibitory activity in vitro on the formation of advanced GLYCATION end products (AGEs)
  3050. Expression of Receptor for Advanced GLYCATION Endproduct in Pheoehromocytoma PC12 Cells and Its Effect on Cell Injury under Condition of Oxygen-Glucose …
  3051. Reduced expression of endogenous secretory receptor for advanced GLYCATION endproducts in hippocampal neurons
  3052. Effects of tetramethylpyrazine on expression of vascular endothelium growth factor induced by advanced GLYCATION end products on retinal pigment epithelium
  3053. Protection of Rat Retinal Neurons From Apoptosis Induced by Glyoxal-Mediated Formation of Advanced GLYCATION End Products (Ages) in vitro
  3054. Advanced GLYCATION Endproduct “AGE” Accumulation in Elderly Hypertensive Canines: Correlation with Effects of AGE Crosslink Breaker
  3055. Rosiglitazone ameliorates the effect of advanced GLYCATION end products on plasminogen activator inhibitor 1 in rat glomerular mesangial cells
  3056. Metabolism Of Advanced GLYCATION End Products (AGEs) By The Polyol Pathway Enzyme-Aldose Reductase Decreases AGE Accumulation In Diabetes
  3057. Evidence for Independent Heritability of the GLYCATION Gap (Glycosylation Gap) Fraction of HbA1c in Nondiabetic Twins: Response to Nuttall
  3058. On the expression of fractalkine by rosiglitazone in human renal mesangial cells induced by advanced GLYCATION end products
  3059. Antioxidant activity of mengkudu fruit juice (Morinda citrifolia) and the role as an inhibitor of advanced GLYCATION and products (AGES) by glycosilation reaction
  3060. Nonenzymatic GLYCATION of guanosine 5′‐triphosphate (GTP) by dihydroxyacetone phosphate (DHAP): an in vitro study of AGE formation
  3061. Response to Letter Regarding Article,“Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced GLYCATION End Products, and Myocyte …
  3062. Proteomic Analysis of Advanced GLYCATION Endproduct (AGE)-Modified Proteins in Müller Cells During High Glucose Exposure: Implications for Macroglial Dysfunction …
  3063. Advanced GLYCATION end-product-induced mitogenesis is dependent on Janus kinase 2-induced heat shock protein 70 in normal rat kidney interstitial fibroblast cells.
  3064. SKIN AUTOFLUORESCENCE, AS A MARKER OF ACCUMULATION OF ADVANCED GLYCATION ENDPRODUCTS AND OF CUMULATIVE STRESS, IS NOT …
  3065. The alteration of thermodynamic characteristics of corneal tissue collagen denaturation as the result of the non-enzymatic GLYCATION
  3066. Possible role of HMG CoA reductase inhibitor on the oxidative stress induced by advanced GLYCATION endproducts (AGEs) in vascular smooth muscle cell of diabetic …
  3067. Treatment With Nitric Oxide (NO) Donors or Pioglitazone Improves CD34+ Cell Dynamics on Advanced GLYCATION End Product (AGE) Modified Basement Membrane
  3068. Possible Role of HMG CoA Reductase Inhibitor on the Oxidative Stress induced by Advanced GLYCATION Endproducts (AGEs) in Vascular Smooth Muscle Cell (VSMC) …
  3069. Enhanced cellular oxidant stress by the interaction of advanced GLYCATION endproducts-modified hemoglobin with monocytes bearing CD163 receptors
  3070. Advanced GLYCATION end-product-inhibited cell proliferation and protein expression of beta-catenin and cyclin D1 are dependent on glycogen synthase kinase 3 beta in …
  3071. Consequences of the interaction of amyloid beta with amyloid binding alcohol dehydrogenase and the receptor for advanced GLYCATION end products
  3072. Reduced expression of endogenous secretory receptor for advanced GLYCATION endproducts in hippocampal neurons of Alzheimer’s disease brains
  3073. Vascular Endothelial Growth Factor (VEGF) and Advanced GLYCATION End Products (AGEs) Overexpression in the Retina and Serum and Lens Opacities of …
  3074. ACUTE KAWASAKI DISEASE IS ASSOCIATED WITH REVERSE REGULATION OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (SRAGE …
  3075. Expression of Receptor for Advanced GLYCATION End Product mRNA and Protein in Cultured Hepatic Stellate Cells Inhibited by Specific Small Interfering RNA
  3076. Receptor for Advanced GLYCATION End Products (RAGE) Plays an Integral Role in Non-Diabetic Atherosclerosis and Oxidized LDL Stimulation
  3077. Influence of GLYCATION (non-enzymatic glycosylation) on antigenicity of soy (Glycine max) and pea (Pisum sativum) 7S globulin
  3078. S100A6 Promotes Myocyte Survival by Interacting with the Receptor for Advanced GLYCATION End Products and Activating Akt
  3079. The combination of high glucose and advanced GLYCATION end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced …
  3080. Structural insights into signal-transducing proteins: Regulation of the EF-hand protein S100A2 and activation of the Receptor for Advanced GLYCATION Endproducts
  3081. Targeted Inactivation of Receptor for Advanced GLYCATION Products Reduced Oxidative LDL-Induced Inflammation and Atherosclerosis in Non-Diabetic LDL Receptor …
  3082. Fundus Autofluorescence in a Rabbit Model of Age-Related Macular Degeneration Induced by Advanced GLYCATION End Product Microspheres as Imitation Lipofuscin
  3083. The Structural Modification of Nucleosides by Non‐enzymatic GLYCATION: A Study Based on The in vitro Interactions of Glyoxal and Methylglyoxal with DNA Purines and …
  3084. Reactive oxygen species (ROS) and advanced GLYCATION end products (AGE)‐induced ERK5‐SUMOylation antagonizes anti‐inflammatory effect of shear stress in …
  3085. Receptor for advanced-GLYCATION end products inhibits myocardin function and induces msx2-dependent osteoblastic differentiation of vascular smooth muscle cells
  3086. Activation of Receptor for Advanced-GLYCATION End Products (Rage) Induces Notch-msx2-Dependent Osteoblastic Differentiation of Vascular Smooth Muscle Cells
  3087. Involvement of Na {sup+}/H {sup+} exchanger 1 in advanced GLYCATION end products-induced proliferation of vascular smooth muscle cell
  3088. 5. Crucial involvement of advanced GLYCATION end-products in experimental diabetes-associated arterial elastocalcinosis.
  3089. Response to Comment on: Thallas-Bonke et al.(2008) Inhibition of NADPH Oxidase Prevents Advanced GLYCATION End Product–Mediated Damage in Diabetic …
  3090. Su. 70. The Receptor for Advanced GLYCATION End Products (RAGE) is Associated with the Tumor Cell Response to Stress
  3091. 103: Is the receptor for advanced GLYCATION end products (RAGE) involved in preterm birth?
  3092. Flavan-3-ols from the roots of Actinidia arguta inhibit the formation of advanced GLYCATION end products (AGEs) in vitro
  3093. High mobility group box 1, receptor for advanced GLYCATION end products and IkappaB kinase are potential pharmacological targets in cerebral ischemia
  3094. 264: In severe preeclampsia, activation of the receptor for advanced GLYCATION end-products (RAGE) system occurs independent of antigenic N-carboxymethyl-lysine …
  3095. hnRNP K-Mediated Regulation of COX-2 Expression in Monocytes by Ligation of the Receptor for Advanced GLYCATION End Products (RAGE).
  3096. Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and its Regression by BMP-7 and Advanced GLYCATION End-Product Inhibitors
  3097. 766: Evidence for participation of high mobility group box 1 protein (HMGB1) in activation of receptor for advanced GLYCATION end-products (RAGE) and toll-like …
  3098. Histone H1 studies: 1) in vivo evidence of nuclear protein damage; 2) in vitro studies of natural product GLYCATION inhibitors
  3099. Fluorine-18 radiolabeling of S100/calgranulins: a potential approach for characterization of receptors for advanced GLYCATION endproducts in vivo
  3100. … -CT Imaging Demonstrates Impairment of Matrix Metalloproteinases Activation in Ischemic Peripheral Angiogenesis in Type-1 Diabetes Associated with GLYCATION
  3101. Nrf2/ARE mediated activation of HO-1 by advanced GLYCATION endproducts in bovine aortic endothelial cells: involvement of JNK and NADPH oxidase
  3102. 2-Deoxy-D-Ribose Produces Oxidative Damage Through Mechanisms of Protein GLYCATION in Pancreatic β-Cells.
  3103. Poster 185: Effects of Insulin and Endurance Exercise on Accumulation of Advanced GLYCATION Endproduct in Skeletal Muscle of Rats with Diabetes Mellitus
  3104. Advanced GLYCATION end‐products and the kidney
  3105. Advanced GLYCATION end products in foods and a practical guide to their reduction in the diet
  3106. Dietary advanced GLYCATION end products and aging
  3107. Does accumulation of advanced GLYCATION end products contribute to the aging phenotype?
  3108. Hyperglycemia and GLYCATION in diabetic complications
  3109. Advanced GLYCATION end products, oxidative stress and diabetic nephropathy
  3110. Advanced GLYCATION end-products: implications for diabetic and non-diabetic nephropathies
  3111. Nutrition and aging skin: sugar and GLYCATION
  3112. The role of advanced GLYCATION end products in retinal ageing and disease
  3113. Advanced GLYCATION end-products and bone fractures
  3114. The sour side of neurodegenerative disorders: the effects of protein GLYCATION
  3115. The Maillard reaction in the human body. The main discoveries and factors that affect GLYCATION
  3116. Rutin metabolites: novel inhibitors of nonoxidative advanced GLYCATION end products
  3117. Trends in advanced GLYCATION end products research in diabetes mellitus and its complications
  3118. Characterization of type I collagen gels modified by GLYCATION
  3119. Significance of advanced GLYCATION end products in aging-related disease
  3120. Soluble form of a receptor for advanced GLYCATION end products (sRAGE) as a biomarker.
  3121. Inhibitory effects of guava (Psidium guajava L.) leaf extracts and its active compounds on the GLYCATION process of protein
  3122. The receptor for advanced GLYCATION end products (RAGE) and the lung
  3123. Comparison of anti-GLYCATION capacities of several herbal infusions with that of green tea
  3124. A perspective on the Maillard reaction and the analysis of protein GLYCATION by mass spectrometry: probing the pathogenesis of chronic disease
  3125. The receptor for advanced GLYCATION endproducts (RAGE) and cardiovascular disease
  3126. Advanced GLYCATION end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes
  3127. Inhibitory effects of Chrysanthemum species extracts on formation of advanced GLYCATION end products
  3128. Changes in non-enzymatic GLYCATION and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate
  3129. RAGE (Receptor for Advanced GLYCATION Endproducts), RAGE ligands, and their role in cancer and inflammation
  3130. Identification and relative quantification of specific GLYCATION sites in human serum albumin
  3131. Advanced GLYCATION endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced GLYCATION endproducts mediate …
  3132. Advanced GLYCATION end products accumulate in the reproductive tract of men with diabetes
  3133. Reaction of GLYCATION and human skin: the effects on the skin and its components, reconstructed skin as a model
  3134. Soluble receptor for advanced GLYCATION end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases
  3135. Neoformation of antioxidants in GLYCATION model systems treated under subcritical water extraction conditions
  3136. Advanced GLYCATION end products strongly activate platelets
  3137. The effect of GLYCATION on foam and structural properties of β-lactoglobulin
  3138. Antioxidative activity, polyphenolic content and anti-GLYCATION effect of some Thai medicinal plants traditionally used in diabetic patients
  3139. Advanced GLYCATION end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells
  3140. Oxidative damage to DNA and lipids: correlation with protein GLYCATION in patients with type 1 diabetes
  3141. Advanced GLYCATION end-products enhance calcification in vascular smooth muscle cells
  3142. Elevated serum advanced GLYCATION end products and poor grip strength in older community-dwelling women
  3143. Processing of type I collagen gels using nonenzymatic GLYCATION
  3144. Accumulation of advanced GLYCATION end products and chronic complications in ESRD treated by dialysis
  3145. Non-enzymatic GLYCATION of proteins: from diabetes to cancer
  3146. Plasma advanced GLYCATION end products are decreased in obese children compared with lean controls
  3147. Advanced GLYCATION end products and receptor–oxidative stress system in diabetic vascular complications
  3148. Effect of GLYCATION on the gastrointestinal digestibility and immunoreactivity of bovine β-lactoglobulin
  3149. Tissue-advanced GLYCATION end product concentration in dialysis patients
  3150. Collagen GLYCATION alters neovascularization in vitro and in vivo
  3151. Protection against loss of innate defenses in adulthood by low advanced GLYCATION end products (AGE) intake: role of the antiinflammatory AGE receptor-1
  3152. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced GLYCATION end products (RAGE) and RAGE ligands
  3153. Serum carboxymethyl–lysine, an advanced GLYCATION end product, is associated with increased aortic pulse wave velocity in adults
  3154. Advanced GLYCATION end-products induce tubular CTGF via TGF-β–independent Smad3 signaling
  3155. Nonenzymatic GLYCATION impairs the antiinflammatory properties of apolipoprotein AI
  3156. Inhibitory effects of microalgal extracts on the formation of advanced GLYCATION endproducts (AGEs)
  3157. PROGRESS IN UREMIC TOXIN RESEARCH: Highlights and Hotspots of Protein GLYCATION in End‐Stage Renal Disease
  3158. Homodimerization is essential for the receptor for advanced GLYCATION end products (RAGE)-mediated signal transduction
  3159. Interactions between advanced GLYCATION end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors …
  3160. Advanced GLYCATION end products increase endothelial permeability through the RAGE/Rho signaling pathway
  3161. Advanced GLYCATION endproduct (AGE) accumulation and AGE receptor (RAGE) up‐regulation contribute to the onset of diabetic cardiomyopathy
  3162. GLYCATION of PDGF results in decreased biological activity
  3163. Advanced GLYCATION end products enhance amyloid precursor protein expression by inducing reactive oxygen species
  3164. Advanced GLYCATION end products as biomarkers and gerontotoxins–a basis to explore methylglyoxal-lowering agents for Alzheimer’s disease?
  3165. Effects of heating and GLYCATION of β-lactoglobulin on its recognition by IgE of sera from cow milk allergy patients
  3166. Effects of atorvastatin on serum soluble receptors for advanced GLYCATION end-products in type 2 diabetes
  3167. Advanced GLYCATION end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women
  3168. Immunological detection of fructose-derived advanced GLYCATION end-products
  3169. Relationship of an advanced GLYCATION end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study
  3170. Advanced GLYCATION end product (AGE) accumulation on Bruch’s membrane: links to age-related RPE dysfunction
  3171. Regular moderate exercise reduces advanced GLYCATION and ameliorates early diabetic nephropathy in obese Zucker rats
  3172. Advanced GLYCATION end products (AGEs) activate mast cells
  3173. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced GLYCATION end products
  3174. Advanced GLYCATION end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK
  3175. Receptor for advanced GLYCATION end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
  3176. Protein GLYCATION inhibitory activities of Lawsonia inermis and its active principles
  3177. Cancer malignancy is enhanced by glyceraldehyde-derived advanced GLYCATION end-products
  3178. The receptor for advanced GLYCATION end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival
  3179. Effects of GLYCATION of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells
  3180. Plasma levels of receptor for advanced GLYCATION end products, blood transfusion, and risk of primary graft dysfunction
  3181. Association between circulating soluble receptor for advanced GLYCATION end products and atherosclerosis: observations from the Dallas Heart Study
  3182. Antihyperglycemic activity and inhibition of advanced GLYCATION end product formation by Cuminum cyminum in streptozotocin induced diabetic rats
  3183. Advanced GLYCATION end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways
  3184. Skin autofluorescence as a measure of advanced GLYCATION endproduct deposition: a novel risk marker in chronic kidney disease
  3185. Chondroprotective effects and mechanisms of resveratrol in advanced GLYCATION end products-stimulated chondrocytes
  3186. Deletion of the receptor for advanced GLYCATION end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
  3187. Anti-GLYCATION activity of gold nanoparticles
  3188. Dihydrochalcones: Implication in resistance to oxidative stress and bioactivities against advanced GLYCATION end-products and vasoconstriction
  3189. Alternative splicing of the murine receptor for advanced GLYCATION end‐products (RAGE) gene
  3190. Non-enzymatic GLYCATION alters microdamage formation in human cancellous bone
  3191. Analysis of protein GLYCATION using phenylboronate acrylamide gel electrophoresis
  3192. Higher plasma soluble receptor for advanced GLYCATION end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in …
  3193. Advanced GLYCATION end products in senile diabetic and nondiabetic patients with cataract
  3194. Role of the receptor for advanced GLYCATION end products in hepatic fibrosis
  3195. Phenolic content and in vitro inhibitory effects on oxidation and protein GLYCATION of some Thai medicinal plants
  3196. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced GLYCATION end …
  3197. Rapid GLYCATION with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells
  3198. Increased GLYCATION and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin
  3199. Receptor for advanced GLYCATION end products: its role in Alzheimer’s disease and other neurological diseases
  3200. Association between carotid diameter and the advanced GLYCATION endproduct N ε-Carboxymethyllysine (CML)
  3201. Advanced GLYCATION end-products affect transcription factors regulating insulin gene expression
  3202. GLYCATION of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro
  3203. The effects of GLYCATION on the binding of human serum albumin to warfarin and L-tryptophan
  3204. Atorvastatin decreases serum levels of advanced GLYCATION endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness …
  3205. Recent advances in the recovery and improvement of functional proteins from fish processing by‐products: use of protein GLYCATION as an alternative method
  3206. Receptor for advanced GLYCATION end products is detrimental during influenza A virus pneumonia
  3207. Advanced GLYCATION end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2
  3208. Receptor for advanced GLYCATION end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer.
  3209. … GLYCATION end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced GLYCATION …
  3210. GLYCATION and phosphorylation of α-lactalbumin by dry heating: Effect on protein structure and physiological functions
  3211. Advanced GLYCATION end product (AGE) modified proteins in tears of diabetic patients
  3212. … GLYCATION end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced GLYCATION …
  3213. Advanced GLYCATION end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase
  3214. Formyline, a new GLYCATION compound from the reaction of lysine and 3-deoxypentosone
  3215. Receptors for advanced GLYCATION end-products targeting protect against hyperoxia-induced lung injury in mice
  3216. Advanced GLYCATION end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages
  3217. Circulating soluble receptor for advanced GLYCATION end products is inversely associated with body mass index and waist/hip ratio in the general population
  3218. Effects of plant‐derived polyphenols on TNF‐α and nitric oxide production induced by advanced GLYCATION endproducts
  3219. The receptor for advanced GLYCATION end products impairs host defense in pneumococcal pneumonia
  3220. Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced GLYCATION end-products (RAGE)
  3221. Kaempferol modulates pro-inflammatory NF-κB activation by suppressing advanced GLYCATION endproducts-induced NADPH oxidase
  3222. Decrease in serum levels of advanced GLYCATION end-products by short-term lifestyle modification in non-diabetic middle-aged females
  3223. Evaluation of α-glucosidase, α-amylase and protein GLYCATION inhibitory activities of edible plants
  3224. Possible involvement of advanced GLYCATION end products in periodontal diseases
  3225. Quantitative measurement of specific biomarkers for protein oxidation, nitration and GLYCATION in Arabidopsis leaves
  3226. Advanced GLYCATION end products and their circulating receptors and level of kidney function in older community-dwelling women
  3227. Molecular susceptibility to GLYCATION and its implication in diabetes mellitus and related diseases
  3228. Anti-receptor for advanced GLYCATION end products therapies as novel treatment for abdominal aortic aneurysm
  3229. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced GLYCATION end products
  3230. Inhibitory effect of the cree traditional medicine wiishichimanaanh (Vaccinium vitis‐idaea) on advanced GLYCATION endproduct formation: identification of active …
  3231. Plasma carboxymethyl‐lysine, an advanced GLYCATION end product, and all‐cause and cardiovascular disease mortality in older community‐dwelling adults
  3232. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces GLYCATION and tau fibrillation
  3233. Protein GLYCATION inhibitory activity of wheat bran feruloyl oligosaccharides
  3234. Preventive effects of chebulic acid isolated from Terminalia chebula on advanced GLYCATION endproduct-induced endothelial cell dysfunction
  3235. Effects of alagebrium, an advanced GLYCATION end‐product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL …
  3236. Soluble receptor for advanced GLYCATION end products in physiological and pathological pregnancy
  3237. GLYCATION of a food allergen by the Maillard reaction enhances its T-cell immunogenicity: role of macrophage scavenger receptor class A type I and II
  3238. Analysis of advanced GLYCATION endproducts in dairy products by isotope dilution liquid chromatography–electrospray tandem mass spectrometry. The particular case …
  3239. Role of the receptor for advanced GLYCATION end products (RAGE) in inflammation
  3240. Receptor for advanced GLYCATION end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury
  3241. Advanced GLYCATION end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells
  3242. Association of polymorphism in the receptor for advanced GLYCATION end products (RAGE) gene with circulating RAGE levels
  3243. Advanced GLYCATION end products in patients with cerebral infarction
  3244. Short-term low calorie diet intervention reduces serum advanced GLYCATION end products in healthy overweight or obese adults
  3245. GLYCATION Endproducts, Soluble Receptor for Advanced GLYCATION Endproducts and Cytokines in Diabetic and Non‐diabetic Pregnancies
  3246. S100B Interaction With the Receptor for Advanced GLYCATION End Products (RAGE) A Novel Receptor-Mediated Mechanism for Myocyte Apoptosis Postinfarction
  3247. Advanced GLYCATION end products inhibit the expression of collagens type I and III by human gingival fibroblasts
  3248. Mitigating effects of antioxidant properties of Artemisia campestris leaf extract on hyperlipidemia, advanced GLYCATION end products and oxidative stress in alloxan …
  3249. Smooth muscle cell pathophysiology and advanced GLYCATION end products (AGEs)
  3250. Advanced GLYCATION endproducts increase EPC apoptosis and decrease nitric oxide release via MAPK pathways
  3251. ERM protein moesin is phosphorylated by advanced GLYCATION end products and modulates endothelial permeability
  3252. Hemoglobin GLYCATION index: a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients
  3253. Regulation of advanced GLYCATION end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease
  3254. Citrus Fruit Extracts Reduce Advanced GLYCATION End Products (AGEs)- and H2O2-Induced Oxidative Stress in Human Adipocytes
  3255. The formation of intracellular glyceraldehyde-derived advanced GLYCATION end-products and cytotoxicity
  3256. Soluble receptors for advanced GLYCATION end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention
  3257. Advanced GLYCATION End Products Inhibit Glucose-Stimulated Insulin Secretion through Nitric Oxide-Dependent Inhibition of Cytochrome c Oxidase and Adenosine …
  3258. Decreased plasma levels of soluble receptor for advanced GLYCATION endproducts (sRAGE) in patients with nonalcoholic fatty liver disease
  3259. Serum levels of soluble receptor for advanced GLYCATION end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk …
  3260. Evidence for activation of Toll-like receptor and receptor for advanced GLYCATION end products in preterm birth
  3261. Stilbene glucoside from Polygonum multiflorum Thunb.: a novel natural inhibitor of advanced GLYCATION end product formation by trapping of methylglyoxal
  3262. Circulating soluble receptor of advanced GLYCATION end product inversely correlates with atherosclerosis in patients with chronic kidney disease
  3263. Advanced GLYCATION end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy
  3264. Ribosylation rapidly induces α-synuclein to form highly cytotoxic molten globules of advanced GLYCATION end products
  3265. Phase I clinical studies of the advanced GLYCATION end-product (AGE)-breaker TRC4186
  3266. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for advanced GLYCATION end product-dependent manner
  3267. Identifying advanced GLYCATION end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in …
  3268. Transport of the advanced GLYCATION end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1
  3269. Misconceptions about high-fructose corn syrup: is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced GLYCATION endproducts?
  3270. Low serum level of the endogenous secretory receptor for advanced GLYCATION end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of …
  3271. Red blood cell adhesion in diabetes mellitus is mediated by advanced GLYCATION end product receptor and is modulated by nitric oxide
  3272. The inhibition of advanced GLYCATION end-products-induced retinal vascular permeability by silver nanoparticles
  3273. Monocyte CD147 is induced by advanced GLYCATION end products and high glucose concentration: possible role in diabetic complications
  3274. Seasonal phytochemical variation of anti-GLYCATION principles in lowbush blueberry (Vaccinium angustifolium)
  3275. Blockade of PKC-beta protects HUVEC from advanced GLYCATION end products induced inflammation
  3276. Androgens associated with advanced GLYCATION end-products in postmenopausal women
  3277. Diabetes impairs hippocampal function via advanced GLYCATION end product mediated new neuron generation in animals with diabetes-related depression
  3278. Aging, proteotoxicity, mitochondria, GLYCATION, NAD+ and carnosine: possible inter-relationships and resolution of the oxygen paradox
  3279. Pyridoxamine, an inhibitor of advanced GLYCATION end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice
  3280. Biologic variability in plasma glucose, hemoglobin A1c, and advanced GLYCATION end products associated with diabetes complications
  3281. Receptor for Advanced GLYCATION End Products Facilitates Host Defense during Escherichia coli–Induced Abdominal Sepsis in Mice
  3282. Plasma levels of advanced GLYCATION end products are associated with haemolysis‐related organ complications in sickle cell patients
  3283. GLYCATION isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma
  3284. Glycated albumin, a precursor of advanced GLYCATION end‐products, up‐regulates NADPH oxidase and enhances oxidative stress in human endothelial cells …
  3285. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced GLYCATION end-products and is …
  3286. Effect of circulating soluble receptor for advanced GLYCATION end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in …
  3287. Elevated levels of the receptor for advanced GLYCATION end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in …
  3288. Monitoring of malting process by characterization of GLYCATION of barley protein Z
  3289. Advanced GLYCATION end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells
  3290. Monoacylglycerol (MAG)-oleic acid has stronger antioxidant, anti-atherosclerotic, and protein GLYCATION inhibitory activities than MAG-palmitic acid
  3291. Receptor for advanced GLYCATION end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease
  3292. Advanced GLYCATION end-products suppress neuropilin-1 expression in podocytes
  3293. Blockade of advanced GLYCATION end product formation attenuates bleomycin-induced pulmonary fibrosis in rats
  3294. Precursor of advanced GLYCATION end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD (P) H oxidase 4
  3295. Serum‐soluble receptor for advanced GLYCATION end product levels in patients with amyotrophic lateral sclerosis
  3296. Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced GLYCATION endproducts in ovaries of reproductively-aged mice.
  3297. Advanced GLYCATION end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia
  3298. Blockage of receptor for advanced GLYCATION end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice
  3299. Metformin restores impaired HDL-mediated cholesterol efflux due to GLYCATION
  3300. Amyloid β interaction with receptor for advanced GLYCATION end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood …
  3301. Low levels of soluble receptor for advanced GLYCATION end products in non-ST elevation myocardial infarction patients
  3302. Pigment epithelium-derived factor inhibits advanced GLYCATION end product-elicited mesangial cell damage by blocking NF-κB activation
  3303. Mass spectrometry characterization of the GLYCATION sites of bovine insulin by tandem mass spectrometry
  3304. Proteomic studies on receptor for advanced GLYCATION end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
  3305. HbA1c and serum levels of advanced GLYCATION and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus
  3306. Receptor for advanced GLYCATION end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury
  3307. Microglial receptor for advanced GLYCATION end product-dependent signal pathway drives β-amyloid-induced synaptic depression and long-term depression …
  3308. Soluble receptor for advanced GLYCATION end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer
  3309. Beneficial effects of cinnamon proanthocyanidins on the formation of specific advanced GLYCATION endproducts and methylglyoxal-induced impairment on glucose …
  3310. Expression of advanced GLYCATION end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis
  3311. ATP-dependent mechanism protects spectrin against GLYCATION in human erythrocytes
  3312. Non-enzymatic GLYCATION of proteins: from diabetes to cancer
  3313. PPARγ-mediated advanced GLYCATION end products regulation of neural stem cells
  3314. A novel role for the Receptor for Advanced GLYCATION End-products in neural progenitor cells derived from adult SubVentricular Zone
  3315. Receptor for advanced GLYCATION end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse
  3316. Lipoprotein GLYCATION in atherogenesis
  3317. Terminalia bellirica stimulates the secretion and action of insulin and inhibits starch digestion and protein GLYCATION in vitro
  3318. Advanced GLYCATION end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow …
  3319. Irbesartan inhibits advanced GLYCATION end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
  3320. The role of the receptor for advanced GLYCATION end-products in a murine model of silicosis
  3321. Plasma advanced GLYCATION endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes
  3322. Elevated plasma and alveolar levels of soluble receptor for advanced GLYCATION endproducts are associated with severity of lung dysfunction in ARDS patients
  3323. Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced GLYCATION end-products in human myocardium
  3324. Advanced GLYCATION end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells
  3325. Receptor for advanced GLYCATION endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells
  3326. Serum carboxymethyl-lysine, a dominant advanced GLYCATION end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging
  3327. Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced GLYCATION end products (RAGE) transcript forms
  3328. Anti-GLYCATION effect of mixed herbal extract in individuals with pre-diabetes mellitus a double-blind, placebo-controlled, parallel group study
  3329. Preferential recognition of Amadori-rich lysine residues by serum antibodies in diabetes mellitus: role of protein GLYCATION in the disease process
  3330. Non-enzymatic GLYCATION induces structural modifications of myoglobin
  3331. Studies on the impact of GLYCATION on the denaturation of whey proteins
  3332. A new perspective on therapeutic inhibition of advanced GLYCATION in diabetic microvascular complications: common downstream endpoints achieved through …
  3333. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic GLYCATION on aortic collagen
  3334. 3, 5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein GLYCATION, aldose reductase, and cataractogenesis
  3335. Plasma levels of soluble receptor for advanced GLYCATION end products are associated with endothelial function and predict cardiovascular events in nondiabetic …
  3336. Advanced GLYCATION endproducts induce photocrosslinking and oxidation of bovine lens proteins through type‐I mechanism
  3337. Positive association of serum levels of advanced GLYCATION end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic …
  3338. Low-density-lipoprotein (LDL)-bound flavonoids increase the resistance of LDL to oxidation and GLYCATION under pathophysiological concentrations of glucose in vitro
  3339. Role of zinc along with ascorbic acid and folic acid during long-term in vitro albumin GLYCATION
  3340. Internalization of the receptor for advanced GLYCATION end products (RAGE) is required to mediate intracellular responses
  3341. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced GLYCATION endproducts in vascular smooth muscle cells of diabetic …
  3342. Detection of GLYCATION sites in proteins by high-resolution mass spectrometry combined with isotopic labeling
  3343. Functional and molecular properties of calcium precipitated soy glycinin and the effect of GLYCATION with κ-carrageenan
  3344. Drugs of abuse that mediate advanced GLYCATION end product formation: a chemical link to disease pathology
  3345. Small-dense LDL and LDL GLYCATION in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes
  3346. Ectodomain shedding of the receptor for advanced GLYCATION end products: a novel therapeutic target for Alzheimer’s disease
  3347. Inhibitors of Aldose Reductase and Formation of Advanced GLYCATION End-Products in Moutan Cortex (Paeonia suffruticosa)
  3348. Scopoletin from the flower buds of Magnolia fargesii inhibits protein GLYCATION, aldose reductase, and cataractogenesis ex vivo
  3349. Homoisoflavanones from Polygonatum odoratum rhizomes inhibit advanced GLYCATION end product formation
  3350. Expression of senescence-associated β-galactosidase (SA-β-Gal) by human skin fibroblasts, effect of advanced GLYCATION end-products and fucose or rhamnose-rich …
  3351. Pigment epithelium-derived factor inhibits advanced GLYCATION end products-induced retinal vascular permeability
  3352. Receptor for advanced GLYCATION end products in donor lungs is associated with primary graft dysfunction after lung transplantation
  3353. Advanced GLYCATION endproducts and rat dental implant osseointegration
  3354. Carboxymethyl-lysine, an advanced GLYCATION end product, and decline of renal function in older community-dwelling adults
  3355. Constituents of the flowers of Platycodon grandiflorum with inhibitory activity on advanced GLYCATION end products and rat lens aldose reductase in vitro
  3356. Ethanol and water extract of purple sweet potato exhibits anti-atherosclerotic activity and inhibits protein GLYCATION
  3357. The polyphenolics in the aqueous extract of Psidium guajava kinetically reveal an inhibition model on LDL GLYCATION
  3358. Oxidative stress mediates protein kinase C activation and advanced GLYCATION end product formation in a mesangial cell model of diabetes and high protein diet
  3359. Advanced GLYCATION end products increase transglutaminase activity in primary porcine tenocytes
  3360. Blockade of renin-angiotensin system attenuates advanced GLYCATION end products-mediated signaling pathways
  3361. Comparison of distinct protein isoforms of the receptor for advanced GLYCATION end-products expressed in murine tissues and cell lines
  3362. Effects of trace elements on albumin and lipoprotein GLYCATION in diabetic retinopathy
  3363. Accumulation of advanced GLYCATION end (AGEs) products in intensive care patients: an observational, prospective study
  3364. Use of human vascular tissue microarrays for measurement of advanced GLYCATION endproducts
  3365. Mitochondrial dysfunction, proteotoxicity, and aging: causes or effects, and the possible impact of NAD+-controlled protein GLYCATION
  3366. Receptor for advanced GLYCATION end products is upregulated in optic neuropathy of Alzheimer’s disease
  3367. Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to GLYCATION and fatty acids
  3368. Quantitative analysis of GLYCATION sites on human serum albumin using 16O/18O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass …
  3369. Expression of receptor for advanced GLYCATION end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma
  3370. Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced GLYCATION end products
  3371. Levels of soluble receptor for advanced GLYCATION end products in acute ischemic stroke without a source of cardioembolism
  3372. Positive association of circulating levels of advanced GLYCATION end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population
  3373. Reactive immunization suppresses advanced GLYCATION and mitigates diabetic nephropathy
  3374. C-reactive protein (CRP) up-regulates expression of receptor for advanced GLYCATION end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells …
  3375. Microwave-assisted Maillard reactions for the preparation of advanced GLYCATION end products (AGEs)
  3376. Flavonoids from the leaves of Thuja orientalis inhibit the aldose reductase and the formation of advanced GLYCATION endproducts
  3377. Effects of nitric oxide and antioxidants on advanced GLYCATION end products-induced hypertrophic growth in human renal tubular cells
  3378. Mutagenic Potential of DNA GLYCATION: Miscoding by (R)- and (S)-N2-(1-Carboxyethyl)-2′-deoxyguanosine
  3379. Modulation of the cellular expression of circulating advanced GLYCATION end-product receptors in type 2 diabetic nephropathy
  3380. Association of 1704G/T and G82S polymorphisms in the receptor for advanced GLYCATION end products gene with diabetic retinopathy in Chinese population
  3381. Genetic predisposition to advanced GLYCATION end products toxicity is related to prognosis of chronic hemodialysis patients
  3382. Anti-GLYCATION and anti-albuminuric effects of GLY-230 in human diabetes
  3383. Circulating levels of advanced GLYCATION end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) …
  3384. Vitamin B6 metabolism in chronic kidney disease–relation to transsulfuration, advanced GLYCATION and cardiovascular disease
  3385. Expression of high-mobility group box 1 and of receptor for advanced GLYCATION end products in chronic obstructive pulmonary disease
  3386. Advanced GLYCATION end‐products, anti‐hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction
  3387. Role of Toll-like receptors 2 and 4, and the receptor for advanced GLYCATION end products in high-mobility group box 1–induced inflammation in vivo
  3388. Effects of glucose and advanced GLYCATION end products on oxidative stress in MIN6 cells
  3389. Advanced GLYCATION end products‐induced apoptosis attenuated by PPARδ activation and epigallocatechin gallate through NF‐κB pathway in human embryonic …
  3390. Increased cation conductance in human erythrocytes artificially aged by GLYCATION
  3391. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced GLYCATION end products (AGEs)
  3392. C-reactive protein upregulates receptor for advanced GLYCATION end products expression and alters antioxidant defenses in rat endothelial progenitor cells
  3393. Hepatocyte growth factor prevents advanced GLYCATION end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial …
  3394. … ‐derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced GLYCATION end products (AGEs)
  3395. Salvia reuterana extract prevents formation of advanced GLYCATION end products: an in vitro study
  3396. Maillard reaction of proteins and advanced GLYCATION end products (AGEs) in food
  3397. Advanced GLYCATION end products and lipopolysaccharide synergistically stimulate proinflammatory cytokine/chemokine production in endothelial cells via activation of …
  3398. Inhibitory activity of advanced GLYCATION endproducts (AGE) formation of edible plants for development of anti-wrinkle ingredients
  3399. Advanced GLYCATION end products downregulates peroxisome proliferator-activated receptor γ expression in cultured rabbit chondrocyte through MAPK pathway
  3400. Advanced GLYCATION end products and C-peptide—modulators in diabetic vasculopathy and atherogenesis
  3401. … , an angiotensin‐converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced GLYCATION end‐product‐mediated …
  3402. The different isoforms of the receptor for advanced GLYCATION end products are modulated by pharmacological agents
  3403. Low levels of plasma soluble receptor for advanced GLYCATION end products are associated with severe leukoaraiosis in acute stroke patients
  3404. Neuropathy induced by exogenously administered advanced GLYCATION end‐products in rats
  3405. Crosstalk between calcium, amyloid β and the receptor for advanced GLYCATION endproducts in Alzheimer’s disease
  3406. Advanced GLYCATION end products enhance monocyte activation during human mixed lymphocyte reaction
  3407. GLYCATION and lipid peroxidation in children and adolescents with type 1 diabetes mellitus with and without diabetic complications
  3408. Advanced GLYCATION end‐products activate extracellular signal‐regulated kinase via the oxidative stress‐EGF receptor pathway in renal fibroblasts
  3409. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced GLYCATION end products
  3410. Nifedipine inhibits advanced GLYCATION end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator …
  3411. PLC/CAMK IV–NF-κB involved in the receptor for advanced GLYCATION end products mediated signaling pathway in human endothelial cells
  3412. Molecular study of receptor for advanced GLYCATION endproduct gene promoter and identification of specific HLA haplotypes possibly involved in chronic fatigue …
  3413. Anti-GLYCATION effect of spices and chilies uses in traditional mexican cuisine
  3414. Quantitation of markers of protein damage by GLYCATION, oxidation, and nitration in peritoneal dialysis
  3415. Mechanical ventilation during experimental sepsis increases deposition of advanced GLYCATION end products and myocardial inflammation
  3416. Circulating soluble receptor for advanced GLYCATION end-product levels are decreased in patients with calcific aortic valve stenosis
  3417. Effects of puerarin on receptor for advanced GLYCATION end products in nephridial tissue of streptozotocin-induced diabetic rats
  3418. Advanced GLYCATION end products (AGEs) in diabetes
  3419. Serum leptin, but not adiponectin and receptor for advanced GLYCATION end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and …
  3420. Improvement of functional properties of egg white protein through GLYCATION and phosphorylation by dry-heating
  3421. Accumulation of advanced GLYCATION end products in canine atherosclerosis
  3422. Glucagon-like peptide-1 (GLP-1) inhibits advanced GLYCATION end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing …
  3423. An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced GLYCATION end products (AGEs) in patients with type 2 …
  3424. Advanced GLYCATION end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis
  3425. Advanced GLYCATION end product-mediated matrix metallo-proteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes
  3426. Dietary phenolic acids attenuate multiple stages of protein GLYCATION and high‐glucose‐stimulated proinflammatory IL‐1β activation by interfering with chromatin …
  3427. Utilization of the linear mode of MALDI‐TOF mass spectrometry in the study of GLYCATION during the malting process
  3428. Increased concentration of two different advanced GLYCATION end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of …
  3429. The association between the− 374T/A polymorphism of the receptor for advanced GLYCATION endproducts gene and blood pressure and arterial stiffness is modified by …
  3430. Flavonoid glycosides from the leaves of Uvaria rufa with advanced GLYCATION end-products inhibitory activity
  3431. Enrichment of Amadori products derived from the nonenzymatic GLYCATION of proteins using microscale boronate affinity chromatography
  3432. Thioredoxin GLYCATION: A novel posttranslational modification that inhibits its antioxidant and organ protective actions
  3433. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced GLYCATION end products in type 2 diabetes mellitus patients
  3434. Inhibitory activity of caffeoylquinic acids from the aerial parts of Artemisia princes on rat lens aldose reductase and on the formation of advanced GLYCATION end …
  3435. High plasma levels of the soluble receptor for advanced GLYCATION endproducts in patients with symptomatic carotid atherosclerosis
  3436. GLYCATION of ovalbumin in solid-state by conductive and microwave heating
  3437. Soluble receptor for advanced GLYCATION end products (sRAGE) in plasma and synovial fluid is inversely associated with disease severity of knee osteoarthritis
  3438. Association between serum levels of the soluble receptor (sRAGE) for advanced GLYCATION endproducts (AGEs) and their receptor (RAGE) in peripheral blood …
  3439. Tissue-specific expression profiling of receptor for advanced GLYCATION end products and its soluble forms in esophageal and lung cancer
  3440. Relation between polymorphisms of receptor for advanced GLYCATION end products (RAGE) and cardiovascular diseases in Chinese patients with diabetic nephropathy …
  3441. Nifedipine, a calcium channel blocker, inhibits advanced GLYCATION end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) …
  3442. GLYCATION sites in neoglycoglycoconjugates from the terminal monosaccharide antigen of the O‐PS of Vibrio cholerae O1, serotype Ogawa, and BSA revealed by …
  3443. Inhibitory effect of fermentation byproducts on formation of advanced GLYCATION end-products
  3444. Hyperglycemia attenuates acute permeability response to advanced GLYCATION end products in retinal microvasculature
  3445. INFLUENCE OF NONENZYMATIC GLYCOSYLATION (GLYCATION) OF PEA PROTEINS (PISUM SATIVUM) ON THEIR SUSCEPTIBILITY TO ENZYMATIC …
  3446. Involvement of advanced GLYCATION end-products, pentosidine and Nɛ-(carboxymethyl) lysine, in doxorubicin-induced cardiomyopathy in rats
  3447. Endocytosis of advanced GLYCATION end-products in bovine choriocapillaris endothelial cells
  3448. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced GLYCATION end product-induced expression of tumor necrosis factor-α and matrix …
  3449. Neutralization of receptor for advanced GLYCATION end-products and high mobility group box-1 attenuates septic diaphragm dysfunction in rats with peritonitis
  3450. Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced GLYCATION end products in patients with Wagner grade 0 diabetic foot: a …
  3451. The effects of the receptor for advanced GLYCATION end products (RAGE) on bone metabolism under physiological and diabetic conditions
  3452. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced GLYCATION end product (AGE)-exposed fibroblasts via …
  3453. Study on the effect of vitamin C on the in vitro albumin GLYCATION reaction
  3454. Advanced GLYCATION end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells …
  3455. Independent determinants of soluble form of receptor for advanced GLYCATION end products in elderly hypertensive patients
  3456. Advanced GLYCATION end products induce T cell apoptosis: Involvement of oxidative stress, caspase and the mitochondrial pathway
  3457. Does hepatitis C increase the accumulation of advanced GLYCATION end products in haemodialysis patients?
  3458. Characterization of anti-advanced GLYCATION end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products
  3459. Alagebrium chloride, a novel advanced GLYCATION end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury …
  3460. Advanced GLYCATION of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction
  3461. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced GLYCATION end-products and circulating DNA in patients with acute …
  3462. Aggregation and self assembly of non-enzymatic GLYCATION of collagen in the presence of amino guanidine and aspirin: an in vitro study
  3463. Receptor of advanced GLYCATION end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes
  3464. Flavan-3-ols having a γ-lactam from the roots of Actinidia arguta inhibit the formation of advanced GLYCATION end products in vitro
  3465. Epigallocatechin gallate (EGCG) binds to low-density lipoproteins (LDL) and protects them from oxidation and GLYCATION under high-glucose conditions mimicking …
  3466. Oxidative stress-associated rise of hepatic protein GLYCATION increases inflammatory liver injury in uncoupling protein-2 deficient mice
  3467. Insulin resistance is an independent correlate of high serum levels of advanced GLYCATION end products (AGEs) and low testosterone in non-diabetic men
  3468. Ligands of the receptor for advanced GLYCATION end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli …
  3469. The 1.5 Å crystal structure of human receptor for advanced GLYCATION endproducts (RAGE) ectodomains reveals unique features determining ligand binding
  3470. Effect of elementary and advanced GLYCATION products of nisin on its preservative efficacy and digestibility
  3471. Anthraquinones from the roots of Knoxia valerianoides inhibit the formation of advanced GLYCATION end products and rat lens aldose reductase in vitro
  3472. Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced GLYCATION endproducts, and oxidative stress in …
  3473. Study of Nonenzymatic GLYCATION of Transferrin and its Effect on Iron–Binding Antioxidant Capacity
  3474. Monitoring of early and advanced GLYCATION in relation to the occurrence of microvascular complications in children and adolescents with type 1 diabetes …
  3475. Circulating levels of a soluble form of receptor for advanced GLYCATION end products and high-mobility group box chromosomal protein 1 in patients with acute …
  3476. Regulation of alternative splicing of the receptor for advanced GLYCATION endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear …
  3477. Reduced formation of advanced GLYCATION endproducts via interactions between glutathione peroxidase 3 and dihydroxyacetone kinase 1
  3478. RETRACTED: Pigment epithelium-derived factor inhibits advanced GLYCATION end-product-induced angiogenesis and stimulates apoptosis in retinal endothelial cells
  3479. Nɛ-(carboxymethyl) lysine linkage to α-synuclein and involvement of advanced GLYCATION end products in α-synuclein deposits in an MPTP-intoxicated mouse model
  3480. Vitamin C and urea inhibit the formation of advanced GLYCATION end products in vitro
  3481. Pathological role of D-amino acid-containing proteins and advanced GLYCATION end products in the development of age-related macular degeneration
  3482. … chaperones and have significant impact on the treatment of chronic diseases associated with increased oxidative stress and the formation of advanced GLYCATION end …
  3483. Insulin prevents latent skin lesions by inhibiting the generation of advanced GLYCATION end products in streptozotocin-induced diabetic rats
  3484. Inhibition of human muscle-specific enolase by methylglyoxal and irreversible formation of advanced GLYCATION end products
  3485. High-mobility group B1 (HMGB1) and receptor for advanced GLYCATION end-products (RAGE) expression in canine lymphoma
  3486. Minimum stable structure of the receptor for advanced GLYCATION end product possesses multi ligand binding ability
  3487. Advanced GLYCATION end products (AGEs) damaged IgG, a target for circulating autoantibodies in patients with type 1 diabetes mellitus
  3488. Modulation of advanced GLYCATION end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study
  3489. Ciprofloxacin inhibits advanced GLYCATION end products‐induced adhesion molecule expression on human monocytes
  3490. Advanced GLYCATION end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft …
  3491. COX‐2 and iNOS are critical in advanced GLYCATION end product‐activated chondrocytes in vitro
  3492. … -γ activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced GLYCATION end products and …
  3493. Intra-coronary administration of soluble receptor for advanced GLYCATION end-products attenuates cardiac remodeling with decreased myocardial transforming growth …
  3494. Repairing extracellular aging and GLYCATION
  3495. Up-regulation in receptor for advanced GLYCATION end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro
  3496. Interaction of zinc, ascorbic acid, and folic acid in GLYCATION with albumin as protein model
  3497. Immunohistochemical detection of advanced GLYCATION end products in human bladder with specific monoclonal antibody
  3498. Linking the advanced GLYCATION endproducts/receptor for advanced GLYCATION endproducts pathway in diabetics with inflammation and topical antiinflammatory …
  3499. Involvement of the receptor for advanced GLYCATION-end products (RAGE) in β-amyloid-induced toxic effects in rat cerebromicrovascular endothelial cells cultured in …
  3500. GLYCATION of wood frog (Rana sylvatica) hemoglobin and blood proteins: in vivo and in vitro studies
  3501. Cytotoxic effect of advanced GLYCATION end products
  3502. Elevated serum advanced GLYCATION end products and their circulating receptors are associated with anaemia in older community-dwelling women
  3503. Differential expressions of the receptor for advanced GLYCATION end products in prostate cancer and normal prostate
  3504. Relationship of a dominant advanced GLYCATION end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal …
  3505. Age-related increase of prostaglandin D2 synthase concentration and GLYCATION in ovine cerebrospinal fluid
  3506. Two new dihydrofuranoisoflavanones from the leaves of Lespedeza maximowiczi and their inhibitory effect on the formation of advanced GLYCATION end products
  3507. Advanced GLYCATION end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2
  3508. Advanced GLYCATION end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity
  3509. Advanced GLYCATION end products inhibit Na+ K+ ATPase in proximal tubule epithelial cells: role of cytosolic phospholipase A2α and phosphatidylinositol 4 …
  3510. GLYCATION end products
  3511. Prostaglandin E2 inhibits advanced GLYCATION end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human …
  3512. Non-enzymatic GLYCATION of human fibrillin-1
  3513. Associations of− 374T/A polymorphism of receptor for advanced GLYCATION end products (RAGE) gene in Turkish diabetic and non-diabetic patients with coronary …
  3514. Inhibitory effects of β-cyclodextrin and trehalose on nanofibril and AGE formation during GLYCATION of human serum albumin
  3515. Advanced GLYCATION end product accumulation in rho0 cells without a functional respiratory chain
  3516. Effect of nicotine on advanced GLYCATION end product-induced immune response in human monocytes
  3517. Screening of Korean herbal medicines with inhibitory activity on advanced GLYCATION end products (AGEs) formation (III)
  3518. Glucagon-like peptide-1 counteracts the detrimental effects of Advanced GLYCATION End-Products in the pancreatic beta cell line HIT-T 15
  3519. Influence of GLYCATION of wheat albumins and globulins on their immunoreactivity and physicochemical properties
  3520. Therapeutic intervention in diseases with advanced GLYCATION end products in their pathogenesis
  3521. Role of pyridoxamine in the formation of the Amadori/Heyns compounds and aggregates during the GLYCATION of β-lactoglobulin with galactose and tagatose
  3522. Age-and passage-dependent upregulation of fibroblast elastase-type endopeptidase activity. Role of advanced GLYCATION endproducts, inhibition by fucose-and …
  3523. Protein GLYCATION, insulin sensitivity and pancreatic beta cell function in high-risk, non-diabetic, first degree relatives of patients with type 2 diabetes.
  3524. Labile A1C is inversely correlated with the hemoglobin GLYCATION index in children with type 1 diabetes
  3525. Translational aspects of bone quality—vertebral fractures, cortical shell, microdamage and GLYCATION: a tribute to Pierre D. Delmas
  3526. 7-O-Galloyl-D-sedoheptulose Is a Novel Therapeutic Agent against Oxidative Stress and Advanced GLYCATION Endproducts in the Diabetic Kidney
  3527. Reduced endogenous secretory receptor for advanced GLYCATION end products (esRAGE) in young people with type 1 diabetes developing microalbuminuria
  3528. Advanced GLYCATION end products and antioxidant status in nondiabetic and streptozotocin induced diabetic rats: effects of copper treatment
  3529. Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced GLYCATION endproducts: heparin’s effect on binding
  3530. Expression of advanced GLYCATION end products and related molecules in diabetic fibrovascular epiretinal membranes
  3531. Impaired transcription factor interplay in addition to advanced GLYCATION end products suppress podocalyxin expression in high glucose-treated human podocytes
  3532. GLYCATION pattern of peptides condensed with maltose, lactose and glucose determined by ultraviolet matrix‐assisted laser desorption/ionization tandem mass …
  3533. Soluble receptor for advanced GLYCATION end products (sRAGE) in tracheobronchial aspirate fluid and cord blood of very low birth weight infants with chorioamnionitis …
  3534. Screening of herbal medicines from China and Vietnam with inhibitory activity on advanced GLYCATION end products (AGEs) formation (IV)
  3535. Influence of GLYCATION and pepsin hydrolysis on immunoreactivity of albumin/globulin fraction of herbicide resistant wheat line
  3536. Advanced GLYCATION end products down-regulate gap junctions in human hepatoma SKHep 1 cells via the activation of Src-dependent ERK1/2 and JNK/SAPK/AP1 …
  3537. Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin GLYCATION assay
  3538. Expression of advanced GLYCATION end‐product receptors in the cochlea
  3539. β2-adrenoceptor stimulation inhibits advanced GLYCATION end products-induced adhesion molecule expression and cytokine production in human peripheral blood …
  3540. GLYCATION of proteins: their analysis and physiological aspects
  3541. Low‐Density Lipoprotein Levels are One of the Independent Determinants of Circulating Levels of Advanced GLYCATION End Products in Nondiabetic Subjects
  3542. XLF-III-43, a novel coumarin–aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced GLYCATION end products
  3543. Modulation of advanced GLYCATION endproduct synthesis by kynurenines in human lens proteins
  3544. Histamine inhibits adhesion molecule expression in human monocytes, induced by advanced GLYCATION end products, during the mixed lymphocyte reaction
  3545. Increased accumulation of advanced GLYCATION endproducts in patients with Wegener’s granulomatosis
  3546. Different role of advanced GLYCATION end products in pathology of transplanted heart in patients with or without diabetes mellitus type 2
  3547. Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced GLYCATION endproducts, in a population of high school …
  3548. Functional analysis of the common haplotype in the receptor for advanced GLYCATION end-products gene previously identified as a susceptibility factor for diabetic …
  3549. Advanced GLYCATION end products and acute myocardial infarction
  3550. Histamine inhibits advanced GLYCATION end products-induced adhesion molecule expression on human monocytes
  3551. The breakdown of preformed peritoneal advanced GLYCATION end products by intraperitoneal alagebrium
  3552. Immunofluorescence detection of advanced GLYCATION end products (AGEs) in cookies and its correlation with acrylamide content and antioxidant activity
  3553. Open tubular capillary electrochromatography: a useful microreactor for collagen I GLYCATION and interaction studies with low-density lipoprotein particles
  3554. Pyridoxine improves platelet nitric oxide synthase dysfunction induced by advanced GLYCATION end products in vitro
  3555. The anti-apoptotic activity of albumin for endothelium is inhibited by advanced GLYCATION end products restricting intramolecular movement
  3556. Relevance of apoptosis and tolerance to hypoxic stress in cells transfected with receptor for advanced GLYCATION end products (RAGE)
  3557. Evidence for the presence of GLYCATION adducts in protein therapeutics
  3558. N-Terminal 2, 3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced GLYCATION endproduct (AGE) formation
  3559. Relationship between impaired GLYCATION and the N-terminal structure of the Hb Görwihl [β5 (A2) Pro→ Ala] variant
  3560. Inhibiting LDL GLYCATION ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in …
  3561. Reactivity of rare sugar D-allose during GLYCATION of human serum albumin
  3562. Ne {open}-(carboxymethyl) lysine linkage to α-synuclein and involvement of advanced GLYCATION end products in α-synuclein deposits in an MPTP-intoxicated mouse …
  3563. Increased retinopathy occurrence in type 1 diabetes patients with increased serum levels of the advanced GLYCATION endproduct hydroimidazolone
  3564. 2-Deoxy-D-ribose induces cellular damage by increasing oxidative stress and protein GLYCATION in a pancreatic β-cell line
  3565. Pigment epithelium-derived factor (PEDF) inhibits diabetes-or advanced GLYCATION end product (AGE)-induced platelet CD40 ligand overexpression in rats
  3566. Technology of advanced GLYCATION endproducts fluorescence measurement and precorrection
  3567. GLYCATION of aspartate aminotransferase by methylglyoxal, effect of hydroxycitric and uric acid
  3568. Application of fluorescence spectrum technology in the detecting for advanced GLYCATION endproducts
  3569. Preventive effects of Rosa rugosa root extract on advanced GLYCATION end product-induced endothelial dysfunction
  3570. Characterization of GLYCATION sites on human serum albumin using mass spectrometry
  3571. Scavenging effects of dietary flavonoids on reactive dicaronyl species and their possible implications on the inhibition of the formation of advanced GLYCATION …
  3572. Increased receptor for advanced GLYCATION endproducts immunocontent in the cerebral cortex of vitamin A-treated rats
  3573. Association of the receptor for advanced GLYCATION end products (RAGE)-374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 …
  3574. Advanced GLYCATION endproducts in sepsis and mechanical ventilation: extra or leading man?
  3575. Canadian diabetes association national nutrition committee technical review: advanced GLYCATION end-products in diabetes management
  3576. Inhibitory Effects of eel (Anguilla japonica) extracted carnosine on Protein GLYCATION
  3577. Novel application of surface plasmon resonance biosensor chips for measurement of advanced GLYCATION end products in serum of Zucker diabetic fatty rats
  3578. Visfatin and endogenous secretory receptor for advanced GLYCATION end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis
  3579. Phenolic content and in vitro inhibitory effects on oxidation and protein GLYCATION of some thai medicinal plants
  3580. Maillard reaction of ribose 5-phosphate generates superoxide and GLYCATION products for bovine heart cytochrome c reduction
  3581. Apparatus for detecting advanced GLYCATION Endproducts fluorescence of skin
  3582. Effect of arginine on GLYCATION and stability of recombinant human interferon-gamma
  3583. GLYCATION of LDL is an important atherogenic modification and opposed by paraoxonase-rich HDL
  3584. Prostaglandin E2 inhibits advanced GLYCATION end product-induced adhesion molecule expression on monocytes, cytokine production, and lymphocyte proliferation …
  3585. Plasma protein GLYCATION in diabetic nephropathy
  3586. Study of lysozyme GLYCATION reaction by mass spectrometry and NMR spectroscopy
  3587. Role of protein kinase C in advanced GLYCATION end products-induced epithelial-mesenchymal transition in renal proximal tubular epithelial cells
  3588. Impaired glucose tolerance, angiopathy and advanced GLYCATION end products [J]
  3589. Advanced GLYCATION End-Products Increase Calcification in Rat Vascular Smooth Muscle Cells [J]
  3590. Design of advanced GLYCATION endproducts fluorescence spectrum detecting system
  3591. Advanced GLYCATION end products, rage, and aging
  3592. In Situ Gelable GLYCATION-Resistant Hydrogels Composed of Gelatin and Oxidized Alginate
  3593. Covalent binding antibodies suppress advanced GLYCATION: on the innate tier of adaptive immunity
  3594. Inhibitory Effects of Ethanol Extract from Toona sinensis Leaves on the Formation of Protein Non-enzymatic GLYCATION in vitro
  3595. GLYCATION of mitochondrial proteins, oxidative stress and aging
  3596. Effect of Acetyl Salicyilic Acid on GLYCATION and Mutability of Escherichia Coli Chromosomal DNA
  3597. Biological variation of GLYCATION and mean blood glucose have greater influence on Hba1c levels in type 1 young diabetic patients than glucose instability
  3598. Advanced GLYCATION end products alters functions of end othelial progenitor cells in vitro [J]
  3599. GLUT-1 expression in bovine retinal capillary endothelial cells and pericytes exposed to advanced GLYCATION end products
  3600. Plasma protein GLYCATION status in Pakistan type 2 diabetic patients with or without nephropathy
  3601. CHANGES IN THE STABILITY AND KINETIC PARAMETERS UP ON GLYCATION OF THERMOSTABLE α‐AMYLASE FROM BACILLUS SUBTILIS
  3602. Prokaryotic expression of receptor for advanced GLYCATION end product and screening of its interaction proteins [J]
  3603. Diet high in advanced GLYCATION end products exacerbates pulmonary inflammatory response and impairs lung compliance in mice following gastric aspiration
  3604. Comparison of solid‐state GLYCATION of whey proteins through Maillard reaction between microwave and conductive heating
  3605. Effects of short-term streptozotocin-induced diabetes and vitamin C on platelet non-enzymatic GLYCATION
  3606. Advanced GLYCATION End Products in Histone H1 In Vivo
  3607. Effects of advanced GLYCATION end products on expressions of EMMPRIN and MMP-2 in mouse osteoblasts
  3608. Intake of advanced GLYCATION endproducts: Role in the development of diabetic complications
  3609. Comparative study of serum/plasma GLYCATION and lipid peroxidation of young patients with type 1 diabetes mellitus in relation to glycemic compensation and the …
  3610. The effects of advanced GLYCATION end products and homocystein on the expression of vascular cell adhesion molecule-1 via NADPH oxidase in human umbilical vein …
  3611. The Receptor For Advanced GLYCATION End-Products (RAGE) exerts renoprotective effects via the AT-2 receptor in Diabetic Nephropathy
  3612. Low serum level of the endogenous secretory receptor for advanced GLYCATION end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of …
  3613. Effects of advanced GLYCATION end products on proliferation and apoptosis of human heptical cell line LO2 [J]
  3614. A Study of Pioglitazone Biokinetics, Renal Clearance and its Effect on GLYCATION Level
  3615. Evidence for Excretion of GLYCATION Agents from E. Coli Cells During Growth
  3616. The Receptor for Advanced GLYCATION End Products (RAGE) Activates Ras and NFκ-β in Pulmonary Epithelial Cells Exposed to Cigarette Smoke.
  3617. Non-Invasive Method for Detecting Skin Autofluorescence of Advanced GLYCATION End Products
  3618. Effect of isoflurane on advanced GLYCATION end products and oxidative stress in rat brain
  3619. Effects of advanced GLYCATION end products on the expression of urotensin in rat NRK-52E cells
  3620. Experimental Study on Advanced GLYCATION end Products Induced Proliferation of Rat’s Vascular Smooth Muscle Cells in Vitro [J]
  3621. Determination of advanced GLYCATION end-products on IgG in liver cirrhosis.
  3622. Identification of methylglyoxal-lowering agents for the treatment of advanced GLYCATION end products-related diseases
  3623. The Pro‐Adipogenic Effect of Advanced GLYCATION End‐Products (AGEs) in Adipogenesis
  3624. Role of advanced GLYCATION end products and nitric oxide in patients with diabetic peripheral neuropathy [J]
  3625. Advanced GLYCATION Endproducts Alters Functions in Endothelial Progenitor Cells Through Oxidant Stress [J]
  3626. Effect of Alpinia officinarum on the Formation of Advanced GLYCATION Endproducts and Aldose Reductase Activity
  3627. Self-Made Monoclonal Antibodies Detect Diabetic Rat Kidney and Heart GLYCATION End Products [J]
  3628. Activation of RAGE/STAT3 axis by advanced GLYCATION endproducts in vascular remodeling diseases
  3629. Effect of Advanced GLYCATION End Products on Expression of Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 [J]
  3630. A pathophysiologic evaluation of the receptor for advanced GLYCATION end products (RAGE) in the lung
  3631. Improved methods for quantifying plasma protein advanced GLYCATION end products as biomarkers for age-related macular degeneration
  3632. Effect of advanced GLYCATION end products of different concentration on the expression of Fractalkine in human tubular epithelial cells [J]
  3633. 99mTc-Labeled anti-receptor for advanced GLYCATION endproducts polyclonal antibody F (ab’) 2 fragments
  3634. Effects of Advanced GLYCATION End Products on Activity and Expression of Nitric Oxide Synthase in Human Umbilical Vein Endothelial Cells and the Protective Effects …
  3635. Effect of depside salt from salvia miltiorrhizae in repairing advanced GLYCATION end products-induced late endothelial progenitor cell dysfunction and its molecular …
  3636. Letter by Hartog et al Regarding Article,” Advanced GLYCATION End Products Accumulate in Vascular Smooth Muscle and Modify Vascular but Not Ventricular …
  3637. The Effect of Advanced GLYCATION End Products on the Expression of Matrix Metalloproteinase Inducer and the Activity of Matrix Metalloproteinase-9 in Cultured Mouse …
  3638. Adiponectin suppression of advanced GLYCATION endproducts induced CD40 high expression in human umbilical vein endothelial cells
  3639. Comparison of inhibitory activities of advanced GLYCATION end products and angiotension-I-converting enzyme by the extract from wild and cultured Inonotus Obliquus …
  3640. Relationship between plasma level of endogenous secretory receptor of advanced GLYCATION end products and oxidative stress in diabetic patients with hypertension
  3641. Common pathogenetic features between calcific aortic stenosis and atherosclerosis: role of receptor for advanced GLYCATION end-products
  3642. Lens and skin protein GLYCATION, lipid peroxidation and glutathione levels in vitamin C administered diabetic rats.
  3643. Emblica officinalis stimulates the secretion and action of insulin and inhibits starch digestion and protein GLYCATION
  3644. Oxidative stress, advanced GLYCATION end products and residual renal function in the rat model of unilateral ureteral obstruction: effects of phlogenzym and losartan
  3645. Advanced GLYCATION end products induce expression of PAI-1 in cultured human proximal tubular epithelial cells through NADPH oxidase dependent pathway
  3646. Receptor for advanced GLYCATION end products is associated with systemic and organ-specific severity of acute lung injury and acute respiratory distress syndrome
  3647. Globular adiponectin protects human umbilical endothelial cells against apoptosis induced by advanced GLYCATION end products through increasing adiponectin …
  3648. Microarray-Based Gene Set Analysis: Pathway Analysis of Advanced GLYCATION Endproduct (AGEs) or Amyloid Beta (Aβ) Stimulation of Human RPE in vitro
  3649. Inhibiting low-density lipoprotein GLYCATION ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation …
  3650. CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Bone quality in chronic kidney disease: enzymatic and non-enzymatic GLYCATION or oxidation induced …
  3651. Advanced GLYCATION end products and food
  3652. Deletion of bone marrow derived receptor for advanced GLYCATION end-products (RAGE) does not attenuate plaque formation but inhibits plaque progression in a …
  3653. Anti‐GLYCATION Effect of Gold Nanoparticles
  3654. Increased GLYCATION and Oxidative Damage to
  3655. Quantitative analysis of protein GLYCATION in clinical samples
  3656. OxiSelect™ Advanced GLYCATION End Product (AGE) ELISA Kit
  3657. Estrogen Attenuates the Inhibition of Nitric Oxide Synthase Type 3 Induced by Advanced GLYCATION End-Products [J]
  3658. Non-enzymatic GLYCATION Effects of Aging
  3659. Role of advanced GLYCATION end products and nitric oxide in patients.
  3660. Advanced GLYCATION and Inflammatory Phenomena in Renal Transplantation
  3661. Metabolic syndrome in dialyzed patients. Advanced GLYCATION end-products, adipocytokines, and principles of treatment
  3662. Novel neutraceutical properties of some Sri Lankan traditional rice: Inhibition of protein GLYCATION and breaking of cross links of advanced GLYCATION end products
  3663. Preparation and identification of monoclonal antibody of advanced GLYCATION end products
  3664. Comparison of Anti-GLYCATION Capacities of Several Herbal Infusions with that of Green Tea
  3665. IDENTIFICATION OF NEW ADVANCED GLYCATION END PRODUCTS INHIBITORS: DEVELOPMENT OF A 96-WELL PLATE SCREENING
  3666. GLYCATION sites in neoglycoglycoconjugates from the terminal monosaccharide antigen of the O-PS of Vibrio…
  3667. Hypertension enhances haemoglobin GLYCATION in diabetics
  3668. Effect of fatty acid binding on the GLYCATION of human serum albumin
  3669. Cancer and GLYCATION–Using Human Tissue Culture Model to Probe the Metabolic Effects of GLYCATION Flux
  3670. The effect of advanced GLYCATION end products on biological activity of hepatic stellate cell
  3671. Quercetin as an Inhibitor of Protein GLYCATION
  3672. Study of hemoglobin and human serum albumin GLYCATION
  3673. The effect of advanced GLYCATION end products on biological activity of hepatic stellate cell
  3674. Effects of hexue Composita on advanced GLYCATION and products in kidneys of diabetic rats [J]
  3675. Advanced GLYCATION End Products (AGES): Pathological Entanglement
  3676. A Novel Biomaterial for the Targeted Removal of Advanced GLYCATION End Products from Blood
  3677. Leukozytenrekrutierung in „Receptor for Advanced GLYCATION Endproducts “gendefizienten Mäusen in vivo
  3678. Clinical observations on correlation between advanced GLYCATION end products and coronary heart disease or diabetes
  3679. Effect of Advanced GLYCATION End-products on High Gluclose Induced Transdifferentiation in NRK-52E Cells
  3680. Advanced GLYCATION End Products in Patients with Leukoaraiosis
  3681. Automating a 96-well microtiter plate assay for advanced GLYCATION end-products inhibitors or inducers identification: application to the screening of a small natural …
  3682. The correlation of serum level of advanced GLYCATION end products and the expression of receptor for advanced GLYCATION end products in white blood cells with senile …
  3683. Ruhuang Preparation on Advanced GLYCATION Endproducts (AGEs) in Cirrhotic Rats
  3684. Association Between Diet-Induced Advanced GLYCATION End Products, AMD and Cataract
  3685. Banked RBCs Increase Endothelial Cell Oxidative Stress through Advanced GLYCATION Endproducts.
  3686. Effect of advanced GLYCATION end products on aortic structure and function in diabetic rats
  3687. Estimation of Advanced GLYCATION End Products in Saliva of Diabetic Patients
  3688. Levels of serum advanced GLYCATION endproducts and its clinical significance in patients of diabetes mellitus with hepatic dysfunction
  3689. Advanced GLYCATION End Products Impair Function of Endothelial Progenitor Cells
  3690. Study of nonenzymatic GLYCATION of transferring and its effect on iron-binding antioxidant capacity
  3691. Formation of advanced GLYCATION end products (AGE) in vitro and their impact on adipocyte function
  3692. A Rapid Method for Identifying GLYCATION Sites in Therapeutic Proteins by Isotopic Labeling with 13C6-glucose
  3693. Effect of nicotine on advanced GLYCATION end products-induced immune
  3694. Study of Damaging Effect of Exogenous Advanced GLYCATION End Products on Vascular Endothelial Cell in Vitro
  3695. Advanced GLYCATION Endproducts (AGEs) Favor LDL Retention in the Fundus
  3696. Physico-Chemical Changes of Human Serum Albumin During in Vivo and in Vitro GLYCATION Processes
  3697. Advanced GLYCATION end products (AGEs) and high glucose in endothelial cells: gene expression analysis
  3698. A Research on Lysozyme, Advanced GLYCATION End-products (AGEs) and Diabetic Complications [J]
  3699. Effects of GLYCATION on Dynamic Mechanical Properties and Penetration of Articular Cartilage
  3700. Role of Advanced GLYCATION End Products and Vascular Endothelial Growth Factor in Pathophysiology of Diabetic Retinopathy
  3701. Advanced GLYCATION; non-enzymatic but relatively specific reaction more than expected?
  3702. D-ribose can induce protein GLYCATION and AGEs generation in vivo
  3703. ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTOR RAGE IN SYSTEMIC AUTOIMMUNE DISEASES
  3704. Effect of Advanced GLYCATION End Products on the Activity of Na~+/H~+ Exchanger 1 of Vascular Smooth Muscle Cell in Rat
  3705. Induction of Advanced GLYCATION End Products and Alterations of the Tensile Properties of Articular cartilage
  3706. Relationship between advanced GLYCATION end-products, inflammatory factors and diffuse coronary artery disease in patients with diabetes mellitus
  3707. Advanced GLYCATION end product precursors in diabetes: a crucial link between oxidative stress and inflammation?
  3708. Stability of whey protein derived peptides upon severe protein GLYCATION
  3709. Advanced GLYCATION Endproducts Induce Photocrosslinking and Oxidation of Bovine Lens Proteins Through Type-I Mechanism
  3710. Effect of GLYCATION in the presence or absence of soluble wheat proteins on major whey allergens
  3711. Receptor for advanced GLYCATION end-products: Expression and signaling
  3712. Outcomes of blood purification on clearance of serum advanced GLYCATION end products and beta 2-microglobulin
  3713. Mechanisms of disordered cell cycle in keratinocytes mediated by advanced GLYCATION end products
  3714. Protein GLYCATION and methylglyoxal metabolism in Parkinson’s disease
  3715. Promoting effect of receptor for advanced GLYCATION end product in periodontitis
  3716. A preliminary report on age‐related elevations of saliva advanced GLYCATION endproducts (AGEs) and arNOX
  3717. Expressions of advanced GLYCATION end products and their receptors in keloid.
  3718. Collagen GLYCATION Promotes Myofibroblast Differentiation
  3719. GLYCATION induced modification and identification of AGEs-precursors and AGEs in human serum albumin
  3720. Effects of Saengjihwangeum-ja Extracts on the Expression of Inflammatory Response in Human Monocyte Cells Induced by Advanced GLYCATION End Product
  3721. Correlation between GLYCATION End Product Receptor, P-Selectin and Preeclampsia
  3722. Concentration time profiles of plasma pentosidine in healthy volunteers following a breakfast rich in advanced GLYCATION end products
  3723. Advanced GLYCATION end-products (ages) in transplanted heart pathology of patients with or without diabetes mellitus type 2 (DM)
  3724. Advanced GLYCATION End-Products, Release Of Their Soluble Receptors (es And SRAGE) And Relationship To CRP After Surgery Necessitating Cardiopulmonary …
  3725. Receptors for Advanced GLYCATION Endproducts Cause Decreased Collateral Vessel Formation in the Face of Uncontrolled Diabetes
  3726. Effect of Advanced GLYCATION End Products on Inducing Rat Retinal Microvascular Endothelial Cells to Form New Blood Vessels
  3727. Effects of metformin on the proliferation of vascular smooth muscle cells induced by advanced GLYCATION end products
  3728. Effect of advanced GLYCATION end-products on high gluclose inducing oxidative stress in NRK-52E and inhibited by probucol
  3729. Effect of advanced GLYCATION end products on dilation of rat skeletal muscle arterioles
  3730. Detection of trace amount soluble receptor for advanced GLYCATION end-productin in human CSF.
  3731. Advanced GLYCATION End Products Stimulate Vascular Endothelial Growth Factor Production From Human Airway Epithelial Cells In Vitro And In Vivo
  3732. Soluble receptors for advanced GLYCATION end products as predictors of restenosis following percutaneous coronary intervention
  3733. Decreased plasma levels of soluble receptor for advanced GLYCATION endproducts (sRAGE) in patients with nonalcoholic fatty liver disease
  3734. Mechanism of advanced GLYCATION end products-stimulated phosphorylation of ERM protein in human umbilical vein endothelial cells
  3735. Non-enzymatic GLYCATION weakens trabecular bone and may influence changes in bone quality
  3736. ADVANCED GLYCATION END-PRODUCTS (AGES) IN LATE PATHOLOGY OF TRANSPLANTED HEART IN PATIENTS WITH OR WITHOUT DIABETES MELLITUS …
  3737. Advanced GLYCATION Endproducts (ages) Modulate Some but Not All Retinal Neuroglial Alterations During Diabetes With Links to a Pro-Inflammatory Phenotype
  3738. GLYCATION of Lipoproteins and the Role of High Density Lipoprotein and Paraoxonase-1
  3739. Expression of Advanced GLYCATION Receptor Products (RAGE) after Cerebral Ischemia
  3740. The Isolation of the Receptor for Advanced GLYCATION End‐Products from Avian Vasculature
  3741. GLYCATION and Oxidation: the causes of nephropathic, neuropathic and cardiovascular diabetic pathologies
  3742. Protein GLYCATION and methylglyoxal metabolism in Parkinson’s disease
  3743. Inhibition of glutathione on vascular smooth muscle cell proliferation mediate by advanced GLYCATION end products
  3744. Soluble Receptor for Advanced GLYCATION Endproducts (sRAGE) Induces Human Monocyte Survival and Differentiation (38.23)
  3745. Effects of advanced GLYCATION end products on the expression of VEGF and NF-κB in cultured human RPE cells
  3746. Covalent binding antibodies suppress advanced GLYCATION: on the innate tier of adaptive
  3747. Effects of irbesartan on renal advanced GLYCATION end products and their receptor in rats with early diabetic nephropathy
  3748. Effects of advanced GLYCATION end products on tubule-like structure formation and collapse in cardiac microvascular endothelial cells and their mechanisms
  3749. Inhibition of the advanced GLYCATION endproducts receptor (RAGE) protects pancreatic beta cell
  3750. Correlation of the receptor of advanced GLYCATION end-products and angiogenesis in nasopharyngeal carcinoma
  3751. Tissue advanced GLYCATION endproducts in two populations associated with increased oxidative stress: Normal in cirrhosis but elevated in haemodialysis patients
  3752. Association of polymorphisms in receptor for advanced GLYCATION end products gene with diabetic retinopathy
  3753. The effect of amioguanidine and baicalin on tissue nonenzymatic GLYCATION and retinal apoptosis in diabetic rats
  3754. Effects of isoflurance on learning and memory function and receptor for advanced GLYCATION end products expression of hippocampus in rats
  3755. Effect of advanced GLYCATION end products on secretion of MMP-2 in cultured mouse embryo/fetus calvaria fibroblasts
  3756. Effects of isoflurane on expression of receptor for advanced GLYCATION endproducts in hippocampus in rats
  3757. THE INFLUENCE OF SERUM ENDOGENOUS SECRETORY ADVANCED GLYCATION END-PRODUCTS RECEPTOR ON ARTERIAL ELASTICITY IN PATIENTS …
  3758. Direct Myocardial Actions of Advanced GLYCATION Endproducts (AGEs) on Cytosolic Calcium Transients Mediated Through Reactive Oxygen Species
  3759. Effects of advanced GLYCATION end products on proliferation and differentiation of neural precursor cells from embryonic rat hippocampus
  3760. Chronic Alcohol Ingestion Decreases Protein Expression of the Receptor for Advanced GLYCATION End Products in the Rat Lung.
  3761. Advanced GLYCATION end products (AGEs) up-regulate the expressions of nuclear factor-kB and cyclooxygenase-2 in rat cardiac microvascular endothelial cells …
  3762. Effects of Genistin on Oxidative Stress State and Expression of TGF-β_1 in Advanced GLYCATION End-Products Stimulated SD Rat Renal Mesangial Cells
  3763. Effect of Advanced GLYCATION Endproducts on Human Smooth Muscle Cell proliferation by Co‐culture System with Endothelium and Monocytes.
  3764. Effects of advanced GLYCATION end products on the expressions of β1-integrin and focal adhesion kinase (FAK)
  3765. Tissue Advanced GLYCATION End-products Are Associated With Diastolic Dysfunction and Aerobic Exercise Capacity in Diabetic Patients With Heart Failure
  3766. Effects of advanced GLYCATION end products on expressions of EMMPRIN and MMP-2 in mouse osteoblasts.
  3767. Advanced GLYCATION end products increased angiopoietin-1 expression via oxidative stress and NF-κB pathways in cultured NRK-49F cells
  3768. Characterizing the advanced GLYCATION endproducts formation of proteins and nucleotides by methylglyoxal and glyoxal
  3769. The effects of aminoguanidine on tissue nonenzymatic GLYCATION and kidney apoptosis in diabetic rats
  3770. Advanced GLYCATION Endproducts (AGEs) Modulate Microglial Activation and Link to Proinflammatory Pathology During Diabetic Retinopathy
  3771. Advanced GLYCATION Endproducts Regulate CD40 Expression in the Human Umbilical Vein Endothelial Cell via LOX-1
  3772. ALBUMINURIA IS ACCOMPANIED BY INCREASED CIRCULATING SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HYPERTENSIVE …
  3773. Receptor for advanced GLYCATION endproducts (RAGE) regulates ß-catenin function and chemosensitivity in pancreatic cancer cells
  3774. Inhibitory effects of the compounds isolated from Purple corn on aldose reductase and advanced GLYCATION end-products formation
  3775. The Dimerisation of the Receptor for Advanced GLYCATION End-Products (RAGE) Is Essential for AGE-Induced Signaling in Diabetic Retinopathy
  3776. Effect of compound Chinese sour taste herbs on advanced GLYCATION end products content and gene expression of their receptors in aorta of rats with type 2 diabetes …
  3777. The Role of the Receptor for Advanced GLYCATION End Products (RAGE) in Idiopathic Pulmonary Fibrosis
  3778. Response to Letter Regarding Article,“Advanced GLYCATION End Products Accumulate in Vascular Smooth Muscle and Modify Vascular but Not Ventricular Properties …
  3779. Receptor for advanced GLYCATION end products protects against Klebsiella pneumoniae induced pneumonia in mice
  3780. C reactive protein induced the expression of the receptor for advanced GLYCATION end products via NF-κB
  3781. Comparing Effects of Aminoguanidine and Metformin on Lowering Advanced GLYCATION Endproducts (AGEs) in STZ‐induced Diabetic Rats
  3782. Ligands of receptor for advanced GLYCATION end-products in stable coronary artery disease: their potential contribution to atherogenesis exceeds beyond diabetes …
  3783. Establishing the links between the soluble receptor for advanced GLYCATION end products, asymmetric dimethylarginine and low-grade inflammation in essential …
  3784. Advanced GLYCATION end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts.
  3785. Post-Infarct Remodeling is Altered in Diabetes: Role for Receptor for Advanced GLYCATION End-Products and S100B
  3786. … Advances in Hemoglobin A1c Measurement: Biologic Variability in Plasma Glucose, Hemoglobin A1c, and Advanced GLYCATION End Products Associated with …
  3787. Receptor For Advanced GLYCATION End-products Is A Marker Of Acute Lung Injury In Critically-ill Patients, Regardless Of Associated Sepsis
  3788. Inhibitory action of crocetin on the expression of E-selectin in bovine endothelial cells induced by advanced GLYCATION end products
  3789. The effect of amioguanidine and baicalin on tissue nonenzymatic GLYCATION and renal apoptosis in diabetic rats.
  3790. Arterial Stiffness and Urinary Albumin Excretion in Hypertension: The Emerging Role of the Soluble Receptor for Advanced GLYCATION End Products
  3791. Advanced GLYCATION End Products activate MMP‐9 secretion in macrophage cells, the involvement of MAP Kinase and NF‐kappaB signaling pathways
  3792. Low Serum Level of the Endogenous Secretory Receptor for Advanced GLYCATION End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures …
  3793. Effects of PPAR-γ activation on the expressions of TGF-β and CTGF mRNA in rat mesangial cells induced by advanced GLYCATION end products
  3794. Glyceraldehyde-derived advanced GLYCATION end products decrease white adipose tissue weight and downregulate leptin, adiponectin, and macrophage marker
  3795. The Receptor for Advanced GLYCATION End Products (RAGE) Is a Marker of Alveolar Epithelial Damage in ARDS.
  3796. Relation of Serum Levels of Endogenous Secretory Receptor for Advanced GLYCATION End-products and Glycated Albumin to Coronary Artery Disease in Type 2 …
  3797. Plasma and alveolar fluid levels of Receptor for Advanced GLYCATION Endproducts (RAGE) are associated with severity of ARDS
  3798. Terminalia bellerica (Belliric Myrobalan) stimulates the secretion and action of insulin and inhibits starch digestion and protein GLYCATION
  3799. Effects of grape seed proanthocyanidin extracts on advanced GLYCATION end products and expression of bone morphogenetic protein-7 in diabetic nephropathy rats.
  3800. Effects of Ligustrazine on Expression of Extracellular Matrix in Human Proximal Renal Tubular Epithelial Cells Induced by Advanced GLYCATION End Products
  3801. Circulating Levels and Dietary Intake of the Advanced GLYCATION End-product Marker Carboxymethyl Lysine in Chronic Kidney Disease Patients on …
  3802. Receptor for advanced GLYCATION end products (RAGE) polymorphisms are associated with SLE, RA, and disease severity in lupus nephritis
  3803. Effect of peanut skin phenolics on pancreatic amylase activity and fructose‐mediated albumin GLYCATION
  3804. Rosiglitazone attenuates advanced GLYCATION end products induced endothelial progenitor cells dysfunction via upregulating Akt/eNOS signal pathways
  3805. Effect of C-RP on the expressions of receptor of advanced GLYCATION end-products and monocyte chemoattractant protein-l in human saphenous vein endothelial cells …
  3806. Effect of storage on phytochemical stability, color, antioxidant activity, and inhibition of formation of fructose-induced advanced GLYCATION endproducts of an …
  3807. The thiamine analogue and advanced GLYCATION endproducts crosslink breaker ALT-711 does not interfere with transketolase activity
  3808. Conditional up‐regulation of Receptors for Advanced GLYCATION End‐Products (RAGE) in Alveolar Epithelium Causes Respiratory Distress and Perinatal Lethality
  3809. The Expression of Receptor Advanced GLYCATION End-products and Type IV Collagen in Ovary Tissues of Women with Polycystic Ovary Syndrome
  3810. The role of scavenging antioxidants and the transcription factor NRF2 in protection against advanced GLYCATION end products in a neuronal-derived cell line
  3811. Effect of Advanced GLYCATION End Products on Expression of Urotensin Ⅱ and G-Protein-Couple Receptor mRNAs in Rat Mesangial Cells
  3812. Effect of siRNA targeting TGF-β inducible early gene on expression of advanced GLYCATION end products-mediated Smad2 in renal tubular epithelial cells
  3813. Influence of C-type natriuretic peptide on expression of natriuretic peptide B receptor suppressed by advanced GLYCATION end products and on post-receptor signal …
  3814. … RECEPTOR BLOCKER AND CALCIUM CHANNEL BLOCKER REDUCE THE EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS IN …
  3815. Ligands of the receptor for advanced GLYCATION end products (RAGE), including high mobility group box (HMGB) 1, limit bacterial dissemination during …
  3816. Diesel Particulate Matter Induces Receptor for Advanced GLYCATION End‐Products (RAGE) Expression in Alveolar Epithelial Cells and Mediates an Inflammatory …
  3817. … ; Inhibitory Activity of Caffeoylquinic Acids from the Aerial Parts of Artemisia princeps on Rat Lens Aldose Reductase and on the Formation of Advanced GLYCATION End …
  3818. Gly82Ser Polymorphism of the Receptor for Advanced GLYCATION End Products Gene (RAGE) and the Endogenous Secretory RAGE (esRAGE) and its …
  3819. Proteomic Analysis of Advanced GLYCATION End-Product (Age) Modified Proteins in High Glucose-Exposed Retinal Müller Glia: Evidence for Age-Mediated Cell …
  3820. … V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM. Reduction of the accumulation of advanced GLYCATION end products by …
  3821. Na~+/H~+ exchanger 1 and renal cortical injury induced by advanced GLYCATION end products
  3822. e0305 The effect of profilin-1 on vascular injury caused by advanced GLYCATION end products
  3823. Serum matrix metalloproteinase-9 and advanced GLYCATION end-products in diabetic patients with or without diabetic foot problems
  3824. Quercetin-3-rutinoside, a flavonol glycoside from Teucrium polium suppresses advanced GLYCATION end products (AGEs) formation: A structural study
  3825. 010 Advanced GLYCATION end products induce functional impairment in neonatal rat cardiomyocytes through enhanced production of reactive oxygen species
  3826. 186. The Receptor for Advanced GLYCATION End-Products (RAGE) Limits NK Activity
  3827. 702: Receptor for Advanced GLYCATION End Products Expression in Lung Allograft Recipients with Primary Graft Dysfunction (PGD)
  3828. Effect of mitogen-activated protein kinase kinase 6-p38 alpha signal pathway on receptor for advanced GLYCATION end-product expression in alveolar epithelial cells …
  3829. Analysis of the impact of heparin on the affinity of high mobility group box-1 protein and the receptor of advanced GLYCATION end products by surface plasmon …
  3830. 210 GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE (EGCG) INHIBITS ADVANCED GLYCATION END PRODUCTS-INDUCED EXPRESSION …
  3831. Role of microRNA-214-targeting PTEN in advanced GLYCATION endproducts-induced apoptosis delay of monocytes (89.35)
  3832. 463 Autocrine regulation of receptor for advanced GLYCATION endproducts (RAGE) by S100A4 promotes migration and invasion in A375 melanoma cells
  3833. Inhibition of advanced GLYCATION endproduct formation by foodstuffs
  3834. Role of advanced GLYCATION end products in cardiovascular disease
  3835. The GLYCATION of albumin: structural and functional impacts
  3836. Advanced GLYCATION end products and neurodegenerative diseases: mechanisms and perspective
  3837. GLYCATION research in amino acids: a place to call home
  3838. Advanced GLYCATION end products
  3839. GLYCATION stress and photo-aging in skin
  3840. An update on advanced GLYCATION endproducts and atherosclerosis
  3841. Advanced GLYCATION end products and diabetic cardiovascular disease
  3842. Susceptibility of LDL and its subfractions to GLYCATION
  3843. Advanced GLYCATION endproducts and their pathogenic roles in neurological disorders
  3844. Lipid GLYCATION and protein GLYCATION in diabetes and atherosclerosis
  3845. Naturally occurring inhibitors against the formation of advanced GLYCATION end-products
  3846. Molecular basis of arterial stiffening: role of GLYCATION–a mini-review
  3847. Advanced GLYCATION end products: key players in skin aging?
  3848. Advanced GLYCATION endproducts and their receptor RAGE in Alzheimer’s disease
  3849. Pathological significance of mitochondrial GLYCATION
  3850. Role of advanced GLYCATION end products (AGEs) in osteoporosis in diabetes
  3851. Role of advanced GLYCATION end products (AGEs) and oxidative stress in vascular complications in diabetes
  3852. Serum advanced GLYCATION end products (AGEs) are associated with insulin resistance
  3853. Rates and impact of human antibody GLYCATION in vivo
  3854. GLYCATION a promising method for food protein modification: Physicochemical properties and structure, a review
  3855. Comparison of modification sites formed on human serum albumin at various stages of GLYCATION
  3856. Natural products as anti-GLYCATION agents: possible therapeutic potential for diabetic complications
  3857. Advanced GLYCATION end product recognition by the receptor for AGEs
  3858. GLYCATION and insulin resistance: novel mechanisms and unique targets?
  3859. Advanced GLYCATION endproducts: from precursors to RAGE: round and round we go
  3860. Advanced GLYCATION end products affect growth and function of osteoblasts
  3861. Role of advanced GLYCATION end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes
  3862. Targeted reduction of advanced GLYCATION improves renal function in obesity
  3863. Effect of dietary advanced GLYCATION end products on mouse liver
  3864. Crosstalk between advanced GLYCATION and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases
  3865. Advanced GLYCATION end products are direct modulators of β-cell function
  3866. Advanced GLYCATION end product level, diabetes, and accelerated cognitive aging
  3867. Raman spectroscopy provides a powerful diagnostic tool for accurate determination of albumin GLYCATION
  3868. Advanced GLYCATION end products and its receptor (RAGE) are increased in patients with COPD
  3869. GLYCATION products in infant formulas: chemical, analytical and physiological aspects
  3870. Advanced GLYCATION end products (AGEs), oxidative stress and diabetic retinopathy
  3871. Antioxidant and anti-GLYCATION properties of Thai herbal teas in comparison with conventional teas
  3872. Controlling GLYCATION of recombinant antibody in fed‐batch cell cultures
  3873. Evidence for consistency of the GLYCATION gap in diabetes
  3874. Advanced GLYCATION end products, soluble receptor for advanced GLYCATION end products, and risk of colorectal cancer
  3875. Gaps in the GLYCATION gap hypothesis
  3876. Reduced soluble receptor for advanced GLYCATION end-products in COPD
  3877. Higher plasma levels of advanced GLYCATION end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year …
  3878. Characterization of site-specific GLYCATION during process development of a human therapeutic monoclonal antibody
  3879. The novel function of advanced GLYCATION end products in regulation of MMP-9 production
  3880. D-ribose in GLYCATION and protein aggregation
  3881. Advanced GLYCATION end-products and their receptor-mediated roles: inflammation and oxidative stress
  3882. Serum levels of advanced GLYCATION end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects
  3883. Advanced GLYCATION endproducts are increased in rheumatoid arthritis patients with controlled disease
  3884. Effects of alagebrium, an advanced GLYCATION endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure
  3885. Relationship between advanced GLYCATION end products and increased lipid peroxidation in semen of diabetic men
  3886. Evidence for a role of advanced GLYCATION end products in atrial fibrillation
  3887. Early-and advanced non-enzymatic GLYCATION in diabetic vascular complications: the search for therapeutics
  3888. Physicochemical studies on GLYCATION‐induced structural changes in human IgG
  3889. Skin advanced GLYCATION end product accumulation and muscle strength among adult men
  3890. The roles of glycated albumin as intermediate GLYCATION index and pathogenic protein
  3891. Restriction of advanced GLYCATION end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1
  3892. Role of advanced GLYCATION endproducts and glyoxalase I in diabetic peripheral sensory neuropathy
  3893. Septic shock is associated with receptor for advanced GLYCATION end products ligation of LPS
  3894. Effects of sevelamer on HbA1c, inflammation, and advanced GLYCATION end products in diabetic kidney disease
  3895. The diverse ligand repertoire of the receptor for advanced GLYCATION endproducts and pathways to the complications of diabetes
  3896. Advanced GLYCATION end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology
  3897. Cinnamic acid and its derivatives inhibit fructose-mediated protein GLYCATION
  3898. GLYCATION of whey protein to provide steric hindrance against thermal aggregation
  3899. Role of advanced GLYCATION end products in hypertension and cardiovascular risk: human studies
  3900. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced GLYCATION end products and oxidative stress in diabetic rats
  3901. Oral advanced GLYCATION endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1
  3902. Inhibitors of advanced GLYCATION and endoplasmic reticulum stress
  3903. Advanced GLYCATION end products in diabetes mellitus: mechanism of action and focused treatment
  3904. Inhibition of advanced GLYCATION end product formation by medicinal plant extracts correlates with phenolic metabolites and antioxidant activity
  3905. Advanced GLYCATION end products, measured as skin autofluorescence and diabetes complications: a systematic review
  3906. Genistein inhibits advanced GLYCATION end product formation by trapping methylglyoxal
  3907. Signal Transduction in Receptor for Advanced GLYCATION End Products (RAGE)
  3908. Advanced GLYCATION end products in diabetic and non-diabetic human subjects suffering from cataract
  3909. The receptor for advanced GLYCATION end products is a central mediator of asthma pathogenesis
  3910. The expression of the receptor for advanced GLYCATION endproducts (RAGE) is permissive for early pancreatic neoplasia
  3911. Receptor for advanced GLYCATION end products binds to phosphatidylserine and assists in the clearance of apoptotic cells
  3912. GLYCATION of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes
  3913. Low plasma albumin levels are associated with increased plasma protein GLYCATION and HbA1c in diabetes
  3914. Advanced GLYCATION end products and diabetic retinopathy
  3915. Fisetin lowers methylglyoxal dependent protein GLYCATION and limits the complications of diabetes
  3916. GLYCATION‐altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age‐related disease (in nondiabetics)
  3917. Advanced GLYCATION end products inhibitors from Alpinia zerumbet rhizomes
  3918. GLYCATION and biomarkers of vascular complications of diabetes
  3919. Advanced GLYCATION end-products induce injury to pancreatic beta cells through oxidative stress
  3920. Advanced GLYCATION end-product Nɛ-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes
  3921. In situ accumulation of advanced GLYCATION endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption
  3922. GLYCATION in diabetic nephropathy
  3923. Multiphoton spectral microscopy for imaging and quantification of tissue GLYCATION
  3924. Catalase, a target of GLYCATION damage in rat liver mitochondria with aging
  3925. Hibiscus sabdariffa Polyphenolic Extract Inhibits Hyperglycemia, Hyperlipidemia, and GLYCATION-Oxidative Stress while Improving Insulin Resistance
  3926. Involvement of advanced GLYCATION end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathy
  3927. Phytochemicals from berries and grapes inhibited the formation of advanced GLYCATION end‐products by scavenging reactive carbonyls
  3928. Modulation of physicochemical and conformational properties of kidney bean vicilin (phaseolin) by GLYCATION with glucose: Implications for structure–function …
  3929. Antioxidant, anti-GLYCATION and anti-inflammatory activities of phenolic constituents from Cordia sinensis
  3930. Inhibition of the formation of advanced GLYCATION end products by thymoquinone
  3931. Participation of the receptor for advanced GLYCATION end products in efferocytosis
  3932. Advanced GLYCATION end-products, a pathophysiological pathway in the cardiorenal syndrome
  3933. Advanced GLYCATION endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer’s disease
  3934. GLYCATION compounds in peanuts
  3935. ERK and Akt signaling pathways are involved in advanced GLYCATION end product-induced autophagy in rat vascular smooth muscle cells
  3936. Comprehensive identification of glycated peptides and their GLYCATION motifs in plasma and erythrocytes of control and diabetic subjects
  3937. Anti-GLYCATION effect of gold nanoparticles on collagen
  3938. Effect of heating and GLYCATION on the allergenicity of 2S albumins (Ara h 2/6) from peanut
  3939. Cathepsins D and L reduce the toxicity of advanced GLYCATION end products
  3940. The role of receptor for advanced GLYCATION endproducts (RAGE) in infection
  3941. Advanced GLYCATION end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro
  3942. Glycated albumin is a useful GLYCATION index for monitoring fluctuating and poorly controlled type 2 diabetic patients
  3943. Up-regulated expression of advanced GLYCATION end-products and their receptor in the small intestine and colon of diabetic rats
  3944. Advanced GLYCATION end products induce a prothrombotic phenotype in mice via interaction with platelet CD36
  3945. Heterogeneous GLYCATION of cancellous bone and its association with bone quality and fragility
  3946. Advanced GLYCATION end products, diabetes, and the brain
  3947. Soluble receptor for advanced GLYCATION end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
  3948. Insulin GLYCATION by methylglyoxal results in native-like aggregation and inhibition of fibril formation
  3949. … induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced GLYCATION end products in brain …
  3950. The receptor for advanced GLYCATION end products and acute lung injury/acute respiratory distress syndrome
  3951. Sodium nitrite de-stiffening of large elastic arteries with aging: role of normalization of advanced GLYCATION end-products
  3952. Determination of advanced GLYCATION endproducts by LC-MS/MS in raw and roasted almonds (Prunus dulcis)
  3953. Advanced-GLYCATION-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1
  3954. Inhibitory effects of Lemon balm (Melissa officinalis, L.) extract on the formation of advanced GLYCATION end products
  3955. Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance GLYCATION end-products
  3956. Soluble form of the receptor for advanced GLYCATION end products is a marker of acute lung injury but not of severe sepsis in critically ill patients
  3957. The relative contributions of non-enzymatic GLYCATION and cortical porosity on the fracture toughness of aging bone
  3958. Role of advanced GLYCATION on aggregation and DNA binding properties of α-synuclein
  3959. Moderate GLYCATION of serum albumin affects folding, stability, and ligand binding
  3960. Receptor for advanced GLYCATION end products (RAGE) and implications for the pathophysiology of heart failure
  3961. Total soluble and endogenous secretory receptor for advanced GLYCATION end products as predictive biomarkers of coronary heart disease risk in patients with type 2 …
  3962. Advanced GLYCATION end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells
  3963. The role of advanced GLYCATION end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction
  3964. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced GLYCATION end products in …
  3965. Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced GLYCATION end-product levels
  3966. Evidence that serum levels of the soluble receptor for advanced GLYCATION end products are inversely associated with pancreatic cancer risk: a prospective study
  3967. Alpha-synuclein deficiency leads to increased glyoxalase I expression and GLYCATION stress
  3968. D-ribose induces cellular protein GLYCATION and impairs mouse spatial cognition
  3969. Rehmannia glutinosa suppresses inflammatory responses elicited by advanced GLYCATION end products
  3970. Advanced GLYCATION end‐products inhibition improves endothelial dysfunction in rheumatoid arthritis
  3971. Advanced GLYCATION endproducts and diabetes. Beyond vascular complications
  3972. Reference values for the Chinese population of skin autofluorescence as a marker of advanced GLYCATION end products accumulated in tissue
  3973. Enhanced expression of receptor for advanced GLYCATION end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes
  3974. Tissue advanced GLYCATION end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients
  3975. Potential clinical utility of advanced GLYCATION end product cross-link breakers in age-and diabetes-associated disorders
  3976. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced GLYCATION end product–receptor axis
  3977. Inhibition of advanced GLYCATION end-product formation on eye lens protein by rutin
  3978. Increased accumulation of skin advanced GLYCATION end products is associated with microvascular complications in type 1 diabetes
  3979. Pyridoxamine, advanced GLYCATION inhibition, and diabetic nephropathy
  3980. Inhibition of the receptor for advanced GLYCATION endproducts (RAGE) protects pancreatic β-cells
  3981. The receptor of advanced GLYCATION end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis
  3982. Differential effects of advanced GLYCATION end‐products on renal tubular cell inflammation
  3983. Role of advanced GLYCATION end product receptors in the pathogenesis of diabetic retinopathy
  3984. Serum levels of advanced GLYCATION endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes
  3985. Advanced GLYCATION end products measured by skin autofluorescence in a population with central obesity
  3986. Advanced protein GLYCATION in psoriasis
  3987. Bioguided fractionation and isolation of natural inhibitors of advanced GLYCATION end-products (AGEs) from Calophyllum flavoramulum
  3988. The role of receptor for advanced GLYCATION end products (RAGE) in the proliferation of hepatocellular carcinoma
  3989. Plant-derived agents with anti-GLYCATION activity
  3990. Advanced GLYCATION end products of human β2 glycoprotein I modulate the maturation and function of DCs
  3991. Solution structure of the soluble receptor for advanced GLYCATION end products (sRAGE)
  3992. Dietary advanced GLYCATION end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus
  3993. Cyclopeptide alkaloids of Ziziphus oxyphylla Edgw as novel inhibitors of α-glucosidase enzyme and protein GLYCATION
  3994. Activation of receptor for advanced GLYCATION end products induces osteogenic differentiation of vascular smooth muscle cells
  3995. Chlorogenic acid inhibits the formation of advanced GLYCATION end products and associated protein cross-linking
  3996. Calycosin protects HUVECs from advanced GLYCATION end products-induced macrophage infiltration
  3997. Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced GLYCATION end product, in adults
  3998. Genotoxicity and immunogenicity of DNA-advanced GLYCATION end products formed by methylglyoxal and lysine in presence of Cu2+
  3999. Insight into the GLYCATION of milk proteins: an ESI-and MALDI-MS perspective
  4000. Molecular basis of maillard amide-advanced GLYCATION end product (AGE) formation in vivo
  4001. Advanced GLYCATION end products as environmental risk factors for the development of type 1 diabetes
  4002. Role of advanced GLYCATION endproducts and potential therapeutic interventions in dialysis patients
  4003. Elevated serum levels of advanced GLYCATION end products and their monocyte receptors in patients with type 2 diabetes
  4004. Inhibitory activity of coumarins from Artemisia capillaris against advanced GLYCATION endproduct formation
  4005. Phlorotannins from Brown Algae (Fucus vesiculosus) Inhibited the Formation of Advanced GLYCATION Endproducts by Scavenging Reactive Carbonyls
  4006. Advanced GLYCATION end products: possible link between metabolic syndrome and periodontal diseases
  4007. Predictive value of advanced GLYCATION end products for the development of post-infarction heart failure: a preliminary report
  4008. Advanced GLYCATION end products promote proliferation of cardiac fibroblasts by upregulation of K Ca 3.1 channels
  4009. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced GLYCATION end product, in adults: the Energetics Study
  4010. Impairment of human keratinocyte mobility and proliferation by advanced GLYCATION end products-modified BSA
  4011. The soluble form of the receptor of advanced GLYCATION endproducts increases after bariatric surgery in morbid obesity
  4012. Inhibitory effect of polysaccharides from pumpkin on advanced GLYCATION end-products formation and aldose reductase activity
  4013. Estimation of the GLYCATION gap in diabetic patients with stable glycemic control
  4014. Advanced GLYCATION end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced GLYCATION end product-mediated activation of …
  4015. Accumulation of tissue advanced GLYCATION end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal …
  4016. Receptor for advanced GLYCATION end-products signals through Ras during tobacco smoke–induced pulmonary inflammation
  4017. Immunohistochemical distribution of advanced GLYCATION end products (AGEs) in human osteoarthritic cartilage
  4018. Advanced GLYCATION end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling
  4019. Metformin inhibits advanced GLYCATION end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor …
  4020. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced GLYCATION end-products and advanced lipoxidation end …
  4021. Quantitative analysis of GLYCATION patterns in human serum albumin using 16O/18O-labeling and MALDI–TOF MS
  4022. Water extracts of cinnamon and clove exhibits potent inhibition of protein GLYCATION and anti-atherosclerotic activity in vitro and in vivo hypolipidemic activity in …
  4023. Advanced GLYCATION end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients
  4024. Positive association between serum level of glyceraldehyde-derived advanced GLYCATION end products and vascular inflammation evaluated by [18F] …
  4025. Effect of micronutrients on methylglyoxal-mediated in vitro GLYCATION of albumin
  4026. Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced GLYCATION endproducts, autophagy and vascular endothelial growth …
  4027. Advanced GLYCATION urinary protein-bound biomarkers and severity of diabetic nephropathy in man
  4028. Accumulation of argpyrimidine, a methylglyoxal-derived advanced GLYCATION end product, increases apoptosis of lens epithelial cells both in vitro and in vivo
  4029. Paradoxical function for the receptor for advanced GLYCATION end products in mouse models of pulmonary fibrosis
  4030. Interaction between advanced GLYCATION end products formation and vascular responses in femoral and coronary arteries from exercised diabetic rats
  4031. S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced GLYCATION end products (RAGE)
  4032. Inhibition of advanced GLYCATION end-product formation by Origanum majorana L. in vitro and in streptozotocin-induced diabetic rats
  4033. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced GLYCATION end product in mouse mesangial cells cultured in high glucose
  4034. Advanced GLYCATION end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes
  4035. Advanced GLYCATION endproducts in horses with insulin-induced laminitis
  4036. Effect of benfotiamine on advanced GLYCATION endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy
  4037. The Receptor for Advanced GLYCATION End-products (RAGE) protects pancreatic tumor cells against oxidative injury
  4038. Glycated lysine residues: a marker for non-enzymatic protein GLYCATION in age-related diseases
  4039. Proteolytic release of the receptor for advanced GLYCATION end products from in vitro and in situ alveolar epithelial cells
  4040. Association of serum soluble receptor for advanced GLYCATION end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)
  4041. Lack of the Receptor for Advanced GLYCATION End-Products Attenuates E. coli Pneumonia in Mice
  4042. What is the role of the receptor for advanced GLYCATION end products–ligand axis in liver injury?
  4043. Pravastatin inhibits advanced GLYCATION end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level
  4044. Inflammatory effect of advanced GLYCATION end products on human meniscal cells from osteoarthritic knees
  4045. Effect of milk protein GLYCATION and gastrointestinal digestion on the growth of bifidobacteria and lactic acid bacteria
  4046. Increased levels of soluble receptor for advanced GLYCATION end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with …
  4047. Receptor for advanced GLYCATION endproducts (RAGE) deficiency protects against MPTP toxicity
  4048. ELISA detection of hazelnut proteins: effect of protein GLYCATION in the presence or absence of wheat proteins
  4049. Targeting receptor for advanced GLYCATION end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth
  4050. Levels of soluble advanced GLYCATION end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot
  4051. Advanced GLYCATION end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models
  4052. Interaction between glycated serum albumin and AGE-receptors depends on structural changes and the GLYCATION reagent
  4053. Methylglyoxal, advanced GLYCATION end products and autism: is there a connection?
  4054. Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced GLYCATION end products (RAGE)-independent …
  4055. Increased receptor for advanced GLYCATION end products in spermatozoa of diabetic men and its association with sperm nuclear DNA fragmentation
  4056. The functional− 374T/A polymorphism of the receptor for advanced GLYCATION end products may modulate Crohn’s disease
  4057. Advanced GLYCATION end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease
  4058. Regulation of heparanase by albumin and advanced GLYCATION end products in proximal tubular cells
  4059. Constituents with α-glucosidase and advanced GLYCATION end-product formation inhibitory activities from Salvia miltiorrhiza Bge.
  4060. Peripheral RAGE (receptor for advanced GLYCATION endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response
  4061. Levels of oxidized LDL and advanced GLYCATION end products–modified LDL in circulating immune complexes are strongly associated with increased levels of carotid …
  4062. Mutagenesis and Repair Induced by the DNA Advanced GLYCATION End Product N2-1-(Carboxyethyl)-2′-deoxyguanosine in Human Cells
  4063. Puerarin inhibits the retinal pericyte apoptosis induced by advanced GLYCATION end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress
  4064. Plasma levels of soluble receptor for advanced GLYCATION end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid …
  4065. Activation of the receptor for advanced GLYCATION end products system in women with severe preeclampsia
  4066. Zingiber officinale extract exhibits antidiabetic potential via modulating glucose uptake, protein GLYCATION and inhibiting adipocyte differentiation: an in vitro study
  4067. Role of Aβ-receptor for advanced GLYCATION endproducts interaction in oxidative stress and cytosolic phospholipase A2 activation in astrocytes and cerebral …
  4068. Cranberry phytochemicals inhibit GLYCATION of human hemoglobin and serum albumin by scavenging reactive carbonyls
Related Posts

Novel Flavonoid

Preventing Skin Aging

Vitagenes

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping